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ABSTRACT 
 
All research involving human subjects should be conducted in accordance to the general 
ethical principles of autonomy or respect for persons, beneficence and justice.  Competent 
adults can exercise their autonomy and can choose to take on risk for the sake of others, 
therefore are able to protect their own interests while in the pediatric research the ‗best 
interests of the child‘ takes precedence over autonomy.  In other words giving informed 
consent in the pediatric context, is not ‗who decides‟ but „what is the best decision for the 
child‟. Due to lack of consensus gold standard to guide researchers and assess the quality of 
parental informed consent in Botswana, the practical and ethical challenges posed in 
obtaining parental informed consent for child enrolment in pediatric HIV clinical trials were 
examined. The study aimed to determine the readability of the consent forms used in 
pediatric HIV clinical trials; assess communication methods, practices and perceptions of the 
trial staff regarding the informed consent process; assess the extent to which parents recall 
and understand the information disclosed to them and their satisfaction with the informed 
consent process as well as to identify and describe the reasons for parental approval to child 
enrolment into HIV clinical trial studies. The study used a cross-sectional exploratory 
descriptive design and applied triangulation methods which included readability analysis of 
consent forms; in-depth interviews and two focus group discussions with trial staff who 
conduct the informed consent process as well as face-to-face semi-structured interviews 
conducted with 151 parents/guardians. Results showed that all the 10 consent forms analyzed 
for readability were found to be difficult to read as they were written for higher grade level 
than that of most participants. Majority of trial staff were females with relevant qualifications 
in various medical disciplines and multiple tasks. Majority of trial staff were of the opinion 
that possession of good background knowledge of participants‘ culture; research ethics 
regulations, clinical trials research, and pre-assessment of readability of consent forms were 
an asset to obtaining valid informed consent. Trial staff were of the opinion that the 
information disclosed to the parents was too much and complex for comprehension and valid 
decision making. The common method of disclosing information was found to be mainly the 
paternalistic type which does not promote autonomy of the parents. The parents who 
participated in this study were mostly females, with low education levels, social economic 
status and mainly from the rural areas. Bivariate analyses from the parents‘ results showed 
that the age, previous experience in research and relationship of parent to the child were 
significantly associated with the parents‘ ability to recall disclosed information. Motivation of 
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the parent to child enrolment was significantly associated with the numbers of clinic visits, 
previous experience in research, being a biological parent and being paid for participation in 
the study. Overall, findings seemed to suggest that the main motivation factor for child 
enrolment into HIV clinical trials by parents was the illness of the child and accessing health 
care for the child rather than altruism. This raises questions about the autonomy, 
voluntariness of the parents and the validity of the consent obtained. These findings were 
used to develop a model. The study demonstrated the need to develop a standard model 
consent form to guide research involving children, the importance of researchers having 
knowledge of participants‘ culture and the need for availability of context standard guidelines 
and laws to guide researchers conducting research involving children. 
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CHAPTER ONE 
 
1.0 Introduction 
 
All research involving human subjects should be conducted in accordance to the general 
ethical principles of autonomy or respect for persons, beneficence and justice (Faden and 
Beauchamp, 1986). Autonomy requires that those who are capable of deliberation about their 
personal choices should be treated with respect for their capacity for ―self-determination‖ and 
those who are dependent or vulnerable should be afforded security against harm or abuse 
(Council for International Organization of Medical Science (CIOMS), 2000 p. 17).The most 
vital mechanism for ensuring autonomy is seeking informed consent when conducting 
research involving human subjects because it protects the individual‘s freedom of choice. The 
doctrine of informed consent is a product of the Declaration of Helsinki that was drafted by 
the World Medical Association in 1964 in an effort to ensure the protection of human 
research subjects. This process consists of four essential elements namely; full disclosure of 
information about the research, subject understanding of the information, voluntary consent 
and subject competence to consent (Faden and Beauchamp 1986; Levine 1986). 
 
When children are involved in research especially non-therapeutic research that poses no 
prospects of direct benefit to them, issues of autonomy raise ethical and regulatory challenges 
because for practical and legal reasons, children are considered incapable of giving the 
necessary consent to expose themselves to research risks (CIOMS, 2002). This has raised 
debate regarding the legal and moral justification for involving children in research, as well 
as the requirement for extra protections and safeguards to be put in place to ensure protection 
through various research regulations (Weisstub, 1998). Safeguarding includes; protecting 
children from maltreatment, preventing impairment of a child‘s health or development and 
ensuring that children are growing up in circumstances consistent with the provision of safe 
and effective care (Furey, Kay, Barley et al., 2010). In addition, Beauchamp and Childress, 
(2008) argue that children must be afforded extra protection from unwarranted research risks, 
especially since they are a vulnerable population who lack adequate autonomy to understand 
and evaluate research risks for themselves. The safeguards and extra protection are obtained 
through seeking ‗parental permission‘ or permission from legally authorized persons to enrol 
a child in research. Therefore  ‗permission‘ rather than ‗consent‘ is used to more accurately 
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capture the ethical consideration involved in seeking parental approval before a child is 
enrolled in a clinical trial or any other type of research. Ross (2006) explains this as a legal 
and moral responsibility of the parent who raises the child and shoulders all social, emotional, 
moral and legal obligations. Parental permission also reflects respect for the parent‘s 
autonomy, authority and responsibility to determine the proper development and upbringing 
of the child. Furthermore, Weisstub (1998) explains that parental permission offers some 
external evaluation of the research‘s inherent risks, apart from that of the investigators and 
the ethics committees. Although the latter are better positioned to objectively evaluate the 
risks created, parents are arguably in a better position to evaluate the possible subjective risks 
(physical, psychological or otherwise) presented in relation to their child. Although 
‗permission‘ is a more accurate term for the parental decision-making role, common practice 
in the research environment is to refer to this process as ‗consent‘. For the sake of 
consistency with terminology, the researcher has continued to use the word ‗consent‘ 
throughout this thesis. In addition, depending on the age, maturity and psychological 
development of the child, CIOMS (2002) guideline 14, recommends that as a means of 
respecting the developmental autonomy of the child and probably educating the child on the 
importance of moral consciousness, the ‗assent‘ of the child is also required. This is to ensure 
understanding and positive agreement of the child to participate in the trial, to the extent that 
he/she is capable. This thesis however will not deal with assent because the topic requires a 
distinct line of investigation because different ethical challenges arise when competent 
children are involved in clinical trials. 
 
Despite the legal and ethical restrictions on research involving children because of their 
vulnerability, clinical investigations involving children have been recently recognized as a 
scientific necessity to ensure the efficacy and safety of pediatric drugs, vaccines and 
diagnostics. Chan (2006, p.21) observed that lack of such investigations could result in a 
paucity of safety and effectiveness of data on children‘s drugs and biological products. This 
would ultimately result in therapies that were assumed in the absence of research to be safe 
and effective causing harm to children. Although the involvement of children in research is 
crucial, Weisstub (1998) cautions that this research must be scientifically necessary ethically 
sound, with an appropriate balance of risks and benefits, and parental permission must be 
sought. In response to these requirements, many domestic and international regulations have 
been developed to ensure protection of the rights and welfare of children. These requirements 
however make the application of the ethical principle of autonomy in pediatric research 
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different from that in the adult research context. Chappuy, Doz & Blance (2006 p.112) 
differentiate the two contexts as follows. Competent adults can exercise their autonomy and 
can choose to take on risk for the sake of others, therefore are able to protect their own 
interests while in the pediatric research context the ‗best interests of the child‘ legal standard 
takes precedence over autonomy. In other words application of informed consent in the 
pediatric context, is not ‗who decides‟ but „what is the best decision for the child‟.  
 
Against this background, the current thesis examines the practices as well as practical and 
ethical challenges posed in obtaining parental informed consent for child enrolment in 
pediatric Human Immunodeficiency Virus (HIV) clinical trials conducted in Botswana. It 
focuses on the informed consent forms, the information disclosure process, parental 
comprehension of the information provided and the decision-making process, and 
voluntariness.  The study also reviews the existing ethical theories of autonomy, models of 
informed consent, researcher-participant/patient interaction models and public health models 
so as to develop one that will guide the process of obtaining parental informed consent in 
Botswana.  
 
1.1 Motivation 
 
The researcher‘s interest in issues relating to consent came from working as the Botswana 
Research Ethics Committee (REC) administrator and as a member of the University of 
Botswana Institutional Review Board (IRB). The work partly involved reviewing consent 
forms written in English. These forms were overly long some ranging from 11-22 pages and 
used complex scientific language. These challenges are a major ethical issue especially for 
studies involving vulnerable groups such as children. A preliminary study conducted by the 
researcher (Kasule, 2009- unpublished: International Bioethics Training Practicum) to 
analyze the readability and understandability of consent forms used in clinical trials in 
Botswana showed that the consent forms were  difficult to read and prepared at a level much 
higher than the recommended 6-8
th
 grade according to United States standards . Although 
English is the Botswana official language, a large percentage of Batswana use the language 
mainly orally and may have difficulty understanding the information presented in a consent 
form written in English at a level of sophistication like a clinical trial consent form. 
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Due to the above concerns and the fact that currently there is no consensus gold standard used 
to guide researchers and assess the quality of parental informed consent in Botswana, this 
study used a holistic approach unlike many studies that have looked at improving particular 
steps of the informed consent process. This was done in three phases. The study initially 
analyzed the informed consent forms used by trial staff to conduct the informed consent 
process for ease of readability and understandability. The second phase involved 
identification of methods commonly used by trial staff to disclose information to the parents; 
how trial staff facilitate understanding, decision-making and promote voluntariness. The third 
phase involved an examination of parental perceptions about the informed consent process 
through assessing their awareness about the elements of the informed consent process 
disclosed, understanding of the elements, factors influencing their decision-making and 
voluntariness. I argue that both the trial staff and parents face challenges during the consent 
process and understanding how the two parties fulfil their obligation to reach a valid 
informed decision is important in improving parental informed process. 
 
In this thesis the term ‗parent‘ is used synonymously to refer to a biological parent, adoptive 
parent, or guardian as described in the International Conference of Harmonization (ICH)  11 
(2000). Categorization of pediatric patient will also be based on the same document as shown 
below: 
• Preterm new born infants   
• Term new born infants (0 to 27 days)  
• Infants and toddlers (28 days to 23 months)  
• Children (2 to 11 years)  
• Adolescents (12 to 16-18 years (dependent on region) 
 
As mentioned earlier, among the above categories are competent children that participate in 
HIV clinical trials in Botswana. However this thesis will not deal with ―assent‖ because the 
process of assent or decision making by children in the research setting is a separate process 
warranting ethical consideration. Therefore I have chosen to focus on parents as decision-
makers. 
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1.2 Statement of the problem 
1.2.1 Background to the Problem 
 
The HIV pandemic has offered opportunities for the proliferation of pediatric HIV clinical 
trials in sub-Saharan countries including Botswana due to the worldwide need to discover 
new drugs and vaccines and develop new strategies for treatment and prevention. HIV has 
been a major public health problem for the past three decades and has gradually shifted from 
exclusively adult populations to include the paediatric populations as well (United Nations 
AIDS (UNAIDS) Agency, 2010). Worldwide, at the end of 2009, there were 2.5 million 
children living with HIV, 400 000 became newly infected and of the 1.8 million people who 
died of AIDS one in seven were children (UNAIDS, 2010). Botswana is one of the nine 
southern African countries that continue to bear the global burden of HIV and AIDS with an 
estimated 350 557 people living with HIV and of these 19125 are children aged 0-14 years 
(Botswana HIV/AIDS Impact Survey III, 2008). Despite increased availability of 
antiretroviral therapy in the developing world, children remain a neglected population 
because, as noted by Keeton (2007), the development of medicines for children lags years 
behind those of adults. 
 
For the above reason, the World Health Organization (WHO, 2006) and other bodies such as 
the FDA (Food and Drug Administration, 2003) and the Clinical Trials Directive 2001/20/EC 
of the European Parliament and of the Council recommend and promote pediatric research 
into childhood diseases and other conditions that particularly affect children. The Clinical 
Trials Directive 2001/20/EC of the European Parliament and of the Council in particular 
recognise the need for investigation of medicinal products in the vulnerable population of 
children (i.e. minors in the meaning of the Clinical Trials Directive) and says in part: 
 “... There is a need for clinical trials involving children to 
improve the treatment available to them. Children represent a 
vulnerable population with developmental, physiological and 
psychological differences from adults, which make age and 
development-related research important for their benefit. 
Medicinal products, including vaccines, for children need to be 
tested scientifically before widespread use. This can only be 
achieved by ensuring that medicinal products which are likely 
to be of significant clinical value for children are fully studied. 
The clinical trials required for this purpose should be carried 
out under conditions affording the best possible protection for 
the subjects.”  (p.34) 
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This urgency and importance of the goals of HIV preventive (in this case vaccine) and 
treatment, research can however overshadow the need to protect the well-being and human 
rights of vulnerable trial participants like children. Therefore the National Bioethics Advisory 
Commission (1998) stipulates that promoting and protecting the rights of trial participants is 
as important as advancing science because medical research is also about human 
development. Protecting trial participants rights may also help to promote good science and 
public confidence in the research and its findings. 
 
One important mechanism that needs to be put in place when  conducting research involving 
children is obtaining informed consent from their  parents or guardians. This procedure 
represents the ethical position adopted towards volunteers in clinical trials as it gives meaning 
to the ethical principle of autonomy. The conceptual framework for the process of obtaining 
informed consent is focused around information sharing, understanding, voluntariness and 
competence. The World Medical Association Declaration of Helsinki (2004) states that in 
order for informed consent to occur potential participants must be informed about what the 
study entails, be able to distinguish between research and standard clinical treatments; 
understand the potential for medical or other benefits; and understand the potential for 
discomfort, toxicity or other risks that occur as a result of participation in research. Potential 
research participants must also be made aware of their rights to withdraw from participation 
any time. However, in the case of clinical trials involving non-consenting participants such as 
pediatric patients, the principle of informed consent may be compromised.  
 
Article 2(j) of the Clinical Trials Directive (2001/20/EC, p.121) gives a comprehensive 
definition of the term informed consent, as well as the situations and process of obtaining it, 
as follows: 
―A decision, which must be written, dated and signed, to take 
part in a clinical trial taken freely after being duly informed of 
its nature, significance, implications and risks. The decision 
must be made by any person capable of giving consent or, 
where the person is not capable of giving consent, by his or her 
legal representative; if the person concerned is unable to read, 
oral consent in the presence of at least one witness may be 
given in exceptional cases, as provided for in national 
legislation.”(p. 37) 
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This position is similar to that of the ICH/WHO Good Clinical Practice (2000). However, 
Ellis and Bochener (1999) cited in Delany (2005, p.4) observe that the process of obtaining 
informed consent is highly subjective and complex, as they note that:  
“Informed consent is dependent as much on how we feel in 
conversation, our relationships with those giving information, 
how information is given, as with the substantive content of 
what we are actually told. Informed consent is volatile, 
emotional and processual. People make up their minds, 
change, hold on, become confused, disagree, rationalize, 
blame, accept responsibility, reinterpret, misinterpret, and do 
cost-benefit analyses and then act on what their emotions 
instruct them to do instead, or do not act, and simply do not 
know what to do”.(p. 4) 
 
This observation indicates that giving valid consent involves intellectual competence, moral 
and emotional maturity, as well as cognitive capacity which enables individuals to have 
autonomy and rights. Since children do not have these attributes due to their developmental 
limitations, their participation in clinical research as consenting individuals would be 
considered unethical (Fombad, 2005). Therefore they depend on their parents‘ judgment and 
beliefs regarding issues of consenting to research (Lederer & Grodin, 1994). 
 
Although a large body of bioethics literature on obtaining informed consent from adult 
participants in clinical research has been reported (Sugarman, McCrory, Powell, and 
Krasney, 1999), only a few studies have been reported  on obtaining parental consent for 
child participation in clinical research (Rothman &Rothman, 2005). This is despite the fact 
that the use of children in human experiments dates back to the 1700s when clinicians used 
children with measles, pertussis, syphilis, gonorrhoea and other infectious diseases for human 
experiments (Katz, 1972). It was not until the 1900s that public controversy over such 
research practices led to the establishment of committees that issued recommendations and 
legislative proposals for ethical research conduct (Vollmann and Winau, 1996). Even after all 
these proposals, protections for child participants were still lacking. For example, even the 
Nuremberg Code (1949) and the Universal Declaration of Human Rights (1948) which was 
later adopted in 1966 as the International Covenant on Civil and Political Rights that were 
designed to protect the integrity of research subjects did not specifically target child 
participants in clinical research. Similarly, the initial World Medical Association of the 
Declaration (WMA) of Helsinki (1964) did not provide for research involving children, 
however its revisions dedicated a section ‗Guidance Note 1‘ to research involving children 
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and set the conditions under which such research should be conducted and consented as well 
as confidentiality issues. 
 
During the 1960s, criticism of unethical practices in research involving children gained new 
attention as a result of an article by Henry Beecher (1996) in which mentally retarded 
institutionalized children were deliberately fed extracts of fecal solutions from hepatitis 
infected patients and later injected with a more purified form of hepatitis. Faden and 
Beauchamp (1986), report that one of the main ethical concerns with this study was the 
inadequacy of the process for securing parental consent. Although this study contributed to 
public health, it also raised debate over the drive for tighter regulation on children 
participation in clinical research. Even then, there are still reports of unethical research 
involving children being conducted. For example, the 1996 Trovan clinical trial (Abdullah v. 
Pfizer, 2003) conducted by Pfizer during an epidemic of meningococcal meningitis in Nigeria 
where researchers were alleged not to have obtained informed consent from the 
parents/guardians of children that were recruited in this study. Such incidents call for 
improved regulatory frameworks. Currently several international and national organizations 
have issued ethical guidance on clinical trials with specific provision on participation of 
children (CIOMS, 1993 and revised in 2002; the International Council on Harmonization 
(ICH) Guidelines for Good Clinical Practice (2000). 
 
Controversy still rages within pediatric research over ethical rules and regulations that guide 
research involving children. Some researchers (Punch, 1998; Swain, 1998; Small, 2001; 
Goodwin, 2003) have argued that the ethical rules and regulations of the informed consent 
process do not necessarily translate well to pediatric research; partly because the ethical 
dilemmas that arise in pediatric research are context-specific. Other researchers (Homan & 
Bulmer, 1982; Punch, 1998) argue that adhering to specific ethical rules in relation to 
research can affect the very issue that is being studied, such that it becomes impossible to 
conduct research involving children. Given that over 50% of medicines used in children are 
not licensed for use either for the disease states or for the age group (Tan, Cranswick, Rayner, 
and Chapman, 2003). This particular argument is plausible in pediatric research. Another 
challenge to obtaining parental informed consent is the commitment to uphold the child‘s 
rights (Alderson, 2004; Homan & Bulmer, 1982). Within pediatric research for instance it is 
doubtful if consent is indeed a process of sharing information that facilitates the individual‘s 
right to self-determination as Tait, Voepel-Lewis and Gauger (2011) claim. Yet, despite its 
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good intentions, the process of obtaining informed consent is rarely examined. As such, there 
are only limited studies with respect to parental consent practices within pediatric research 
and only a few of them deal with the broad aspects of the process (Pace et al., 2005; Eder 
2007; Marshall 2006; Rajaraman, Jesuraj and Geiter, 2011). These few studies of obtaining 
parental consent for pediatric research suggest inadequacies in competence, information, 
understanding, or voluntariness for valid consent to occur. 
 
1.2.2. Formulation of the problem 
 
This study followed an inter-disciplinary approach in that it applies related concepts from 
other disciplines of public health, science, socio-sciences, health sciences and research ethics 
to examine the process of obtaining parental informed consent in Botswana. These 
approaches allowed assessing the readability and comprehension of the text of consent forms 
used by trial staff to conduct the consent process; the trial staffs‘ perspectives of the informed 
consent process; parents‘ perspectives on information disclosure and comprehension and 
voluntariness in decision making.  
 
The background to parental informed consent described above demonstrates the nature of 
challenges that can be encountered in obtaining valid parental informed consent. Currently 
there is a paucity of literature in Botswana about the adequacy of obtaining parental informed 
consent and the factors that influence parents‘ decision making. Studies conducted thus far 
have mainly concentrated on adult informed consent (Shaibu, 2007; 2006). Drawing from my 
experiences as a reviewer of the informed consent forms submitted for approval to the 
Research Ethics Committee, the overly lengthy consent forms contribute to readability 
difficulties, voluminous and complex information that inhibits comprehension leading to   
invalid decisions and consent. Furthermore, the high HIV prevalence rates of 17.6% in the 
general population (NACA, 2008), and the government commitment to combating HIV/AIDS 
and other opportunistic infections have led to an increase in volume and complexity of 
children HIV clinical trials being conducted in Botswana. However, the country ethics review 
capacity and regulatory oversight lags behind these developments. 
 
Secondly, the challenge facing pediatric research in Botswana is that most of the researchers 
who conduct pediatric HIV clinical trials are from outside Botswana. This is bound to raise 
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challenges of comprehension due to language and cultural differences. It must also be noted 
that most of the clinical trials conducted in Botswana are multisite studies where the consent 
forms are developed by institutions outside Botswana. This is likely to raise problems of lack 
of sensitivity on the part of the researchers to the values and culture of Botswana and failure 
to contextualize the information provided to participants. Furthermore, differences in socio-
economic status, authority/power, and health care systems between the trial staff and parents 
may also have an influence on the voluntariness with which decisions are made by the 
parents. Low levels of literacy (Maruatona & Cervero, 2004), and high rates of income 
inequalities may also contribute to the challenges posed to obtaining valid parental informed 
consent (Joint United Nations Programme on HIV/AIDS, 2004). Additionally, it is doubtful 
that parents with chronically sick children asked to enrol their children in clinical trials would 
be expected to decline such participation. 
 
Thirdly, at the moment Botswana lacks an established research ethics regulatory framework 
governing the conduct of pediatric research in terms of research guidelines, standard 
operating procedures and a legislation Act. Only a draft of the Botswana Clinical Trials 
Guidelines (v. 2008) is available. However the document does not comprehensively cover 
issues of child participation in research. Also available is a consent form guide document 
(Botswana Ministry of Health, Research Unit 2005), which caters for all types of research 
and has no special provision for child participants. This means that, there is no standardized 
way for researchers to prepare consent forms for child participation in clinical trials. As noted 
earlier, Botswana has signed and ratified to the United Nations Convention for Children‘s 
Rights that compel countries to respect and protect children‘s rights, but these have not been 
translated into policies regarding participation of children in research (Fombad, 2005). 
Additionally the laws, policies and practices guiding children‘s health rights regarding HIV 
treatment and care reveal inconsistencies and anomalies requiring harmonization (Kuwabara, 
2008).  
 
The fourth concern is the lack of a clear legislation regarding age of consent to participation 
in research or dealing with the capacity of children to make medical decisions. Currently the 
age of consent in Botswana is 21 years (section 49 of the Interpretation Act, 1984)applies for 
consent to participation in research but the Roman-Dutch law principles dealing with 
children‘s legal capacity to perform legal acts also applies (Fombad, 2005). This situation 
raises ethical challenges considering that children 14 years and above have the capacity to 
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make choices. The definition of a child also varies according to different settings. For 
example according to Botswana Children‘s Act (1981), Chapter 28:04, Part 1, Preliminary 
(ss-1-2), a ―child‖ is defined as any person under the age of 14 years.  Under this Act, 
children under the age of 14 years require a fully informed consent of the parent to whom 
most of the information is commonly discussed with. In the context of pediatric research, the 
above laws create an ethical dilemma for the trial staff in enrolling children in clinical trials, 
as it is not clear at which age limit parental consent is required for child participation in 
research. In addition, parents that are under 21 cannot consent for their children‘s 
participation in research regardless of their capacity and competence to do so. Such parents 
are denied the opportunity of their children to benefit from research participation where the 
research has prospects of benefit. Furthermore, considering the burden of nursing a 
chronically ill child, poverty, cultural and literacy levels might influence decision making of 
parents to child enrolment into research.  
 
The other complexity about seeking parental informed consent revolves around the conflict 
between Botswana culture and the international instruments like the Convention on the 
Rights of the Child (United Nations General Assembly, 1989) and the African Charter on the 
Rights and Welfare of the Child (1990) which Botswana has ratified to, but have not been 
fully incorporated into law. These two instruments emphasize that ―the best interest of the 
child must be the primary consideration and children are rights holders‖. However, Botswana 
culture as cited in Fombad (2005) like many other African cultures, believes that adults know 
what is best for the children and they are in a position to articulate the view of the children. 
Therefore the fact that parents might be torn between the requirements of the laws and their 
culture might affect the validity of the consent given. 
 
In conclusion, the challenges recounted above imply that obtaining valid parental informed 
consent in Botswana is problematic and a model would go a long way in alleviating the 
problem.  
1.3 Rationale 
 
There is a paucity of literature in Botswana about the adequacy of the parental consenting 
process and the factors that influence decision-making limit a deeper understanding of the 
process which would help facilitate designing a parental consent model that can guide the 
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process in Botswana. The ethical conduct of research requires a comprehensive ethical and 
regulatory oversight framework, which currently is inadequate or non-existent in Botswana. 
It is also worth noting that most of the clinical trials conducted in Botswana are multisite 
studies, institutions outside Botswana develop the consent documents and most of the mainly 
investigators who conduct the clinical trials are from outside of Botswana. This is likely to 
raise a problem of lack of sensitivity of the investigators to the values and culture of the 
Botswana communities and fails to contextualize some of the information provided to 
participants. Currently no studies documenting the challenges of obtaining informed consent 
for child participation in HIV clinical research have been documented in Botswana although 
such studies are very important in ensuring that children‘s rights and welfare as well as those 
of the parents or guardians who enrol their children in clinical trials are protected. The 
specific objectives of the study are presented in the following section. 
 
1.3.1 Aim of the study 
 
The general aim of this thesis was to conduct a situational analysis of the current practices of 
obtaining parental consent for pediatric HIV clinical trials conducted in Botswana in order to 
evaluate the quality of the process and use the findings to develop a conceptual model that 
can be used as a framework to guide the parental consent process.  
 
1.3.2 Objectives of the study 
 
The study set out to: 
 To determine the readability and comprehension of the consent forms used to obtain 
consent from parents who enrol their children in HIV clinical trials in Botswana.  
 To identify the communication methods, practices and perceptions of the trial staff 
regarding informed consent information disclosure.  
 To assess the extent to which parents are able to recall and understand the information 
disclosed to them and their satisfaction with the informed consent process 
 To identify and describe the reasons for parental approval to child enrolment into trial 
studies.  
 To develop a model to enhance and strengthen the process of informed consent for 
child participation in HIV clinical trials relevant to Botswana. 
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1.3.3 Research questions 
 
It is evident from the above discussion that obtaining parental informed consent for child 
participants in HIV clinical trials poses challenges. The research aimed to examine the above 
mentioned challenges by answering the following research questions: 
  
 How readable and understandable are the consent forms used to obtain parental 
informed consent? 
 How effective are the trial staff–parent communication methods and practices from 
the trial staff and parents perspective? 
 To what extent do parents recall and understand the information provided during the 
communication processes?  
 What are the parental perceptions of, and levels of satisfaction with, the informed 
consent process?  
 What motivates parents to enrol their children in HIV clinical trials? 
 To what extent is the parental decision to enrol their children in HIV clinical trials 
voluntary?  
 How can the process of informed consent for child participation in HIV clinical trials 
conducted in Botswana be enhanced? 
 
1.4 Research framework 
 
This thesis followed a cross-sectional exploratory design (Creswell, 2003) to conduct a 
holistic analysis of the current practices of obtaining parental consent for pediatric HIV 
clinical trials conducted in Botswana. Mixed methods both qualitative and quantitative were 
followed, based on the data collected from consent forms readability analysis, in-depth 
interview transcripts, focus group transcripts and face-to-face parent interviews using 
completed semi-structured questionnaires respectively.  
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1.4.1 Assumptions 
 
The following assumptions guided this study: 
 That the language used in the consent form is complex and difficult for parents to read 
and understand so as to make an informed decision which is in the best interest of the 
child. 
 That differences between the researcher and parent due to socioeconomic diversities 
make it difficult for researchers to obtain adequate parental informed consent 
  That parental understanding of the difference between clinical practice and research 
is doubtful. 
 That a parental decision to enrol children in HIV clinical trials is not voluntary. 
 That social coercion and monetary inducement due to high levels of poverty, language 
difficulties, and lack of true understanding of the entire study purposes influence 
parents to enrol their children in HIV clinical trials 
  That the counselling process prior to and during the HIV clinical trials is not done in 
a friendly and enabling environment, therefore not effective for obtaining valid 
parental informed consent  
 That parental informed consent is based on Western standards and models 
 
1.5 Methodology 
 
The thesis utilized a cross-sectional exploratory descriptive design and applied mixed 
quantitative and qualitative methods for data collection and analysis. Further, the thesis drew 
from the consequentialist and non-consequentialist theories of informed consent, and the 
significant models that guide autonomous decision-making and researcher/patient-participant 
interaction. 
 
This thesis was conducted in two phases. Phase One involved a situational analysis of the 
current parental consenting process to generate concepts that were used for model 
development. The Creswell (2003) dominant-less-dominant model that uses a single 
dominant paradigm with an alternative less dominant component drawn from different 
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paradigms was adopted. The qualitative component, which used a purposively selected 
smaller sample of trial staff and consent forms, formed the less-dominant component. 
Qualitative data collection techniques involved the use of in-depth interviews with 11 trial 
staff and two focus group discussions with a total of 18 trial staff who conduct the consent 
process. Data collection and analysis for the qualitative component of the thesis were 
conducted simultaneously in order to generate data for concept formation and development. 
The dominant component was the quantitative survey involving a larger sample of parents. 
Face-to-face interviews with from 151 parents were conducted using a semi-structured 
questionnaire. Descriptive methods were used in reporting the quantitative data. Chi-Square-
tests and ANOVA were determined. Furthermore, linear regressions assessed the relationship 
between demographic factors, levels of understanding. 
 
1.6 Operational terms 
  
1.6.1 Readability 
 
In this thesis, the term ‗readability‘ is used to refer to the reading ease and the grade level an 
individual should have obtained to be able to understand the text easily on first reading of the 
consent form that was used to recruit parents who enrol their children in HIV clinical trials. 
This understanding id borrowed from Johnson, (1998). 
1.6.2 Informed consent 
 
In this thesis, the term ‗informed consent‘ is used to refer to the process by which a parent 
voluntarily confirms his or her willingness to child enrolment in the HIV clinical trial, after 
having been informed of all relevant aspects of the trial. 
 
1.6.3 Clinical trials 
 
In this thesis the term ‗Clinical trials‘ refers to clinical trials conducted to test drug safety and 
efficacy in children.  
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1.6.4 Autonomy/Respect for persons 
 
In this thesis these two terms are used interchangeably to refer to the parent‘s self-
determination and freedom to decision-making regarding child enrolment in HIV clinical 
trials.  
1.6.5 Model  
 
In this thesis the term ‗model‘ refers to ‗a diagram‘ of proposed relationships among a set of 
concepts, factors, or variables about a particular hypothesis, question, context, problem or 
topics‘. This is in line with Earp & Ennett (1991, pg 163) definition. 
 
1.6.6 Child 
 
In this thesis ‗child‘ refers to anyone under the age of 21 years as stipulated by the Botswana 
Laws‘ Matrimonial Causes Act (1973) 
 
1.6.7 Parent 
 
In this thesis, the term ‗parent‘ refers to any legal caregiver of the child. This may include the 
biological parent(s), grandparent(s), and/or any other member of the extended family, or 
institutions such as orphanages. 
 
1.6.8 Trial staff 
 
Using insights from the ICH (2000) guidelines, this thesis  uses the  term ‗trial staff‘ to refer 
to the   investigator, or the  person designated by the investigator to inform the parent  of all 
the pertinent aspects of the clinical trial. This includes people who research institutions may 
designate as research nurse, study nurse, study coordinator, or recruiter.  
1.6.9 Pediatric population 
 
For the purposes of this thesis, ‗pediatric populations‘ will include newborns (birth to 1 
month of age); infants (1month to 2 years of age); children (2 to 12 years of age) and 
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adolescents (12 to 21 years of age) as sourced at: http://www.fda.gov / (US Department of 
Health and Human Services, Food and Drug Administration) 
 
1.7 Organization of the thesis 
 
The thesis comprises of five chapters as follows: 
Chapter one presents the introduction, background to the problem, statement of the problem, 
the theoretical framework, and the rationale of the study. It also states the aims, objectives, 
assumptions, and the research questions. Chapter Two presents the literature reviewed. 
Chapter Three presents the methodology. The chapter covers the research design, sampling 
techniques, description of the sample, and data collection and analysis. Chapter Four presents 
the findings and discussion. Chapter Five deals with the conclusions and Chapter Six presents 
the model. 
 
1.8 Conclusion 
 
This chapter provided a broad account of informed consent in the research context and its 
regulatory framework. The chapter also described the motivation of the study, and discussed 
informed consent in the context of public health and individual bioethics. The chapter also 
discussed the conceptualization of the study and showed how the topic was refined by 
literature. The chapter also outlined the research framework, and the overall design. 
 
The next chapter examines the literature that guided this thesis. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.0. Introduction 
 
This chapter reviews the literature on informed consent for pediatric research starting with 
examining the relationship between public health ethics, individual ethics and pediatric 
research. It also explores literature on the assessment of readability and comprehension of the 
consent forms; the perceptions and challenges regarding information disclosure; parental 
understanding of the information disclosed; decision-making process and voluntariness to 
child enrolment into pediatric HIV clinical trials. A review of the ethical theories, models of 
informed consent and models of physician-parent interaction aimed at improving parental 
informed consent process is also conducted.  
 
2.1 Public health ethics and pediatric research 
 
HIV clinical trials can be regarded both as public health and individual interventions. This 
means investigators have to apply both public health ethics and individual-based bioethics in 
decision making about involving children in research. Public health ethics is population-
based, as a specialty area distinct from bioethics with an individual-based focus. According to 
the Institute of Medicine (IOM, 1998), public health is the societal approach to protecting and 
promoting health rather than individual oriented actions to achieve this goal. Research like 
HIV clinical trials combines both public health ethics and bioethics because it ensures 
minimization of threats of disease in the community as well as among individuals. Winslow‘s 
(1920, p.148) cited in Noland, Troxler and Torrens Salami (2004, p. 24), classical definition 
of ‗public health‘ is instructive in HIV pediatric research. He defined public health as: 
“the science and the art of preventing disease, prolonging life, 
and promoting physical health and efficiency through 
organized community efforts for the sanitation of the 
environment, the control of community infections, the 
education of the individual in principles of personal hygiene, 
and the organization of medical and nursing service for early 
diagnosis and treatment of disease” [boldface own emphasis] 
(Noland, Troxler and Torrens Salami (2004), p. 24) 
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Acknowledging that Winslow was certainly not thinking about pediatric HIV clinical trials in 
the 1920‘s, today these clinical trials  are an essential part of public health interventions 
aimed at preventing this disease, prolonging life, promoting physical health, including early 
diagnosis and treatment of the disease. In this regard both public health ethics and bioethics 
respect and value individual dignity and worth as stated in the United Nations' 1948 
Universal Declaration of Human Rights. However the relationship between public health 
ethics and research especially with vulnerable populations like children is a complex one. 
While individual research ethics refers to the moral deliberation, choice and accountability on 
the part of the individual throughout the research process (Edwards & Mauthner, 2002, p. 
14), from a public health research ethics perspective, a wide range of ethical issues arise due 
the tension between societal rights versus individual liberties regarding autonomy. In this 
case, the question that arises is, ―What is the right thing to do?‖ in making decisions that will 
affect both the public's and the individual‘s health.  
 
There is currently a growing interest and recognition of the difference between public health 
ethics and bioethics regarding participants‘ right to voluntary and informed consent. Since 
individual ethics and public health ethics differ in terms of who is protected; the individual 
versus the community, Lappe (1986) noted that individual rights could be compromised for 
the sake of community interests. So there is need for a balance such that benefit outweighs 
the risk and the absolute level of infringement on individual rights is minimized. Involving 
children in HIV clinical trials might create such tension; extra safeguards must be put in place 
to protect their safety and wellbeing taking into account the model of ‗best interests of the 
child‘ as stipulated by the Belmont Report (1978). 
 
Regarding the justification and explaining the dilemmas that surround the decisions by 
investigators to involve children in research, several ethical theories have been suggested. For 
example Deyhle, Hess, & Lecompte (1992), cited in Miles &Huberman (1994, p 289) 
suggested two key ethical theories. The first one is the Mills‘ teleological or consequentialist 
theory which judges actions according to primary ends or their specific consequences, 
benefits and costs for various audiences. The second one is Kant‘s (1993, p.70) deontological 
or non-consequentialist theory based on duties and rights and respects individuals as ends in 
themselves. Kant‘s categorical and practical rules raise questions like: (a) would I like this 
action to be applied to everyone including me?  (b) will I treat every person I encounter as an 
end and not as a means to something I want? Furthermore, several models of informed 
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consent linked to the above theories have been proposed to describe the doctor-patient 
relationship in sharing of information and facilitating understanding about the disease and 
treatment that can be applicable to the research setting. For example, the ‗Event Model‘ 
(Wear, 1998); the ‗Transparency Standard Model‘ (Brody, 1987); the ‗Shared Decision 
Making Model‘ (Charles, 1998); the ‗Process Model‘ (Lidz, Appelbaum & Meisel, 1988); 
and the ‗Conversational Model‘ (Katz,) described in detail in section 2.4.1 below. The next 
section looks at the legal requirements for obtaining parental consent. 
 
2.2 History of research involving children and existing regulations 
 
Scientific experimentation with human subjects has historically been tainted with scandals of 
abuse which are only being investigated in the 21st century, the latest being the Obama 
Presidential Commission for the Study of Bioethical Issues (2011). Some of the worst abuses 
and exploitation of children who participated in medical experiments without the knowledge 
or consent of their caretakers have been documented and are reported (Advisory Committee 
on Human Radiation Experiments (ACHERE), 1995), cited in Vollman & Winau, (1996).  
This kind of research reflects a gruesome history of studies involving children and would be 
categorized as ‗greater than minimal risk‘ with no prospects of direct benefit to the individual 
except to future populations (International Conference on Harmonization (ICH)-Good 
Clinical Practice (GCP) guidelines 2000). Most of these experiments either resulted in death, 
severe birth deformities or disabilities like brain damage. Ultimately, since 1945 many codes 
and regulations have been put in place to ensure adequate protection of child subjects, 
particularly in developing countries that often do not have adequate regulatory institutions or 
standards governing clinical research.  
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Table 2.1 History of unethical research involving children 
 
Source: Vollman & Winau (1996).  
 
Examples of codes and regulations include; the Declaration of Helsinki (1964); World Health 
Organization (WHO) guidelines for Good Clinical Practice (1995); the 2002 CIOMS); the 
ICH-GCP guidelines (1996); U.S. Department of Health and Human Services, Common 
Rule, Code of Federal Regulations Title 45 CFR 46, Subpart D, 1979).  
The Common Rule is also applicable to research conducted in 
 
1896 Dr. Arthur Wentworth performs spinal taps on 29 children at Children‘s Hospital in 
Boston to determine if procedure is harmful. 
1931 75 children die in Lubeck, Germany from pediatrician‘s experiment with tuberculosis 
vaccine. 
1946-1974 The Atomic Energy Commission authorized experiments in which mentally retarded 
children were fed radioactive oatmeal without the consent of their parents or being 
informed that their children were subjects of an experiment, and without any 
expectation of a positive benefit.  
1949-1953 Atomic Energy Commission studies of mentally disabled school children fed 
radioactive isotopes at Fernald and Wrentham schools 
1953 New born Daniel Burton rendered blind at Brooklyn Doctor's Hospital during study on 
RLF and the use of oxygen 
1958-1960 Injection of hepatitis into mentally disabled children at Willowbrook School on Staten 
Island in an attempt to find vaccine. 
1962 Thalidomide withdrawn from the market after thousands of birth deformities blamed in 
part on misleading results of animal studies. 
1990 More than 1500 six-month old black and Hispanic babies in Los Angeles are given an 
"experimental" measles vaccine that had never been licensed for use in the United 
States. The Center for Disease Control later admits that parents were never informed 
that the vaccine being injected to their children was experimental. 
1996 About 200 children in Nigeria treated with an experimental drug Trovan were 
negatively affected; 11 died and many others were left severely disabled with blindness, 
deafness, brain damage, and paralysis. 
1998 -Three children die at St. Jude Children's Hospital in Memphis during participation in 
clinical trial for acute lymphoblastic leukemia. 
-One year-old Gage Stevens dies at Children's Hospital in Pittsburgh during 
participation in Propulsid clinical trial for infant acid reflux. 
-18-year-old Jesse Gelsinger dies after being injected with 37 trillion particles of 
adenovirus in gene therapy experiment at University of Pennsylvania. His death triggers 
a still on-going re-evaluation of the conflicts of interest plaguing human subject 
research. 
2001 Biotech company in Pennsylvania asks the FDA for permission to conduct placebo 
trials on infants in Latin America born with serious lung disease though such tests 
would be illegal in U.S. 
2004 The state Health Department launched a probe into potentially dangerous drug research 
conducted on HIV-infected infants and children at a Manhattan foster-care agency. 
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 Botswana as stated in section 101. All these guidelines emphasize the necessity of parental 
permission; children giving assent where appropriate after assessment of their capacity and 
maturity and advocating for extra protections to be put in place whenever children are 
involved as subjects in research. 
 
More recent regulations include the Joint United Nations Program on HIV/AIDS (2000), and 
the UNAIDS Guidance Document on Ethical Considerations in HIV Preventive Vaccine 
Research (available at: http://data.unaids.org/publications) accessed on 20 September, 2012) 
offer guidance for HIV studies involving children. The documents have specific guidance 
that identify children as a vulnerable population and support the ethical principle of 
autonomy in research. For purposes of this thesis, the specific relevant guidelines are cited in 
full below: 
 Guidance Point 7: vulnerable populations where relevant the 
research protocol should describe the social contexts of a 
proposed research population that create conditions for 
possible exploitation or increased vulnerability among 
potential research participants, as well as the steps that will be 
taken to overcome these and protect the dignity, safety and 
welfare of the participants. This point applies to children as 
they are categorized as a vulnerable population (p. 22) 
 Guidance Point 12: independent and informed consent based 
on complete, accurate, appropriately conveyed and understood 
information should be obtained from each individual while 
being screened for eligibility for participation in an HIV 
preventive vaccine trial, and before s/he is actually enrolled in 
the trial (p.32. 
 Guidance Point 13: special measures should be taken to 
protect persons who are, or may be, limited in their ability to 
provide informed consent (p. 36). 
 Guidance Point 15: a plan for monitoring the initial and 
continued adequacy of the informed consent process and risk-
reduction interventions should be agreed upon before the trial 
commences (p.39). 
 Guidance Point 18: children should be included in the clinical 
trials to verify safety, immunogenicity, and efficacy from their 
standpoint as future recipients of HIV preventive vaccine 
(p.46). 
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Despite all the above safeguards, evidence from recent abuses like the 1996 Trovan clinical 
trial mentioned in Chapter One shows that ethical and practical challenges still arise 
whenever children are involved in clinical trials or research in general. Therefore, substantive 
and procedural protections must be put in place before children are enrolled in clinical trials, 
in order to uphold the ethical principle of autonomy. 
 
2.3 Informed Consent in Clinical trials involving children 
 
The need for studies involving children despite the vulnerability of these subjects was 
defended in chapter one. I examine herein detail the justification and further clarify the basis 
of parental informed consent. Sugarman et al. (1999) explained that informed consent is 
based on the ethical principle of autonomy and the core requirements for obtaining valid 
informed consent include; possession of decision-making capacity (competency to participate 
in the informed consent process); the individual must be fully and accurately informed; and 
the consent must be given voluntarily. As mentioned earlier, children do not have these 
competences so their consent to research is provided by the parent or legal guardian as a 
safeguard and protection from research risks (Kopelman and Murphy, 2004).  
 
Several foundational ethical theories of autonomy that guide the informed consent process 
mentioned earlier are discussed in detail below. The first one is the Kant‘s deontological or 
non-consequentialist theory of autonomy was developed by Kant (1993, p. 52). This theory 
places value on the intentions of the individual rather than the outcomes (consequences) of 
any action. The theory also focuses on rules, obligations and duties of the individual, and 
acting from duty is viewed as ethical (Waller, 2005). One of the key criticisms of applying a 
strictly deontological approach to healthcare is that it can lead to conflicts of interest between 
equally entitled individuals. For example the non-consequentialist theory would regard 
seeking parental informed consent as a rule, duty or obligation irrespective of the overall 
expected consequences of doing so. For example, a researcher conducting HIV pediatric 
clinical trial that exposes children to risks and has no direct benefit to the child would be a 
contradicting his/her obligation and the duty of non-maleficence. Furthermore, evidence of 
non-consequentialist views in public health is exhibited in legislations such as Public Health 
Acts that regulate individuals that can endanger public health and safety. For example 
regulations like no smoking in public places contradict the individual respect for person and 
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goes against individual liberties. Kopelman (2005) noted that although the mission of public 
health is to achieve the greatest health benefit for the greatest number of people, individual 
rights need to be protected and exposure to undue risk must be avoided. Therefore individuals 
and institutions that are involved in the conducting of HIV clinical trials have an obligation to 
ensure that child participants‘ rights are protected and their wellbeing is safeguarded and one 
way of doing this is through seeking parental consent. 
 
The second ethical theory of autonomy known as the Mills (cited in Delany, 2005) 
teleological or consequentialist theory of autonomy holds the view that the correct moral 
response is related to the outcome, or consequence, of the act therefore contradicting the non-
consequentialist theory. Its central aim is the premise of 'maximizing the greatest good for the 
greatest number‘. The 'good' referred to can be expressed in a variety of ways and may refer 
to values or 'utility' such as happiness, being pain-free or symptom-free or any other life 
enhancing outcome. As an ethical theory, consequentialism is attractive as there is always an 
outcome and the correct moral response is the one that will produce the greatest good for the 
greatest number.  However, it does have limitations as it can endorse acts that could be 
contrary to the rights of individuals even if the end result is one which would improve care 
for many others. For example in this thesis, the theory would imply that, if a few children 
were enrolled in an HIV clinical trial testing a new drug regardless of their parents‘ consent 
and the children are exposed to some risk, this would be acceptable as long as the general 
pediatric population benefits from the outcome. According to Mill‘s consequentialist theory, 
the end justifies the means. Therefore the decision with the best overall expected 
consequences or which benefits the majority is the one we ought to take. The theory therefore 
upholds the public health model in its prioritizing the population over the individual. By 
inference Alderson (2004) observes that public health professionals would be in support of 
this theory since they are said to act for the ―common good‖ (Weed & McKeown, 1998). 
Beauchamp and Childress (1994) however argued that from a population point of view, this 
might imply that any given intervention must result in more good than harm; and that the 
public health model assumes that the appropriate mode of evaluating options is balancing 
risks and benefits. This is because the mission of public health is to achieve the greatest 
health benefit for the greatest number of people.  If we oversimplify the public health 
approach which is interested in securing the greatest benefits for the most people, 
consequentialism appears to permit, or even require that the most fundamental interests of 
individuals be sacrificed in order to produce the best overall outcome. It could also mean that 
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the origin of good or pleasure is irrelevant as long as the outcome benefits most people. 
However it is important to note that most public health interventions are intended to benefit 
the entire population without knowingly harming individuals or groups (Public Health 
Encyclopedia :http://www.endnotes.com/public-health-encyclopedia). Thus when researchers 
involve children as participants in clinical trials, their belief is that since all children will 
benefit when an effective intervention is discovered it is right to put a few children at risk for 
the benefit of many. This contradicts the non-consequentialists who believe that this should 
not be done at the expense of sacrificing the children‘s fundamental rights or interests to 
produce the best overall outcome. Therefore justification of informed consent according to 
the consequentialist theory would raise dilemmas for both the researcher and parent, as it 
would contradict the ethical principle of autonomy of the participants‘ right to self-
determination. 
2.3.1 The consent form 
 
An important element of informed consent is full information disclosure and according to 
CIOMS (2002), this information needs to be documented and communicated in a language 
understood by the potential participant. However data from studies on informed consent 
readability shows that consent forms and consent information templates are usually written at 
about the 11
th
 grade level or higher than the recommended 6
th 
- 8
th
 grade. This therefore 
defeats the achievement of the goal of comprehension (Briguglio, Cardella, Fox, Hopper, 
TenHave, 1995; Johnson, 1998; Friedman and Hoffman-Goetz, 2006; Knapp, Raynor, 
Silcock, Parkinson, 2009; Kithinji and Kass, 2010). Equal interest has been shown in 
determining the nature and adequacy of various consent procedures in research and clinical 
contexts (Sugarman, McCrovy, and Hubal, 1999; Flory and Emanuel, 2004; Ryan, Prictor, 
McLaughlin and Hill, 2008). For example, research has focused on the value to the consent 
process of various educational approaches and materials (brochures, videotapes, and 
information sheets) and has found that the use of such materials enhances comprehension 
(Cooley, Moriarty, Berger, Selm-Orr, Coyle and Short, 1995; Doak, Doak, Doak and Root, 
1996; Fureman, Meyers, McLella, Metzger and Woody, 1997; Agre, Stieglitz and Milstein, 
2006). Some authors however argue that in clinical research, both patients and providers 
place little weight on the value of informed consent (Lidz, Meisel, Osterweis, Holden, Marx 
and Munetz, 1983). Sugarman, Popkin, Fortney and Rivera (2001) recommended that 
informed consent should never be focused merely on the written form, which constitutes only 
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a fragment of the process, but should be considered as a document and a record that shows 
that ethically relevant information has been discussed and understood to lead to a valid and 
voluntary decision. More importantly, informed consent should be considered as an evolving 
process as opposed to a statistic one-time event. 
 
Some studies have exposed the misunderstanding that the informed consent process was 
synonymous to the consent form; and that the consent form is either seen by consenters as a 
legal document or as a contract that is signed once information has been exchanged.Getz and 
Borfitz (2002) highlight the need to distinguish the informed consent process from the 
consent form and for investigators to take an active role in ensuring that consent is voluntary 
and informed. For example, the authors noted that one out of seven adult participants reported 
that they did not even read the consent form before giving their consent. Additionally, as 
noted by Federman, Hanna and Rodrigues (2002), sometimes it is sponsors and research 
institutional risk managers who deliberately fail to treat the informed consent process as an 
on-going, interactive dialogue between research staff and research participants. It is important 
that the process involves the disclosure and exchange of relevant information, discussion of 
that information, and assessment of the individual's understanding of the discussion 
throughout the duration of the study. 
 
With child participants, one of the major ethical challenges of conducting research is the 
complexity of the informed consent process because proxy consent has to be obtained from a 
consenting parent or guardian (Federman, Hanna and Rodrigues, 2002). Certain perspectives 
from developing countries on this complexity have attributed it to the fact that the 
international ethical codes and regulations governing the informed consent process are based 
on western legal perspectives that have to be interpreted in accordance with local laws and 
procedures applicable in the host countries (Bwakure-Dangarembizi, Musesengwa, Mhute 
and Vhembo, 2012). Some authors have observed that although there is a large body of 
literature describing issues that govern practices related to informed consent and the 
insufficiency of obtaining competent adult informed consent (Benatar, 2000; Molyneux, 
Wassenaar, Peshu & Marsh, 2005).; Geissler and Pool, 2005), there is a paucity of literature 
regarding informed consent in studies involving children (Pace, Talisuna, Wendler, Maiso, 
Wabwire-Mangen, Bakyaita, Okiria, Garrett-Mayer, Emanuel, and Grady, 2005). Another 
observation by Erb and Sugarman (2000) is that the consent process has been investigated as 
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a fragmented process, unit by unit and not in its entirety. This thesis will attempt to attend to 
these gaps. 
2.3.2 The Legal and ethical challenges of conducting pediatric trials 
 
The legal definition of a child is one the challenges in obtaining parental consent in different 
settings. Therefore the next task in the review of literature was to ascertain the definition of a 
child in Botswana. Botswana law is not very clear about the legal definition of a child 
because various Acts and statutes define a child differently. For instance, according to the 
legislation of Botswana, the  Botswana Children‘s Act (1981) a child is any person under the 
age fourteen; the Botswana Adoption Act (Chapter 28-01, 1952), defines a child as someone 
below the age of nineteen; the Botswana Matrimonial Causes Act (1973) defines a child as 
someone below the age of twenty one; the Botswana Affiliation of Proceedings Act (1999) 
defines a child as someone below the age of sixteen; while the Botswana Laws Interpretation 
Act 20 (1984) makes the age of majority 21 years. In reality however, children in Botswana, 
younger than 21 as the law of majority puts it have children  as elsewhere and some have had 
to take on responsibility of their siblings due to the loss of their parents to AIDS. In this case 
such children would be considered mature minors who can give parental consent (Maundeni, 
2005).There is no evidence in the literature reviewed on Botswana‘s  specifying the legal age 
of consent to participate in research. It is therefore safe to regard the age of majority which is 
21 years as legal age to participation in research. Therefore in Botswana children under the 
age of 21 need parental permission and/or assent where appropriate to participate in research 
although some have the competence and capacity to consent. 
 
It is also important to understand the legal ethical definition of a parent in the Botswana text 
because a parent is the decision maker in the informed consent process. We scanned the 
literature to establish who is regarded as a parent in the Botswana context so as to know who 
qualifies to give parental informed consent. For this purpose, the review included a brief 
examination of authoritative writings on the matter by Fombad (2005) and revealed a 
complicated understanding of ‗parent‘. According to this author, Botswana has a dual legal 
system combining Roman Dutch Law and Customary Law and therefore, children 
guardianship rights depend on the law applied. Previously under Customary Law, women in 
Botswana had no rights regarding child custody, but since the abolition of the Marital Power 
of 2005 which regarded women as minors, both partners are now accorded equal power in a 
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family even though this has to be in a marriage registered under community of property. 
Therefore for married women, their guardianship rights to children depend on the legal 
system under which she was married. A woman married under the Customary Law or with 
the stipulation of community of property is viewed as a legal minor and requires her 
husband's consent in making decisions about the child. Secondly, under Customary Law 
unmarried fathers do not automatically have parental responsibility for their children but the 
same law treats men as the head of the family and they have guardianship rights over women 
and children. Under the same law, the child's maternal grandfather has the duty of supporting 
his unmarried daughter's child. In the opinion of Ditswanelo (1997) this situation reflects the 
view that a woman remains her father's "property" until marriage, at which time she becomes 
her husband's property. Although under Roman Dutch law, women have legal custody over 
their children (Cailleba and Kumar, 2010), under Customary Law, unmarried women fall 
under the guardianship of their fathers and if such women have children, the responsible 
parent who can give parental consent would be this grandfather. Consequently, in Botswana 
being a biological parent does not accord that individual legal representation of the child 
because in many cases the legal representative of a child could be the grandparents or other 
members of the immediate or extended family.  
 
Other twists to the understanding of ‗parent‘ are incidences of children being their own 
caretakers themselves. Such incidences are very common in Botswana as evidenced from the 
number of orphans which escalated drastically due to the high prevalence of HIV 
(Government of Botswana, 2008). In other cases children were placed under the custody of 
relatives (Maundeni, 2009). By 2007, Botswana had an estimated 137,805 orphans and 
vulnerable children (OVC), representing 17.2% of the number of children below the age of 
18 years (Government of Botswana, 2008). Over 68% of such orphans are taken in by 
female-headed households, 34% live with grandparents, and 11% are cared for by other 
relatives (UNICEF, 2005). Despite these legal categories, in this thesis the term ―parent‖ will 
refer to any legal caregiver of the child. We note that in view of the many factors influencing 
parental decision making discussed above, these differences in understanding of ‗parent‘ have 
a bearing on the validity of the consent granted. In view of the above discussions it seems 
culture and the law can have a bearing on the process of obtaining parental informed consent 
in the Botswana context. Therefore the next section examines how these two attributes are 
linked to parental informed consent. 
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2.3.3 Botswana Culture and the law 
 
Alderson (2004) makes the claim that it is well established in law that parents make decisions 
regarding child‘s rearing including decisions related to the child‘s welfare and health care. If 
we accept this claim, then the parents or legal guardians have the responsibility to consent to 
the children‘s medical research. However, in many communities, culture rather than the law 
carries greater force. For example, in Botswana, cultural practices regarding gender can affect 
obtaining valid informed consent since women are generally regarded as legal minors 
dependent on men (Brown, 1983). Unfortunately, women in Botswana are mainly the 
caregivers for the sick, the elderly and those orphaned (Maundeni, 2009). Furthermore, 
although Botswana has child-specific legislation, namely the Botswana Children‘s Act 
(1981), Chapter 28:04, Part 1, Preliminary (ss-1-2), and the Act mainly deals with children in 
need of care and juvenile offenders and at the core of the Act is the ‗Best Interest of the 
Child‘ principle. This principle requires that when dealing with children all parties concerned 
should be guided by what is in the best interest of the child. However, in pediatric research 
the protection of the subject becomes particularly critical because the parent who is a third 
party is making the decision about participation and this decision is supposed to be in the 
subject‘s best interest. Sometimes the decision might be for the parent‘s personal interest 
instead of the best interest of the child. 
 
Another safeguard for children‘s rights is the United Nations‘ Universal Declaration of 
Human Rights.  Article 1(http://www.un.org/events/humanrights/) of this declaration states 
that: ―We are all born free and equal in dignity and rights. Therefore when children are 
involved in clinical trials or research in general assent must be obtained regardless of the 
anticipated benefits from the research in order to protect the dignity, privacy and 
confidentiality of child participants. However as mentioned in Chapter One this study focuses 
only on parental consent. 
 
Regarding autonomy and the age of consent, we reviewed literature concerning the age at 
which children become competent to make decisions by themselves. Traditionally in law, 
competence has always been regarded as a function of age but the ages at which children can 
do certain things have been defined by the country‘s relevant laws, a notion which is being 
increasingly questioned in relation to matters concerning health care (De Lourdes, Larcher, 
and Kurz, 2003). According to Alderson (2004) younger children may be able to consent to 
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research only if they have enough maturity and ability to understand the benefits and risks of 
what is being proposed and its alternatives. This has introduced the concept of ‗mature 
minor‘ or ‗emancipated minors‘ to refer to groups of children whose age ranges from 14-18 
years being regarded as mature enough to give their own consent without the permission of 
the parent, particularly, where it is assumed that the decision is beneficial for the adolescent 
and he/she does not want the parents to be involved. Unfortunately many developing 
countries including Botswana have no laws defining the age at which a child can consent to 
research. 
 
2.3.4 Pediatric clinical trials 
 
A clinical trial is defined as a study in which participants are assigned to receive one or more 
interventions (or no intervention) so that researchers can evaluate the effects of the 
interventions on biomedical or health-related outcomes (National Institute of Health (NIH) at: 
http://www.clinicalTrials.gov). The interventions are determined by the study protocol and 
participants may receive diagnostic, therapeutic, or other types of interventions. In order to 
protect the best interest of children that are enrolled in HIV clinical trials, child specific-
guidelines have been laid down in many international research regulations. For example the 
conduct of clinical trials is mainly guided by the ICH-GCP guidelines (2000); specifically 
section 2.6.3 which stipulates the requirements of involving children in clinical trials. 
DeMets, Friedman and Furberg (2010), categorize clinical trials as Phases I - IV according to 
sample size as explained below: 
Phase I  clinical trials test a new biomedical intervention in a small group of human 
  subjects (20-80 subjects) for the first time to evaluate safety (dosage and side 
  effects). 
 
Phase II  studies the biomedical or behavioral intervention in a larger group  
  (hundreds) to determine the efficacy and to further evaluate its safety. 
 
Phase III  studies investigate the efficacy of biomedical or behavioral intervention in  
large groups of human subjects (several hundred to several thousands) by 
comparing the intervention to other standard or experimental interventions as 
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well as to monitor adverse effects, and to collect information that will allow 
the intervention to be used safely. 
Phase IV  studies are conducted after the intervention has been marketed. These studies 
  are designed to monitor effectiveness of the approved intervention in the  
  general population and to collect information about any adverse effects with 
  wide spread use. 
 
Research ethics requires that such clinical trials be conducted in accordance with the three 
basic ethical principles of biomedical research in humans, namely: autonomy, beneficence 
and justice. The next section discusses the research governance framework.  
 
2.3.5 Research regulatory Frameworks in the wake of HIV/AIDS 
 
The HIV/AIDS epidemic in Botswana led to an escalation of scientific and medical research 
on HIV/AIDS including pediatric HIV research in the past two decades. Unfortunately, like 
in many developing countries, the provision of a regulatory framework to guide the process 
has not kept pace with this increase (Pace, Talisuna, Wendler, Maiso, Wabwire-Mangen, 
Bakyaita, Okiria, Garrett-Mayer, Emanuel, and Grady, 2005). Although the Botswana 
Legislation Public Health Act [Chapter 63:01 (e)] (1971) mandates the Ministry of Health to 
promote, regulate, and carry out research in connection with prevention and treatment of 
human diseases and to prepare and publish reports and statistics or other information relative 
to public health and HIV clinical trials, this Act does not provide for guidelines and 
regulations for ethical conduct of this research. 
 
Effective regulatory frameworks are critical for the conducting of clinical trials involving 
human subjects given that clinical trials have the potential to invade the right to personal 
autonomy and personal dignity of participants and also carry risks. Unfortunately the 
regulatory framework for the conduct of clinical trials in Botswana is very basic at the 
moment.  Reference to clinical trials is only found in Part IV, Regulation 18 (1-20) of the 
Botswana Drugs and Related Substance Act of 1992. Clinical trials are also conducted in 
accordance with Botswana Ministry of Health, Health Research Clinical Trials Guidelines 
(2008) that guides the National Research Ethics Committee on how to review and approve 
research proposals and the Botswana Ministry of Health Guide-Consent Form (2005) used as 
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a template to guide researchers conducting both research involving adults and children. 
Regarding the involvement of children in research Section 3.4.6 of the Botswana Clinical 
Trials guidelines (2008) states that: 
“When children are involved in research, the regulations require that 
the assent of the child and the consent of the parent(s) must be sought. 
Given that children have not reached their full intellectual and 
emotional capacities and are legally unable to give valid consent, 
involving children in research requires the permission of their parents 
or legally authorized representatives. The Health Research and 
Development Committee (HRDC) will determine whether the 
permission of both parents is necessary, and the conditions under 
which one parent may be considered "not reasonably available". (Page 
26) 
 
However, in the literature reviewed, there is no evidence of explicit national guidelines for 
research involving children. Additionally, Botswana does not have national guidelines 
specific for HIV clinical trials research however international guidelines are adapted to 
Botswana. Unfortunately, as noted earlier, the adapted international guidelines are based on 
western laws that need to be contextualized to the local setting. It is however important to 
note that although Botswana recognizes the rights of the child and has ratified to two 
important international conventions dealing with the rights of the child namely, the United 
Nations Convention on the Rights of the Child (CRC), (1989) and the African Charter on the 
Rights and Welfare of the Child (1990), these have not been translated into law and policy 
(Fombad, 2005). These conventions are very important as far as the children‘s rights 
especially in the context of HIV/AIDS testing and treatment are concerned regarding 
children‘s rights to informed consent.  Most important are Article 3 of the CRC and Article 4 
of African Charter which emphasize that the short and long term best interests of the child 
must be the primary consideration in all decisions and actions that may affect the present and 
future of the children.  Zuch, Mason-Jones, Mathews and Henly (2012) report that South 
Africa is one of the few countries in Africa  that has a legislation protecting children 
participating in health-related research under the law through the South African National 
Health Act, No 61, (2004) implemented on March 1, 2012. The law mandates active consent 
from a parent or legal guardian for all research conducted with research participants under the 
age of 18 years. Such legal acknowledgment of parental authority and responsibility is also 
needed in Botswana. Considering all what has been so far discussed about the requirements 
and informed consent and the inadequacies in the process, the next section discusses the 
factors that affect parental informed consent  
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2.4 Factors affecting Parental informed consent 
 
Parental informed consent unlike adult informed consent is unique because it focuses more 
on parental decision making and the assumption that parents know their children intimately 
and care deeply for their welfare. Some consensus has emerged on the basic ethical 
requirements for pediatric clinical trials. First and foremost, Guideline 9 of CIOMS states that 
children must be protected from unnecessary research risks, especially since they are 
considered a vulnerable population who lack adequate capacity to understand and evaluate 
research risks for themselves before participation in research (CIOMS, 2002). At this point, it 
is important to differentiate between the term competence and capacity when it comes to 
parental informed consent. Beauchamp and Childress (2001), describe the term competence 
as a legal term which assumes adults to be competent and able to make decisions for 
themselves unless proven otherwise. Thus, the law considers children as incompetent and 
dependent regardless of their maturity until the legal age of majority. Capacity on the other 
hand is described as the ability of an individual to make decisions if he/she can understand 
the problem, risks and benefits of alternatives and can express a choice (Kipnis and Gerhard, 
1995). Therefore the term capacity could be a more useful description to describe an 
individual‘s ability to make decisions about participation in research, because although 
parents may be legally competent, they may possess inadequate decisional capacity to give 
informed consent on behalf of the child especially when burdened with a child suffering from 
a chronic disease like HIV. This is likely to destabilize the parent‘s emotional stability and 
rendering the parent vulnerable. This situation could be considered as a limitation in applying 
informed consent directly in pediatrics. However, courts recognize the parent‘s rights to make 
decisions (proxy consent) for minor children based on parental autonomy since all 
responsibility of for the child‘s care lies with them (Cooper and Koch, 1996).  
 
Despite the legal rights, parents who make decisions on behalf of the child must be 
committed to the child‘s interests, must have adequate knowledge and information, emotional 
stability and ability to make reasoned or rational judgments (Childress, 1997). Therefore 
different approaches like ‗best interest of the child‟ and ‗rational-parent standard‟ are 
applied as the theoretical basis for parental decision making.  The best interest of child 
standard weighs quality of life considerations, whereby the parent has to take into account the 
potential benefits of the intervention and the real and potential burdens of the treatment or 
research as judged by a reasonable person (Beauchamp and Childress, 1994). The rational-
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parent standard requires the parent to demonstrate ability to prioritize options for the child 
using the parent‘s own coherent and consistent value system (Cooper and Koch, 1996). 
Therefore trial staff need to take into account these standards in determining and facilitating 
valid parental informed consent.  
 
As mentioned in Chapter One section 1.0, when parents agree to child enrolment they are not 
giving informed consent but informed ‗permission‖ (Zawistowski, 2003 p.408).The 
requirements for parental permission serve as an ethical obligation for trial staff to respect 
and protect vulnerable individuals (Faden and Beauchamp, 1986). This makes informed 
consent to have a limited application in pediatrics but rather parental permission applies. 
Parental permission ensures that the rights and welfare of children that participate in clinical 
trial research are protected and confirms that parents have control over their children‘s 
decisions and that the decisions are consistent with their values, interests and preferences 
(Fombad, 2005). Ross (2006 p.200) provides three additional attributes that qualify the 
parents to be the best representatives of the child regarding granting informed consent 
namely; (i) parental decision promotes children‘s best interests (ii) parents have the right to 
raise their children according to their own standards and values without state intervention, 
and (iii) they have the capacity to do a risk/benefit analysis before consenting to their child‘s 
enrolment into research studies. However, other than the law, competency and decisional 
capacity of the parent, there are a number of other factors that range from personal to social-
environmental that can cause barriers in voluntary decision-making. For example, although 
literature shows that parental decision–making is likely to be based on the parent‘s cognitive 
and emotional reaction to the information provided (Faden and Beauchamp, 1986), some 
empirical studies have shown that often personal and cultural values play a major role in 
decision-making (Frimpong & Monash, 2007; Marshall, 2006; Shaibu, 2007) provided 
evidence of family and community participation in decision making in many developing 
countries. Other specific factors identified in the literature (Kyriaki, Panagiotou, 
Katsaragakis, Tsilika & Parpa, 2009 p.49) that may influence decision making include:  
 
 parents‘ stress due the illness of the child 
 trust of physician‘s assessment rather than parents own assessment of risks and 
benefits 
 prospects of payments or reimbursements for participation 
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 access to improved medical care 
 practical advantages like transport, a meal, or a chance to visit urban areas  
 
This review also came across several recently published studies that shed light on why 
parents accept or decline to enrol their children in medical research and how they understand 
and balance risks against potential benefits (Tait, Voepel-Lewis, Malviya, 2003a; Greenley, 
Drotar, Zyzanski and Kodish; 2006; Tait, Voepel-Lewis, Malviya, 2003b; Rothmier, Lasley 
and Shapiro, 2003; & Hulst, Peters, van den Bos, 2005). These studies found that many 
parents had inadequate understanding of the information presented to them during the 
informed consent process. The studies also showed that  factors like age, higher education 
level, lower anxiety, greater perceived clarity of information, greater degree of listening to 
the explanation of the research, greater degree of reading the consent document and 
perceptions of the study‘s importance, risks and benefits were significantly associated with 
greater parental understanding. Another example from a children‘s leukemia clinical trial 
showed that, approximately half of the parents failed to understand random assignment at the 
time of enrolment and even six months later (Greenley, Drotar, Zyzanski and Kodish, 2006). 
However, factors in the same study factors like being  a member of a majority ethnic group, 
higher socioeconomic status, presence of a nurse during the informed consent, parental 
reading of the consent document and physician discussion of specific components of the 
randomized controlled trial were associated with better understanding. 
 
A study that compared parents who consented to their child‘s research participation and  
those who declined,  showed that the parents who exhibited less uncertainty in their decision 
making, were more trusting of the medical system and believed that the environment in 
which the consent was sought was less pressured (Tait et al, 2003b). Rothmier, Lasley and 
Shapiro (2003) found that although many parents exhibit altruistic motives such as a desire to 
contribute to medical knowledge, the most compelling motive for parents accepting to enrol 
their children is learning more about their child‘s illness, as well as access to care. While 
Hulst, Peters and van den Bos (2005) found payment for participation not to play a significant 
role in parental decisions, obtaining free medications gained importance as the 
socioeconomic status declined; and that although the severity of the child‘s illness did not 
decrease the probability of obtaining parental permission, parents who perceived that the 
research would be burdensome to the child were significantly less likely to consent. 
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Additionally, Lindegger and Richter (2000) cite social desirability as another factor that that 
can affect parental consent. The author explains social desirability as the tendency of 
volunteers to behave in what they deem socially acceptable in order to win a favour or avoid 
displeasure of the researcher as particularly prevalent in situations where differences in power 
and status exist between the consenter and parent particularly in poor resourced settings. 
Meisel and Roth (1983) caution that assessments of understanding test short-term memory 
other than tests of understanding rendering their findings unreliable. Nevertheless, the 
Declaration of Helsinki (1964) dictates that volunteers must have the freedom to make a 
decision about participation without any form of coercion as a fulfillment of the ethical 
principle of autonomy. On the basis of the many factors identified above, obtaining valid 
informed consent has been conceptualized by Lindegger and Richter (2000) as a framework 
of four overlapping core elements namely; information disclosure, understanding, social 
desirability, and freedom from coercion.  
 
In conclusion, the big challenge for trial staff to try and minimize these negative influences 
during the informed consent process. This thesis will examine the factors that affect obtaining 
parental informed consent for HIV pediatric studies conducted in Botswana and use the 
findings to develop a model that can enhance the process that suits this context. The next 
section examines literature on the nature of each of the steps of this process.  
 
2.5 Information disclosure process 
 
As indicated in the previous section, obtaining valid informed consent has been 
conceptualized by Lindegger and Richter (2000) as a framework of four overlapping core 
elements namely; information disclosure, understanding, social desirability, and freedom 
from coercion. The first step in the informed consent process is the provision of full and 
transparent information. According to the Nuffield Council on Bioethics (1995), this 
information protects research subjects from acts of deception, manipulation, deliberate 
misdescription of what is proposed, lack of disclosure of material facts, or conﬂicts of 
interest. Gaps in how information is communicated to potential have been identified. For 
instance, in a multi-center study by Williams and Zwitter (1994, p. 905) that asked research 
investigators about information they had disclosed to potential participants, 58% indicated 
having disclosed full information, 42% only gave information on the proposed treatment, 
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while 12% had not informed patients about the trial prior to randomization and 38% did not 
tell the patients about randomization while 5% did not seek consent at all. In the same study, 
however  at least more than 90% of  the investigators had provided the participant with a 
copy of the consent form, an opportunity to read before coming for the next visit and 
information about risks. However less than 56% of the investigators had emphasized 
randomization and only 8.5 % had made a formal assessment of understanding. This shows 
that some key information may not be communicated at all.  
 
In response to this gap, three standards of disclosure were developed as a guide to ethical 
communication of information (Beauchamp and Childress, 1994, p. 148). Although these 
standards were developed for treatment purposes, they could also apply to HIV clinical trials 
settings which combine treatment and research. These standards include: (i) the professional 
practice standard, (ii) the reasonable person standard and (iii) the subjective standard. The 
professional practice standard is determined by the medical community and it emphasizes the 
patient‘s best medical interest.  This standard is frequently criticized because it assumes that 
the physician is capable of determining what is in the patient‘s best interest implying 
paternalism.  The reasonable person standard supposes a ―hypothetical reasonable person‖ 
(Beauchamp & Childress, 1994, p.148) and takes into consideration the patient‘s need for 
information, rather than the physician‘s opinion of the patient‘s needs. This shows respect for 
the patient‘s autonomy and his/her right to self-determination which is central to obtaining 
valid informed consent.  The difficulty with this standard is that it is difficult to determine 
what a reasonable person is. According to Beauchamp and Childress (1994), the most 
preferred standard of information disclosure is the subjective standard.  This standard 
emphasizes that for the principle of autonomy to be maximized, the level of disclosure of 
relevant information should be tailored to the person‘s individual needs.  In addition, Argard 
(2005, p.634) acknowledges the difficulty associated with setting strict standards for 
information adequacy across different clinical and research contexts and recommends that the 
subjective standard procedure could be the best since it acknowledges that the information 
provided should be tailored to match the specific information needs of the potential 
participants taking into account their culture, values, beliefs and health status. However, 
Pedroni and Pimple (2001 at: http//www.poynter.indiana.edu) added  that, in practice, the 
best way to facilitate informed consent may be to design consent forms and other 
informational materials to satisfy a reasonable person standard, supplemented by 
conversations intended to elicit and answer any questions that are not otherwise addressed. 
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Therefore, information should be presented at a level that the person understands, based on 
their intellectual ability, and taking into consideration cultural differences, functional 
limitations and language barriers. 
 
Certain basic elements have to be disclosed in order to fulfil the requirement of full 
information disclosure. For purposes of this thesis, these elements are summarized in Table 
2.2 and will be used to assess recall of information and comprehension in Chapter Three. 
 
Table 2.2: Basic elements of informed consent 
 
 
 Basic elements of  informed consent 
1 A statement that the study involves research; an explanation of the purposes of the research and 
the expected duration of the subject's participation; a description of the procedures to be 
followed; and the identification of any procedures which are experimental 
2 A statement that taking part is voluntary; refusal to take part will involve no penalty or loss of 
benefits to which the subject is otherwise entitled; and the subject may stop taking part at any 
time without penalty, or loss of benefits to which the subject is otherwise entitled 
3 A description of any reasonably foreseeable risks or discomforts to the subject from the study 
procedures - these may be potential physical, psychological, legal or social risks 
4 A description of any benefits to the subject or to others which may reasonably be expected from 
the research 
5 A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject 
6 A statement describing the extent, if any, to which confidentiality of records identifying the 
subject will be maintained 
7 For research involving more than minimal risk, an explanation as to whether any compensation is 
available for injury and an explanation as to whether medical treatments are available if injury 
occurs, and if so, what they consist of, or where further information may be obtained 
8 An explanation of whom to contact for answers to pertinent questions about the research and 
research subjects‘ rights, whom to contact in the event of a research-related injury to the subject, 
and a 24 hour phone number for the PI. 
Source: ICH-Harmonized Tripartite Guideline (Guideline for Good Clinical Practice E6 (R1, 1996) 
 
As shown in table 7.2, consent forms carry large amounts of information in order to fulfil the 
legal and ethical requirements. However the quality and quantity of information to be 
disclosed depends on the objective of the investigator or person designated by the 
investigator to fully inform the subject of all relevant information, for the subject to 
reflectively select what s/he wants and for the investigator to execute what has been selected 
(ICH-GCP 2002, section 4.8.5). Some international regulations have added more to the basic 
elements. For example, CIOMS (2008), guideline 19 requires more details namely, the 
alternative procedures or treatments available; what responsibility, if any, lies with the 
 
 
 
 
  
39 
 
investigator to provide medical service to the subject; and provision of free treatment for 
injuries related to research. Studies that have analyzed inclusion of these elements found that 
majority of forms include all the elements and participants were aware of these elements. For 
instance, a study by Silverman (2001) that analyzed 267 Phase I clinical trials consent forms 
showed that 99% of the participants knew that the trial was research, 92 % knew that the 
purpose was safety testing, 99% knew that they had a right to withdraw, 67% knew death as a 
risk and 84% knew that there were unknown risks while only 5% knew cure as a possible 
benefit. 
Federman, Hanna and Rodrigues (2002) however caution that the idea of the process of 
informed consent as a provision for sharing information and educating the research 
participant has fallen prey to the idea of  being a document to be signed by the participant, 
constructed by the research sponsor or site to comply with the regulations. The same authors 
further elaborate that, in clinical research, these documents typically include lengthy 
descriptions of diagnoses, prognoses, treatment alternatives, risks and benefits of the 
alternative treatments, the risk of no treatment, the right to refuse, the commitment to provide 
care even in the face of refusal, and the injury compensation policy of the sponsoring 
institution. These details seem to indicate that the purpose of the document is to be compliant 
with regulations while the spirit of the document is clearly the articulation of every possible 
danger so that any subsequent participant complaint can be countered with the argument that 
the participant had been informed and had accepted this risk. Therefore research investigators 
have to be cautious and sensitive to these intentions by those who prepare the consent forms. 
 
Regarding the critical issue of language, CIOMS (2002) and the National Consensus 
Conference (1997, p: 32) recommend that information provided to a participant about the 
study be provided in a language he/she can understand, at their level of comprehension and 
be allowed time to ask questions, obtain answers and to reﬂect and give due consideration to 
their decision. Although this information is normally given in a written document, in the case 
of illiterate participants or those who speak a language with no written form, it is given 
verbally. Often consent forms are translated from one language to one that a participant is 
comfortable with. An analysis of the comprehension of a survey translated into 11 languages 
(Yuling and Landreth, 2009) concluded that translations must reflect the cultural values and 
social practices of the research setting. For example, issues like the general linguistic rules 
governing the use of the language for information exchange, the language-specific rules, such 
as the sentence structure or discourse structure of a language that may be different from the 
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language originally used to prepare the document e.g. English language. This can result in 
different presentation of information in a target language and the cultural norms of doing 
certain things in a given culture, such as appropriate level of politeness in expressing a 
message. If cultural norms and social values are not observed there is a danger that the 
information conveyed to participants may be incomplete or misunderstood. 
 
The nature of the process of obtaining valid informed consent has been considered as both a 
legal and ethical obligation to distinguish, the legal indemnity stems from the understanding 
between the researchers and volunteer (Richter and Lindegger, 2002, p.317). That is why 
Faden and Beauchamp (2003) refer to the ethical approach as signifying the autonomous 
authorization based on understanding and absence of control by others, and the legal 
approach as the social rules of consent based on legal authorization as determined by the 
rules. These two obligations lead to different decisions and guidelines when it comes to 
information disclosure. Faden and Beauchamp (cited in Richter and Lindegger, 2000 p.315) 
observed that commonly, it is primarily the legal approach that receives focus in practice with 
emphasis on the documentation of itemized checklists of what is included in informed 
consent. However, Meisel and Kuczewski (1996, p.2523) noted that regarding the quality and 
quantity of information to be disclosed to a volunteer, the legal approach would be concerned 
with liability necessitating all the information to be disclosed. The ethical approach however, 
would be concerned with the moral facilitation leading to shared decision-making but this 
approach can be undermined by excessive information. Marshall (2004) doubts whether  
providing consent forms that contain all the defined key elements necessarily offers the 
would-be participants the opportunity to be fully informed and able to make autonomous 
decisions. Consent information is usually represented in a written document; the next section 
examines the qualities of this document that facilitate decision making and valid consent. 
2.5.1 Readability and comprehension of the consent form 
 
When parents are presented with the option of enrolling their children in HIV clinical trial, 
they have to undergo a consenting process for the investigators to obtain their valid informed 
consent. In most cases the informed consent information is presented in a written document 
called an informed consent form which the parents must read or it must be read to them to 
understand the information provided and make an informed decision.  Ability to read and 
understand a text requires a combination of literacy skills and a certain level of formal 
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education and the importance of literacy and education as part of the social and economic 
determinants of health is well documented (WHO: http://www.who.int 
/topics/social_determinants/). The Ad Hoc Committee on Health Literacy, 1999, (cited in 
Kickbusch, 2001, p.293) stresses that education influences an individual‘s ability to navigate 
the health care system, to interpret health information and to communicate effectively with 
physicians and other professionals. However it also notes that most health professional are 
not aware of their patient‘s low literacy levels or that most patients are embarrassed to 
indicate to them that they have not understood. There is need to assess individual literacy 
competence in order to judge levels of comprehension of information provided. 
 
Literacy levels are related to public health outcomes and literacy is context and content 
specific. Therefore in the health context we talk of health literacy.  A distinction needs to be 
made between general literacy and health literacy. Health literacy has been defined 
differently defined by many authors but they all capture the issues of the context in which the 
health literacy demands are made and the skills that people bring to that situation. For 
example,  Ratzan& Parker (2000) cited in Nielsen-Bohlman, Panzer and Kinding (2004 p.32) 
define health literacy as ― the degree to which individuals have the capacity to obtain, process 
and understand basic health information and services needed to make appropriate health 
decisions‖. Nielsen-Bohlman, Panzer and Kinding (2004 p.37) associate this process to a 
collection of skills namely; an individual‘s ability to read, write and understand written 
language that is familiar. The same author also associates it to back ground knowledge of 
print literacy; reading or text literacy, related to characteristics of the text being read, such as 
complexity and format and functional literacy as well as the use of literacy in order to 
perform a particular task. Therefore, Rudd (2003) cited in Nielsen-Bohlman, Panzer and 
Kinding (2004 p.32) argues that health literacy is a shared function of the individual‘s 
education system, culture, societal factors and the health system.  
 
Various methods are used to assess readability and comprehension of informed consent 
forms. The readability of consent forms can be determined using a wide range of readability 
formulas. These are formulas commonly used to predict the ability of a reader to read and 
comprehend a written text. The formulas can only be used on text written in English.  
The scores generated from these formulas are an indication of how difficult or easy it is for a 
reader to read and understand a text and the number of years of education that a person needs 
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to be able to understand the text on the first reading. In general, readability is determined by 
analysing word and sentence length in the text. Online computer software programs like the 
online utility :http://www.online-utility.org/english/ that use a combination of formulas 
namely; the Flesch-Kincaid Reading  Ease (FKRE)  and Flesch-Kincaid Grade Level 
(FKGL), Gunning-Fog index, the Simplified  Measure of Gobbledygook (SMOG) and Fog 
formulas exist for the purpose. Johnson (2004) noted that the formulas work mainly by 
measuring the number of words in a sentence and the number of letters or syllables per word 
as well as the semantic factor (the difficulty of the words) and the syntactic factor (the 
difficulty of the sentence). The Flesch Kincaid Reading Ease Scores range from 0-100, the 
higher the score the easier it is to read the text. Generally, scores below 30 are very difficult 
to read and can only be read by individuals that have graduate education. Scores above 90 are 
very easy to read and can be read by individuals with a fifth grade education. Texts written 
for the public are recommended to be at 6th -8th grade reading level (Johnson, 1998).  
However the message behind all these formulas is that if you use shorter average sentence 
lengths and fewer big-lettered words, you can increase the readability level, the speed and 
ease of reading. 
 
Regarding the use of the above methods, Chall (1995) however cautioned that, although these 
methods are easy to use and have the ability to broadly predict text difficulty, they cannot be 
regarded as a precise final measure. Thus factors beyond those measured by formulas need to 
be considered. Bruce, Rubin and Starr (1981) argue that readability factors mainly deal with 
sentence length and word difficulty, but miss out on discourse cohesion, number of 
inferences required, number of items to remember, complexity of ideas, rhetorical structure, 
dialect, and background knowledge required. The same authors also note that because 
formulas are measurements based on a text isolated from the context of its use, they cannot 
reflect reader-specific factors such as motivation, interest, values and purpose. 
 
The recommended reading age of consent form is 6-8th grade based on the American reading 
age system (Johnson, 1998). For subjects in Botswana these recommended levels may not 
apply because of differences in education systems and language. Furthermore, although the 
adult literacy level in Botswana is currently at 83% , it means  that about 17% of the adult 
population performs below basic reading level and do not have the  proficiency necessary to 
perform more than basic literacy activities (Maruatona,  Cervero and Ronald, 2004). The 
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question therefore for Botswana would be; how can evidence derived from American based 
formulas be relevant to respondents in Botswana settings with different linguistic, 
educational, literacy, cultural and social practices? In the absence of appropriate readability 
assessment tools, the readability formulas provide an estimation of the challenges for readers 
in Botswana and an indication of the levels of difficulties in understandability of informed 
consent information. 
 
The result of manipulating consent forms to meet regulatory requirements is increased length, 
complexity, linguistic sophistication, and generally daunting nature of such documents. 
Consequently, consent forms are not conducive to increasing understanding, but rather serve 
to overwhelm participants. Hochhauser (2004) identified certain factors to consider when a 
reader reads a text, and one of these is the difficulty of assembling words into meaningful 
sentences. So another area of concern we found in the literature is the readability and 
comprehension of the consent form. When the information about the study is disclosed using 
a written informed consent document, the readability and comprehension of the text is very 
critical for conveying study information to enable a potential participant to arrive at a 
decision concerning their willingness to participate in it. Readability refers to the ease with 
which a written text can be read and understood. Johnson (2004) uses it to refer to all the 
factors that affect success in textual reading and understanding including the interest level 
and motivation of the reader, the legibility of the print, and the complexity of words and 
sentences in relation to the reading ability of the reader. The same author also noted that the 
determination of readability addresses the problem of matching individual reading levels to 
the difficulty of the text. Ideally, the goal is to develop consent forms that are both short and 
written in simple and comprehensible language so that they facilitate a greater level of 
understanding and enable potential subjects to make truly informed decisions about research 
study participation. 
 
The South African Department of Health (2006) observed that consent forms often present 
highly complex information that must be understood by patients. The complexity of these 
forms is a major barrier to comprehension for many research volunteers especially those with 
low literacy skills. Some of the barriers to comprehension identified include the form‘s 
excessive length, lack of adequate time to read the form, high reading levels, and poor format 
and layout of the form; barriers which Hochhauser (2004) rightly says increase risks to both 
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the researcher and participants, lead to therapeutic misconceptions, poor enrolment and 
failure to follow up. 
 
2.5.2 Researcher/participant communication models 
 
Physician -participant interactions have been studied and patterns of behavior have been 
theorized in the form of models mostly in clinical settings but only a few studies have looked 
at the process in research settings. For example, Kodish, Michelle, Robert, et al. (2004) 
observed that physician-patient interactions in clinical trial settings  differ from the  
researcher-participant ones in that in the former there is a greater need to discuss with 
patients their potential concerns, examine their feelings and expectations from the  treatment 
plan. This is because the objective of the physician-patient interaction is for the physician to 
provide the patient with all relevant information, for the patient to reflectively select the 
medical interventions he or she wants and for the physician to execute the selected 
interventions and provide explanations and feedback to enable informed decision-making 
(Brown, Weston and Stewart (1989).  
 
A great deal of variance in physician-patient communication styles mainly in clinical settings 
has been observed (Korsch, Freemon, and Negrete (1971) and this can compromise the 
success of the communication process. The basic principle that governs informed consent is 
autonomy or respect for persons which have become symbols of integrity (Beauchamp and 
Childress, 2001). Several models of informed consent linked to ethical theories have been 
proposed and are used to explain how the informed consent process is integrated into the 
ethical principle of autonomy and how they are applicable to autonomous decision making in 
the informed consent practice (Delany, 2005). These models namely,  the ‗Event Model‘ 
(Wear, 1998), the ‗Transparency Standard Model‘ (Brody, 1989), and the ‗Shared Decision 
Making Model‘ (Charles, 1997), have been observed not to promote autonomy as they are 
essentially prescriptive, describing what the physician should say in  communication 
encounters and dictate the elements to be complied with. On the other hand, two other models 
of informed consent process namely; the ‗Process Model‘ (Lidz, Appelbaum & Meisel, 
1988); and the ‗Conversation Model‘ (Katz, 2000); cited in Delany (2005, p.73-84) were 
found applicable to autonomous decision-making because they promote thinking and 
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reflection on the value and meaning of autonomy. A brief overview of the Process Model and 
Conversational model is given below. 
 
(i) The Process Model 
 
Developed by Lidz, Appelbaum & Meisel (1988), this model this model sets out three 
requisites for successful decision-making namely; the recognition and delineation of roles; 
acknowledgement of the differences in values and beliefs about health and illness; and 
clarification of the relative values and expectations held by those involved in the informed 
consent process about illness, treatment or research. Thus this model recognizes the 
patient‘s/participant‘s expert knowledge of the history and context of their problem and 
regards them as part of the treatment or research team. The model also promotes mutual 
sharing of information, calls for respect for autonomy and time to reflect on proposed 
options, risks, and benefits during the informed consent process.  
 
(ii)  The Conversation Model of Interaction 
 
Developed by Katz (2000), this model marks a shift from the traditional paternalistic 
prescriptive models. It involves active reflection on the values, motivations, expectations and 
interests that may influence implementation of the informed consent process (Delany, 2005). 
This thesis will adapt this model because of its capacity for recognizing that ‗meaningful 
clinical conversation rests in a particular understanding and assumption of patient/participant 
autonomy and right to self-determination.  
 
As a guide to describing patient-doctor relationship in communicating information, four 
models were developed by Emanuel and Emanuel (1992). Although the models do not 
specifically refer to the principle of autonomy and are mostly applied in treatment settings, 
they reflect the necessary communication methods and the need for upholding autonomy in 
the doctor-patient relationship so are applicable to clinical research settings like HIV clinical 
trials. These models include the ‗Paternalistic model‘, the ‗Informative model‘, the 
‗Interpretive model‘ and the ‗Deliberative model‘ used to explain the assumptions made by 
physicians or researchers during the interaction process of obtaining informed. The models 
are summarized in Table 2.2 below and a brief overview of each model is given. 
 
 
 
 
  
46 
 
The section below gives a brief interpretation of the assumptions of each of the above 
models.  
 
(iii) The paternalistic model 
 
As shown in Table 2.2, this model is seen as the traditional one-way practice which assumes 
that the physician and patient share common values and the physician acts in the best interest 
of the patient to restore the patient's health or alleviate pain using selected information that 
will encourage the patient to consent to the intervention. This would be considered paternalist 
but it depends on the characteristic of the patient. For example, patient preference of the 
physician style, some patients may prefer an informative physician while others may prefer 
not to know. Emanuel and Emanuel (1992, p. 222) also suggested that age, gender, socio-
economic status, education and type of diagnosis may affect the extent to which patients play 
an active role in information disclosure interaction process. 
 
(iv)  The informative model  
 
Table 2.2 shows that this model assumes that participants know their own values and 
preferences and the physician just provides the means (information) for the patient to exercise 
control and make an informed decision. This model treats the patient as a consumer, thereby 
allowing them choice, therefore it could be said to facilitate autonomous decision making. 
 
(v) The interpretive model 
 
This model as shown in Table 2.2 assumes that participants may have conflicting or not fully 
formed values that may require clarification. The physician in this case acts as an advisor or a 
counselor to provide both factual information and help to interpret relevant patient values. 
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Table 2.3:  The four models for guiding physician-patient communication 
 
Source: Emanuel & Emanuel (1992, p.222)  
 
(i) The deliberative model  
In this model physicians play the role of participant‘s teacher or friend and provide factual 
information and the values underlying the choices with the assumption that participant‘s 
values are open to development. This means the physician helps the participant to determine 
and choose the best health related values that can be realized. In this case the participant‘s 
autonomy will comprise of moral self-development and determination in decision–making 
which are relevant components of autonomy. This thesis will draw from each of these models 
in the development of the model for obtaining parental informed consent. 
The next section reviews literature on the understanding or comprehension of the information 
disclosed. 
 
 Models 
Informative Interpretive Deliberative Paternalistic 
 
Patient Values 
Defined, fixed 
and known to the 
patient 
Conflicting or not 
fully formed values 
that may require 
clarification. 
Open to 
development and 
revision through 
moral discussion 
Objectives 
shared by the 
physician and 
patient 
 
 
Physician 
Obligation 
Providing factual 
information and 
implementing 
patient‘s selected 
intervention 
Elucidating and 
interpreting relevant 
patient values as 
well as informing 
the patient and 
implementing the 
patient‘s selected 
intervention 
Articulating and 
persuading the 
patient of the most 
admirable values as 
informing the 
patient and 
implementing the 
patient‘s selected 
intervention 
Promoting 
the patient‘s 
well-being 
independent 
of the 
patient‘s 
preferences 
 
Conception of 
patient‘s 
autonomy 
Choice of control 
over medical care 
Self-understanding 
relevant to medical 
care 
Moral self-
development 
relevant to medical 
care 
Conforming 
to objective 
values 
Conception of 
patient‘s  roles 
Competent 
technical expert 
Counsellor or 
advisor 
Friend or teacher Guardian 
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2.5 Comprehension of information  
 
Literature on adult individual‘s understanding of and decisions about their own participation 
in research is considerably more extensive than the corresponding literature on parents 
making decisions about their child's participation in research. The reasoning that the 
decisions that adults make on their own behalf are generally relevant to the understanding of 
the information provided. However, many studies (Ruccione, Kramer, Moore and Perin, 
1991; Levi, Marsick, Drotar and Kodish, 2000) have reported that parents may have anxieties 
associated with making decisions on behalf of their child, especially one's sick child and that 
this may put particular stress on an adult's comprehension, reasoning, and decision-making 
capacities. 
 
Most research evaluating people's understanding of the difference between research and usual 
clinical care has involved adults consenting to research participation in their own right. It 
generally indicates that avoiding or overcoming the therapeutic misconception can be a 
formidable challenge. As Appelbaum, Roth, Lidz, Benson and Winsdale (1987) observed, 
subjects have the ability of maintaining their therapeutic misconceptions, while they gave the 
appearance of having a good general understanding of the study. Other studies also suggest 
that research participants may have difficulty understanding the purpose of research 
(Daugherty, Ratain, Grochowski, Stocking, Kodish, Mick and Siegler, 1995). A review of 61 
studies about attitudes toward clinical trials by Edwards, Lilford and Hewison (1998) found 
that people mentioned self-interest more often than altruism as the reason for participating in 
trials. Often, however, the specific questions and methods were not fully described to provide 
a clear picture of the results. These authors also cite three studies from the 1990s that 
reported a near majority or majority of physicians believed that research participants did not 
understand the information given them or did not realize that they were participating in 
research. 
 
Furthermore, other studies have suggested that research participants frequently have 
expectations of benefit (Daugherty et al., 1995, Schutta and Burnett, 2000). Likewise, 
although participants may understand and approve the knowledge-generating purpose of 
research in general, participants may view their own participation primarily in terms of 
benefit to themselves (Cassileth, Lusk, Miller and Hurwitz, 1982; Bevan, Chee, McGhee and 
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McInnes, 1993; Aby, Pheley and Steinberg, 1996; Hutchison, 1998). An interview survey 
conducted by the Advisory Committee on Human Radiation Experiments (ACHRE, 1995) on 
a fairly large sample of more than 1800 patients at 19 health care institutions reported a 
number of interesting findings about people's understanding of research participation. A third 
of those surveyed believed that patients who participated in medical research usually or 
always benefited medically compared with those who did not. About two-thirds of the 
patients who had participated in research indicated that they had done so to obtain better 
treatment; a similar percentage reported that being in research gave them hope. The 
researchers, however, reported that patients who had been in diagnostic, epidemiologic, or 
survey research were more likely to differentiate between research and treatment than those 
who had participated in studies testing a potentially therapeutic intervention. 
 
Other reports have shown that some patients consider research participation may not 
necessarily result in improvement in their condition from the intervention being tested, but 
they may expect to receive better diagnostic evaluation, closer medical monitoring and 
follow-up, and more information about their condition (Mattson, Curb, and McArdle 1985; 
ACHRE, 1995; Yoder, O'Rourke, Etnyre, Spears and Brown, 1997; Madsen, Holm, 
Davidsen, and Riis, 2000). For example, for Danish patients in a trial of interventions for 
inflammatory bowel disease, an important reason for participating in the research was ―the 
expectation of being ‗a special patient' during the trial‖ (Madsen et al., 2000, p. 463). 
 
According to Meisel and Roth (1983), the following factors have been observed as 
determinants of participants‘ ability to comprehend information: 
 Lack of provision of psychological information required to make informed decisions 
such as recognition of personal value systems that allow potential participants to 
evaluate information. 
 Separation of patients‘ understanding and judgment (objective) of facts from their 
attitudes or feelings (subjective) about those facts. 
 Failure to assess comprehension of implications as well as facts. 
 Impact of emotional factors on participants‘ ability to evaluate information (anxiety 
arising from excess information or apprehension of risk). 
 Giving matters related to legal liability priority and not what the participant would 
like to know or what they consider would be helpful to have been told. 
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Therefore in addition to factors that influence readability, personal factors like values, 
emotional factors, attitudes and feelings should also be considered when seeking informed 
consent as they may influence comprehension. 
 
Beauchamp and Childress (2001) suggested that information given to participants requires a 
level of adequate comprehension and appreciation for meaningful deliberation about a 
decision. The authors refer to this as substantial understanding which means that autonomous 
decisions must reflect what one intends to do; which is only possible if the individual 
adequately comprehends the relevant information. Marshall (2006) provided evidence from 
empirical studies on informed consent which suggest that even when provided with 
information about the nature of research, participants systematically misinterpret the 
risk/benefit ratio of participating in research because they fail to understand the underlying 
scientific methodology.  In such cases, what the participants actually authorize differs 
substantially from what they intend to authorize, and thus informed consent is frustrated. For 
example, Pace et al. (2005) found that although most respondents in comprehension of 
consent to a randomized trial among HIV positive individuals in Thailand said they were well 
informed, only one third correctly reported that half of the participants would receive the 
experimental therapy. Such misunderstandings may arise from use of complex 
epidemiological terms like randomized assignment, placebo control groups, double blinded 
procedures and fixed treatment protocols. The case of parental comprehension may also 
affected by the anxiety and fear created by the illness of the child and need to access health 
services for the child (Ross, 2006). As observed in this section autonomous decision-making 
can only result from adequate comprehension of information disclosed. The next section 
examines the decision-making component of informed consent. 
 
2.6 Decision-making 
 
Decisional capacity is critical in decision-making to participation in research. Decisional 
capacity refers to an individual‘s psychological abilities to form rational decisions (Raphael, 
2007). Appelbaum and Grisso (1988) identified four elements related to decisional capacity 
first described by namely; the ability to communicate a choice, the ability to understand the 
relevant information, the ability to appreciate a situation and its consequences and the ability 
to reason rationally. Arnold and Feldman (1986 p. 340) noted that an individual‘s choice is 
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influenced not only by the perceptions of his/her goals but the anxiety and confusion 
experienced while making the decision. In research an individual capable of informed choice 
should demonstrate the ability to understand the nature of research participation, appreciate 
the consequences of such participation, exhibit the ability to deliberate on alternatives, 
including the ability not to participate in research and evidence ability to make a reasoned 
choice (Appelbaum and Grisso, 1998). As mentioned earlier, children have no legal authority 
to make decisions, therefore surrogate decisions are made on their behalf by the parents. 
Cooper and Koch, (1996) cited in Zawistowski, (2003 p.408), suggested that the rational-
parent standard approach is the best approach to apply  for surrogate decision making in case 
of younger  children who lack the capacity to demonstrate intelligence. This standard requires 
the surrogate to demonstrate the ability to prioritize options for the child using the parent‘s 
own coherent and consistent value system.  
 
All international guidelines recognize the principle of ―respect for persons‖ and emphasize 
the importance of freedom of choice and personal decision-making. However, according to 
Arnold & Feldman (1986), the major concern about decision-making is that rational decision-
making is of the assumption that all decision-makers have mental capacities for analysis and 
evaluation to do so. However, the same author observed that persons giving consent must 
have reasonably stable preferences, goals, and values with which they genuinely identify, 
suggesting that a certain level of maturity is necessary.  Additionally, decision-making further 
requires that prospective subjects are able to assess the possible consequences of participation 
or non-participation with respect to their individual interests, and must be able to come to a 
reliable decision as a result of these deliberations.  
 
Despite having the requisite skills, women and children may not be able to exercise their 
decision-making capacity because of the environments and cultures that significantly limit 
opportunities for individual choice. Marshall (2004) observed that historically, beliefs and 
values about autonomy and personal decisional capacity are grounded within social and 
cultural patterns of the community obligations and family ties. As noted by Molyneux et. al. 
(2005), in the western culture decision making is individual while in non-western settings 
decision-making involves family and sometimes the community; and Ajayi (1980) observed 
that in certain regions of the world, respect for family and community elders strongly 
influences a community‗s receptivity to participation in medical research. A survey of 540 
investigators from developing countries found that 66% of the investigators thought that the 
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informed consent process focused too much on the individual rather than community or 
family in research with adults, while 19% sought consent from another family member other 
than the participant especially where verbal consent was sought (Kass & Hyder, 2001). A 
study by Loue, Okello & Kawuma (1996), reported that in Uganda the civil law recognizes 
an 18-year old male living with his parents as having a right to make his own decisions but 
according to customary law he has to obtain consent from his father prior to entering into 
obligation or contracts whereas most Ugandan women seek the consent of their husbands 
before making any decision regarding their participation into research.  
 
 CIOMS (2002) states that only the informed consent of the woman herself is required for her 
participation and that in no case should the permission of a spouse or partner replace the 
requirement of individual informed consent. If women wish to consult with their husbands or 
partners or seek voluntarily to obtain their permission before deciding to enrol in research, 
that is not only ethically permissible but in some contexts highly desirable. A strict 
requirement of authorization of spouse or partner however violates the substantiate principle 
of respect for persons. However in most developing countries setting, this is not the case, 
although there are exceptions that would include approaching a woman‘s husband or partner 
/father before speaking with her directly (Macklin, 2004). 
 
2.7 Voluntariness and consent authorization 
 
In order for individuals to exercise their autonomy they must have the capacity to make free 
choices without coercion or undue influence (Schiffman and Kanuk, 1997) which reflects 
voluntariness. However, voluntariness is a difficult concept to operationalize because 
although legally children have rights, they cannot express their developing autonomy because 
they lack the legal rights, intellectual and emotional maturity, therefore parents or guardians 
consent on their behalf (Karim, Karim, Coovadia, & Susser, 1998; Beauchamp & Childress, 
2001). In Botswana like in many developing countries, the health care of children is mostly a 
woman‘s responsibility. However, decision-making by women may be compromised by 
gender bias and power issues (Wassenaar, Bardorf & Richter, 2005).  For example, Marshall 
(2004) found that nearly one-third of more than 400 participants married women interviewed 
in Nigeria to participate in the hypertension and breast cancer study needed permission from 
their spouses. Pace, et.al. (2005) also noted that voluntariness can be compromised by the 
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stress caused by the nature of illness of the child as well as other socio-economic factors and 
these may erode decision making capacity.   
 
 Some studies have considered refusal to participate, feeling of pressure to join a study and 
freedom to withdraw as indicators of voluntariness. For example Gross (2002) reported that 
in a cardiac intervention study only 7% of the potential participants refused to participate 
Pace et al. (2005) reported that 58% of the parents in malaria treatment study done in Uganda 
felt pressured to join because of their children‘s illness while only 48% of Bangladesh 
pregnant women involved in an iron supplement trial knew they could quit the study anytime. 
Issues of information disclosure, understanding and voluntariness among parents who enrol 
their children in HIV pediatric studies have not been critically analyzed in Botswana. 
Therefore the thesis aims to assess the current situation and develop a conceptual model for 
obtaining parental informed consent for HIV clinical trials involving pediatric populations.   
 
2.8 Conclusion 
 
This chapter discussed literature under the elements of informed consent, the need to involve 
children in clinical research, regulatory challenges of research involving children and parental 
consent and the key steps of the informed consent. The literature highlighted the ethical and 
practical challenges encountered in conducting research involving children focusing on 
parental informed consent. Further, it emerged that parental informed consent in research 
involving is critical but there is a paucity of literature on parental informed consent in sub-
Saharan Africa including Botswana. Literature also showed that the process of informed 
consent is inadequately implemented and consent forms are becoming longer and more 
complex for ease of readability and comprehension by potential participants. Furthermore 
potential participants‘ understanding is variable and lacking especially in certain aspects of 
clinical trials like randomization and freedom to quit a study. Therefore more research is 
required to embrace these issues in order to enhance the understanding of the informed 
consent process as well as improve the process and voluntary decision making in a variety of 
settings. The next chapter describes the procedures that were followed to collect and analyse 
data for this thesis. 
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CHAPTER THREE 
METHODOLOGY 
 
3.0. Introduction 
 
This chapter reports on the methodology used in this thesis. The chapter begins by giving a 
brief overview of the research methodology, and provides a brief explanation of the research 
design and its appropriateness in addressing the research questions. Finally, it describes the 
tools and instruments used for data collection, data collection procedures, and analysis, as 
well as the ways in which ethical issues material to the study were addressed. 
 
3.1 Research Design 
 
This thesis followed a cross-sectional exploratory design (Creswell, 2003) to conduct a 
holistic analysis of the current practices of obtaining parental consent for pediatric HIV 
clinical trials conducted in Botswana. A mixed methods approach using both qualitative and 
quantitative techniques was followed, including a readability assessment, in-depth interviews, 
focus groups and face-to-face semi-structured interviews.  According to Wiersma (1995), 
qualitative research investigates the complex phenomena experienced by participants by 
examining people‘s words and actions in descriptive ways thereby allowing the researcher to 
operate in a natural setting. This paradigm was relevant to this study since it was examining 
the informed consent process as used in the context of a clinical trials research environment. 
As noted in chapter one, the general aim of this study was to conduct a situational analysis of 
the current practices of obtaining parental consent for pediatric HIV clinical trials conducted 
in Botswana in order to use the findings to develop a conceptual model that can be used as a 
framework to guide future parental consent processes. On the other hand the quantitative 
method was used as a triangulation technique to strengthen the findings obtained from the 
qualitative data by cross-checking information collected from the parents. 
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3.2. Study Setting 
3.2.1. The country 
 
Botswana is a landlocked semi-arid country situated in Southern Africa. It is bordered by 
South Africa, Namibia, and Zimbabwe. According to Botswana Central Statistics Office 
(CSO), Botswana has an estimated population of 1.8 million (CSO, 2009a) which is sparsely 
distributed in a land of about 582 000 km2. This terrain makes distribution of services quite a 
challenge. About 34% of the population is less than 15 years old. Most of this population is 
concentrated in the south eastern part of the country where the soil conditions are more 
favorable to arable production and, in Gaborone, the capital city, employment opportunities 
are more prevalent. It is estimated that more than 40% of the population lives in rural areas 
(CSO, 2009b). Although most biomedical research institutions are located in urban areas, 
many of those seeking medical care for their children come from rural areas. 
 
Botswana is a middle-income country whose economy has been rated as one of the strongest 
in Africa as well as in the Southern Africa Development Corporation (SADC) region. The 
Ministry of Finance and Development Planning (MFDP), 2011 reported a Gross Domestic 
Product (GDP) average growth of 8% and this economic growth is mainly been attributed to 
the mining sector, in particular the diamond industry, which accounts for 80% of export 
revenue (MFDP, 2006b). Revenue from exports together with returns from various types of 
taxes (e.g. non-mineral income tax, and export duties), non-tax items (e.g. mineral royalties 
and dividends, fees, charges and sundry) and grants constitute government general revenue 
and is used to fund all government activities. .  
 
Despite the above successes, poverty and unemployment are still some of the major 
challenges facing the country. Unemployment rate is estimated at 31.6% (CSO, 2009b). High 
rates of income inequalities have led to an estimated percentage of 21% of the population 
living below the national poverty line (CSO, 2011).The Botswana 2009/2010 Core Welfare 
Indicators Survey (BCWIS) showed that persistent poverty is more prevalent in rural areas 
and among female-headed households especially among the youth and lowly-skilled people 
(UNICEF, 2011). Therefore the above situation might have a bearing on obtaining valid 
informed consent from study participants in Botswana like has been suggested elsewhere. For 
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example, Marshall, (2006) cited literacy levels, language and poverty as some of the factors 
that influence obtaining valid consent.  
 
The 2003 Sentinel Survey  showed that in 2001 Botswana  life expectancy at birth had 
dropped from 66 years in 1966  to 56 years in 2001 (Republic of Botswana/ United Nations, 
2004). The Second National Literacy Survey 2003 reported a lower literacy rate among males 
(47%) than among females (53%). An estimated 70 per cent of the population is ethno-
linguistically homogenous and speaks Setswana which is the national language, although 
English is considered as the official language. The other 30 per cent of the population speaks 
about 28 other languages (Maruatona & Cervero, 2004).   
 
3.3. Study sites 
 
Institutions that conduct pediatric HIV clinical trials in Botswana were used for this study.  
 
3.4. Study population 
 
This study utilized two populations: (i) trial staff directly involved in consent processes for 
pediatric HIV clinical trials and (ii) parents who had previously provided consent for their 
children‘s inclusion in a clinical trial. With permission from the research institutions, a total 
of 29 research staff participated in the qualitative portion of the study: 11 in in-depth 
interviews and 18 in two focus groups discussions. The quantitative component of this study 
comprised a sample of 151 parents of children 0-20 years of age whose children had been 
enrolled in HIV clinical trials at the selected sites. 
 
3.5 Measures and instruments 
 
A summary of variables and instruments that were used to measure the independent variables 
is shown in Table 3.1. The study used a triangulation method to allow for a holistic 
examination of the informed consent process. The triangulation of data enabled comparing of 
data from different sources. In addition to the instruments used to examine the informed 
consent process, information gathered from the focus groups were used to support and clarify 
other findings and were not the source of measurable data itself. Using illustrative examples 
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from the focus groups helped to confirm and give an in-depth understanding of the methods 
and practices used in obtaining parental informed consent process at the selected sites.   
 
Table 3.1: Variables measured and instruments used 
 
 
3.6. Sampling Techniques and Sample size 
 
3.6.1 Consent forms 
 
The purpose of analyzing the consent forms using readability formulas was to assess text 
readability. A nonprobability purposeful sampling technique was used to select 10 pediatric 
biomedical research consent forms used in HIV clinical trial studies. These studies were 
categorized as of greater than minimal risk as they were mainly Phase I, II and III trials (Food 
Variables Instruments 
Dependent variable Readability of consent form  Readability Calculator 
Independent Variables: 
Consent form 
Readability 
Total Number of pages Readability 
Calculator/formulas 
http://www.online-
utility.org/english/ 
Total number of words 
Average number of sentences 
Average number of syllables per word 
Average number of words per sentence 
Reading Ease 
Reading Grade level 
Independent variables:  
Trial staff 
Demographic characteristics  
Consenter In-depth 
interview & Focus 
Group Guide  
 
Perceptions of parent 
Involvement in consent form drafting 
Information disclosure methods and practices 
Facilitation and assessment of understanding 
Facilitation of shared decision making 
Independent variables : 
Parent 
Demographic characteristics of the parent and 
child  
 
 
Face-to Face interview 
Information disclosed 
Parents‘ perceptions about information 
disclosed  
Manner in which information was provided 
Information provided 
Importance of information provided 
Level of understanding  
Voluntariness: Choose not to participate, feel 
pressure to join and knowing that one can 
refuse or withdraw  
 
 
 
 
  
58 
 
and Drug Administration (FDA) 21CFR 50.51, 2001) and eligible for children 0-18 years. 
These forms had also been approved by the national ethics committee, were registered at the 
clinical trials registry at http://www.clinicaltrials.gov/ and had been used to seek consent 
from parents/guardians during the pediatric clinical trials between 2008 -2010. For anonymity 
the 10 consent forms were coded as CT1 to CT10. 
 
3.6.2 Trial Staff 
 
Two samples were used to collect qualitative data from trial staff securing permission from 
parents to enrol their children in HIV clinical trials at the four selected sites. The sample was 
obtained using a non-probability   purposive sample technique.  Ten (10) of the eleven (11) 
trial staff who participated in the in-depth interviews were Batswana nationals and one was 
non-Motswana. For anonymity purposes the country of origin of this participant is withheld. 
The two focus group discussions were composed of only Batswana trial staff. The inclusion 
criteria was as  follows: Direct involvement in the consenting of parents/guardians, a  
minimum qualification of a diploma in any medical/Health science field or social-behavioral 
field, at least a minimum of 1 year working experience in a research environment involving 
children as research subjects.  
 
A non-probability purposive sampling technique was appropriate to select the consenters 
because only a few pediatric HIV clinical trials are conducted in Botswana and the country 
has a few research institutions that conduct pediatric research. The method also helped in the 
development of explanations from the emerging data during the data analysis process since 
the qualitative approach was guided by the ‗grounded theory‘. It was necessary to keep 
selecting new samples in order to build interpretive theories from emerging data to elaborate 
on developed theories. The sample of consenters was determined by the data that was being 
generated. According to Strauss & Corbin, (1998), it is impossible to know how many 
participants to involve in a qualitative study. A total of eleven (n=11) trial staff participated 
in the in-depth interviews and a total of eighteen (18) trial staff participated in the two focus 
groups discussions. The focus group discussion at site A comprised of 8 participants while 
the one at site B comprised of 10 participants. Only individuals who worked as HIV clinical 
trial staff and were involved in the seeking of parental informed consent were for recruitment 
of children in HIV clinical trials were selected.  
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3.6.3 Parents 
 
Data collected from the parents constituted the quantitative component of the study as 
described in section 3.1. A random sampling technique was used to draw from a sampling 
frame of parents who had previously agreed to the enrolment of their children in HIV clinical 
trials. This technique was adopted because very little is known about the population regarding 
the practices and quality of parental informed consent process in Botswana; this allowed each 
parent/guardian to stand an equal chance of being selected and generate generalizable results. 
The sample size for the quantitative component of the study was calculated as shown below. 
The parent sample size was calculated according to proportions. Since no such surveys had 
ever been conducted before in Botswana, a 50% proportion was used in calculating the 
parent/guardian sample size using the formula below. The sample size was determined using 
Cochran‘s sample size calculation formula for categorical data to enable detection of 
difference at α=.05 and margin of error =.06 (Bartlett, Kotrlik & Higgins, 2001, Israel, 1992) 
 
Sample size calculation 
 
Sample size     =       ______n______________ 
                                  1 + (n/population) 
   n=   Z*Z [P (1-p) (D*D)] 
P= True proportion of factor in the population, or the expected frequency value 
D= Maximum difference between the sample mean and population mean or expected 
frequency Value minus (-) Worst acceptable value 
Z= Area under normal curve correspondence to the desired confidence level.  
 
Assumptions 
The sample to be taken must be a simple random or otherwise a representative sample.  
Values necessary for calculating the sample size: 
The total estimated population of parents that had agreed to enrolment of their children in 
HIV clinical trials was = 600 
 An expected frequency (P) of good scores of 50% is recommended for dichotomous 
variables as it results in maximization of variance and produces maximum sample size 
(Bartlett, Kortik & Higgins, 2001).  
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In order to calculate ―n‖, a confidence interval of 6 percent, worst acceptable frequency of 56 
percent or 44 percent and confidence level of 95 percent were used. 
Value for Z at 95 percent confidence level = 1.960 
 
Calculation for ‘n’ 
P= Expected frequency values = 50 percent 
D= (expected frequency – Worst acceptable) = 56-50 = 6 percent or 50-44 = 6 percent 
Z= 1.960 with Confidence level of 95 percent 
n= Z*Z [P (1-P) (D*D)] 
 n= 1.960*1.960[0.50(1-0.5) (0.06*0.60) 
 n= 1.960*1.960[0.50(1-0.50) (0.0036) 
n= 1.960*1.960[.25/0.0036]  
n= 1.960*1.960[.69.44) 
n= 1.960*136.11  
n= 266.78  
n= 267 
 
Since the value of ‗n‘ exceeds 5 percent of the population (600x 0.05= 30), Cochran‘s (1977) 
correction formula was used to calculate the final sample size (Bartlett, Kotrlik & Higgins, 
2001). Sample size (S) was therefore calculated for the given population of 600 participants 
as follows: 
S =   _______n________ 
 1+ (n/population) 
S= 267/ [1+ (266.78/600) 
 S=267/ [1+.444] 
S= 267/1.444 
S= 184 
 
Out of the calculated sample size of 184 parents, only 151 parents agreed to participate in the 
study. 
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3.7 Procedures for data collection 
 
3.7.1. Readability assessment 
 
The readability of the consent forms was qualitatively assessed by means of the Flesch–
Kincaid Reading Ease and Flesch–Kincaid Grade Level, using a computer Readability 
Calculator: http://www.online-utility.org/english/.The software generates scores of the 
reading ease of the text and the grade level needed in order to be able to understand the text 
easily on the first reading. Ten (10) copies of coded consent forms CT1 to CT 10 written in 
English  that underwent ethics review and used at least at one of the study sites between the 
years 2008-2010 were scanned as a Text and Image file then saved as Rich Text File.  Each 
consent form was cleaned for scanning errors and copied separately from the word document 
and pasted unto the ‗Reading Calculator‘ software space provided. The software 
automatically generated the readability scores. The variables included total number of pages 
and words, average number of sentences, syllables per word, and words per sentence, and 
Flesch Kincaid Reading Ease and Grade level which were used as predictors to calculate the 
descriptive statistics.  
 
A limitation with using this method of evaluating readability in this study is that all 
readability calculators are designed to predict an approximate representation of the US grade 
levels needed to comprehend text written in English which might not be applicable for the 
Botswana setting. Secondly, readability tests alone may not be the only evaluator of the 
suitability of text, which is another limitation. Other factors may need to be considered such 
as the size of type and length of line, sentence structure, the number of words per page, the 
use of color, the use of diagrams, the page layout, and the use of space between paragraphs 
(Johnson, 2004). Some words used in the research context do not exist in Setswana or have 
different meanings. 
 
3.7. 2 Collection of data from trial staff 
 
Qualitative data was collected from trial staff at the selected sites using in-depth interviews 
and focus group discussions. Informed consent was sought from each of the potential 
participants and those who agreed to participate signed a consent document (Appendix1). In-
depth interviews were conducted by a trained research assistant in English to elicit 
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information regarding trial staff demographic characteristics; parents‘ age, education, social 
economic status, previous research experience and importance of knowledge of culture of 
parents; information disclosure, parental understanding of clinical trial and decision making. 
The instrument used for the in-depth interview guide (Appendix 2) contained mostly open-
ended questions which allowed participants to freely express their opinions.  Interviews were 
held in each participant‘s office. Every effort was made to maintain anonymity, privacy and 
confidentiality during the in-depth interviews. Therefore when reporting the results, trial staff 
who participated in the in-depth interviews were referred to as „respondents‟. On average 
each   interview lasted between 45 minutes to an hour. Since all the trial staff work in close 
proximity to each other and interviews were conducted on different days, there was a 
moderate risk of bias given that participants would have had the opportunity to discuss 
interview questions with others who had not yet been interviewed. To the extent that this 
occurred, it is unlikely that it would have resulted in inaccurate information.  
 
Two focus group discussions were held with a total sample of 18 trial staff using a focus 
group guide as an instrument (Appendix 3). The focus group discussion at site A comprised 
of 8 participants while the one at site B comprised of 10 participants. The two groups were 
small enough (8-10 people), homogeneous regarding demographics, academic qualification 
(all had attained tertiary education), and all of them worked for research institutions that 
conduct HIV clinical trials as trial staff involved in conducting the consent process. The 
homogenisity helped to avoid inhibition of group interaction, assisted in in exploring the 
topic in greater depth unlike when if the groups were heterogeneous and helped to eliminate 
idiosyncratic individual characteristics from data. The groups also provided information that 
met the specific set objectives. 
 
The focus group guide instrument consisted of open-ended questions which created a more 
interactive environment in which more in-depth discussions about the informed consent 
process were encouraged. Focus groups were audiotaped and notes and observations were 
recorded by the facilitators. For anonymity purposes, the trial staff who participated in the 
focus group discussions were referred to as „participants‟. Individual informed consent 
(Appendix 4) and group informed consent (Appendix 5) were sought from all participants. 
The focus group guide comprised of open-ended questions that were grouped into five main 
categories that elicited information on the perceptions of the trial staff about characteristics of 
parents who agree to child enrolment  into HIV clinical trials (age, education, social 
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economic status, previous research experience and  perceived importance of  participant‘s 
familiarity with cultural background of parents on the consenting process); the drafting  of the 
consent form document; information disclosure, parental understanding of clinical trial and 
decision making. According to Babbie & Moutom (2005), focus group discussions tend to 
allow a space in which people create meaning among themselves other than individually.  
 
A trained professional facilitator with bioethics and epidemiology training as well as 
experience in these fields, and unknown to the participants facilitated the focus group 
discussions with an observer taking notes. The discussions were audio-taped. The two focus 
groups were facilitated by the same facilitators and the two groups were   coded as A and B 
for anonymity to ensure confidentiality. Invitations were sent out to participants at all the 
selected sites.  The two focus group discussions took place in separate locations on separate 
days. Discussions were held in English because all participants were fluent in English. Focus 
group A comprised of 8 trial staff who were given codes P 1 to P8used to address the trial 
staff during the discussions and transcribing. However, for reporting the results the trial staff 
were referred to as participants. Discussions for group A were held in a research setting 
located in a rural area where the participants worked. Focus group B comprised of 10 
participants who worked at urban sites. The participants were given codes P1 to P 10 and 
these codes were only used to address the participants during the sessions and for 
transcription purposes but were not used in the write up of the results and discussion for 
confidentiality purposes. Each session lasted on average one to one and half hours.  The 
discussions started off with introductions, getting to know about the background of the 
participants, followed by discussions on the documentation of the consent form, information 
disclosure, parental recall of information disclosed, motivation and voluntariness to 
participate, and ended with a wrap up in which the participants were thanked and promised to 
be given feedback about the findings. The wrap up also gave the participants an opportunity 
to ask questions and give further input. Soon after each session the facilitators verified 
whether the tape recorders had worked by listening to the recordings, they also noted any 
major observations made about the discussions. 
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3.7.3 Data collection from the parents 
 
Quantitative data was collected by two trained research assistants using a slightly modified 
semi-structured questionnaire instrument adopted from Pace et al., (2005). The research 
assistants read out the questions to the parents and filled in the responses from the parents. Of 
the 184 participants included in the sample, 25 did not respond and questionnaires from 8 
participants were not included in the analysis because they contained too many missing cases. 
Before the parents were interviewed, consent was sought from each of them by the research 
assistant reading out the consent form to them and explaining what the study was about either 
in English (Appendix 6) or in Setswana (Appendix 7). The questions from the semi-
structured questionnaire were read to the parents/guardians who had agreed to participate in 
the study and had previously agreed to child enrolment in a pediatric HIV clinical trial in a 
language that they preferred, using either the English semi-structured questionnaire 
(Appendix 8) or the Setswana semi-structured questionnaire (Appendix 9) by the research 
assistants. This was in order to enhance understanding and accommodate low literacy levels 
and overcome possible parental inabilities in read and write. In addition the research assistant 
wrote down any observations and notes. Every parent participated once irrespective of the 
number of children she had on the study or number of times he/she visits the site clinic. Each 
session lasted 30-45 minutes.  Participants signed or put a thumb print on the consent form to 
acknowledge agreement to participation in the study. 
 
3.8. Procedure for Data Analysis 
 
3.8.1 Analysis of Readability Assessment 
 
A sample of 10 pediatric biomedical research consent forms was included in the analysis. The 
number of pages and words, average number sentences, syllables per word and words per 
sentence as well as Flesch-Kincaid Reading Ease and Grade Level Scores generated by the 
Readability Calculator were copied from the computer generated data into Excel sheets. 
Readability statistics were then calculated including the mean, standard deviation and range. 
The Flesch-Kincaid Reading Ease and Grade Level Scores were mapped against the 
corresponding readability levels based on the value scale as shown in Table 1. It is generally 
understood that texts written for the public should be at 6
th
-8
th
 grade level (Johnson, 1998). 
Descriptive statistics were calculated in SPSS and the indicators were compared to the 
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readability scores using the t-test in SPSS to determine the relationship between the indicator 
variables was also calculated. 
 
Table 3.2: Interpretation of Flesch Reading Ease score to Readability level 
 
 
 
 
 
 
 
 
         
 
 
      Source: Flesch (1948) and Dubay (2004). 
 
3.8.2 Analysis of qualitative data 
 
Audio-taped data collected from the in-depth interviews and focus group discussions 
(appendix 13 and 14) were transcribed. The data were analyzed simultaneously as it was 
being collected. According to Seidel (1998), qualitative data analysis involves noticing 
interesting things from the data, collecting them and thinking about them. Audio-taped data 
from twelve (11) separate in-depth interviews and two focus group discussions were 
transcribed verbatim to generate a record of what each respondent had said. The transcripts 
were read over and over thoroughly before further analysis to observe trends. 
 
Open coding was done from each of the in-depth interview transcripts using different colour 
highlighters to generate coding units of analysis or concepts commonly referred to as 
categories and sub categories. Miles and Huberman (1994, p.56) described coding units as 
―tags or labels‖ for assigning units of meaning to the descriptive or inferential information 
compiled during a study. The categories identified were typed, printed cut out and pasted on 
smaller cards. These coding units included words, phrases, sentences and or entire paragraphs 
about, demographic data, observations made during the sessions, and opinions about certain 
KFRE Score Reading Ease Number of years of formal 
education 
0–29   Very difficult  College Graduate 
30–49  Difficult 13th -16th grade 
50–59 Fairly difficult 10th -11th grade 
60–69  Standard 8th-9th grade 
70–79  Fairly easy 7th grade 
80–89 Easy 6th grade 
90–100  Very easy 5th grade 
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topics like the consent form, information disclosure, parental understanding and 
voluntariness. According to Charmaz (1983:112), codes serve to summarize, synthesize, and 
sort the many observations made of the data, so it is a fundamental means of developing the 
analysis. Researchers use codes to pull together and categorize a series of otherwise discrete 
events, statements, and observations which they identify in the data. 
 
Axial coding was performed from the many coding units or concepts earlier to regroup or 
disintegrate the data by selecting key codes and concepts of interest in order to generate a 
central scheme. This was done through concept formation and development. Concept 
formation involved comparison of categories and subcategories generated from open coding 
to explore differences and similarities across events or occurrences within the data collected. 
Through this process further codes that emerged were observed and collected. The new 
concepts formed were further explored in greater depth and incorporated into ‗core variable‘ 
or main theme which according to (Hutchinson, 1993:193).  During this process any codes 
that were overlapping or irrelevant were discarded. Records had to be read over and over 
again to generate patterns and the data sequence that could generate concepts of 
comprehensible patterns. A summary of the process is shown in figure 3.2 below. The 
transcripts from the focus group discussions were not coded as they were only used to 
provide examples that supported the readability results, in-depth interview results and parent 
interviews. 
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Figure 3.1:  Showing connections among data generation, treatment and analysis. 
 
3.8.3 Qualitative data notions of objectivity 
 
 Trustworthiness 
 
Trustworthiness is an approach used to clarify the notion of objectivity as it is manifested in 
qualitative research (Babbie and Mouton, 2005). Trustworthiness of this study was enhanced 
by ensuring that data collection occurs until saturation occurs. The triangulation methods 
used in this study ensured that information is collected about the different variables from 
different viewpoints because different questions were asked, from different sources using 
different methods. The data was also collected using different materials e.g. audio tapes, 
observation notes and memos. Consultation with my supervisors and colleagues with 
experience in the field of bioethics but outside the context of this study was done to review 
perceptions, insights and analyses. A thorough data check was done to correct for obvious 
errors. 
 
Data Source 
Interviews 
Transcribing verbatim to generate data and noticing trends 
Open coding by breaking up the transcribed data, separating smaller themes 
Axial coding to disaggregate coding units from open- coding to generate key 
concepts 
 Level I= Substantive codes 
 Level II=Categorization 
 Level III= Basic social-psychological process identified 
Concept formation and development: comparison of categories, reduction of 
data, selective sampling of literature and data 
Core Variables 
Field Notes Observation Literature 
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 Credibility, dependability and confirmabilty 
 
Guba and Lincoln, (1984) state that in qualitative research, there can be no credibility without 
dependability. Credibility refers to the notion of compatibility between the constructed 
realities that exist in the minds of the respondents and those that are attributed to them 
(Babbie and Mouton, 2005). Dependability refers to the fact that an inquiry must provide 
results that if it were to be repeated with the same or similar respondents in the same context, 
the findings would be the same (Babbie and Mouton, 2005). In order to ensure that the results 
of this study were credible, the researcher ensured that data was collected both from parents 
and trial staff until saturation was reached through prolonged engagement. Triangulation 
methods were also used to enhance validity by combining document analysis, in-depth  
interviews, focus groups, and observations whose results were compared and contrasted in 
order to reach as rich a picture of the situation as possible and to increase credibility.  
Referential adequacy was also ensured by the use of different methods to document findings 
e.g. audio taping and note making from observations were used. Peer debriefing was also 
conducted through constantly consulting with experienced scholars in the field of bioethics. 
These included my former lecturers and colleagues from the international Bioethics course as 
well as my two supervisors.  Credibility was also ensured though continuously double 
checking the sources of my data and the interpretations that were being generated from data. 
This allowed correction of errors and assessing the overall adequacy of the data. The 
researcher attempted to ensure dependability through the use of what Babbie and Mouton, 
(2005) refers to as inquiry audit. This was achieved through the use of triangulation methods 
and critically examining the data gathered against the results, interpretations and 
recommendations to ensure that they are supported by the data gathered. The same technique 
also ensured confirmability. Confirmability refers to the degree to which the findings are the 
product of focus of the inquiry and not the biases of the researcher (Babbie and Mouton, 
2005).   
 
  Transferability 
 
Transferability is the extent to which the findings can be applied in other contexts or with 
other respondents (Babbie and Morton, 2005). The researcher cannot claim that the 
qualitative knowledge gained from this study can be will have relevance in another context or 
could be generalized. Therefore in order to try and ensure transferability, the researcher used 
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the purposive sampling technique in order to maximize the range of specific information that 
could be obtained from key informants. 
 
3.8.4   Quantitative data analysis 
 
Descriptive statistics were run for the quantitative data in this thesis. Questions from the 151 
parents/guardian interviews were analyzed using SPSS software 16.0. The data were cleaned 
and analysis was done. Frequencies and distributions were created for all dependent 
variables. For categorical variables, calculations were made and proportions were compared 
in each category via Chi-Square χ2 tests where the observed values were large or Fischer‘s 
exact test where the observed values were small. The dependent variables were aggregated 
outcome measures from the demographic data, information disclosure, understanding/ and 
perceived voluntariness gathered from the parent semi-structured questionnaire.  
 
The analysis from both the quantitative and qualitative approaches were then interpreted and 
compared. The mixed methods allowed for confirmation, cross-validation, or corroboration 
of findings within a single study, and were meant to offset the weaknesses inherent with the 
use of one method by using strengths from each method.  
 
For validation purposes, instruments used were pre-tested. The researcher‘s in-depth 
interview instrument and the parent/guardian semi-structured interview instruments were pre-
tested on a few trial staff and parents respectively in order to identify any difficulty with the 
methods or instruments and to investigate the accuracy and appropriateness of the 
instruments to be used. 
 
3.9. Quantitative data notions of objectivity 
 
 Validity and Reliability 
 
Validity refers to the extent to which an empirical measure adequately reflects the real 
meaning of the concept under consideration (Babbie and Mouton, 2005). To ensure validity 
the researcher used a slightly modified semi-structured questionnaire instrument adopted 
from Pace et al., (2005).  The tool was peer-reviewed and pre-tested before being 
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administered for this study. Babbie and Mouton (2005) refers to the term reliability as a way 
of ensuring that someone else using the same method in the same circumstances should be 
able to obtain the same findings i.e. the findings are repeatable . This was achieved by the use 
of a slightly modified questionnaire that had been previously used in a similar study (Pace et 
al., 2005). An attempt to avoid threat to validity and reliability was made through the use of 
an exploratory design since the researcher had limited knowledge about the topic.  In 
addition, use of an already established tool during data collection also helped in avoiding 
threats to validity and reliability. 
 
3.10 Ethical Considerations 
 
 Permission to review and approve this study was sought from the Health Research 
and Development Committee which serves as the national research ethics committee 
of the Botswana Ministry of Health (Appendix 11) and the ethics committee at the 
University of Western Cape. Permission was also sought from the institutions where 
data were collected.  
 The three (3) research assistants and the two (2) focus group discussions facilitors had 
Good Clinical Practice (GCP) training.  
 Participation was voluntary and informed consent was sought from each parent either 
in English (Appendix 7) or Setswana (Appendix 8) and each trial staff during the in-
depth interviews (Appendix 1) and individual and group consent was sought from 
each trial staff who participated in the focus group discussion (Appendix 4 and 5 
respectively) after full disclosure of information about the study. 
 The research was conducted in accordance with the three basic ethical principles, of 
Respect for persons, Beneficence and Justice.  
 Access to the data was restricted only to the research team using a password and 
backups in different locations will be created to minimize data loss. 
 Interviews with trial staff were conducted in private offices and the parent/guardian 
semi-structured interview guides for the parents were translated into the local 
language (Setswana). The research assistants were fluent in both Setswana and 
English. 
 Personal identity of the trial staff and parents were kept anonymous. Codes were used 
in identifying the questionnaires used and addressing the participants during all trial 
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staff and parent interviews and focus group discussions. Data collected was be entered 
in a computer and secured using a password. 
 
3.12 Conclusion 
 
This chapter elucidated on the methodology that was followed in this thesis, including the 
research design, sampling techniques, data collection and analysis methods. The research 
design was described and reasons for its choice outline. The purposive and random sampling 
techniques used to select the samples were also described and reasons for their suitability 
mentioned. Details of the tools used namely; the in-depth interview guide, focus group guide 
and semi-structured questionnaire were also described in the data collection section (section 
3.6). The qualitative and quantitative data analysis methods and their relevance to the study 
were also described. The study validity, reliably and trustworthiness as well as the ethical 
considerations put in place to protect the research participants and study sites were also 
explained. The findings from this study are described in chapter four and five. 
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CHAPTER FOUR 
 
RESULTS FROM CONSENT FORM READABILITY ANALYSES, TRIAL STAFF 
IN-DEPTH INTERVIEWS AND FOCUS GROUP DISCUSSIONS 
 
4.0 Introduction 
 
The study investigated the parental informed consent process for pediatric HIV clinical trials 
with a purpose to develop a model that can guide future consenting processes. This chapter 
presents results from informed consent form readability analyses, trial staff in-depth 
interviews and focus group discussions. Results are presented according to the five thematic 
areas of the informed consent process namely; communication, comprehension, motivation, 
decision making and voluntariness. The presentation however begins with a summary of the 
quantitative descriptive data on the informed consent forms that were analyzed (Table 4.1) 
and the demographic information of the trial staff (Table 4.2) so as to provide background 
information about the population. 
 
4.1 Summary of the quantitative descriptive data 
 
A summary of quantitative data collected from the ten (10) consent form analyzed and the 
demographic characteristics of the trial staff is shown in Tables 4.1 and Table 4.2 
respectively.  
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 Table 4.1: Summary of the Descriptive statistics of the consent form readability (n=10) 
 
 
 
Overall out of the ten (10) consent forms analyzed the length of the consent forms ranged 
from 7-21 pages with a mean length of 13 pages.  The mean KFRE of 50.9 shows that the 
reading ease of the consent forms was lower than the standard of 60-69. This shows the text 
was fairly difficult to read. The mean FKGL of 11.50 also shows that the consent forms were 
written for higher grade level participants than the recommended 6-8
th
 grade level. 
 
Table 4.2 above shows a summary of the demographic characteristics of the trial staff who 
participated in the in-depth interviews. The demographic characteristics helped in identifying 
the information relevant to the process of communicating clinical trial information and 
facilitated in identification of the adequacy (or otherwise) of the professional qualifications of 
the trial staff. The mean age of those involved in the in-depth interviews was 40 years. Eight 
participants were female.  The education levels of the trial staff ranged from bachelor‘s 
degrees, diplomas and certificates. A number of them had postgraduate qualifications. All the 
trial staff reported   having completed training in Good Clinical Practice (GCP) and the 
training was done every two years or in some cases each time they started a new study. Some 
trial staff had more than one type of training in human subjects protection offered either done 
online or thorough seminars or workshops. All trial staff had some form of pediatric training 
and experience. 
  
 
 
 
 
 
Variable Descriptive Statistics 
 
No of pages 
                Min           Max      Mean          SD 
7 21 12.7 5.293 
No. of words/form 3224 8297 5003 1714.919 
Avg. No of sentences/form 162 382 254 0.377 
Avg. No. of Syllables/word 1.59 1.66 1.59 0.337 
Avg. No. of words/sentence 16.45 24.96 21.88 2.5729 
FKRE 41.92 57.05 50.29 4.9253 
FKGL 9.35 13.61 11.50 1.259 
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Table 4.2 Summary of the descriptive statistics of trial staff demographic data (n=11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Communication 
 
Communication process is a very vital first step in the informed consent process where 
potential participants are provided with full and transparent information to protect them from 
acts of deception, manipulation, deliberate misdescription of what is proposed, lack of 
disclosure of material facts, or conﬂicts of interest as well protection of their rights and 
welfare. The process also ensures the researcher that the legal and indemnity requirement are 
 
Variable Frequency 
Gender 8 
     Female  
     Male 3 
Age  
      30-40 7 
       40-50 4 
Education Level  
Diploma 6 
Degree  4 
Certificate 1 
*Occupation  
Research Nurse 4 
Study Coordinator 5 
Social Worker  1 
Medical Doctor              1 
*Training in bioethics  
Good Clinical Practice (GCP)               11 
GCP and CITI                1 
GCP and workshops              4 
GCP& Human subjects protection 
(HSP) 
            1 
*Pediatrics  
Basic training           9 
Specialization in pediatrics          1 
Experience in Pediatrics         5 
Neither training nor experience        1 
CITI=Collaborative Institutional Training 
initiative, GCP=Good Clinical Practice training, 
HSP=Human Subjects Protection 
Some respondents had more than one qualification 
in bioethics and pediatrics 
* Trial Staff had more than one of the listed 
variables therefore the total is more than  eleven 
(11) 
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met. During this step, it is important that potential participants also understand the 
implications of participating in research. Findings on trial staff perceptions about the 
communication process of the informed consent process are reported under the subsections 
below starting with results from the readability of the consent forms used to seek consent 
from parents for child enrollment into pediatric HIV clinical trials. 
 
4.2.1 Readability of informed consent forms 
 
It is on the basis of how readable and comprehensible informed consent forms are that 
potential study participants are empowered to make an informed voluntary shared decision. 
The study analyzed the readability of ten (10) informed consent forms. Table 4.3 shows that 
overall, most (n=7) of the consent forms were longer than 12 pages, the longest being 21 
pages implying that they would require a lot time   to read and understand. More importantly, 
the KFRE and FKGL which were used to determine the reading ease and grade level 
respectively revealed a mean FKRE score of 50.29 ± 4.920 indicating that the forms were 
difficult to read while the mean FKGL of 11.50, p<0.001) indicated that the forms were 
written at a grade level far higher than the average grade level of the parents who were asked 
to read them. The FKRE and FKGL scores are however based on the English metrics and so, 
for second language readers in Botswana, the scores show that the difficulty is far too high. 
  
Table 4.3: Readability scores for the consent forms (n=10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FKRE= Flesch-Kincaid Reading Ease, FKGL= Flesch-Kincaid Grade Level 
 
 
                                  Readability scores 
 
Clinical 
Trial 
(n=10 
No. of 
Pages 
No. of 
words 
Avg. No. 
of 
Sentences 
Avg No. 
Syllables/ 
word 
Avg. No. 
of words 
/sentence 
FKRE FKGL 
1 7 3594.0 162.0 1.6 22.2 46.0 12.35 
2 20 8297.0 382.0 1.59 21.72 49.89 11.69 
3 11 4001.0 188.0 1.59 21.28 50.88 11.45 
4 7 3224.0 196.0 1.59 16.45 55.92 9.55 
5 7 3358.0 194.0 1.56 17.31 57.05 9.6 
6 12 4663.0 205.0 1.66 21.77 44.69 12.43 
7 12 4805.0 206.0 1.54 23.33 53.05 11.66 
8 21 5790.0 232.0 1.65 24.96 41.92 13.61 
9 12 4958.0 241.0 1.56 20.57 53.85 10.86 
10 18 7449.0 334.0 1.59 22.3 49.73 11.86 
Mean 12.7 5013.90 234.0 1.593 21.18 50.29 11.50 
SD 5.293 1714.919 69.862 0.377 2.5729 4.9253 1.249 
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A correlation coefficient of r =.995 was found which indicated a strong linear relationship 
between the reading ease and length of sentences (mean =12.7), average number of words per 
sentence (mean =21.2) and average number of syllables per word (mean=1.59). The 
coefficient of determination (r
2
) was also high at 99.1%. The overall ANOVA test was 
significant at p < 0.001 and (F=84.006) indicating  that the length of sentences, average 
number of words per sentence and average number of syllables per word had a significant 
effect on the reading ease of the selected consent forms.  
 
Results from analysis of the different sub-sections of selected elements that appeared in all 
the 10 consent forms (Table 4.4) showed that the mean KFRE score was 47.8, much  lower 
that the recommended 60 and the KFGL was 11.5 higher than the recommended 6-8
th
 grade.  
 
Table 4.4: Mean scores of FKRE and FKGL of sub-parts of selected key elements of the 
consent forms (n=10) 
 
Subsection  Mean   
KFRE 
Mean 
KFGL 
Participant rights 62.5 8.3 
Statement of research 58.0 9.4 
Study procedures 55.0 11.1 
Risks 50.6 11.4 
Benefits 48.4 12.4 
Compensation for injuries as a result of participation in the study 45.6 11.1 
Purpose of study 44.6 12.5 
Payment for participation 43.4 12.4 
Confidentiality 39.2 13.1 
Cost of participation to parent 31.5 13.9 
Mean Scores                                                                                                      47.8 11.5 
 
4.3 Findings from In-depth interviews and focus group discussions 
 
This section reports the findings from trial staffs‘ background knowledge about clinical trials, 
their perceptions about parent demographic characteristics and how these influence the 
informed consent process are reported. The section also reports about the perceptions of trial 
staff regarding their interaction with the parents during the information disclosure process; 
parents‘ comprehension of information disclosed to them; what motivates parents to enroll 
their children into HIV clinical trials and their voluntariness to participation in the trial 
studies. Throughout this chapter, for anonymity, privacy and confidentiality purposes the 
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eleven (11) trial staff who participated in the in-depth interviews will be referred to as 
respondent(s) while the 18 trial staff who participated in the focus group discussions will be 
referred to as participant(s). 
4.3.1Trial staff background knowledge about clinical trials 
 
Trial staff are expected to have some basic knowledge about clinical trials especially the 
phases and risk categories in order to be able to conduct a risk benefit analysis to assist the 
potential participants make an informed choice. At the cost of yielding important benefits, 
pediatric HIV clinical trials carry significant risks that may arise from the investigational 
drugs being tested and/or those of social nature like confidentiality and stigmatization. 
Therefore, during the in-depth interviews, for the clinical trial they had conducted parental 
consent process for, respondents were asked to briefly explain its Phase and give examples of 
its risk categories. The immediate response to this question by most respondents was silence 
and facial expressions of doubt. However majority of respondents reported that they had 
conducted consent process mainly for Phase II and III clinical trials but indicated that they 
carried minimal risk as these two answers below show: 
For example, answers like the ones below were given: 
―A bit of risk because we do not know the side effects” 
“Low risk because we draw blood, so we prick them but I have not 
seen any danger”  
 
The same question about the phases of clinical trials their and risk categories were asked 
during both focus group discussions and there was silence in both groups, and whispers of not 
wanting to commit to answering the question which indicated doubt until one respondent 
asked the facilitator ―How do you categorize your phases?” Another participant requested for 
further explanation on the criteria used to determine study „risk categories‟. In one of the 
focus groups, participants were adamant that the clinical trials they had conducted the consent 
process for were all minimal risk given that some of the drugs used were already registered in 
Botswana with known side effects, or simply involved standard procedures like blood draws.  
It is clear that trial staff need further education on the issue of risk categories. 
 
To assess the parents‘ potential to fully benefit from information communicated, the study 
examines at length how trial staff perceived the parents who enrol their children in the trials.   
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4.3.2 Perceptions of the trial staff about the characteristics of parents 
 
Since communication involves a receiver, the study sought to establish how the trial staff 
viewed the recipients of the consenting information, the parents. During the in-depth 
interviews respondents were asked to comment on the age of parents who agreed to child 
enrolment into the HIV clinical trials, their education levels, social economic status, and 
previous research experiences. All respondents reported that the age of consent according to 
Botswana law is 21 years of age. Therefore only parents that were 21 years of age and above 
could enrol their children. Any parent below that age needed to be accompanied by someone 
21 years old or above. One respondent elaborated as follows during the in-depth interviews:  
“We enrol only children whose parents are 21 years and above 
because of the Botswana laws‟ limitation of the age of consent being 
21. Those parents that [are] less than 21 have to be represented by 
their parents or grandparents. Sometimes even those above 21 bring 
an elder because they are the caregivers. This is very important 
because they take care of the children in the absence of the biological 
parents”. 
 
Regarding parent‘s education level, respondents stated that majority of parents had low levels 
of education. For instance one respondent commented that: 
“Majority of parents I see have primary education or junior school, 
only a few have secondary education and very few reached tertiary 
level”. 
 
Two other respondents linked low education to the fact that parents reside in the rural areas 
while one of the respondents expressed a preference for parents with low education and said:  
“I prefer those without much education because those with some 
education think they know and they give a lot of trouble with 
adherence”.  
However, the general opinion was that the parents have very low education because, 
according to one, “those with high education rarely come to our clinics because they can 
afford to go to private doctors”. More perceptions on the parents‘ education emerged from 
the focus group discussions.  Several participants commented that the parents they interacted 
with had low health literacy although this was not elaborated and some even accused parents 
with high education of not interested in research. Because the point of recruitment was the 
public health facilities, parents from the middle and high social class cannot be reached 
because these social classes attend private clinics as one clearly put it: 
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 “Only low to middle income class parents came to the research 
centres, those from high income class do not come because of 
stigma”. 
 
A participant from one of the focus groups said; “we go to places where there is high burden 
of disease where recruitment will be quicker”.  
 
Most focus group participants also perceived the parents as submissive as one respondent 
from one of the focus groups elaborated:  
―It is very interesting when you talk about levels of education…you 
find that majority of these people with low social economic status are 
submissive to the health personnel. The other reason might be that 
they do not know their rights, they believe that as a patient you have 
to listen so cannot say no to enrolment of a child”. 
 
Regarding the socioeconomic status of the parents, all the respondents in the in-depth 
interviews and participants in the focus group discussions reported that majority of the 
parents came from a low socioeconomic class.  
 
The study also sought to find out from trial staff if parents‘ previous experience in research 
affected the informed consent process in any way. During the in-depth interviews  most of the 
respondents agreed that parents that had enrolled a child in research previously easily agreed 
to child subsequent enrolment and one respondent pointed out specifically that this could be 
attributed to the problem of possible lack of understanding of the difference between research 
and treatment (therapeutic misconception) among some parents as expressed below: 
“Umm…… not a lot of parents have previous experience in research 
but I have realized that when I started to be involved in research in 
2001 very few parents participated in research but by 2008 a lot of 
parents knew about research and the research centers. Some even 
decided to have more babies saying that the research centre will help 
them [with treatment].” 
 
Another respondent observed that parents who had previously enrolled their children in HIV 
clinical trials showed enthusiasm: 
“You find that most of our participants whenever a study they had 
enrolled their child in closes, most of them will come forward and ask 
if there are any other studies they can enrol their child in.” 
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To assess whether the culture of a parent had an influence on the outcome of the informed 
consent process, respondents in the in-depth interviews were asked to comment on the 
importance of familiarity with parents‘ culture, values and beliefs before the start of the 
study. As expected, responses were unanimous that trial staff familiarity with parents‘ 
culture, especially language, values and social norms was very important and played a major 
role in the success or failure of the consenting process. During the in-depth interview the 
phrase “very important” was frequently heard.  The five responses sampled below provide 
the many angles the issue of familiarity with culture can be understood: 
“Culture promotes understanding of the parent‟s behavior and 
reactions, for example those parents who say must go back home and 
consult, and it is usually an indirect way of refusal”. 
  
“I think you cannot take out the culture issue because before even 
any recruitment can start, we have to go through the Chief (Kgosi) of 
the village and the parents also can ask the trial staff whether they 
got permission from the chief! I also have experiences where parents 
admit that their babies are taking traditional medicines. I respect 
their culture so cannot stop them but advise. The issue of consultation 
with elders or spouses is also a problem because many parents 
cannot enrol their children before getting permission from the elders 
or the spouse. The child belongs to the family and the community 
because they are all caretakers”. 
 
“Culture is very important [passionately emphasized], especially 
knowing the local language because it can determine the success of 
the consent processes. This knowledge helps to get all the details and 
understand the client”. 
 
“Very important because HIV issues are delicate some language used 
can be offensive or taboo to the participant, some participants may 
even refuse to enrol their children if not culturally respected”.  
 
“Batswana culture is diverse with different values and norms among 
people of the north and south, different languages also have a major 
impact, the way you talk with someone with respect also differs even 
how you ask how the patient is feeling so respect for persons is 
expressed differently”. 
 
As these responses show, familiarity with culture involves several understandings: of 
etiquette in terms of a polite refusal; of protocol in terms of recognizing the Chief first and 
foremost; of taboos regarding HIV; and of the local language and its dialects and/or varieties. 
Participants in one of the focus group discussions had a lengthy discussion about the culture 
issue and yet more understandings of culture emerged: 
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“I think it is very important because what they believe in or their 
cultural background would in a very big way influence the decision 
that they make. For example if you are asking a mother to formula 
feed, you want to find out the cultural challenges she will face at 
home and in the society. When you understand that, then both of you 
are able to know how to work your way around it unlike when you do 
don‟t know. The mother will breast feed at home and formula feed 
only when she comes to the clinic”. 
 
“The parents feel involved and respected”. 
 
“It helps to understand how many people have an influence on the 
decision the parent makes. You might be talking directly to the baby‟s 
mother but her decision might be influenced by the grandmother. It 
also helps retention of participants in the study and the participants 
to give information to other people that are involved in the care of the 
child”. 
 
To summarize, the trial staff perceptions of the parents were examined from a 
variety of angles. Thus far, the study has identified factors that might affect the 
consenting process, namely, (i) that the legal age of consent disadvantages some 
parents (ii) that trial staff awareness of phases and risk categories is lacking (iii) 
that a rural location, poverty, parents‘ low education levels, and the inability to 
distinguish between research and treatment make parents vulnerable to consenting 
without fully understanding the process involved (iv) that familiarity of trial staff 
with the parents‘ culture is beneficial. 
The next section will focus on the information disclosure process. 
 
4.3.3 Information disclosure process 
 
Iinformation disclosure was investigated from the point of view of the trial staff because they 
are the ones who perform this responsibility. The first step in information disclosure is 
drafting the informed consent document. Therefore, trial staff were asked about their 
involvement in the drafting process and their responses are presented. 
 
During the in-depth interviews, most respondents reported non-involvement in the 
drafting of the consent forms except as translators but there was also some indication of 
unclear involvement in statements such as “we use the format and contextualize it to the 
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Botswana setting‖  and “at times if consulted we could change some of the things!”  
What came out clearly however, was that consent forms are developed by the researcher 
who was variously referred to by the respondents as “the sponsor”; “the research 
team”; “the study coordinator and the doctors involved in the study”; or “the 
institution”. One of the respondents summarized the process by saying:  
“the last time I heard about the preparation of the consent document 
some of the coordinators --- they were translating. To tell the truth 
they are the ones who prepare the form. Then we have a site meeting 
where the head nurse and doctors give an input”. 
 
Attention was drawn to the length of the consent forms and trial staff were asked for their 
comment. In one of the focus group discussions, one of participant remarked: 
“it‟s like a book, so we have to read everywhere so the participant 
can understand to make a decision. Sometimes it can take more than 
one hour because they ask questions!” 
 
This was echoed by one participant who added that: 
“the forms can be more than 20 pages long. But you will find that 
sometimes most of the pages are about the intervention which at the 
end of the day you can extract from [that] and put it aside and wait 
for the participant to consent then you can tell them about it. The 
translated version can go up to 25 pages”. 
 
However, one of the respondents in the in-depth interviews did not see length as a 
disadvantage because, according to her: 
“nurses are able to summarize the information from lengthy forms to 
about 6 pages, a page sometimes. Although they are long nurses with 
experience know how to pick the most important issues‖  
 
Participants in one of the focus group discussions had mixed opinions regarding the excessive 
length of the consent form as captured by one of the participants saying: 
“we are not saying we are happy but what we are saying is that if 
there could be a strategy that ensures that all the information is 
included without making it that lengthy”.  
 
This dilemma was elaborated clearly during the in-depth interview as follows 
where one respondent said: 
“In my opinion, I think the pages are ok although the package looks 
bulky. But if someone is at home with all the time to read they can 
understand. The form is well detailed unlike when you summarize. 
When you are the one doing the consenting you would understand but 
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the potential participant who takes the form home to read would not 
understand. So may be encouraging the potential participants to read 
a few pages at a go until they understand would help. I think it is 
important that they get all the information”.  
 
Another respondent concluded the debate on the excessive length of the consent form by 
resignedly admitting that “It‟s long and that is a problem, but it is worth it”.   
 
And finally, a word to the form‘s readability from one participant in one of the focus group 
discussions: 
“When designing a consent form you need to think of the bigger 
picture. For example who is going to read it? So if all the information 
is available in a short form it is ok. I have attended a workshop where 
we were asked; how long should a consent form be? We never 
reached a conclusion! Take into consideration all reader‟s needs”.  
 
And a wish to the future generation of researchers by one of the participants in the 
same group: 
“I hope we can find the best way and I am hoping the PhD student 
will come back and tell us the best way. Because even if it is long, it is 
how you administer it that matters! Establish what the potential 
participant needs to know and start with that and take your time!”   
The challenge therefore is how to involve the trial staff in the drafting process given their 
clear understanding that the consent form document is too long. 
 
The information disclosure process was investigated further to identify the effectiveness of 
the procedures followed. The study sought to identify the communication practices followed 
and perceptions of the effectiveness of the procedures used for recruiting potential 
participants, the language used, initial source of information about the study, the quantity and 
complexity of information disclosed, elements of the informed consent document, and 
methods used to communicate information. 
 
 The most common method reported was the use of recruiters and advertisements in the form 
of posters and flyers posted at the clinics or other public places. Self-referrals, referrals from 
public clinics/hospitals, and the use of the investigator‘s health facility (clinic/hospital) to 
approach individuals already in their database were also reported. One respondent during the 
in-depth interview was able to provide a concise summary of the recruitment process: 
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 “We hardly use the radio, but we use mainly posters put at the 
clinics. We also use the patient meetings, wards, antenatal clinics 
especially in the rural areas. A few patients come as self-referrals 
from private clinics. We identify a population that is need of ARVs 
(vulnerable) like the last study we did, we focused on ARV clinics so 
we were going there in advance to pick clients to talk to them in 
person or by phone, then we do home visits. Some of those who come 
to the clinic we get their contacts and some of them are in our 
database”.  
Three (3) other respondents echoed similar recruitment procedures. For example one 
respondent said that: “Our recruiters [they] go to the government clinics every morning and 
they talk to our patients”. 
 
From the discussions it became clear that the primary language of communication was 
Setswana except in the case of one who reported using English only and mainly provided 
information to parents by reading the consent form to them. Two other respondents however 
indicated that they offer parents a choice to communicate either in Setswana or English: “I 
talk to the parents in Setswana but some prefer English, [chuckles] most educated Batswana 
prefer to use English.” Another respondent noted the challenge of information complexity 
saying “The information provided is complex but we try as much as possible to simplify. It 
seems Setswana has a way round many English words”. 
 
A participant from one of the focus group discussions complained about the consent form 
being translated only in Setswana while there are many other languages spoken by potential 
participants and argued that this problem needed to be addressed as it compromised parental 
understanding. Given the sensitivity with which language issues are debated in Botswana 
(Moeng, 2013), this speaker, quickly dropped the topic saying dismissively, “use the day-to-
day language, although I do not know how it will be considered by the national ethics 
committee, whether they will see it as ethical”. Another participant captured the challenge of 
disclosing complex scientific information in a local language and the likelihood of 
misinformation in the following words:  
“We do not have some of the words in Setswana, but as long as I tell 
them what I understand and break down the technical language”. 
 
Majority (6) of the respondents complained during the in-depth interviews that the 
information given to parents was too much; two respondents rated the quantity as average; 
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and three said it was enough for the parents to make a decision. However, one respondent 
observed that having to listen to someone reading to you a lengthy text placed high demands 
on the parents‘ listening capability saying: 
“too much? Yah, you can say they have too much information. When 
you think someone is here and you are reading a 20 page document, 
you can‟t really expect her to understand it all, it‟s too much 
information” 
 
In her own angry utterance below, one participant in one of the focus group discussions 
dramatized the meaninglessness of too much information and how this leads to confusing 
parents when she says with a shake of the head: 
“Um.....to me, sometimes it feels like it‟s too much and sometimes I 
feel like we are just confusing her. We are telling the mother, that 
time when you came for registration, the baby is going to be 
tested.....then we start telling them…” 
 
Perhaps due to the respondents‘ GCP training, there was the reluctant acceptance that the 
information was “too much, but necessary and part of the ethical principles” and that it was 
“enough for a person to make a decision”.  
 
One participant in one of the focus group discussions expressed doubt whether all of the 
information disclosed was useful to the parents and said: 
“For a long consent form, about half of it is about drugs, so I 
concentrate on the section where the participant has been given a 
drug. Most of them cannot memorize the drug names”.  
 
As a way to minimize the confusion created by too much information, one respondent 
suggested making the consenting session as interactive as possible saying ―It‟s ok because 
after explaining you allow time to ask question”. 
 
During the in-depth interviews, respondents were asked the following questions relating to 
the complexity of the information provided with particular reference to the technical language 
used: 
1.  Considering the complexity of the technical language used in the consent form, what 
standard of disclosure do you use to disclose information to the parents?  
2. How do you rate the complexity of the information you provide to the parents?  
In response to the first question, the phrase “all the information” was heard from seven 
respondents during the in-depth interviews.  In response to the second question, the phrase 
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“too complex” was echoed nine times implying that the problem of technical language is a 
real challenge and according to one of the respondents, “Scientific terms can be very complex 
and are a challenge to explain”. There was no clear agreement on the accuracy of the 
translations from English to Setswana, with one respondent admitting that “sometimes we 
lose the meaning of certain words when we explain in Setswana”. Another stated that “It 
depends on the study but most studies I have worked on have been very complex, but the 
translation covers how you can explain”. The issue of complexity of information was also 
discussed at length during one of the focus group discussions. In an effort to simplify the 
complex technical terms, one participant said: 
“we do appreciate that Setswana has the written and spoken type, but 
we say some English words in Setswana way of translation, local 
language specialist need to be involved in the translation since the 
Setswana language has different dialects.” 
 
The linguistic challenge was acknowledge by all the participants as real. It left many of them 
doubting whether so much technical and complex information was beneficial to the 
consenting process of a desperate and vulnerable parent.  
 
During the in-depth interviews each respondent was asked to comment about the specific 
elements in the consent form they found most difficult to explain. Results showed that 
majority found explaining technical terms like ‗randomization‘ and ‗placebo‘ difficult and for 
as indicated by one of the respondents: ―It is difficult to bring out the meaning in Setswana”, 
while another respondent said: 
“I describe it [randomization] as the distribution, but even myself I 
do not know. I would not say it has no effect because somewhere 
patients switch their medication to get to know which one works”.   
 
‗Risks‘ and ‗study procedures‘ were elements of informed consent process that were 
specifically mentioned by several (5) respondents as difficult to explain. The demand to 
explain procedures clearly according to one of the respondents is “because that is where most 
parents base their decision”. Another respondent said, but without explaining how, that she 
uses analogies for the difficult terms that do not exist in Setswana and added that “It is 
difficult to explain, but I have long experience so am able to address most of the issues”. 
Very few respondents reported that they were comfortable communicating all the consenting 
elements with one of them outlining how she handles the task thus:  
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“I do not find any section difficult because I follow the form as it is, 
may be when it comes to difficult medical terms, I say them the 
simple way for example „gastroenteritis‟ I would say diarrhea”. 
Another respondent added that: 
―It‟s not that easy because sometimes you end up using other words. 
Fortunately some of the parents can read English, so after that we  
give them the English version to read at home”. 
 
Respondents were quite outspoken during the in-depth interviews about the issue of 
communication as the following comments indicate: 
“To me communicating is not a problem. But many people feel 
Setswana is difficult to read. There are some other words that are 
difficult to understand. So to me it‟s important to master Setswana”.  
 
“I communicate to the parents verbally by reading to them in Setswana 
but the English consent form can be given to them to read during the 
session”. 
 
―If the study is too long, I tell them by verbally reading but with time 
am able to give a summary, stop if a client has a question. Most clients 
are able to read so I encourage them to take the form home and read”. 
 
“You try to explain everything but to a level of the patient‟s 
understanding in order to understand each other. These days people 
are knowledgeable and some have previous experience in research so 
this helps”. [Chuckles]... We tell them everything in case something 
goes wrong, we do not leave out any information”.   
 
In the next section the study focuses on what respondents thought about levels of 
understanding. 
 
4.4 Comprehension of information 
 
Another theme that was analyzed was the perceptions of trial staff on the levels of 
understanding of the information disclosed to the parent. The next section presents the results 
from the trial staff‘s in-depth interviews and focus group discussions. 
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4.4.1. Trial staff perceptions about parental understanding of information disclosed 
 
As part of assessing parents understanding of the information disclosed, trial staff were asked 
about their perceptions of parents‘ initial reaction to enrolling their child into an experimental 
study.  They were also asked if parents understood the difference between research and 
treatment. To assess parental understanding the trial staff were also asked if parents asked 
any questions during the consenting process, what methods they used to test levels of 
understanding, and what they thought was a favorable duration for the consenting process. 
 
Responses given during the in-depth interviews about their perceptions regarding parents‘ 
initial reaction to experimentation on their children were mixed.  Some of the respondents 
described most parents as being „anxious‟, while others said parents were expressionless but 
appeared frightened. One respondent described the parents as being “more anxious than 
when they came” and “hopeful”. Another respondent described the parents as “mostly 
initially anxious” especially for those whose children have never been tested for HIV by 
saying that “I think some of them think there is something seriously wrong with the child”. A 
few respondents said the parents looked „ok‟, without elaborating. However, other 
observations were also made. For example, one respondent observed that “Some parents are 
shy because the culture makes it difficult for them to express themselves”. 
 
Another respondent reported that: 
“Some parents are happy because of the care they get at the research 
center. For example no long ques, more privacy and more time with 
the doctors and nurses. Even after the study closes they do not want to 
be transferred back to the public facilities”. 
 
One respondent observed that parents from rural areas were eagerly keen on clinical trials and 
said thoughtfully,  
“Um… one thing that I have noticed is that those from the rural areas 
when they hear about a study which is about to start, it is like when 
should I bring my child‟?... it is not a struggle because they also 
believe in being tested. Also due to shortage of staff at the public 
clinics, the parents prefer coming to the research centres”. 
 
During the in-depth interviews, the distinction between research and treatment was vaguely 
made by most trial staff; explanations given were shallow and it seemed as if the trial staff 
themselves were not really sure whether parental understanding of the difference occurs or 
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they just did not want to commit themselves.  One respondent sounded almost unconcerned 
saying “Some do [understand the difference] as they have participated in other studies”, 
while another said ―We try to explain”. This was echoed by yet another “Not really but we 
try until we feel they have understood”. That trial staff are committed to proper conduct of 
the consenting process came from this response: 
―Most of them say am happy because my child will be treated but we 
continue to explain the difference. We keep reminding them from the 
beginning that this is research”.  
Only one of the trial staff confidently said “yes parents understand the difference between 
research and treatment” but did not elaborate. From the focus group discussions, came this 
detailed explanation that conveyed the general perception of the whole group that the 
distinction is very marginal: 
“There is a thin line between the care [they] get from the public 
facilities and the care they can get here such that on referral a parent 
can say „I am coming from the clinic because I was told to come‟, then 
we ask them, „do you understand why you are here?‟ and they respond 
to say , „No‟. Until you get them to understand that this is a research 
institution and not like the other clinics” 
Given the respondents‘ doubts regarding parental understanding of the distinction between 
research and treatment, we wanted to know how trial staff ascertained whether or not parents 
understood the information that was provided. It was revealed by all the respondents that the 
study team is tasked with developing a tool called “Assessment of Understanding” which 
trial staff administer verbally or in writing on every parent who must score above a given 
minimum mark for their child to be enrolled in the study. One respondent said a parent “must 
score 7 out of 10; if lower I re-book them for another session”; but another respondent was 
less objective and said “judge from facial expression and gestures”. 
 
Respondents were asked during the in-depth interviews whether parents asked any questions 
during the consenting process, and if they did, what the parents‘ main concerns were; and if 
they did not ask questions what were the reasons. Six respondents reported that some parents 
“especially the educated” asked questions mostly about the safety of the child, and the 
benefits, and about the frequency of the visits to the research center. A few asked about 
compensation for transport, and according to one respondent: 
“some come when they have made up their mind, they will not even 
care much about risks. Some do not even consider risks explained as 
risks and in such cases we experience difficulties with following them 
up” 
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Opinion was divided regarding why parents do no ask questions. One respondent thought the 
parents do not ask questions often because “Batswana are submissive by nature. Initially they 
are quiet but with time they ease up”.  Another reason for parental silence which may be 
attributed to the view that participation would bring benefits was given by one saying: 
“for now I have not had many of them asking questions because to 
them they think we are going to help them by testing the babies. Some 
just want to have their babies tested they would not be intending to 
participate in the study”. 
One respond mentioned that: “respect and trust for medical personnel and feeling more at 
ease with nurses than with doctors” could be attributed to parents‘ inability to distinguish 
between treatment and research. It is perhaps for that reason that “some are just quiet and 
you will not know whether they are listening or not”. Another respondent explained that the 
reasons why parents do not ask questions as follows: 
“with the burden of the responsibility over a sick child, parents 
perhaps develop fear for their children to be involved in research due 
to lack of understanding and concern about risks; and may be because 
they are not ready or not sure which decision to make. You may 
assume that they have understood so you have to check whether they 
understand but sometimes it is lack of knowledge”. 
 
During the in-depth interviews respondents‘ opinions were also sought on how long the 
consenting sessions should last to enable adequate understanding. It became clear that 
duration varied case by case. For example one respondent said it “may be one hour but for 
those who need more time we book them to come another day”. Another respondent reported 
that: 
“some come ready to consent or not to consent, so we give them the 
form to take home and read and give them a time frame when they 
should come back with an answer”. 
However, some respondents reported that the process should be conducted a few times before 
the parent makes a final decision. For example one respondent said: 
“at least two to three encounters, usually I try not to make the 
participant sign at the first encounter. I allow them time to think about 
the request [child enrolment] and consulting with family”.  
 
 Two other respondents expressed similar views about the length of the sessions; one of them 
specifically said that “depending on the study, I give them choice to come again if they are 
tired”.  
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The next section reports findings from in-depth interviews and focus group discussions in 
response to questions that assessed parental understanding of selected elements of the 
informed consent process. 
 
4.5 Trial staffs’ perceptions about parent’s motivation and decision making 
 
In order to understand what motivated  parents to make a  decision to enrol their children in 
HIV clinical trials, trial staff opinions were sought on the  importance of consulting both 
parents and relatives of the child even after the person who has brought the child to the clinic 
has agreed. 
 
All respondents agreed that it was important to consult both parents and other family 
members, because most parents insist on going back to consult especially for studies that 
involve drugs. One respondent elaborated that consulting was important for purposes of 
retaining children in the study. On who exactly the respondents the parents consulted, 
majority of respondents reported that it was either the grandmother or the spouse or both. 
Another respondent added that other relatives could also be consulted. However, on whether 
the outcome of the consultation influences the consenting process, one respondent could not 
hide her unhappiness and said:  
“it delays the process but there is nothing you can do. If someone 
requests I just let them. Another one requested to go back and consult 
but I had to push because the condition of the child was bad and it 
needed emergency treatment”. 
Another respondent shared similar sentiments echoing the tension that sometimes occurs: 
“but it delays the process because there might be disagreement on the 
decision. Some do agree to participate while at the clinic but later 
come back and refuse to enrol the child”. 
 
Consultation is however beneficial because “after consulting they come back more relaxed, 
relieved and comfortable to enrol the children in the study”. 
 
On how agreement to child enrolment by parents was being indicated, all the respondents 
said that this is done by signing the consent form. When the respondents were asked about 
parents‘ attitude to the signing of the consent form after the lengthy discussion process, one 
of the respondents said “parents are happy to sign but some do not want to take a copy of the 
form with them”. Several respondents expressed similar sentiments and one respondent 
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specifically saw the signing as bringing relief to the parent, saying the parent is “relieved that 
they will get into the study”. However, one with long consenting experience noted that:  
“Sometimes we can tell that the parent is not comfortable with the 
signing so we can involve a counselor or a senior nurse or doctor to 
help. Young mothers prefer trial staff of relatively the same age as they 
are and vice versa”. 
 
To conclude the interview sessions, trial staff were asked if they had anything they had to say 
regarding the consenting process. It was interesting to hear them voice their experiences as 
trial staff in the search for a cure for the disease. For example one of the respondents said: 
“Some people have realized the importance of doing something about 
the disease; they see the difference in those who participate. They are 
hopeful that a cure might come, a benefit that might help other 
children”. 
Another respondent spoke at length about the cultural practice called ‗confinement‘ which 
sees a mother having to move to back to  her parent‘s home for more than three months soon 
after delivery resulting in ‗loss to follow-up‘ and retention in a study. She also spoke about 
how poverty makes it “difficult for the parents to afford transport to come for appointments” 
and, as also noted by another respondent who  spoke about  how some parents, due to 
poverty, spend the transport money given by the centre on other pressing  needs and having 
spent the money, they are unable to show up for follow-ups. 
 
Respondents also spoke about what attracts parents to the research centres and named the 
good care they receive at the research centre. According to one respondent: 
“our clients say they get the best care while on study than in public 
clinics and complain about inadequate public services like shortage of 
health personnel at the public clinics”. 
Another respondent said “they [the parents] have so much trust in the research centre”. One 
attraction for parents that was mentioned is the re-imbursement of transport money which 
makes the consenting a tactful process for trial staff where for instance, one respondent 
suggested that “providing transport money should be mentioned at the very end or after a 
parent has expressed the need”. One respondent took the opportunity to speak about the 
challenge of over-enthusiasm that trial staff sometimes face and said, “some parents just 
want to enrol their children without discussion, they already know from friends or recruiters. 
Some of them will tell you „You know what I came here for‟, but we insist on discussing and 
test for understanding”. Other challenges were summed up by one respondent:  
“low literacy levels, too much trust put into health workers, the nature 
of HIV disease being chronic and with no cure, research not being well 
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understood and the implications of signing for research when normal 
treatment is not signed for”. 
 
Another respondent raised the challenges of “limited understanding of research and science” 
and the inadequate “compensation money [which] is too little but the cost of transport has 
gone up”. Language barrier was also raised as a challenge by another participant saying that 
“Setswana is difficult to read even for the Setswana speakers. Also many of the English 
scientific terms are not in Setswana”. Respondents made a number of recommendations 
regarding the challenges raised; on delays arising from the parent consulting with other 
family members, one respondent recommended that:  
“Uh!.. I do not know but during the screening the regulations could make 
it a requirement for the parent to come with a partner or caregiver. 
Involve everyone who has been in contact with the potential participant 
in facilitation of understanding and decision making”.  
This would minimize delays arising from consultations with spouse and relatives. One 
respondent recommended public education, not just for concerned parents, saying “sensitize 
the public about research and its importance”. Many respondents wished to have the consent 
form shortened and simplified but without omitting vital details and one elaborated thus:  
“the consent form should not be too long, it makes the patients stay at 
the centre for a long time and they get tired or they think about is to be 
finished with the process and go home. This causes lack of 
concentration during the consenting process. The patient should be 
given the summary to take home and read then the trial staff can 
elaborate during the consenting process”. 
 
4.6 Conclusion 
 
Respondents expressed their concern that a lot of legal, ethical and practical challenges still 
exist, especially therapeutic misconceptions which hinder valid parental consent. However 
they noted that some parents are getting to understand the importance of pediatric research. 
They also felt that the care rendered to the parents during the research should be extended to 
the public facilities to avoid suspicion of undue influence. 
 
The next chapter presents results from the parents‘ semi-structured interviews. 
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CHAPTER FIVE 
RESULTS FROM SEMI-STRUCTURED INTERVIEWS WITH PARENTS 
 
5.0 Introduction 
 
One hundred and fifty-one (151) parents responded to a semi-structured interview 
administered by two research assistants over a period of one year. Methodologically, the 
information gathered from parents through interviews with parents was compared to the 
information from trial staff during the in-depth interviews and focus group discussions. The 
presentation of results is according to the five thematic areas of the informed consent process, 
namely: communication, comprehension, motivation, decision making and voluntariness. The 
chapter begins with a presentation of the summary of the summary of the descriptive statistics 
of the parents‘ and their children‘s demographic characteristics (Tables 5.1). 
 
5.1 Summary of demographic characteristics of the parents and their children 
 
 As shown in Table 5.1, the majority of the interviewees 142(94%) were females aged 
between 31-49 years. More than 60% lived in rural areas. A great proportion of the parents 
were single (76%) while only a few of them were married (21%). Most parents, 99 (65.6%), 
had only completed primary and junior school i.e. 9 years of basic education and were able to 
read and write131 (87%) compared to only a few 20 (13%) who reported being unable to read 
and write.  Almost all136 (90.7%) the parents preferred Setswana as the language of 
communication followed by those who 11 (7.3%) preferred English and very few 3 (2%) 
preferred to communicate in both Setswana and English.  
 
The majority of parents141 (94%) indicated that they were head of household compared to 6 
% who reported ‗other‘ as heads of household. A greater proportion of mothers were single 
parents 113 (76%). About three quarters 79 (58%) of the parents reported that they had paid 
employment, however most of the jobs cited on probing were in the low-income bracket (e.g. 
cleaner, farm worker or shop attendant) and so, many of them appreciated the money 
(Pula.30.00, approximately $5.00) given as compensation for transport. These two comments 
convey this appreciation: 
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―The study was very good because most of the time when coming here I 
was borrowing money from somewhere”  
 
“The study was very good because people used to [lend us] money 
easily while we were on the study but nowadays it is difficult”  
 
Table 5.1 also shows the demographic characteristics of their children. The majority of 
children who were enrolled in the HIV clinical trials were in the age range of 6 to 15 years 
110 (83%) while those who were less than or equal to five years were very few 8 (6.1%). A 
greater proportion (70%) indicated that they were the biological parents of the enrolled 
children. Slightly more than half of the children 77 (51%) had previously been enrolled in 
other clinical trials and about 134 (89%) had been seen in the clinic many times.  
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Table 5.1: Parents and Children Characteristics who participated in the study (n=151) 
 
 
 
 
Parent Characteristics  
Gender Values n % Cumulative 
       % 
Female 142 94% 94 
Male 9 6% 100 
Age (years) ≤=30 25 16.6 16.5 
31-49 98 64.9 81.5 
≥=50 28 18.5 100 
Place of Residence Rural 94 62 62 
 Urban 57 38 100 
**Marital status    
*Marital status Married 32            
21 
21 
 Single 113 76 97 
Widowed 5 3 100 
Education None 13 8.6 8.6 
 Primary& Junior 
School 
99 65.6 74.2 
High school 34 22.5 96.7 
Tertiary 5 3.3 100 
Ability to read and write Yes 131 87 87 
No 20 13 100 
*Preferred language  Setswana 136 90.7 90.6 
English 11 7.3 98 
Both Setswana & 
English 
3 2 100 
Head of household Self 141 94 94 
Other 10 6 100 
Employment Employed 79 52 52 
Not employed 73 48 100 
Children Characteristics     
*Age ≤ 5 8 6.2 6.2 
6-10 56 42.7 48.9 
11-15 54 41.2 90.1 
16-20 13 9.9 100 
Relationship to parent Biological parent 106 70 70 
 Other 44 30 100 
Previous participation in research Yes  77 51 51 
No 74 49 100 
No. of times child  was brought to the 
clinic previously 
Many times 134 89 89 
Few times 17 11 100 
*missing data n≤ than 151 
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5.2 Communication 
 
Parents were asked a range of questions pertaining to communication and the findings are 
reported under the four sections below. 
 
5.2.1 Parents’ awareness of seven basic elements of informed consent 
 
The first element in the informed consent process is disclosure of information about the study 
so that participants can use this information to make informed decisions. This process 
provides knowledge or awareness about the study to facilitate understanding. According to 
Pickard (2007) this knowledge is applied when people remember relevant information. So, 
parents were asked if they were aware or could recall being told about seven key selected trial 
elements during the informed consent sessions with trial staff. As shown in Figure 5.1, 
only129 (85%) of the parents indicated they could remember the purpose of the study while 
22 (14.6%) were not aware of the purpose of the study. A higher proportion (95.3%) of 
parents interviewed indicated that they could remember being told about the risks associated 
with their child‘s participation in the clinical trial. Nearly all the parents 148(99%) affirmed 
they could remember being told about the number of study visits they would have to make 
during the duration of the study. A large proportion (86.4%) of the parents was aware of the 
number of times the child would receive medication.  Regarding receiving of payment for 
child enrolment into the study, only 125 parents out of 151 responded to this question, a few, 
39 (31.2%) parents could remember being told about a payment while a higher proportion 
(n=86, 68.8%) indicated that they could not remember.   
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Figure 5.1: Parents’ awareness/recall of seven key selected elements of informed consent 
covered in the studies (n=151) 
 
The number of parents that were aware that they were free to withdraw from the study at any 
time was high, 122 (81.3%) among the parents interviewed. Out of 140 parents who 
answered the question  about knowing that the doctor would decide which medication would 
be given to the child, over 75% affirmed that they were told as contrasted with 27 (24.6%) 
who indicated lack of knowledge of this aspect of the consent form. Although the percentage 
of those who responded positively to this question was higher it is worth noting that this 
question was skipped by many parents. 
 
Bivariate analyses showed that age was significantly associated with the parents‘ ability to 
remember having been given information about the elements shown in Table 5.2.These 
included the number of study visits (Fischer‘s exact; p =0.0248), number of times the child 
would receive medication (Fischer‘s exact; p = 0.0470) and that the doctor would decide 
which medicines to give to the child (p=0.0132). About 98 (75%) of the parents of middle 
age (31-49 years) remembered most of the elements followed by those who were 30 years 
and younger (n=25, 61%) while those older than 50 years, 28 (63%) could not remember 
much. 
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Parent‘s previous experience in research was also highly associated with the parent‘s ability 
to remember having been told about the risks of child enrolment into the study (Fischer‘s 
exact; p<0.0050) and how the doctor would decide which medication to give the child         
(p< 0.001). Relationship of parent to the child was also associated with the parent‘s ability to 
remember being told about the risks of child participation in the study                          
(Fischer‘s exact; p< 0.0490) and the number of study visits (Fischer‘s exact; p< 0.0250). 
 
5.2.2 Parents’ rating of importance of information disclosed 
 
Parents‘ perceptions were sought regarding how important the information that had been 
disclosed to them was for decision-making either as ‗Important‟, and „Not Important‟. Figure 
5.2 shows the results. A total of 147 parents responded to this question. The elements that 
parents considered as ‗Important‟ for decision-making were knowing why the child had to be 
enrolled in a study, 132 (89.8%), knowing the risks of enrolling the child in a clinical trial, 
141 (96.0%), the number of clinic visits during the study, 142 (96.6%), the number of times 
the child would be receiving medications135 (92.0%) and that the doctor would decide which 
medications to give the child 111 (75.5%). Surprisingly being told about whether the parent 
would receive compensation for child enrolment into the study (n=49, 33.0%) and freedom to 
withdraw child from the study any time (n=88, 60%) were not considered as important by 
quite a number of parents. 
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Figure 5.2 Parental rating of importance of information provided for decision making 
(n=147) 
 
In a separate set of questions, 151 parents were asked whether the information disclosed to 
them had influenced their decision making as to whether to participate in the study or not. 
Overall all 148(98%) of the parents felt that the information disclosed had been very 
important for decision-making and majority of them 149 (99%) reported that they had been 
satisfied with the information that was provided. Furthermore, overall all 149 (99%) the 
parents reported that during the consenting sessions, they felt the trial staff were very honest, 
caring and sympathetic 149 (99%) and were knowledgeable about the study 148 (98%). 
However, quite a number 83 (55%) also felt the trial staff were being persuasive. 
 
5.2.3 How well-informed parents were about the seven key selected trial elements 
 
It is important that research subjects are well-informed before undertaking important 
decisions concerning their lives or those they legally represent. In order to assess how well-
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informed the parents were about seven key selected trial elements parents were asked using a 
―yes‖-or-―no ―responses. The findings are shown in Figure 5.3. 
 
 
Figure 5.3: Responses from parents about how well informed they felt about seven key 
selected trial elements (n=147) 
 
Overall the results in Figure 5.3 showed that slightly more than 50% of the parents did not 
have a full recall of most elements.  For example, 52.4% of the parents reported that they 
were not well-informed about the purpose of study, while 55.8% reported that they were not 
well-informed about the risks of enrolling the child into the study, the number of times the 
child would have medication. Another 54.4% reported that they were not well-informed 
about how the doctor would decide which medications to give the child. However a larger 
percentage of the   parents reported that they were well-informed about the following 
elements; the number of study visits they would need to make to the clinic during the 
duration of the study (90%); not being compensated for child enrolment onto the study 62% 
and 73.5% reported they were well-informed about their right to withdraw the child from the 
study anytime. 
5.2.4 Parent-Trial staff interaction process 
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Parents‘ perceptions about how the trial staff conducted the information disclosure process 
were sought from the parents. Results showed that the majority136 (92.5%) of parents 
preferred to communicate in the local official language Setswana. The parents were also 
asked about the first contact person who talked to them about the study. Out of a total of 151 
parents, 138 (91.4%) said ‗nurses‘ while 12 (7.9%) said ‗doctors‘ and 1(0.7%) said ‗friend‘.  
Regarding the reading of the consent form, parents were asked whether they had read the 
forms by themselves or someone read it to them. A majority, 71(47.6%) indicated that they 
had read it by themselves, followed by 43 (28.9%) who responded that they had read some 
sections on their own and were helped by others to read some of the sections. Some of the 
parents 31 (20.8%) indicated the form was read to them by the trial staff while very few 4 
(2.7%) indicated the form had been read to them by a family member.  Unfortunately details 
of when and where the reading occurred were not asked for. When asked how much time 
they had taken to decide on child enrolment, majority 126 (84.5%) reported that they had 
agreed the same day that they were approached for consent, while a few23 (15.5%) reported 
that they had taken some days to decide. Some of the parents did not answer this question. 
 
Using a format of ―yes‖-or-―no‖ response questions, parents were also asked for their 
opinions about how the consent process was conducted. Overall the results in Figure 5.4 
show that the majority of parents were happy with the way the informed consent process was 
conducted. The majority 124 (91.1%) felt the explanation about the medicines the child 
would receive was clear. Quite a number 109 (73.2%) were of the opinion that the 
information provided had difficult medical terms but they were clearly explained. Regarding 
testing for understanding, almost all the parents agreed that they had been tested for 
understanding 148, (98%), were given an opportunity to ask questions 148 (96.7%) and they 
did ask questions 146 (96.7%). Overall almost all the parents 149 (98.7%) reported that they 
were satisfied with the interaction process and many of the parents 148 (98.7%) were of the 
opinion that that the information provided had been very important for deciding on child 
enrolment into the trial.  
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Figure 5.4: Parents’ self-report of how the information was disclosed (n=149) 
 
It appears that the information disclosure process went well if the responses from the majority 
of the parents are to be believed. To verify the extent to which the responses were credible, 
the study further investigated parents‘ comprehension as reported below. 
 
5.3 Comprehension 
 
Parents‘ retained comprehension of the information disclosed was assessed using a set of 
―true/false‖ statements about each of the key elements of the informed consent process 
namely; purpose of the study, study procedures, alternatives to not enrolling child in the 
study, study risks, randomization and confidentiality. The process involved reading to the 
parents a set of statements about each of the key selected elements of the informed consent 
process to ascertain whether they could recognize if a statement was ―True‖ or ―False‖.  
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5.3.1 Parents’ retained comprehension of the information disclosed 
 
Figure 5.5a shows the results from 5 statements describing the purpose of that study in which 
the parent enrolled the child. Overall a great proportion of the parents correctly recognized 
that the main reason for their child‘s enrolment into the study was not to receive treatment 
(86%), find out which drugs were cheapest (65%) or improve the treatment of future HIV 
patients (97%) but to test the safety of a new HIV drug (77%) and to find out which medicine 
works best in order to help future HIV positive children (58%). Overall three out of the five 
questions (60%) were answered correctly. 
 
 
Figure 5.5a: Parents’ comprehension of purpose of the study (n=149) 
 
Questions were asked about the non-scientific methodology procedures namely; withdrawal 
of child from study any time by the doctors, number of study visits and the duration of the 
study (Figure 5.5b). Out of the 148 parents who answered the questions, the majority 137 
(92.6%) could recall that the child could have been withdrawn from the study anytime and 
the number of times they would bring the child to the clinic 135 (91.8%). However many 
parents 115 (77%) were not sure of how long the child‘s participation in the study would last.  
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Figure 5.5b: Parents’ comprehension of information about non-scientific methodology 
study procedures (n=149) 
 
Comprehension of scientific methodology procedures like randomization process and placebo 
use were also assessed (Figure 5.5c). These included how the doctors decided which 
medicines to give each child and which type of medicines children had received. 
 
Regarding how the doctors decided which medicines to give each child, responses from a 
good proportion of parents (79.1%) indicated that parents could recall and had understood that 
the doctors decided which medicines to give their child based on chance while 81.8% could 
recall that the medicines given to according to the choice of the parent. However more than 
50% indicated that the choice of medicines was based on what was best for the child. 
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Figure 5.5c: Parents’ comprehension of randomization to interventions (n=149) 
 
A large proportion of parents (90%) affirmed that the doctors did not allow them to choose 
which medicines were to be given to their child. Although most parents 122 (82.4%) 
understood that all the children had not received the same medicine, and 134 (90.5%) parents 
knew that HIV positive children had not received different medicines as  all the children were 
HIV positive,  results showed that most parents had a poor understanding of how the 
medicines were allocated to the children. For example, 135 (91.2%) parents did not correctly 
indicate that some children were supposed to receive medicines that were not active and 137 
(91.8%) could not recall that some children were to receive medicines that were being tried. 
However, of concern was the large proportion (69.9%) of the parents who responded that the 
choice of medicines was based on what the doctors thought was best for the child. 
 
Parents‘ retention of comprehension was also assessed regarding their rights to child‘s 
enrolment into the study using a set of five ―True or False‖ statements. Results showed that 
majority of parents could recall their rights regarding child enrolment into the study. For 
example Figure 5.5d shows that a large proportion of the parents could recall that: 
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 they could not have enrolled the child into the study without signing or putting a 
thumb on the consent form (88.5%),  
 they could have withdrawn the child from the study anytime  (92.5%), and that 
 their child could have still been treated at the clinic even if they had refused to enrol 
the child into the study (91.2%).  
However, only 12 (8.1%) parents could recall who would be responsible for payment of 
research related injuries as opposed to 136 (91.9%) who indicated that they had not been told 
about this and 54 (36.5%) who indicated that they did not know. 
 
 
 
Figure 5.5d: Parents’ of comprehension of their rights (n=149)  
 
Parents‘ retention of comprehension   of the elements of confidentiality, risks, benefits and 
alternative to not participating in the study were also assessed. Figure 5.5e shows that parents 
overall only a few parents 41 (28%) could recall  that other trial staff not involved in the 
study  might be  allowed to look at their records and there was a risk that  the  medicines 
given to the child having life-threatening effects on the child 22 (15%). However, 95 (63%) 
of the parents retained an understanding that the benefits to the child of participation were 
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uncertain and 124(82%) could recall that there were no alternative drugs available to their 
child other than through participation in the study. 
 
 
Figure 5.5e: Parents’ overall compression of the elements of confidentiality, risks, 
benefits and alternatives (n=149) 
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A summary of overall understanding of the groups of questions that were asked about each 
element is represented in Figure 5.5f below.  
 
 
Figure 5.5f: Parents’ overall retention of comprehension of selected elements (n=149) 
 
Overall the majority (82%) of the parents had a good retention of comprehension of the fact 
that there were no alternative treatments for their children‘s condition other than participation 
in the study. Likewise, a majority (77%) of the parents had a good retention of 
comprehension of the   purpose of the study, their rights (72%) and the fact that benefits of 
the study were uncertain (63%). However, fewer parents were able to recall the 
randomization process (38%), confidentiality of records (28%) and the risks of enrolling the 
child (15%).  
 
5.4 Parents’ motivation to enrol child into the study 
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the study. Over 65% of the parents indicated that they had been motivated by the ‗illnesses of 
the child, while 32.9% were motivated to „help‟ future HIV infected children. Asked whether 
they would have joined the study if they had not been paid Pula 30.00 (approximately $4.00), 
majority, 129 (85%) said that they would still have enrolled their child. 
 
In order to double check the answers that had been given for motivation, parents were also 
asked whether or not they had been pressured by any other person to enrol the child into the 
clinical trial. Majority, 147 (97%) responded that they had not been pressured by anyone. 
Even when they were directly asked who put pressure on them to enrol their children into the 
study, a large proportion (98%) said that they had not been pressured either by the doctors, 
trial staff, health facility workers, spouse, family or anyone else. However, when asked about 
how much pressure they felt themselves to join the study because of their child‘s illness, 
more than 65% indicated that this had been a major consideration. 
 
5.5 Parents’ decision making and voluntariness 
 
The majority (n=136, 91%) of the parents reported that they had made the final decision to 
enrol the child into the trial by themselves. The rest of the parents, 13 (9%) reported having 
been assisted in the decision-making process by the spouse, trial staff, or doctor. Bivariate 
analyses showed that decision making was significantly associated with the numbers of clinic 
visits (p= 0.0400), previous experience in research (p=0.002), being a biological parent 
(p=0.0599) and being paid for participation in the study (p= 0.011).  
 
Regarding voluntariness, parents were asked whether they could have refused to enrol the 
child in the study if they had wanted to. Majority of parents (n=107, 70%) responded they 
could not have refused mainly because of their child‘s illness and because they had been told 
that they had a right to enrol or not to enroll the child. Some of the comments by the parents 
at the end of the interviews indicated that they had decided to enrol the child even before they 
were talked to by the trial staff also some comments indicated an obligation to help future 
children and others explained that it was because they had understood the study purpose. 
There were also reasons given by individual parents like ―wanting to know the results from 
the tests that were done”; „guilt‟ (my child would have seen clearly that I have refused); one 
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parent said „they‟ were not allowing that‖ and another said it was because of “the trust they 
had in trial staff”. 
 
On a scale of „very easy‟, fairly easy‟, fairly difficult‟ and „very difficult‟, respondents were 
asked to rate the ease with which it would have been difficult to refuse. Out of 151 parents, 
147 responded to this question. Only a small proportion (37%)   felt it would have been very 
easy, while 35% felt it would have been fairly difficult, 28% felt it would have been fairly 
easy  while another  8% felt it would have been very difficult. 
 
Regarding how the parents indicated agreement to child enrolment into the clinical trial, a 
large proportion 89%) did so by signing of the consent form, while 11% put a thumb print on 
the form. Asked whether they would have preferred to consent by just talking to the doctor or 
signing on the form, a large proportion (98%) preferred signing the form rather than agreeing 
verbally. Unfortunately the reasons for this were not asked. Finally the parents were asked 
how much time it had taken them to decide to enrol the child into the study. The majority 126 
(83%) of the parents reported that they had decided the same day while a few, 23 (15%) 
indicated they had decided a few days after being talked to by the trial staff. 
 
At the end of the interview parents were given an opportunity to comment on the entire 
informed consent process. Table 5.2 shows the comments that were made by the parents. 
These comments seem to suggest that parents of children with threatening chronic diseases 
may view research as a form of treatment. For example a number of parents reported that 
they wished the study that their child was enrolled in could be repeated as their child had 
improved a lot during the study, received better drugs than what is offered by the public 
clinics and some reported that they did not notice any drug side-effects.  
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Table 5.2: Some of the comments made by parents at the end of each interview 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These statements raise questions regarding understanding of the information disclosed during 
the informed consent process, the difference between research and treatment and the 
voluntariness of informed consent by such parents. 
 
In summary the findings seem to show that despite the high recall of most of the information 
disclosed to parents, retention of comprehension of information is mainly focused on the 
benefits linked to care the child would receive from participation in the study.  
 
 
 
 
 
Comments from some parents about the trials 
“I joined the study because they had better drugs than the national program. 
For example the tablet … was only given to children on the study” 
“I wish it can repeat again our children are always asking that” 
The study was very good, I wish they can repeat” 
“I want the study to repeat because we were treated special and the child was 
seen by the doctor  every month to see progress 
“The study was very good I wish they can repeat it again” 
“I think this study could continue again 
“The study was very good even the side effects that were mentioned are not 
there” 
The study was very good because my child did not experience any side effects 
which I was scared of from the beginning 
“My child did not have any side effects she was as normal as everyday” 
“Since joining the study my child‟ health improved a lot” 
”When I joined the study my child was very sick but afterwards she improved” 
“The study was very good it helped the child a lot 
“I managed to learn more about HIV when I was on the study” 
“We ended up knowing a lot about ARVs since joining the study” 
“The study was very good because they were teaching us everything” 
“Because I had already decided to join” 
“I think there is hope that medicines will be seen soon” 
“The study was very important to the nation” 
“If that study was there in 2001, my child would not have died” 
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CHAPTER SIX 
DISCUSSION 
6.0 Introduction 
 
The purpose of this study was to conduct a holistic analysis of the parental informed consent 
process for child enrolment in HIV clinical trials in order to develop a model that could be 
used to guide the consenting process in Botswana. The study was accomplished by (i) 
analyzing the readability of the consent forms (ii) examining trial staff communication 
methods and perceptions and (iii) assessing parents‘ experiences of the consenting process. 
The discussion is formatted around themes that emerged from the findings. 
 
6.1 Trial staff training 
 
Since skills are central to the consenting process, this section discusses the training of trial 
staff. All trial staff who participated in this study had adequate and relevant tertiary education 
mainly in the nursing field. They also had informal basic training in human subjects‘ 
protection which was either in the form of online GCP, CITI, short workshops or seminars. 
Despite this training, trial staff seemed to lack theoretical background knowledge in one 
critical area, namely the clinical trial phases and their risk categories. It was quite clear that 
trial staff did not apply this knowledge during the informed consent process which was 
unexpected. It is well documented that clinical research carries significant risks in hopes of 
yielding important benefits, thus posing the most complex ethical dilemmas (Slack et. al., 
2000, p.291). Most importantly, international research guidelines recognize that clinical 
research is ethical only when the risks to participants are reasonable (CIOMS, 2002) 
Appropriate implementation of this requirement is vital to protecting research participants 
and allowing research to proceed when it poses acceptable risks. Therefore, this study argues 
that clarity on risk categories of clinical trials according to their phases is important in 
communication of risks to potential participants and risk/benefit analysis by the trial staff. 
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This would require comprehensive training that offers intensive curricula and practical skills 
which are universally recognized. An important finding that emerged about the occupations 
of trial staff was that conducting the consent process was not a specific job; all trial staff had 
other full time roles and responsibilities to perform. Multiple roles could imply unspecified 
job descriptions, resulting into inconsistency in matching job titles with responsibilities, 
authority, as well as lack of clarity in the professional career position. Performance of 
multiple roles could also imply additional constraints of long working hours, multi-tasking, 
split attention and job burnout. Meyer & Partners, (2009) also argue that vague or ambiguous 
job titles can result into lack of confidence, authority, recognition, motivation, commitment 
and specific job satisfaction. It is important for an employee‘s job title to reflect their 
responsibilities and scope of authority. Adopting a common job title would help in role 
classification and maximization of potential. This study recommends that research 
organizations consider having a position and job title like ‗Research Consenter‘ for trial staff 
who deal specifically with conducting the consenting process. The responsibility of such a 
person would include the adhoc job titles reported by trial staff in this study such as recruiter, 
research nurse, and study coordinator.  This approach would substantially improve 
knowledge in clinical trials, research ethics and communication skills which were identified 
as challenges for trial staff in chapter four.  
 
6.2 Communication 
 
Studies of consent form readability (LoVerde, Prochazka & Byny, 1989; Johnson, 1998) have 
shown that when this information is disclosed using a written informed consent document, 
the readability and comprehension of the text is very critical for conveying study information 
to enable a potential participant to arrive at a decision concerning their willingness to 
participate in research studies. A valid informed consent process requires effective 
communication between the trial staff and the potential participant. The potential participant 
must be given adequate information concerning the study. This provides adequate 
opportunity for the subject to consider all options, and for the trial staff to respond to the 
subject's questions and ensure that the subject has comprehended this information.  
 
The main finding of the readability analysis confirmed that the forms were written at a grade 
level (mean FKRE=50.29 and mean FKGL=11.5) far higher than the average grade level of 
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the parents who were asked to read them and the levels recommended by research 
regulations. Results of similar difficulty were indicated in a study of a larger sample 
(n=2380) of pediatric biomedical research informed consent forms (Tarnowski, Allen, 
Maryhall et al. (1990). Although this evaluation was based on the English version of the 
informed consent standards using US metrics which might not equate to the readability in 
Setswana, in general, it‘s pretty clear the levels of readability are far too high. Some studies 
have revealed the same concern (Hochhauser, 2004; Kithinji and Kass, 2010). However 
readability scores are not without criticism. Valentini, D‘Alonzo, Pirozolli et al. (2013), 
rightly cautioned about basing comprehension of consent form information on readability 
scores since readability scores work only for certain languages mainly English and that 
readability is not equated to understanding because not everything readable is understandable. 
Writing about a topic like clinical trial information is difficult in itself. Readability scores do 
not consider test description like the lists of side effects of a drug or descriptions of disease 
complications. Readability only evaluates the syntax of a document without evaluating other 
parameters like flow of information. Additionally, the score does not reflect level of 
understanding which depends on intrinsic factors such as proficiency in a language, 
motivation, culture and education levels. However, since these reader characteristics and 
textual features lend themselves to subjectivity, subjecting the ten consent forms to the 
readability tests yielded a very objective basis of analysis. 
 
Of concern is the level of assessment of readability of the consent forms by the national 
research ethics committee. Informed consent forms used in all clinical trials must be reviewed 
and approved by an independent ethics committee before practical use in the trials 
(Directive/2001/20/EC). The fact such difficult informed consent forms were allowed by the 
review process, means that Botswana Research Ethics Committee does not assess  readability 
during the reviews sessions. Efforts need to be made by the investigators and the research 
ethics committee to devise ways of simplifying the consent forms without compromising the 
intensions of valid informed consent. One of the trial staff cautioned that there is need to be 
aware of the possibility of functionally illiterate participants, unable to read who may try to 
conceal the difficulty because there is a social stigma attached to not being able to read.  
 
Regarding the drafting of the consent form, trial staff complained about their minimal 
involvement. Without tapping on the knowledge of culture, language and the setting that trial 
staff possesses, the consent form becomes too decontextualized. Their main involvement is 
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only in translation and even this responsibility is the reserve of selected senior staff members 
at the institutions. Some trial staff rightly suggested that if they got the opportunity, there 
were a lot of things they could change in the form and the research setting particularly 
regarding the cultural and social-economic conditions of the parents. Many of the trial staff 
were critical of the excessive length of the consent forms used. The lengthy forms meant that 
too much information was provided and thus overloaded potential participants with 
information to be communicated in the short time available whether at the clinic or at home. 
Even then, significant questions remain about how to deliver the right amount of information 
to parents with different backgrounds and needs to facilitate their decision making. Gikoyo, 
Bejon, Marsh et al. (2008) observed that much of the detail currently prescribed in consent 
forms is designed to protect the investigators and their institutions rather than the participants. 
Dresden & Levitt (2001) noted that it is no surprise that in studies done on the informed 
consent form have found that patients prefer simpler and easier to read; forms that can 
provide them the necessary information to make a decision regarding participation in the trial. 
Shorter versions covering the crucial points only with information sheets covering more 
detailed information that might be relevant were also recommended by the trial staff in this 
study.  Use of short video capsules in waiting areas in the hospital may also serve as a useful 
tool. Some trial staff mentioned that they use illustrations. The National Cancer Institute 
(2013) recommended involving all stake holders namely; the investigators, participants and 
research ethics regulators in the drafting of the consent form document. In addition, outlining, 
use of bullet points and diagrams have been recommended in order to reduce bulk.  
 
Some trial staff though felt the information was adequate both for their legal protection and 
for the participants to read or be read to at home. However, while some trial staff felt a 
summarized version could be used, the question that arises is ―who should decide what is 
important?‖ The fact that informed consent forms are becoming too lengthy and complex and 
that it is essential that they are written in clear, direct language and be administered in small 
proportions to ensure comprehension, are issues that have been raised elsewhere (see Elcoat, 
1986; Kass et al. 2010, To support this  the issue further, other studies have shown that even 
long forms that use simple clear language can pose challenges for comprehension, retention 
of information, and  recognition of the important points as individuals often skim over texts 
that are longer than a 1000 words (Sharp, 2004; Rugege-Hakiza, Glynn, Hutching, et al., 
2003). A study that  aimed at simplifying consent forms for biobanking studies found that a 
2-page form contains the information that most prospective participants identify as important 
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(Beskow et. al., 2010), although  another study (Stunkel et al, 2010) concluded that 
comprehension was not affected either by the length or complexity of the consent form. 
Indeed the trial staff were of the opinion that the issue of determining the length of the 
consent form is very difficult to resolve. It is recommended that the form be written while 
bearing in mind the people who are going to read it. For example, a predominantly rural 
sample with barely any reading skill or experience, such as this study interviewed, would 
require a much simplified version perhaps even accompanied by pictures. Unfortunately, the 
trial staff reported that they are minimally involved in drafting the consent forms despite their 
experience and familiarity with the culture of the study participants. 
 
Regarding the complexity of the information provided both the trial staff and the parents 
confirmed that the medical language used made consent forms difficult to read. Results 
showed that difficulty resulted partly from the unfamiliar medical vocabulary used and the 
syntactic complexity as ascertained by the readability formulas. Graesser et al., (2004) 
observed that sentences with difficult syntactic composition are structurally dense, 
syntactically ambiguous, or ungrammatical. Many reading theorists have also affirmed the 
importance of sentence length in text readability and  recommend that  strategies to simplify 
readability should include using short, familiar words or simple synonyms; limiting the use of 
polysyllabic words; and keeping sentence length less than 12 words and paragraph length less 
than 7 lines (Bormuth, 1969; Chall & Dale, 1995; Kintsch, 1979). Pandiya (2010 p.90) 
recommended that wherever possible, technical terms should be replaced  with common 
terms;  that outlining, bulleting  points, using a large typeface and diagrams help the reader to 
follow complex concepts; and that texts become simple when  active verbs rather than the 
passive voice, short sentences, and frequent paragraphing  are used. These challenges are not 
only unique to consent forms written in English; similar challenges have been identified in a 
study where assessment of readability of non-English-language consent forms was conducted 
(Kithinji and Kass, 2010). 
 
6.3 Models of the consent process that promote autonomy 
 
Many models have been proposed for describing the patient/doctor communication process 
(Emanuel & Emanuel, 1992; Wear, 1998; Brody, 1989; Charles, 1997) cited in Delany, 
(2005). These models capture the key elements of the communication process. The trial staff 
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in this study seem to apply in the research setting the Emanuel & Emanuel (1992) 
paternalistic models described in chapter two as a one-way communication process not 
guided by participant‘s rights or autonomy. This prevails in situations where trial staff would 
be following the legal professional practice by disclosing all information irrespective of 
whether the person recruited understands or not. Using this model, information disclosed is 
intended to encourage/coerce the patient to consent to the intervention which undermines 
individual autonomy. Some trial staff for example reported that they preferred to extract only 
certain information especially about drugs because they felt the parents would not memorize 
drug names. Such decisions raise questions about who decides which information needs to be 
extracted without being paternalistic. Three standards of disclosing information were 
described in chapter two. Results showed that most of the trial staff use the professional 
standard as they reported that they disclose all the information in the consent form to the 
parents. This is a one-way paternalistic interaction which does not promote autonomy. 
Regarding the standard used to communicate information. A few of the trial staff reported 
that they extract only important information to disclose to the parents. This would be similar 
to applying the reasonable person standard where adequacy of disclosure is determined by 
what information is material to the decision that a reasonable or competent person would 
want to understand. The subjective standard would also apply where adequacy of disclosure 
is determined by information a particular person would want to understand.  The reasonable 
standard and subjective standards of interaction have been found to be good options (Baruch, 
2001; Guarino, Lamping & Elbourne, 2006) for shared decision making and respecting 
individual autonomy. These standards are also in line with Emanuel & Emanuel‘s (1992) 
three physician/parent interaction models namely; the informative; interpretative and 
deliberative models which promote autonomy by providing choice control, self-determination 
and moral-self-development (see Chapter Two). It is difficult to decide which standard is 
favorable to use across different research contexts. Argard (2005) proposes that the subjective 
standard could be the best as it acknowledges that information provided should be tailored to 
match the specific information needs of the potential participants taking into account things 
like culture, values, beliefs and health status. However, Pedroni and Pimple (2001) argue that 
none of the three standards discussed above articulates a notion of full or complete 
information, since this is considered unattainable and perhaps even undesirable goal. 
Therefore, they recommended that the best way to facilitate informed consent may be to 
design consent forms and other informational materials to satisfy a reasonable person 
standard, supplemented by conversations intended to elicit and answer any questions that are 
 
 
 
 
  
119 
 
not otherwise addressed. Information methods that require trial-staffs‘ dialogue are unlikely 
to be successfully implemented in the current Botswana setting where the traditional 
paternalistic methods are still common practice, and participants are submissive and trust that 
the doctor acts in the best interest of the patient.   
Overall, results in this study showed that trial staff are legally and ethically bound to disclose 
all the information in the informed consent document as stated in various research regulations 
(CIOMs, 2002, ICH-GCP, 2002. Some trial staff however indicated during the in-depth 
interviews that they would have preferred extracting only certain information due to large 
quantity and complexity of information in the consent form document. Disclosing all 
information without much interaction with the potential participant in form giving them an 
opportunity to ask questions, answering them promptly and completely would tantamount to 
the trial staff being paternalistic. However, we have to acknowledge that trial staff do not 
have the authority to alter or control the consent process.  Trial staff confirmed during the in-
depth interviews and focus group discussions that parents did not ask many questions during 
the discussions although the parents themselves claimed that they asked questions mainly 
about the safety of the child. With this evidence, one can conclude that the communication or 
interaction method mainly used by the trial staff is the paternalistic one which does not 
promote autonomy. Through training, it is possible however for trial staff to learn to use 
methods like those described in chapter two that promote participant autonomy. 
 
Four other informed consent models cited in Delany (2005) that exist assist in the interaction 
process. Three of these models namely; the ‗Event Model‘ (Wear, 1998), the ‗Transparency 
Standard Model‘ (Brody, 1989), and the ‗Shared Decision Making Model‘ (Charles, 1997), 
apply the paternalistic practice , therefore are not applicable to promotion autonomy as they 
are essentially prescriptive, describing what the physician should say in communication 
encounters and dictate the elements to be complied with. For trial staff who extract only 
certain information for disclosure they apply the ‗Process Model‘ which recognizes the 
patient‘s/participant‘s expert knowledge of the history and context of their problem and 
regarded the patient/participant as part of the treatment or research team. This model would 
be ideal to apply when communicating parental informed consent information as it promotes 
mutual sharing of information, calls for respect for autonomy and allows time to reflect on 
proposed options, risks, and benefits during the informed consent process. The ‗Conversation 
Model of Interaction‘ can be used where only certain information is extracted from the form 
for disclosure. This model marks a shift from the traditional paternalistic prescriptive models 
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as it involves active reflection on the values, motivations, expectations and interests that may 
influence implementation of the informed consent process (Delany, 2005). The above models 
have been recommended as favorable because of their capacity to recognize that meaningful 
interaction is based on understanding and assumption of participant autonomy and right to 
self-determination (Katz, 2000) 
 
This study would recommend the application of models that promote autonomy as they 
acknowledge the role of each stakeholder in the process and recognizes the important role of 
significant others such as the spouse, community/family elders, and the chief. However, this 
would require a change in the regulatory requirements by which trial staff are currently bound 
as part of their jobs and would further require assigning them greater latitude in how they 
engage with individual parents. 
 
6.4 Parental consent and the law 
 
Parental consenting requires clear legislation, research ethics regulations and guidelines to 
protect the rights and welfare of both the parent and the child. As explained in chapter two, in 
Botswana legislation about the age of consent to participate in research is ambiguous because 
the legal age of majority is 21 while the Children‘s Act (Cap 28: 04) defines a child as any 
person below the age of 14 years. However, the government reduced the age of consent to 
HIV testing from 21 to 16 (Ministry of Health HIV & AIDS National Treatment Guidelines, 
2012 section 2.3). Hence the current Botswana HIV Testing and Treatment guidelines (2007) 
provide that children at the age of 16 may consent independently to HIV testing and 
treatment but this is not extended to research. This lack of clarity creates an ethical dilemma 
for the trial staff and parents who wish to enrol children into HIV clinical trials. Specifically, 
this denies such mothers the opportunity to enrol their children in HIV clinical trials even if 
they would have wanted to. Furthermore, the Botswana National Co-ordinating Agency 
BIAS III, a Sentinel Surveillance Survey (2011) showed that in 2011, 10% of pregnant 
women aged 15-19 year old and 19% of the 20-24 year old mothers were HIV positive. It 
means this group cannot benefit from the services offered to HIV positive children despite the 
lack of a vaccine or cure for HIV. In the absence of clear legislation to age of consent to 
participation in research, the legal age of consent to medical treatment of 18 years is applied. 
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There is need for research stakeholders, government and the public to initiate dialogue on age 
of consent to HIV research and research in general. 
 
In addition to legislations, many research regulations prescribe that informed consent forms 
used in all clinical trials must be reviewed and approved by an independent ethics committee 
before practical use in the trials (Directive/2001/20/EC; Declaration of Helsinki, 1964). 
These however are only guidelines and not rules which are interpreted differently by different 
ethics committees and reviewers.  
 
6.5 Parental vulnerability 
 
Results from perceptions of trial staff background of parents who agree to child enrolment 
into HIV clinical trials in Botswana and cross-checked against the demographic 
characteristics of the parents confirmed that most parents who agreed to participation in 
research had low levels of education and came from low social-economic backgrounds. This 
situation is likely to render the parents vulnerable. Trial staff also found the parents in this 
category submissive to health personnel so cannot say ‗no‘ to enrolment of their children and 
did not even know their rights. This is a common trend that has been observed in other 
studies where people from communities in the developing world believe the doctor/health 
personnel ‗knows it all‘ and have their best interest at heart (Makgoba, 2002). Similar 
findings have been reported in a number of studies conducted in Africa (Bhutta, 2004; 
Dawson & Kass, 2005). One trial staff showed preference for working with parents with low 
education levels as they showed a lot of interest in the education that was provided and were 
very good with adherence. However, parents with high education levels and social-economic 
status were perceived by trial staff not to be interested in participating in research and many 
of them did not visit the public health clinics where most recruitment occurs. However, this is 
unlikely to change unless such populations are educated more about the importance of 
research. 
 
Interviews with parents revealed that a rural location, poverty, low education levels, and the 
inability to distinguish between research and treatment combine to make parents vulnerable 
to consenting without fully understanding the process due to low levels of both general 
literacy and health literacy. The Institute of Medicine (IOM, 2004) defines health literacy as 
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the degree to which individuals have the capacity to obtain, process and understand basic 
health information and services required to make appropriate health decisions. The report 
further goes on to explain that in order for an individual to read and understand a text, they 
must have prior knowledge about the topic to be discussed including reading fluency, the 
vocabulary used, familiarity with health concepts presented in materials or discussed, and the 
complexity and difficulty of the printed and spoken messages that a person encounters in the 
healthcare environment. To some extent a few parents who had participated in more than one 
HIV clinical trial seemed to display good health literacy levels about research, HIV and 
ARVs. Previous research experience and familiarity with health care settings were found to 
be highly associated with the parent‘s ability to remember having been told about the risks of  
child enrolment into the study and the number of study visits a child would make to the 
clinic. Trial staff also noted these two variables as important for the success or failure of the 
informed consent process because they enabled to the acquisition of new knowledge (health 
literacy) as trial staff reported that parents who had previously enrolled a child in a study 
easily agreed to child enrolment. A similar observation was made by Baker (2007 p.879) who 
noted that prior vocabulary and background knowledge about the disease from written 
documents are likely to improve an individual‘s comprehension. For example, some parents 
during the interviews expressed the wish that studies like the ones in which they had enrolled 
their child in should be repeated while some came back to the clinics to inquire whether there 
were any studies they could enrol their children into. However some trial staff cautioned that 
this could have been due to lack of understanding of the difference between research and 
treatment (therapeutic misconception). It is wrong though to dismiss all rural folk, such as 
those in this study, as lacking in health literacy levels. Indeed Miller, DeWitt, McLeay & 
O‘Keefe (2009) showed that even highly educated people did not understand health 
information educational materials.  
 
In this study, all the trial staff agreed that it was very important for people that implement the 
consenting process to have some background knowledge of the culture of potential 
participants as this would foster understanding of the parents‘ behavior and reactions to child 
enrolment in a clinical trial. For example most parents who requested to go back home and 
consult before agreeing to child enrolment, it was a polite way of declining or silent refusal. 
This was also another way of showing respect to the health personnel, spouse or elders. Trial 
staff themselves having been socialized in the same cultural setting had the same cultural 
beliefs so respected the parents‘ wishes. Such factors were likely to pose challenges if the 
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western conceptualization of bioethics was rigidly adhered to.  For this reason many scholars 
(Faden and Kass, 1998; Ggadegesin, 1988; IJsselmuiden and Faden, 1992) express doubt 
about the successful implementation of individualized informed consent in non-western 
settings. Because informed consent is based on the western belief of individualism, it is not 
understood in communities where the norms of decision-making are collective. They go 
further to argue that informed consent is not appropriate for Africa because culturally, 
individuals are not autonomous; the potential subjects are not ―competent‖ or the 
communication difficulties are insurmountable; and urgency makes informed consent 
requirements unreasonable (i.e., informed consent slows down the search for solutions to 
urgent health problems. For example in many sub-Saharan countries, the spirit of ‗Ubuntu‘ 
which refers to interdependence, communalism, sensitivity towards others and caring for 
others are all part of people‘s lives (Turaki, 2006). Shaibu (2007) reached a similar 
conclusion that in Botswana, implementation of informed consent was influenced by family, 
cultural dynamics relating to gender, respect for older persons and care giving arrangements; 
and that there was a need for research investigators to be culturally sensitive, exercise 
discretionary judgment guided by respect for culture and decision-making protocols 
applicable to a particular setting. In Botswana preservation of cultural values and collective 
identity is recognized in the National Vision 2016 (http://www.vision2016.co.bw/). 
Communities in Botswana have great respect for authority (elders, spouse, and health 
professionals). Individualized consent processes may therefore be inappropriate. These 
considerations also confirm the requirement that clinical research should not violate the 
Kantian principle (cited in van der Graaf R & van Delden, 2012) that ―people must not be 
used merely as a means for the purposes of others‖. 
 
However, the trial staff clarified that encouraging participants to consult with family and 
relatives did not mean informed consent was collective but that it was necessary as a way of 
being culturally sensitive. In Botswana involvement of community leaders like the chief 
(‗Kgosi‘) was reported by the trial staff as important because even participants asked whether 
permission had been sought from the chief before the research was initiated. 
 
Knowing the language of potential participants was also recognized as important for the 
success of the informed consent process. It was found that that the trial staff interacted with 
the parents in Setswana the national language and most parents preferred to be talked to in 
this language. Botswana is multilingual. Hence some trial staff were rightly concerned about 
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the translation of the English informed consent forms only into Setswana and not any other 
languages. Failure to translate sometimes compromises comprehension for those individuals 
whose mother tongue is not Setswana. This is a highly political issue as the current language 
policy in Botswana does not provide room for the use of other indigenous languages in 
conveying information (Nyathi-Ramahobo, 1999) which can deny many people access to 
crucial information (Batibo and Mosaka, 2006). This however does not mean that the use of 
Setswana itself is without problems. Some trial staff indicated that they find written Setswana 
difficult to read and communicate especially interpreting the difficult English technical 
medical terms that do not exist in Setswana. Trial staff rightly recommended that the 
language issue needed to be taken up by the National Research Ethics Committee. Challenges 
of language barrier in full comprehension of study information have also been recognized 
elsewhere (see Bhutta, 2004; Dawson & Kass, 2005). 
 
6.6 The parent dilemmas of proxy consenting 
 
When parents are asked for permission for a child to participate in clinical research, it is often 
a time of great stress and pressure. Molyneux et al. (2013) attribute this to a therapeutic 
misconception a key ethical tension of clinical research whereby many parents who enrol 
their child in a study will think that the research intervention is designed to provide a 
therapeutic benefit, when in actuality the intention is to gather data for the purpose of 
contributing to medical knowledge.  In the current study results showed that the major 
motivating factor for parental child enrolment was the illness of the child. This could have 
been the reason why the elements of number of visits and the fact that doctors could 
withdraw the child from the study any time were well recalled and understood. The number 
of times the child would be brought to the clinic could have been understood by the parents 
as regular care for the child. On the other hand, a doctor withdrawing the child from the study 
was also well understood as it is worrisome to the parents. The sense of responsibility that 
accompanies parents' decision making about trials may paradoxically render them more 
vulnerable, especially to the anticipation of regret. These are dilemmas that have made 
parental consent a complex area in research that has attracted wide scholarship (see Kyriaki, 
Panagiotou, Katsaragakis, and Tsilika, & Parpa, 2009; Zikmund-Fisher, Sarr, Fagerlin & 
Ubel, 2006; Stevens & Pletsch, 2002; Eiser, Davies, Jenney & Glaser, 2005; Canvin & 
Jacoby, 2006; Gilovich & Medvec, 1995). Zawistowski (2003 p.408) distinguished between a 
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parent deciding to give proxy consent for a child to participate in a trial and an adult deciding 
about their own participation in a trial. In the case of proxy consent, the primary 
responsibility is the best interest of their child while for an adult the role is exercising 
individual autonomy. Because all parents want to do the best for their children, their role is to 
care for and protect them. When a child is sick, parents rely on professionals (including 
traditional medicine men) to decide what is best for the child. When the same professionals 
request to enrol the child in research, it is normal for a parent to fear making the 'wrong' 
decision about their child. In non-western setting, parents are socialized to trust medical 
experts who are expected to know and act in the best interest of the child. In this current 
study, the validity of the decision has been observed to differ by parent according to age, 
level of education, personal experiences, values, and the medical situation the child. There 
was also the satisfaction that they acted as good parents to their child whatever decision they 
made. For example one parent when asked whether she would refuse to enrol the child said 
―my child would have seen clearly that I have refused‖. Cohen (1993) rightly notes that for 
parents the diagnosis of serious illness in a child can be a shattering experience. Additionally, 
when consent is sought soon after diagnosis of a life threatening disease without cure like 
HIV, parents will be making decisions when they are distressed and vulnerable (Levi, 
Marsick & Kodish, 2000). Being approached about a trial confronts parents with large 
volumes and complex sets of new information well beyond their everyday experience and 
they can never be certain about what is the 'right' decision. However, whilst they may be 
vulnerable, protecting their child is fundamental to the parental role and this will shape how 
they think about trials. Caldwell, Butow & Craig (2003) report parents who felt personally 
and directly accountable for their child's outcome on a trial and thought that giving consent 
for a child would be much more difficult than deciding to take part in a trial themselves. 
Survey evidence confirms that the responsibility to act in the best interests of one's child is 
keenly felt, with one third of parents in one study reporting that while they might accept 
certain research risks for themselves they were much less certain about accepting the same 
risks for their baby (Singhal, Oberle, Burgess   & Huber-Okrainec 2002). Surprisingly, during 
the parents‘ interviews in the current study, the question that was asked to rate the ease with 
which a parent would have refused to enrol a child if they had wanted  to, slightly more than 
half (55%) of the parents said it would have been very easy and the remainder (45%) said it 
would have been difficult. Considering the fact that most parents were desperate because of 
the child‘s illness it is unlikely that they were providing a genuine answer or were trying to 
say  what the researcher wanted to hear. 
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6.7 Parents’ recall, importance of information disclosed and knowledge of trial elements 
 
Results showed that despite the trial staffs‘ perceptions that the low education and social 
economic-status would compromise recall or awareness of the key elements disclosed, most 
parents had a high level of awareness on the seven key selected elements discussed. This 
could be an indication of the importance attached to these elements. In addition, over 85% of 
the parents could recall being told about the purpose of study (85%), the number of times the 
child would take medications (86%) and their rights (89%). The only element most parents 
could not recall being told about was payment for child enrolment into the study (69%). This 
was because most trial staff reported that they did not mention payment beforehand to avoid 
being accused of undue influence.  Surprisingly, the high level of awareness did not exactly 
match with the importance the parents attached to getting information about each of the 
elements for decision making. For decision making, most parents mainly attached a lot of 
importance to elements like number of study visits they would have to make to the clinic, the 
number of times the child would receive medicines and payment for child enrolment into the 
trial, more than on understanding details of purpose of study and randomization. This could 
possibly be an indication that the motive parents had for enrolling the child into the trial was 
to receive care considering the lack of standard treatment for pediatric HIV and the 
possibility of therapeutic benefit. It could have also been a retrospective reconstruction of 
priorities especially about compensation for child enrolment into the study as most trial staff 
indicated that it was not mentioned until the end of the discussions or if a parent hinted that 
they would not afford to come to the clinic regularly due to lack of transport money. 
However, the majority of parents agreed that they had been given a chance to ask questions 
and they did ask questions and were satisfied with the answers provided. 
 
Findings in this study seem to suggest retention of comprehension was based on the health 
status of the child. Therefore the trend in elements most recalled seemed to show selective 
recall. Most parents seem to have recalled information that they regarded as important to the 
welfare of the child. This could be explained in terms of the role parents have to play in 
caring and protecting their children (natural parental instinct).  The roles and responsibilities 
of the parents to the child were explained in chapter two. Naturally all parents want to act in 
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the ‗best interest‘ of the child; and socially and legally their role is to care for and protect 
them. However in non-western settings where culture dictates collective decision making, 
this role could be reversed when it comes to a sick child. In this situation, parents have to 
depend on the health professionals, spouse, family or relatives to exercise their responsibility 
of deciding what is best for the child. This can be challenging as the parent have to make 
judgments about the threat of the child's condition as well as the risks of the trial and 
judgments from others. Therefore they have to do everything that they can to get as much 
information as possible about what s/he is being requested to do in order not to make a wrong 
decision that would result into regret and blame for others in case something wrong happens 
to the child. Survey evidence on studies that examined parental informed consent confirmed 
that the responsibility to act in the best interests of one's child is keenly felt, with one third of 
parents in one study reporting that while they might accept certain research risks for 
themselves they were much less certain about accepting the same risks for their 
baby (Singhal, Oberle, Burgess & Huber-Okrainec (2002). Mothers whose children were 
enrolled into a bone marrow transplant trial, for example, dreaded the possibility that they 
might have to live with the knowledge that they had made the 'wrong' decision and this was 
intensified when things did not go well for the child (Stevens & Pletsch, 2002).  
 
Regarding parents opinions about how the interaction or communication process was 
conducted, parents expressed their satisfaction with the process. As results showed in chapter 
five, most parents reported that the process had facilitated their decision making as 
information was clearly explained to them, they were given the opportunity to ask questions 
and when they did ask questions the explanations given were satisfactory. All the parents 
agreed that they were tested for understanding which encouraged learning. Overall almost all 
the parents reported that they were happy with the way the information was disclosed to them 
and felt the trial staff were honest, caring and showed empathy. However, there were quite a 
number who felt the trial staff were being coercive. It is difficult to judge the genuineness of 
these opinions as most trial staff reported that interactivity was very low during the trials with 
parents not asking questions. The trial staff indicated that this could be attributed to culture 
e.g., fear of questioning authority and trust for medical personnel making the parents 
submissive. Trial staff also mentioned the possibility of therapeutic misconception as well as 
the stress and desperation about a sick child. The duration between a parent being approached 
and consenting was also regarded as important as most parents agreed to child enrolment the 
same day because the decision is made even before the consenting process and do not pay 
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much attention to the information being disclosed. The difference in care given at the 
research centre and the public facilities also contributed to the parents opinions as shown by 
some of the comments made by the parents in Figure 5.6. Regarding researcher-participant 
interactivity, Shilling, Williamson, Hickey et al., (2011) noted that parents said little during 
the trial process and responded to chunks of information interrupted by closed questions such 
as alright? and ok? posed by the researcher using brief affirmation of „okay‟, „right‟ or 
„yeah‟. The same authors also noted that when parents are asked about the interaction process 
they do not focus on the information provided but more on their experiences with the 
researcher. For example, the sense of security and comfort during the discussion, liking the 
researcher and the confidence that the trial was safe thereby expressing the confidence and 
trust in the researcher. 
 
6.8 Comprehension 
 
Information given to research subjects requires a level of understanding and appreciation for 
meaningful deliberation about a decision. Beauchamp and Childress, (1994) observed that 
understanding on the part of the research participants is not necessarily the same as „true‟ 
understanding because sometimes participants fail to understand the underlying scientific 
methodology of the studies. In such cases, what the subjects actually authorize differs 
substantially from what they intend to authorize, and thus informed consent is unfulfilled 
(Meisel & Roth, 1983). Other literature shows that despite the efforts by research 
investigators and Institutional Review Boards (IRBs) to design carefully worded consent 
forms, the informed consent process seems to be misunderstood and therapeutic 
misconception is common (Ness, Keiling & Lidz, 2009).  Results in the current study showed 
that trial staff did not want to commit themselves to confirming that parents did not 
understand the difference between research and treatment judging from the vague 
explanations given regarding this question and the reluctance with which the question was 
answered. Other factors like age, severity of illness and need, educational level, cognitive 
capacity, familiarity with research, language, values and culture as well as literacy have also 
been found to affect understanding of disclosed information (Pace, 2005). In the case of 
parents who participated in this study comprehension may be compromised by the stress and 
anxiety over a child with a chronic illness that has no cure or a vaccine.  
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The challenge of measuring understanding in the informed consent process is well recognized 
elsewhere. For example, Lindegger et al. (2006 p. 561) tested understanding using four 
different methods of assessment on the same individuals and the results showed different 
levels of understanding.  In this study, results showed that trial staff were doubtful about 
parents‘ understanding of most of the information disclosed to them despite their facilitation 
of the process using institutional assessment tools, going over the information, asking 
questions and encouraging parents to take the consent form to read or be read to.  This could 
be attributed to three factors (1) as already established by readability scores, the forms were 
written at a grade level far higher than the average grade level of the parents who were asked 
to read them; (2) report by trial staff of the anxiety and stress observed among some parents 
when the option of enrolling a child in a trial was presented to them. Some studies (Ruccione, 
Kramer, Moore and Perin, 1991; Levi, Marsick; Drotar and Kodish, 2000) have reported 
similar findings and explained that the anxieties associated with making decisions on behalf 
of one's sick child may put particular stress on an adult's comprehension, reasoning, and 
decision-making capacities. (3) ‗Selective denial‟, a protective mechanism against 
hopelessness explained by Daughterly, Ratin et al. (1994) cited in Tomamichel, Sessa, 
Hertzig et al (1995 p.367) as  the hope of a patient or one‘s child being among the small sub-
group of patients who will respond to the therapy and beat all odds. This was indicated by 
some trial staff who noted that some parents looked happy and hopeful when they were 
approached with the option of enrolling a child in a trial. 
 
The trial staff also identified a number of factors that could undermine comprehension. For 
example, the age and social economic status of the parents, their lack of health literacy and 
lack of cultural background especially language by trial staff. Furthermore, trial staff 
expressed concern of how Botswana legislation and research ethics committee requirements 
of drafting consent form documents and disclosing information pose a threat to 
comprehension and can turn off parents from listening or reading the document.  However 
despite all this criticism, the trial staff acknowledged the necessity and value of detailed 
informed consent documents in achieving an adequate understanding of what is proposed, 
why that is the preferred action among alternatives, and authorization without coercion. 
 
Although results of communication process showed that recall of information was very good, 
and parents felt well-informed and rated the information provided as very important to them 
for decision making, comprehension assessment of some of the elements of informed consent 
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did not reflect this finding. The results of comprehension assessment showed understanding 
of mainly those that do not involve scientific methodology. For example overall analysis of 
comprehension of all key selected elements showed that alternatives, purpose of study, 
benefits being uncertain, parents‘ rights as well as non-scientific methodology study 
procedures (like number of study visits and doctors withdrawing the child from the study 
anytime) were quite well understood. Of note, the most highly recalled element, most well 
informed about, rated as most important and highly understood was the number of study 
visits the child would have to make to the clinic. This showed that the concept of the child‘s 
access to sustained care was very important to majority of parents. In this case, one could 
speculate that the real reason for enrolling the child was the anticipated benefit that the child 
and the parent get out of the trial. This was further confirmed by the trial staffs‘ reports that 
some parents did not pay much attention to the information provided during the interaction 
process because they came with their minds made up to enrol the child  in the trial. Similar 
observations have been made elsewhere (Daughterly et al., 1995) cited in Itoh, Sasaki, Fujii 
(1997 p. 110).  
 
The results also showed some confusion about understanding elements that involved 
scientific methodology such as the trial design procedures, the basis of the choice of 
medicines given to the child, and understanding that some children were given medicines that 
were not active (see Figure 5.5c). Although almost all the parents (99%) knew that they were 
not allowed to choose which medicine the child would receive and that the doctor‘s choice of 
medicines depended on chance and not what was best for the child, less that 10% of the 
parents identified correctly that some medicines given to the children were not active and 
some children received medicines that were being tried. This observation could suggest that 
some parents may not have understood these components of trial design despite the high 
levels of recall and being well-informed. In the literature, this is  referred to as „therapeutic 
misconception‟ where the research subjects transfer to the research setting the assumption 
that the physician always acts only in the best interest of the patient (Appelbaum, Roth, 
Benson et al., 1987 cited in Mfutso-Bengo, Ndebele, Jumbe et al (2008 p. 41). The element of 
risk was also found to have been poorly understood. One could argue that the parents were 
not so concerned about the possible risks but the opportunity of the child accessing care. This 
is expected in situations where there is no alternative to participation in research like the case 
of life threatening diseases like HIV with no cure or vaccine. Generally issues of 
randomization and placebo use have been found difficult to understand by research 
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participants in many African countries (Appelbaum, 2002; Molyneux, Wassenaar, Peshu, 
Marsh, 2005; Tindana, Kass, Akweongo, 2006) cited in   Mfutso-Bengo, Ndebele, Jumbe et 
al., 2008 p. 38; Chaisson, Kass, Chengeta et al. 2011) although they are important for valid 
informed consent.  
Another significant finding was the low levels of perceived risk as illustrated by only 15% of 
the parents who answered correctly that the medicines could have life-threatening effects. 
Comments made by parents also indicated that the parents did not understand the risks of the 
trial. For example a number of parents reported that they were very happy with the study 
because their children did not have any side effects. This shows that parents might have 
underestimated the risks of enrolling their children in HIV trials and were more concerned 
about the child accessing care or it could have been a case of selective denial described 
earlier. The element of confidentiality was also poorly understood. It has been observed that 
maintaining confidentiality during research conducted in developing countries is a major 
challenge. Botswana culture encourages the traditional practice of discussing issues of 
importance in familial and communal settings. Shaibu (2007) observed that participants 
enrolled in research can freely share their private information among neighbors who happen 
to drop by during the interviews. Secondly the family settings or even clinic settings do not 
offer privacy.  
 
Certain gaps have been identified elsewhere regarding comprehension of information. In a 
multi-center study that asked research investigators about information they had disclosed to 
potential participants, 58% indicated having disclosed full information, 42% only gave 
information on the proposed treatment, while 12% had not informed patients about the trial 
prior to randomization and 38% did not tell the patients about randomization while 5% did 
not seek consent at all (Williams & Zwitter, 1994). In the same study, however  at least more 
than 90% of  the investigators had provided the participant with a copy of the consent form, 
an opportunity to read before coming for the next visit and information about risks but less 
than 56% of the investigators had emphasized randomization and only 8.5% had made a 
formal assessment of understanding. This shows that some elements of the consent form may 
not be communicated effectively 
 
Despite all the above identified challenges to comprehension, parents were confident that 
they were well-informed about pediatric HIV trials and had learned a lot about HIV and 
ARVs. This could be attributed to the intensive education given by trial staff. Furthermore 
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parents echoed the good care, honesty and empathy received from the trial staff that 
facilitated understanding (Figure 5.6). 
 
The next section discusses the perceptions of the parents about the informed consent 
communication process. 
 
6.9 Motivation and decision –making to enrol child in HIV clinical trials 
 
As indicated in chapter one, the fourth objective of this study was to identify and describe the 
reasons for parental approval to enrol their children in HIV clinical trial studies. The study 
also aimed to assess the extent to which parents understand the information provided during 
the communication processes. Understanding what motivates parents to agree to child 
enrolment into HIV clinical trials is an important issue in informed consent process.  
Considering the inherent complexity of most real life problems, giving informed consent 
requires both ‗rational‘ and ‗emotional‘ capacity. According to Arnold and Feldman (1986) 
an individual‘s choice is influenced not only by the perceptions of his/her goals but the 
anxiety and confusion experienced while making the decision. This is likely to happen to 
mothers of HIV positive children.  
 
As shown in chapter five, parents cited two important reasons  for child enrolment into HIV 
clinical trials namely; „illness‟ of the child (67.1%) and to ‗help‘ (altruism) future HIV 
positive children (32.9%). Over 85% of the parents confirmed that their motivation was 
without any pressure from spouse, health trial staff or family or by anyone. Quite a number of 
parents reported that before reaching the final decision, they had consulted with their spouses, 
family and close relatives. However, consultation was more of a cultural issue of 
collectivism, respect and trust or fear of blame in case anything went wrong.  All trial staff 
felt that encouraging parents to consult with close family members or friends was important 
as a form of social network support. Although requesting to go home and consult with family 
by some parents was reported by some trial staff as a polite refusal, some trial staff reported 
that some parents actually went back and consulted others and such parents seemed more 
relaxed, relieved and comfortable to agree to child enrolment. Over 70% of the parents 
reported that they had been under so much pressure from others to agree to child enrolment. 
This could have been due to the hopelessness of lack of alternatives and selective denial. 
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Although the results indicated that the parents had understood that the benefits of the study 
were uncertain, having been motivated by the illness of the child could be interpreted to mean 
that parents expected direct benefit from the study which was not a rational decision but 
based on desperation. The rational decision should have been the one of helping future HIV 
positive children. This finding is contrary to what motivates parents from western settings 
(Zupancic, et al, 1997) where altruism is priority. 
 
Some parents gave reasons other than child‘s illness and altruism. For example some said 
they had made the decision to enrol the child even before they were talked to by the trial 
staff, others explained that it was because they had understood the study purpose. There were 
also reasons such as the parent wanting to know the results from the tests that were done; the 
parent‘s fear of guilt (―my child would have seen clearly that I have refused”); and the “trust 
[parent‘s] put into the trial staff”.  Studies on adult informed consent have found that the 
doctor is very influential in decision-making (Jenkins & Fallowfield, 2000). This difference 
could be due to the parental protection responsibilities towards the child.  
 
Regarding decision-making, results showed that for majority of parents, parental consent was 
solely individual. This finding could have been influenced by the fact that most parents were 
single or by the illness of the child. The few parents who indicated that their decision was 
motivated by the social obligation to help could have been a recall of what they had been told 
during the discussions. It seems doubtful that the decision made by most parents was valid 
and whether altruism could have been a genuine motivator.  Parental decision was 
significantly associated with relationship to the child (being a biological parent), number of 
clinic visits, previous experience in research and payment or compensation for child 
enrolment. Other studies have found that a valid decision can be compromised by the trust 
put into medical experts on the principle that ―the doctor knows it all and acts in the best 
interest of the child‖. In addition the parental decisions have been observed to differ 
according to age, level of education, personal experiences, values, and the medical situation 
the child as well as the fear of guilt and being able to feel confident that they have acted as 
good parents to their child whatever decision they make (Mkgoba, 2002; Marley, Lau, 
Davies, 2005).  
 
The case of HIV which is a life threatening disease a child being diagnosed HIV positive can 
be a shattering experience to the parent. So when consent is sought soon after diagnosis, 
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parents will be making decisions when they are distressed and vulnerable. These responses 
show the parental commitment to the child‘s interests, emotional instability and inability to 
make rational decisions because of the vulnerability caused by this kind of illness. Parents 
that are approached about a trial like the one investigated in this study are confronted with 
new and complex information and so they may not be immediately certain about what is the 
'right' decision. Despite being vulnerable, protecting a child is fundamental to the parental 
role and this shapes the decision made.  
 
 According to the results about parental motivation to child enrolment, the voluntariness may 
be questionable. Although almost all the parents were well informed about the element of 
voluntariness, about 70% parents indicated that they could not have refused to enrol their 
children even if they had wanted to because of the child‘s illness and confessed that refusing 
would have been very difficult. This confirms the element of desperation of the parents. 
Although trial staff felt consultation with spouse and family was important, this study 
indicated the opposite. This could have been explained by the secrecy and stigma still 
attached to the HIV disease in Botswana. Mystakidou, Panagiotou et al., (2009 p.49) 
observed that the HIV epidemic had pushed infected individuals of the developing world to 
the margins of their societies. Almost 90 % of parents confirmed their agreement to child 
enrolment into HIV clinical trials by signing on the consent form but very few (9%) 
acknowledged agreement by putting a thumb print on the consent form and almost all the 
parents preferred signing than agreeing verbally. Unfortunately the reasons for this were not 
probed. However, being happy with the signing could have been from the relief that finally 
the child will be helped but without understanding of the legal implications. Of concern, most 
parents reported that they made the decision to enrol the child the same day. It is questionable 
whether this was valid consent or the decision was made because of the pressure parents were 
under to access help for the sick child. The trial staff however contradicted the parents saying 
that the consenting sessions could last more than an hour while some trial staff said they did 
not encourage parents signing the consent form the same day. Such contradiction raises doubt 
as to who was telling the truth and further confirms what the study suspected all along that 
the consenting was not absolutely voluntary. 
 
At the end of the interview parents were given an opportunity to comment on the informed 
consent process. The general comments that they made could be interpreted in two ways 
either some of the parents who commented that the study was very good and they wished it 
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could be repeated did not understand that the child was in an experimental study or those who 
reported that the child had improved were allocated into the arm using an intervention drug 
that was possibly efficacious. Furthermore, parents who appreciated the care given at the 
research center being better than that at the public clinics did not understand the children 
were in an experimental study and needed close observation. The disparities between the care 
given at the research center and that at the public clinics could raise questions about parents‘ 
voluntariness or could be interpreted as undue inducement. For example some parents 
commented that the tablet that the child was receiving was only given to children that were 
on the trial; some said if the study could be repeated they would enrol their child; some said 
they were treated special and the child was seen by the doctor on every clinic visit; some 
reported that the child had improved and had not experienced any of the side-effects that they 
were warned about.  
 
Many parents also appreciated the constant education they received about HIV and ARVs 
and felt the trials were very important for the nation and were hopeful a drug would be found 
very soon.  The observation of disparity in care  and benefits among children on-trial and 
those not on-trial has been observed in a study by Molyneux et al. (2013) where the parents 
and children on-trial were not paying for hospital  stay and were seen by the doctor every 
time they needed to which did not happen for non-participating parents. Considering that all 
parents whose children are admitted for whatever reason love and care for their children 
dearly this preferential treatment extended to research participants would cause resentment. 
For the ethicist this preferencial treatment could be interpreted as undue inducement. There is 
need for governments and sponsors to devise strategies to reduce the disparity between the 
two groups. 
 
6.10 Results conclusions 
 
Chapters 4 and 5 enabled the researcher to identify some of the challenges and gaps in the 
current practices of conducting parental informed consent process for pediatric HIV clinical 
trials in Botswana. The results showed that the consent forms used to seek consent from 
parents who‘re to enrollment of their children into HIV clinical trials in Botswana are 
generally difficult to read and written at a higher level than that of most participants. The 
process of seeking consent is a female dominated area and all trial staff have the relevant 
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qualifications in various medical disciplines and multiple tasks but  need more specialized 
knowing in areas like research ethics, clinical trials research and communication skills which 
could be an added advantage to their role. Results also showed that trial staff were of the 
opinion that the information disclosed to the parents was too much and complex for their 
comprehension and valid decision making. Trial staff mainly used the paternalistic method of 
disclosing information mainly because they have to legally protect themselves. Trial staff 
were also doubtful about parental understanding of the scientific procedures of the trial 
studies. Results showed that mostly women are involved in the care of their children and 
these women have low education levels, social economic status and mainly from the rural 
areas. It was also evident from the results that age, previous experience in research and 
relationship of parent to the child played a major role in the parents‘ ability to recall disclosed 
information. Motivation by most parents to child enrolment was mainly associated with the 
numbers of clinic visits promised, parents‘ previous experience in research, being a biological 
parent and being paid for participation in the study. Overall, findings seemed to suggest that 
the main motivation factor for child enrolment into HIV clinical trials by parents was the 
illness of the child and accessing health care for the child rather than altruism. This raises 
questions about the autonomy, voluntariness of the parents and the validity of the consent 
obtained. The study also demonstrated the importance of knowledge of culture of participants 
by the trial staff and the researchers as well the unavailability of standard guidelines and laws 
to guide researchers and to assess the quality of parental informed consent forms. Therefore 
these findings informed the practice model that was developed in the next chapter. 
 
6.10 Limitations of the study and recommended future research 
 
The study would specifically like to note the limitations relating to the use of readability 
formulas in contexts where scores originally based on American school grade levels are 
transferred without question to predict reading ease elsewhere. Additionally, in this study 
FKRE and FKGL were applied to the English version of the informed consent form only. 
Ideally, the same measure should have been applied to the Setswana version also which is the 
one the participants actually signed. Both these limitations are attributed to the fact that there 
are no existing readability formulas on the market that measure texts written in Setswana. 
The readability scores that the study reports are however useful since they predict the 
readability challenges faced by those who translated the consent form from English to 
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Setswana; challenges that may have affected the Setswana version participants signed.  
Future research using a larger sample and readability tools that measure readability for texts 
written in language like the cloze procedure would improve on these flows. Future research 
also needs to take into account other factors that affect readability mentioned earlier such as 
text organization and reader characteristics. 
 
Another limitation pertains to the small number of institutions that conduct pediatric HIV 
research in and around Gaborone. This resulted in the scarcity of suitable participants and 
difficulty of obtaining permission to sample participants. Due to this the trial staff population 
for this study was not randomly drawn but instead, convenience sampling was used. This 
limitation was overcome by using qualitative approaches that enabled the documenting of 
individual participant‘s experiences. The findings may therefore not be generalizable. Future 
research could include trial staff from other sites outside Gaborone. 
 
Thirdly, the researcher suspects that certain factors in the design of the study must have 
introduced the Hawthorne effect. For example, because the trial staff interviews were not 
conducted at the same time as the actual observation of the consenting process, interview 
responses may have been biased since trial staff were unlikely to criticize their performance 
or that of the institution. Another design factor that may have introduced the Hawthorne 
effect relates to having the parents as participants - parents could not criticize the trial staff 
due to the vulnerability created by the patient/doctor relationship and the nature of HIV 
disease having no satisfactory standard treatment. It was naturally that they do not jeopardize 
their children‘s chances of accessing care. However, as with the original Hawthorne studies, 
these factors may not have had a role in the findings; but it would help if further studies 
minimize bias resulting from these design factors. 
 
Another limitation of this study was the use of TRUE/FALSE closed-ended question to 
measure parental retention of recall of information and comprehension. This method is 
imperfect as it allows participants to guess or just say what they heard whether it was 
understood or not. However, future research like collecting data from on-going studies and 
using open-ended questions would improve on these limitations. 
 
 
 
 
 
  
138 
 
Finally, the data obtained about perceptions of trial staff on information disclosure and 
comprehension excluded clinicians who play a key role in explaining to the parents the 
scientific procedures of the study. 
 
 
CHAPTER SEVEN 
A MODEL FOR OBTAINING PARENTAL INFORMED 
 
7.0 Introduction 
 
The aim of this thesis was to conduct a situational analysis of the current methods and 
practices of obtaining parental informed consent for HIV clinical trials with pediatric patients 
conducted in Botswana in order to use the findings to develop a model that can guide the 
parental informed consent process in future. Models are often used in public health research 
to explain research questions under investigation and various meanings and uses of the term 
exist. In this study, a model is defined according to Earp & Ennett (1991, pg 163) as a 
diagram of proposed  causal linkages among a set of the concepts believed to be related to the 
process of obtaining valid informed consent. The model developed in this study addresses the 
research questions set out in chapter one, section 1.5 namely: (i) how readable and 
understandable the consent forms used to obtain parental informed consent are; (ii) how 
effective  the trial staff-parent communication methods and practices were according to the 
trial staff and parents perspective; (iii) the  extent to which parents recall and understand the 
information provided during the communication processes; (iv) the parental perceptions of, 
and levels of satisfaction with, the informed consent process;  (v) what motivates parents to 
enrol their children in HIV clinical trials; and (vi) the extent to which the parental decision to 
enrol a child in HIV clinical trials was voluntary.  
 
These questions were answered using the methods described in Chapter three, Sections 3.7 
and 3.9; and were reported in chapters 4 and 5; and discussed in chapter 6. The model 
development process was also informed by theories and existing models from literature 
review reported in chapter 2. The main ethical theories applied to the model are Kant‘s non-
consequentialists ethical theory and Mill‘s consequentialist ethical theory. In addition, the 
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many existing informed consent models were scanned to identify the missing links in 
obtaining valid parental informed consent in the Botswana setting. The need to develop a 
model that can guide researchers in future arose from the problems stated as a statement of 
the problem in chapter one, section 1.2 regarding the process of obtaining valid parental 
informed consent. 
7.2 The Model 
 
The model is illustrated by boxes which represent the concepts while the arrows indicate the 
interrelated nature of the causal linkages in the process. Triangulation methods were applied 
in form of document analysis, in-depth interviews, focus group discussions and semi-
structured questionnaire to verify the needs of trial staff for obtaining valid parental informed 
consent and parents‘ perceptions regarding the informed consent process. The results 
presented in chapters 4 and 5   identify the needs and expectations on both the part of the trial 
staff and parents in obtaining valid informed consent. The interpretation  of the results in 
chapter six assisted in identifying the problem areas in obtaining parental informed consent 
and the identified problems were used to develop a model (Figure 7.1)  tailored to respond to 
them. 
 
7.2.1 Steps followed in the development of the model 
 
The following steps adapted from Earp &Ennett (1991) were used in developing the model. 
Step 1: Identification of the specific end point of interest which is valid parental informed 
consent. 
Step 2: A situational analysis of the current practices and perceptions of the trial staff and 
parents was conducted to generate concepts that were used in model development. 
 
Step 3: Analysis and interpretation of data from the mixed methods applied in chapter 6 to 
generate the concepts used to build the framework. 
 
Step 4: Relationships among concepts based on empirical and theoretical evidence as well as 
available knowledge from literature about the problem of obtaining valid parental informed 
consent were used to determine the causal relationships. 
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Step 5: Only concepts that can be realistically addressed for intervention strategies were 
retained on the basis of practical considerations, importance of various concepts, 
relationships, literature and scientific merit, and theoretical considerations. 
 
The model (Figure 7.1) identifies trial staff as one of the two key components of the process 
of obtaining parental informed consent. As indicated in the illustration, in-depth interviews 
with trial staff revealed some of the vital competencies that trial staff require to be able to 
facilitate obtaining a valid informed consent from the parents. For example as shown in box 
one, knowledge, attitudes and skills of research governance framework, clinical trials 
research and research ethics were identified as vital elements to successful information 
disclosure. As noted in the findings the listed elements were found to be lacking. Possession 
of the knowledge and skills would enable good practices that promote autonomy during the 
information disclosure process. The second box from the right illustrates vital competencies 
that individuals conducting the informed consent process require for proper disclosure of 
information that can promote autonomy and facilitate understanding. Furthermore, in order 
for the trial staff to facilitate understanding they should be able to use appropriate methods 
shown in the third box. These methods would lead to a shared decision which is not based on 
therapeutic misconception, coercion or undue influence. In this way the parent would be 
assisted by the trial staff to make an autonomous valid informed consent. 
 
 The second key component of the developed model is that of the parents shown in the lower 
section of the model. The lower first box from the right shows that some of the predisposing 
factors that were identified in this study like gender,  low education levels,  low socio-
economic class, residing in the rural areas and being a single head of a household could have 
an influence on the achieving an autonomous decision by the parents. Such attributes can 
increase a parent‘s vulnerability to coercion and undue influence. These attributes have also 
been identified elsewhere (Kyriaki, Panagiotou, Katsaragakis, Tsilika, & Parpa, 2009).  
 
Results in chapter five also showed that some of the factors like parent‘s previous experience 
in research, and therefore familiar with clinic settings and being a biological parent were 
enabling factors that provided skills, experience, higher health literacy levels and experiences 
which had exerted an influence on recall of information and comprehension of some of the 
elements of the informed consent process. These are shown in the second box from the right 
in the parent component e.g. good health literacy, life experiences and previous experience in 
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research. Therefore trial staff should be cognizant of these factors that can promote 
autonomous decision-making. However, there are other factors that were identified in the 
study that could be reinforcing factors to a parent‘s agreement to child enrolment into clinical 
trials. For example the social-structure of the parents (culture, beliefs, values and attitudes) 
and strong cues like the illness of the child, and need to access health care services. These 
factors are likely to exert an influence on the parent‘s decision-making capacity by increasing 
their motivation to agree to child enrolment into HIV clinical trials. This effect may imply 
that the decision by a parent to child enrolment in trial studies may not have been absolutely 
voluntary.  Therefore trial staff need to recognize that these factors are likely to be coercive 
and can result in undue influence as far as a parent giving a valid informed consent is 
concerned. Generally the reinforcing factors raise questions about the validity and 
voluntariness of the parent‘s consent.  Overall, the model also captures the consenting 
process as a continuous process with the general socio-economic, cultural and environmental 
factors encompassing the trial staff and parental factors.  
 
 In conclusion, although obtaining valid informed consent may seem impossible, the model 
can minimize the challenges encountered by both the trial staff and the parent if the trial staff 
can possess that factors identified in each of their component concepts as well as recognize 
and respect the parents‘ concepts showed in Figure 7.1. 
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Figure 7.1: A model for obtaining parental informed consent for HIV clinical trials research with pediatric patients 
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CHAPTER EIGHT 
GENERAL CONCLUSIONS AND RECOMMENDATIONS 
 
 
8.0 Introduction 
 
Chapter one outlined the statement of the problem regarding the process of obtaining valid 
parental informed consent. One of the major problems is the current increase in volume and 
complexity of pediatric HIV clinical trials conducted in Botswana due to the HIV pandemic, 
the government commitment to combating the disease and recommendations by WHO and 
FDA and other organizations to promote pediatric research into childhood diseases. However, 
the increase has not been accompanied by corresponding strength in the capacity of the 
country‘s research governance framework. There is a need to be mindful of the fact that the 
urgency and importance of the goals of HIV preventive (in this case vaccine) and treatment 
should not overshadow the need to protect the well-being and human rights of vulnerable trial 
participants like children.  
 
The lack of background knowledge of the culture of Botswana by research institutions that 
draft the consent form raises challenges of comprehension due to language and cultural 
differences. Another challenge noted was the fact that most of the clinical trials conducted in 
Botswana are multisite studies where the consent forms are developed by sponsors and 
institutions outside Botswana. This raises problems of lack of sensitivity on the part of the 
researchers to the values and culture of Botswana and failure to contextualize the information 
provided to participants as reported in chapter five. Furthermore, differences in socio-
economic status, authority/power, and health care systems between the trial staff and parents 
were identified to have an influence on the voluntariness with which decisions are made by 
the parents (Maruatona & Cervero, 2004; Botswana/ United Nations report, 2004) and 
confirmed in the results in chapters four and five. Additionally, it is doubtful that parents with 
chronically sick children asked to enrol their children in clinical trials would be expected to 
decline such participation. 
 
Thirdly, at the moment Botswana lacks a standardized consent guide form to guide 
researchers who conduct trials involving children. The consent form guide that exists does 
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not comprehensively cover issues relevant to child participation in research but instead caters 
for all types of research. Chapter one also outlined the lack of translation into law and 
policies of children‘s rights charters like the United Nations Convention for Children‘s 
Rights, Convention on the Rights of the Child (United Nations General Assembly, 1989) and 
the African Charter on the Rights and Welfare of the Child (1990) which compels countries 
to respect and protect children‘s rights regarding participation of children in research 
(Fombad, 2005). 
 
 In addition, Chapter one outlined the lack of a clear legislation regarding age of consent to 
participation in research or dealing with the capacity of children to make medical decisions as 
well as the conflict between Botswana culture and the international instruments. The 
instruments emphasize that ―the best interest of the child must be the primary consideration 
and children are rights holders‖ while Botswana culture as cited in Fombad (2005) like many 
other African cultures, believes that adults know what is best for the children and they are in 
a position to articulate the views of the children. Furthermore, considering the burden of 
nursing a chronically ill child, poverty, cultural differences and the low literacy levels might 
influence decision making of parents to child enrolment into research. Currently there is a 
paucity of literature in Botswana about the adequacy of obtaining parental informed consent 
and the factors that influence parents‘ decision making. Studies conducted thus far have 
mainly concentrated on adult informed consent (Shaibu, 2007; 2006). 
 
This study therefore aimed to conduct a situational analysis of the current methods and 
practices of obtaining parental consent for pediatric HIV clinical trials conducted in 
Botswana in order to determine the readability and comprehension of the consent forms used 
to obtain consent from parents; to identify the communication methods, practices and 
perceptions of the trial staff regarding informed consent information disclosure; assess the 
extent to which parents are able to recall and understand the information disclosed to them 
and their satisfaction with the informed consent process; to identify and describe the reasons 
for parental approval to child enrolment into trial studies and use the findings to develop a 
model that can be used as a framework to guide the parental consent process in future. From 
the aims and objectives mentioned above, conclusions are made about each of the objectives.  
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8.1 Readability of the consent forms 
 
When the information about the study is disclosed using a written informed consent 
document, the readability and comprehension of the text is very critical for conveying study 
information to enable a potential participant to arrive at a decision concerning their 
willingness to participate or not (Johnson (2004). It can be concluded from this study that the 
forms used for obtaining the parental consent process are too lengthy and difficult to be read 
and understood by the parents who were asked to read them and the levels recommended by 
research regulations. Results of similar difficulty were indicated in a study of a larger sample 
of pediatric biomedical research informed consent forms (Tarnowski, Allen, Maryhall et al. 
(1990). Although this evaluation was based on the English version of the informed consent 
standards using US metrics which might not equate to the readability in Setswana, in general, 
it is clear the levels of readability are far too high. Some studies have revealed the same 
concern (Hochhauser, 2004; Kithinji and Kass, 2010). It can also be concluded that there is 
minimal involvement of trial staff in drafting of the consent form. This results in missing out 
on tapping on the knowledge of culture, language and the setting trial staff possess. Another 
conclusion that can be made on readability is that there is no standardized formal assessment 
made on the readability of the consent form prior to its use. As a requirement, informed 
consent forms used in all clinical trials must be reviewed and approved by an independent 
ethics committee before practical use in the trials (Directive/2001/20/EC).  
 
It is essential that consent forms are written in a clear, simple language that the participant 
understands and be administered in small proportions to ensure comprehension (CIOMS, 
2002). In this regard, it can be concluded that the language the consent forms are translated 
into may not be well understood by all the parents who participate in trials research.  
 
8.2 Communication 
 
Another conclusion that can be drawn from the results is that the lengthy forms provide too 
much information. They thus overloaded potential participants with information much of 
which is also very complex. This challenge has been observed elsewhere (Gikoyo, Bejon, 
Marsh et al., 2008; Dresden & Levitt, 2001; Pace et al., 2005). Significant questions however 
remain about how to deliver the right amount of information to parents with different 
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backgrounds and needs to facilitate their decision making. It has been observed that much of 
the detail currently prescribed in consent forms is designed to protect the investigators and 
their institutions rather than the participants (Dresden & Levitt, 2001). The complexity of 
information provided to parents has been observed elsewhere. For example, The South 
African Department of Health (2006) observed that consent forms often present highly 
complex information that must be understood by patients and this was a major barrier to 
comprehension for many research volunteers especially those with low literacy skills. 
 
Results showed in chapter four showed that trial staff disclosed all information without much 
interaction with the potential participant in form of giving them an opportunity to ask 
questions, answering them promptly and completely. However, we have to acknowledge that 
trial staff do not have the authority to alter or control the consent process. In addition trial 
staff confirmed that parents did not ask many questions during the discussions although the 
parents themselves claimed that they did. With this evidence, one can conclude that the 
communication or interaction method mainly used by the trial staff is the paternalistic one 
which does not promote autonomy. Through comprehensive training in communication skills, 
it is possible however for trial staff to learn to use methods like those described in chapter 
two that promote participant autonomy. A great deal of variance in physician-patient 
communication styles mainly in clinical settings has been observed (Korsch, Freemon, and 
Negrete (1971) and this can compromise the success of the communication process. The 
basic principle that governs informed consent is autonomy which have become symbols of 
integrity (Beauchamp and Childress, 2001).  
 
8.3 Comprehension 
 
It can be concluded from the results that trial staff are doubtful about parents‘ specific 
understanding of the difference between research and treatment, randomizations, study risks, 
confidentiality, and the uncertainty about the benefits of the study to their children. Results 
from the parents‘ interviews also showed low recall and comprehension of the above 
mentioned elements. Therefore one can conclude that there is lack of understanding of some 
of the elements of the consent form especially those that are not to do with accessing care for 
the child.  This study interpreted this as stemming from therapeutic misconception. The study 
also concludes that the parents were not so concerned about the possible risks but about the 
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opportunity of the child accessing care. A number of authors have observed lack of 
understanding of disclosed information by research participants. For example, Marshall 
(2006) provided evidence from empirical studies on informed consent which suggest that 
even when provided with information about the nature of research, participants systematically 
misinterpreted the risk/benefit ratio of participating in research because they fail to 
understand the underlying scientific methodology. In such cases, what the participants 
actually authorize differs substantially from what they intend to authorize, and thus informed 
consent is frustrated. Pace et al., (2005) found that although most respondents in 
comprehension of consent to a randomized trial among HIV positive individuals in Thailand 
said they were well informed, only one third correctly reported that half of the participants 
would receive the experimental therapy. Such misunderstandings may arise from use of 
complex epidemiological terms like randomized assignment, placebo control groups, double 
blinded procedures and fixed treatment protocols. Other  barriers to comprehension identified 
include the form‘s excessive length, lack of adequate time to read the form, high reading 
levels, and poor format and layout of the form; barriers which Hochhauser (2004) rightly says 
increase risks to both the researcher and participants, lead to therapeutic misconceptions, poor 
enrolment and failure to follow up. 
 
8.4 Motivation, Decision-making and voluntariness 
 
One major conclusion about motivation of parents to child enrolment into HIV clinical trials 
was self-interest in the form of perceived benefit regardless of the risks to the child. 
Expecting benefit could be attributed to inadequate information disclosure or understanding 
because potential participants should be told about uncertainty of benefits and should 
understand that they should not expect benefits when there is clinical equipoise. Although 
parental decision-making was purely personal many parents preferred to consult from 
significant others before making a final decision and trial staff confirmed that this had 
appositive influence on decision-making. The study concludes that because of the urgent 
need by the parents to access care for the child parental valid consent could have been 
compromised, thereby rendering the consent obtained invalid.  
 
The literature reviewed in chapter two showed that in order for individuals to exercise their 
autonomy they must have the capacity to make free choices without coercion or undue 
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influence (Schiffman and Kanuk, 1997) which reflects voluntariness. The individual‘s choice 
is also influenced by the perceptions of his/her goals, anxiety and confusion experienced 
while making the decision (Arnold and Feldman, 1986 p. 340).  In Botswana like in many 
developing countries, the health care of children is mostly a woman‘s responsibility. 
However, decision-making by women is often compromised by gender bias and power issues 
(Wassenaar, Bardorf & Richter, 2005).  For example, Marshall (2004) found that nearly one-
third of more than 400 participants married women interviewed in Nigeria to participate in 
the hypertension and breast cancer study needed permission from their spouses. Pace, et.al., 
(2005) also noted that voluntariness can be compromised by the stress caused by the nature of 
illness of the child as well as other socio-economic factors and these may erode decision 
making capacity. Decisional capacity is critical in decision-making to participation in 
research. 
 
8.5 Recommendations 
 
The recommendations listed below were drawn from the conclusions above. Implementing 
these recommendations would help to improve the process of obtaining parental informed 
consent for HIV clinical trials pediatric patients. However it worth noting that most of the 
recommendations will require advocacy from the trial staff, research institutions that conduct 
pediatric research and the Botswana national research ethics committee because the consent 
forms are pre-prepared and the trial staff have no authority to alter them as their role is to 
implement.  
 
The first set of recommendations collectively lists all the strategies that can be put in 
place to improve the research governance framework regarding participation of 
children in trial studies: 
 Botswana National REC should draft clear guidelines on clinical trials research 
involving children to guide researchers. 
 Botswana National REC should draft a local standard template of the consent form 
that guides researchers designing parental consent forms. This requires provision of 
regulations and guidelines for seeking parental consent by the research ethics 
authorities. 
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 Botswana government should review some of the laws or include them into the legal 
system for example developing the human research bill.  
The second set of recommendations focuses on improving the readability of consent 
forms: 
 
 Research institutions should tap on the experience and cultural expertise of the trial 
staff, including both English and Setswana specialists, when translating the consent 
forms so as to make the language of the form clear and plain.  
 All pediatric HIV clinical trial research investigators, participants and research ethics 
regulators should work together to in developing a  of the consent form template  
 Government, research institutions and other stakeholders should support short-term 
and long-term training to clinical trials research to enhance their knowledge and skills 
which could lead to specialization in areas identified as inadequate. This could also 
change the mind set and attitudes of clinical trial staff towards the consenting process. 
 Research ethics training and communication skills should be a job requirement for 
those seeking to be employed in the area of seeking consent from parents who enroll 
their children in clinical trials. 
 Research sponsors, investigators and research ethics committees should devise ways 
of simplifying consent forms readability without compromising the intensions of valid 
informed consent.  
 Trial staff should be aware of the possibility of functionally illiterate participants, 
unable to read who may try to conceal the difficulty because there is a social stigma 
attached to not being able to read.  
 Research sponsors, investigators and the research ethics committees should assess the 
readability of the English consent forms to get a general picture of the readability and 
understandability of the consent form submitted for review. They should also engage 
local language specialists to ensure that the translated versions are readable.  
 Research sponsors, investigators and the research ethics committees should draft 
shorter versions of informed consent forms covering the crucial points only with 
information sheets covering more detailed information that might be relevant should 
be considered.  
 Trial staff should diversify methods of disclosing information instead of focusing only 
on written documents. For example, the use multimedia for improving research 
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literacy by using options such as videos in the clinic waiting areas, illustrations in the 
consent form document, outlining, use of bullet points and diagrams should be 
considered.  
 
The third set of recommendations centers around communication  
 
 All research institutions involved in conducting pediatric HIV clinical trials should 
provide comprehensive and intensive prior health information (health literacy) about 
the study to all parents about their child‘s disease and the study procedures before the 
informed consent encounter in order for them to have good background knowledge. 
This knowledge would enhance familiarity with health concepts presented in the 
informed consent form.  
 The trial staff should differentiate between general literacy and health literacy because 
low education levels do not necessarily translate into low health literacy levels. This 
would minimize the paternalism noted above.  
 The trial staff should have some background knowledge of the culture of the potential 
participants in order to disclose information in a culturally appropriate and sensitive 
way. 
 Research Institutions should offer training opportunities in communication skills, 
clinical trials research, pediatrics and research ethics to trial staff at different levels to 
improve their communication practices and methods as well as understand the 
principles and judgments that direct ethical actions. Health training institutions should 
introduce the necessary courses in their curriculum. 
 
The fourth set of recommendations is directed towards comprehension of information 
disclosed: 
 Clinical trial research staff should assess the decision-competency capacity of 
potential participants prior and during the screening process;  
 Research staff should use familiar examples to explain some of the complex 
information; or engage specialists in health education and promotion 
 Researchers should involve senior research team members like the clinicians in the 
consent process since the consent process is continuous. 
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 Governments should empower the research ethics committee members through 
providing resources human and financial, which can enable the members to monitor 
the consenting process regularly. 
 
The fifth set of recommendations is centred around motivation, decision-making and 
voluntariness of participants: 
 Trial staff must be cautious of unintentional coercive influences and avoid giving 
excessive incentives that can interfere with autonomous decision –making. 
 The consent form should clearly explain the participant right of freedom to withdraw 
from the study and assurances that refusal to enrol a child in the study would not in 
any way interfere with the child getting standard care normally provided. 
 Investigators should ensure that auxiliary care is provided to participants during 
research and is relatively similar to what is provided in the public facilities.  
 
In summary this study contributed to an understanding of the legal, ethical and practical 
challenges faced by the trial staff and parents in achieving valid informed consent for 
pediatric HIV clinical trials. This information can be applied to other clinical research 
settings. Although it was clear from the findings that obtaining valid parental informed 
consent is almost impossible due to the vulnerability of the parent created by the child‘s 
illness and need to access care, parents had high regard for research, research institutions and 
the trial staff because of their satisfaction with the consent process, the care and education as 
well as the compassionate nature of the trial staff unlike what happens in public facilities. 
 
The model developed can be used to minimize some the challenges that were identified. The 
recommendations suggested could contribute to the improvement of the parental informed 
consent process in Botswana. The model will be presented to the Ministry of Health, National 
Research Ethics Committee responsible for oversight of all research involving human 
subjects and to research institutions that conduct trials with pediatric patients. The 
information will also be disseminated in form of journal articles and at relevant conferences.  
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LIST OF APPENDICES 
 
APPENDIX 1:  TRIAL STAFF CONSENT FORM 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
What is this study about? 
 
This is a research project being conducted by Mary 
Kasule, for a Ph D study. I am inviting you to 
participate in this research project because you‘re 
conducting an HIV clinical trial that involves children as 
participants. As an Investigator involved in HIV clinical 
trials involving children, you might be in a position to 
provide me with the information that I can use to answer 
some of my research questions. The purpose of this 
research project is to identify the challenges encountered 
by research investigators who conduct clinical trials 
involving children when seeking informed consent from 
parents/guardians who enrol their children in HIV 
clinical trials. It is hoped that the recommendations from 
this study will help in addressing these challenges 
therefore improve the informed consent process for 
children participation in clinical trials in Botswana. 
What will I be asked to do if I agree to participate? 
You will be asked to answer questions by filling out a 
form, someone will interview you and you may also be 
asked to participate in a focus group discussion. The 
interviews will be conducted in a private room at the site 
where you conduct the clinical trial. The interview 
should take less than an hour. The research assistant will 
audiotape the session because we don‘t want to miss any 
of your comments. The questions that you will answer by 
filling in a form will include questions on personal 
information, the second section will have questions on 
the pre-enrolment stage of the consent process and the 
last section will include questions on the enrolment stage 
of the consent process. The interview will last about an 
hour.  
Would my participation in this study be kept 
confidential? 
We will do our best to keep your personal information 
confidential.  To help protect your confidentiality, all 
effort will be made to ensure that the forms that you fill 
in and the recorded tapes will be kept in lockable filling 
cabinets and these will remain locked at all times. 
Identification codes will be used on the forms and no 
other forms of identifiers will be requested from you. The 
Principal Investigator will be the only one with access to 
the key. Data that will be entered in the computer will be 
protected with a password only accessible to the 
Principal Investigator. The transcribing of the recorded 
information will be done by an independent researcher to 
avoid identification of individuals by voice. In case of 
any publications, or report about this research project, 
your identity will be protected to the maximum extent 
possible.   
What are the risks of this research? 
Some of the questions asked in this study might make 
you uncomfortable and you are free not to answer any 
such questions if you do not wish to.  
What are the benefits of this research? 
This study might identify the challenges encountered by 
investigators when seeking informed consent and the 
findings will be used to develop a model that can help 
solve or improve identified challenges. The findings will 
also contribute evidence that can used to inform policy 
and other stakeholders regarding the protection of the 
rights and welfare of children and caregivers who 
participate in clinical trials. 
Do I have to be in this research and may I stop 
participating at any time?   
Your participation in this research is completely 
voluntary.  You may choose not to take part at all.  If you 
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decide to participate in this research, you may stop 
participating at any time.  If you decide not to participate 
in this study or if you stop participating at any time, you 
will not be penalized or lose any benefits to which you 
otherwise qualify. 
What if I have questions? 
This research is being conducted by Mary Kasule at the 
Ministry of Health.  If you have any questions about the 
research study itself, please contact Mary Kasule, 
Ministry of Health, and P/Bag 0038 Gaborone. Tel: 
+267-363-2466. E-mail address: mkasule@gov.b. Should 
you have any questions regarding this study and your 
rights as a research participant or if you wish to report 
any problems you have experienced related to the study, 
please contact:   
Head of Department: Mr. P. Khulumani, Ministry of 
Health, Health Research Division, P/Bag 0038, 
GaboroneTel: 3632018E-mail: pkhulumani@gov.bw 
Audio taping/Videotaping/Photographs/Digital 
Recordings 
This research project involves making audiotapes to 
allow data to come out in its detailed richness and allow 
research assistants to observe the participants and make 
notes. These tapes will be locked up in filling cupboards 
and only the research team will have access to the key. 
The tapes will be destroyed three years after close-out of 
the study. 
Please indicate below whether you agree to be audio 
taped. 
___   I agree to be audio taped during my 
participation in this study. 
 Signature………………………………         
Date…………………… 
___   I do not agree to be audio taped during my 
participation in this study. 
 Signature………………………………..                   
Date………………….. 
Declaration by researcher/research assistant 
I________________________   declare that: 
 I explained the information in this document 
to the participant. 
 I encouraged him/her to ask questions and 
took adequate time to answer them.  
 I am satisfied that he/she adequately 
understood all aspects of the proposed study 
 
Signature of researcher/research 
assistant__________________________ 
Date_________________________________ 
.Audio taping/Videotaping/Photographs/Digital 
Recordings 
This research project involves making audiotapes to 
allow data to come out in its detailed richness and allow 
research assistants to observe the participants and make 
notes. These tapes will be locked up in filling cupboards 
and only the Principal Investigator will have access to the 
key. The tapes will be destroyed three years after close-
out of the study. 
Please indicate below whether you agree to be audio 
taped. 
___   I agree to be audio taped during my participation 
in this study. 
___   I do not agree to be audio taped during my 
participation in this study. 
Signature of 
participant____________________________          
Date___________2009 
Declaration by researcher/research assistant 
 
I________________________   declare that: 
 I explained the information in this document to 
the participant. 
 I encouraged him/her to ask questions and took 
adequate time to answer them.  
 I am satisfied that he/she adequately 
understood all aspects of the proposed study 
 
Signature of researcher/research 
assistant__________________________ 
 
Date_________________________________ 
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APPENDIX 2: TRIAL STAFF IN-DEPTH INTERVIEW GUIDE 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
                                                                                                                                      Start Time………… 
 
QUESTIONNAIRE IDENTIFICATION:               
 
 INTERVIEWER: ……………..                                            QUESTIONNAIRE NUMBER 
 
 DATE:            
Instructions: Please answer the following questions by filling out this form. 
 
PERSONAL INFORMATION 
 No QUESTION ANSWER  
Q1 Gender    O    M       O    F    
Q2 Age    O 20-30 yrs.      O 30-40 yrs.   O 40-50 yrs.      O  over 50 yrs. 
Q3 Highest academic degree awarded  
Q4  Occupation   
*Q 5 Have you had any specialized training in ethics of 
conducting clinical trials research?  
O None 
O Research courses at Tertiary level 
O Good Clinical Practice(GCP) 
O Basic Bioethics 
O Advanced Bioethics 
O Clinical trials 
O Advanced Bioethics 
O Ethics seminars or workshops 
O Other ____________ 
               Please Specify 
Q6 Do you have any specializations in pediatrics? and 
how long have you been involved in 
recruitment/conducting pediatric HIV clinical trial  
 
 
Q7 Citizenship.  
Q8 Place of residence  
PRE-ENROLLMENT STAGE 
    
D D M M Y Y Y Y 
This study is aimed to identify challenges encountered by investigators who conduct children HIV clinical Trials 
regarding seeking informed consent from parents/guardians who agreed to enrolment of their children into HIV clinical 
trials. Your participation in this study is voluntary and you have the liberty not to answer any of the questions; however I 
hope you will participate in this study, as your input will help us to enhance the informed consent process in studies 
where children are enrolled as research subjects. All of your responses will be confidential and will not in any way be 
used to identify you! 
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*Q 9 Which Phase of clinical trial have you been 
involved in? 
Phase I= first introduction into man, healthy volunteers, usually 
single dose, preliminary safety & pharmacokinetic/dynamic 
profile(blood& urine) 
Phase II = therapeutic exploratory studies, small sample size of 
patient groups, efficacy & safety, double-blinded studies, dose 
range and regimen and common side effects 
Phase III= therapeutic confirmatory studies, double-blinded, 
large sample size of patient groups, long term studies, efficacy 
and safety, side effect profile and pre-registration. 
Phase IV=therapeutic use or post marketing surveillance, limited 
to approved indications, differentiate drug from others, dose-
response, general safety. 
Q10 
 
 
 
 
 
 
 
What was the risk category of the clinical trial 
you recently conducted? 
O  Less than minimal risk to the human subject 
O Greater than minimal risk but presents a prospect of direct 
benefit to the human subject 
O Greater than minimal risk with no prospect of direct benefits to 
the human subject but likely to yield generalizable knowledge 
about the human subjects‘ disorder or condition.  
Q 11 On average, what generally is the highest level of 
education attained by the majority of the 
parents/guardian who give consent for their 
children‘s participation in clinical trials? 
O  No education 
O  Primary 
O  Secondary 
O  Tertiary 
O  Don‘t know 
Q12  On average, what is the average age of the 
parents/guardians whom you have obtained 
consent from for their children‘s   participation in 
clinical research? 
O 15- 25 
O 26-30 
O 31-35 
O 36-40 
O 41-45 
O > 45 
Q13 On average how many of your participants have 
previous experience with research on HIV 
disease? 
O Majority 
O Few 
O Very few 
 
Q14  What generally is social economic status of the 
majority of the parents/guardians who participate 
in your studies? 
O High    O Medium 
O Low     O  Very low 
 
 
Q 15 How do you rate the importance of prior of 
knowledge of a research investigator about 
Botswana culture, values and beliefs before the 
start of the study?  
 
O Very important 
O Important 
O Fairly important 
O Not important 
Give a reason for your answer____________ 
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Do you think this knowledge plays any role in the 
success or failure of a consenting process? 
(Please explain) 
Q16 Who prepares the consent form that you use in 
the clinical trial?  
O Sponsor             O  Institution 
O  Principal Investigator    O Research Team 
O  Other _______________ 
           Please specify 
Q17 On average how many pages is your consent 
document? 
1-5 pages 
6-10 pages 
11-15 pages 
>15 pages 
Q 18 
 
 
 
 
 
 
 
 
 
Which of the following research guidelines are 
you familiar with regarding the protection of 
research participants and how helpful they are to 
the consenting process?  
 
 
 
 
 
 
O Botswana laws            O The Belmont Report 
O The Declaration of Helsinki 
O The CFR                     O The CIMOS 
O The ICH(GCP) 
O Botswana Guidelines on conduction of Clinical trials Version 
2008 
O The Botswana Consent form Guide 
 O  The Nuremberg Code 
O Other __________________ 
                 Please specify 
Answer 
*Q 18 b GCP guidelines recommend that both the 
informed consent discussion and the informed 
consent form should include the twenty elements. 
Do your consent forms include all these elements 
and are you able to go through all these during 
your sessions?  
(Please explain) 
Q 19 What challenges do you encounter from the 
sponsors regarding the requirements for 
preparation of the informed consent document for 
the clinical trial if applicable? 
Please briefly explain (translating  into language(s) understood by 
participants) 
Q20 What challenges do you encounter from the 
ethics committees that review your consent form 
if applicable? 
Please briefly  explain 
INFORMATION DISCLOSURE 
Q 21 What recruitment methods do you use to let 
parents/guardians know about this study? (Check all 
that apply.) 
O  Radio announcement 
O  Posters/billboards 
O Circulation of flyers w/in local NGO/Church 
O Circulation of flyers w/in specific    
     communities 
O  In-clinic contact 
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O  Referrals from other clinics or medical  
     professionals 
O  Other ________________________ 
                 (Please Specify) 
Q22 Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
O  Self                              O  Co-investigator 
O Study Nurse                  O Study recruiter 
O Research assistant         O  Other 
_______________________ 
 (Please specify) 
Q 23 In what language are the discussions of the 
information about the study held? 
O English 
O Setswana 
O Other____________________ 
            Please specify 
Q24 How is  the information about the clinical trial 
communicated to the parent/guardian/child 
(verbally/read to the participants/asked participants to 
read) 
O Verbally by reading the consent form to the  respondent in 
English 
O Verbally by reading the questionnaire to the O respondent 
in Setswana 
O  English written consent is given to the parent/guardian to 
go home and read  
O  Setswana written consent is given to the parent/guardian to 
go home and read  
O English written consent is given to the parent/guardian to 
read during the consent session 
O Setswana written consent is given to the parent/guardian to 
read during the consent session 
O Other ________________ 
Please specify 
Q25 From your experience, which of the following 
elements of the consent form do find difficult to 
communicate to participants and why?  
O Purpose of study 
O Procedures to be performed on the child 
O Risks of the study 
O Unforeseen risks 
O Benefits of the study 
O Right to withdraw without reproach  
O Consent for transfer of samples 
O Consenting for use of stored samples for future use 
O Possible alternatives 
O Payment for participation 
O Responsibility for care in case of injury while on the study 
O Confidentiality and privacy 
O How the doctor will decide which treatment to give your 
child 
O The number of times your child will receive the treatment 
O The possibility of quitting the study 
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O Placebo use 
O Randomization 
O Control group 
     Other ____________________ 
          Please specify 
Q26 How would you rate the amount of information 
provided to the parents/guardians in the studies you 
have conducted? Do you consider all the information 
relevant for the participant to make an autonomous 
decision? 
O Too much                 O A lot 
O Average                    O Too little 
O Other ____________ 
          Please specify 
Q27 Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria 
do you use? 
O Reasonable-doctor standard ( doctor may use a 
     reasonable skill and may withhold information)  
O Reasonable-patient standard (doctor has the  
    duty to disclose all the information necessary to 
     making an intelligent and rational choice) 
 O Disclose all the information 
Q28 How would rate the complexity of the technical 
language used in the consent document and how do 
enhance understanding of such language? 
O Too complex          O Fairly complex 
O Understandable       O Other ___________________ 
Please specify and give reasons 
UNDERSTANDING 
Q29  How do majority of participants initially react to 
experimentation on their children? 
 
Do the parents understand the difference between 
research and treatment? 
O Extremely frightened       O Very frightened 
O Fairy frightened                O Anxious 
O More anxious than when they came in 
O Pleased                             O Satisfied 
O Pleased                             O Sad  
O Other ________________ 
               Please specify 
Q 30 Do the parents/guardians ask any questions? O Yes 
O No 
Q31 If yes what are usually their main concerns? 
Briefly explain 
O Safety of the child 
O Payment for participation 
O  Risks  
O Benefits 
O Difference between research and treatment 
O Why was the child chosen to participate 
O What happens in case of refusal to participate regarding 
future treatment 
Other _____________ 
            Please specify 
Q32 If no questions are asked do you find out why? O Yes  
O No 
Q33 What do you think is the most common reason for the 
parents/guardians not asking questions? 
Please specify______________________ 
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Q34 According to your observation, what is usually the 
general emotional state of the parents/guardians 
during the consenting process? 
O Calm                       O Anxious 
O Distraught/upset    O Other _________________ 
       Please explain 
Q35 How do you test the level of understanding of the 
information provided about the trial? 
O Verbally 
O Written test of understanding 
Pictures & stories 
Other_______ 
         Please specify 
Q36 How would you rate the level of attentiveness of the 
parent/guardian during the consent process?  
O  Very high     O  High 
O  Fair               O  Low 
O Very Low 
Q37 How much time do you think is appropriate for the 
informed consent process to enable understanding? 
Please indicate and give reasons 
DECISION MAKING 
 
Q39 Is it important to you to always consult the two 
parents or the relative(s) of the participants even if 
the person who has brought the child to the clinic 
agrees to participate? Do all the parents insist on 
consulting with the spouse or family before making a 
decision?  
O Yes  
 
O  No 
Q40 Who do you mainly consult before enrollment of the 
child into the study? 
O Spouse          O Grandmother 
O Grandfather  O Uncle 
O Auntie           O Other_______________ 
 Please specify 
Q41 Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain 
informed consent? 
O Yes  
O No 
Please give a reason for your answer 
Q42 How do majority of the parents/guardians indicate 
their agreement to their children‘s participation 
clinical research?  
O By signing on the consent form 
O By putting a thumb on the consent form 
O Verbally 
Q43 How do the parent(s)/guardian(s) react to being asked 
to sign a consent form? 
Did not seem to mind 
Were reluctant to sign 
Other_____________ 
Please specify 
 
Q44 How do you facilitate the decision-making process? Please briefly  explain 
Q45 From your interaction can you identify any social, 
cultural, economic or any other factors that you think 
might influence the parents/guardians to agree to 
enroll their children in the study? 
Please briefly  explain 
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Q46 Describe any measures you put in place to ensure that 
participants and the consenting parents/guardians do 
not feel coerced or pressured to join the study as well 
as continued consent during the study. 
Please briefly explain 
Q47 Please describe any general challenges you 
sometimes encounter in the process of seeking 
informed consent from parents/guardians/child 
Please briefly explain 
Q48 Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
Please briefly explain 
Q49 Do you involve competent children in the consent 
process? 
Please state 
Q 50 Children of what age do you engage in the consent 
process 
O 3-8 years 
O  9-15 years 
O  16-21 years 
THANK YOU FOR YOUR TIME AND COOPERATION 
END OF QUETIONNAIRE                         Time…………………………….. 
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APPENDIX 3:  FOCUS GROUP DISCUSSION GUIDE 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
 
Informed consent is recognized as the patient /participant 
safety mechanism for clinical research. Obtaining 
informed consent embodies challenges and complexities 
deeper than may be immediately determined. 
Participant Background Information 
1. Can we start by introducing ourselves? Briefly 
tell us about your educational background and 
what you do regarding the consenting process 
of potential study participants? 
2.  How many of you have been involved in 
pediatric HIV clinical trials/studies? 
3. How do you rate the importance of prior of 
knowledge of a research investigator about 
Botswana culture, values and beliefs before the 
start of the study? 
4. Do you think this knowledge plays any role in 
the success or failure of a consenting process? 
5. On average, what is the highest level of 
education attained by the majority of the 
parents/guardian who give consent for their 
children‘s participation in clinical trials? 
6. Which Phase pediatric clinical trial have you 
been involved in (Phase I , II, III or IV)? 
7. How would you rate the risk category of the 
clinical trials you have been involved in?(Less 
than minimal risk to the human subject, greater 
than minimal risk but presents a prospect of 
direct benefit to the human subject, greater than 
minimal risk with no prospect of direct benefits 
to the human subject but likely to yield 
generalizable knowledge about the human 
subjects‘ disorder or condition) 
8. What does the term informed consent mean to 
you? 
9. From your experience, can you briefly explain 
what the informed consent means to potential 
participants or parents who enroll their children 
in clinical trials? 
10. Can you briefly carry us through a typical a 
typical consenting session? 
Consent form documentation 
1. Please tell us about your role in the 
documentation of consent forms. 
2. On average how long are the consent forms 
that you use? 
3. What are some of the challenges you encounter 
in documentation process? (Language 
complexity, translation, sponsors, ethics 
committee). 
4. Several international and national guidelines 
have been developed to guide the preparation 
of the consent form. How strictly are these 
guidelines followed and applied in the 
preparation process (including all elements)? 
5. Can you suggest some recommendations as to 
how to design a consent form that would be 
contextualized to Botswana‘s context 
regarding, readability and understanding; 
quantity and quality of information to be 
included, clarity and simplicity in order to 
enhance recruitment and adherence to 
procedure? 
6. Any other comments you would like to share 
about the consent form? 
Information disclosure 
1. What recruitment methods do you use to let 
parents/guardians know about research studies? 
2. Who talks to the parents/guardians/children about 
the clinical trial when they came to the 
hospital/clinic? (First contact person) 
3. To what extent are the 
clinicians/doctors/physicians involved in the 
information disclosure process? 
4.  One of the requirements of a valid informed 
disclosure is ―full disclosure‖ of information. 
What is your opinion about the feasibility of 
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achieving this requirement and what methods 
do you use to achieve this? 
5. How would you rate the amount of information 
provided to the parents/guardians in the studies 
you have conducted? Do you consider all the 
information relevant for the participant to make 
an autonomous decision? 
6. What is your opinion about the quantity and 
quality of information usually disclosed to 
participants? 
7.  Do parents ask questions during the 
information disclosure sessions and what type 
of questions do they usually ask? 
8. How do ensure that parents understand the 
difference between treatment and research to 
avoid therapeutic misconceptions. 
 
Understanding  
What is your opinion about this statement ―Information 
disclosure should mainly aims at fulfilling legal 
requirements than facilitating autonomous decision‖? 
1. Can we briefly talk about the challenges you 
encounter in facilitating understanding (i) the 
procedures, (ii) risks and benefits, (iii) 
voluntariness, (iv) scientific and 
epidemiological research terminologies and 
information explained in statistical terms?   
2. Can you suggest any possible solutions to these 
challenges?  
3. Regarding time constraints and sponsor 
requirements how you determine how much 
time is needed for the participant to respond to 
the request of participation. 
4. Can we talk about some of the different 
methods you use to test participant 
understanding and suggest what has worked 
best? 
Voluntariness 
1.  What are some of the factors you have 
observed to influence the decision to enroll 
children in HIV clinical trials. 
2. In cases where children are above 7 years of 
age, to what extent do you involve them in the 
informed consent process and what methods do 
you commonly use to facilitate their 
understanding of what is being suggested to 
them? 
3. Can tell us about the positive things parents say 
about their children‘s participation in HIV 
clinical trials. 
4. Can you tell us the negative things parents say 
about their children‘s participation in HIV 
clinical trials? 
5. Generally how satisfied are you with the 
current practices of the consenting process in 
the studies you have been involved in? 
THANK YOU FOR YOUR TIME AND 
COOPERATION 
END OF DISCUSSION END 
TIME………………………A.M/P.M 
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APPENDIX 4: FOCUS GROUP PARTICIPANT CONSENT FORM (INDIVIDUAL) 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
 
What is this study about? 
This study is being conducted by Mary Kasule, for a Ph D 
study. I am inviting you to participate in this study because 
you are involved in the consenting process of 
parents/guardians who enrol their children in HIV clinical 
trials conducted in Botswana. As a research investigator 
who seeks informed consent from parent/guardians who 
agree to enrol their children in HIV clinical trials conducted 
in Botswana to find out about more about the HIV disease 
prevention, treatment and care among children, you might 
be in a position to provide me with the information that I can 
use to answer some of my research questions. The purpose 
of this study is to conduct a situational analysis of the 
current practices of obtaining parental consent for pediatric 
HIV clinical trials conducted in Botswana in order to 
evaluate the quality of the process and use the findings to 
develop a conceptual model that can be used as a framework 
to guide the parental consent process. Specifically the study 
aims to assess the documentation of consent forms and other 
participant information, information disclosure, 
comprehension of disclosed information and voluntariness 
of parents to enrol their children n HIV clinical trials. It is 
hoped that the recommendations from this study will help in 
addressing these challenges therefore improve the informed 
consent process for child participation in HIV clinical trials. 
Do I have to take part in the focus group discussions and 
if I do can   I stop participating in the focus group 
discussions at any time?   
Your participation in this research is completely voluntary.  
You may choose not to take part at all.  If you decide to 
participate in this research, you may stop participating at any 
time.  If you decide not to participate in this study or if you 
stop participating at any time, this will not affect your 
ongoing research studies in any way. 
 
What will I be asked to do if I agree to participate? 
You will be asked to participate in a focus group discussion 
comprising of researchers involved in the consenting of 
parents/guardians of children who are enrolled in HIV 
clinical trials. Guiding questions will be asked by a trained 
moderator. The discussions will be held at a selected site in a 
room that can afford a maximum degree of privacy and 
individual participants will be not be identified by their 
names but will be assigned a number which will be 
displayed on a nametag. The focus group discussions should 
take a maximum of ninety (90) minutes. The moderator and 
note-taker will be audio taping the session as well as taking 
notes so that we don‘t miss any of your important comments 
and contributions. The questions that you will answer will 
include questions on consent form and participant 
information documentation, information disclosure and 
parental understanding of provided information as well as 
parental voluntariness. 
 
Would my participation in this study be kept 
confidential? 
We will do our best to keep the information you provide 
during the discussions confidential.  Your identity as well as 
that of all team members involved in the focus group 
discussions will remain confidential. The moderator and 
note-maker will not use names or personal identifying 
information in anything written about this focus group 
discussion. To help protect your confidentiality, all effort 
will be made to ensure that the tapes  with the answers to 
your questions and any notes  which will be made during the 
group discussion will kept in lockable filling cabinets which 
will remain locked at all times. The research investigator for 
this study will be the only one with access to the key. Data 
that will be entered in the computer will be protected with a 
password only accessible to the research team. In case of any 
publications, or reports about this research project, your 
identity will be protected to the maximum extent possible.  
Your identity as well as that of the focus group team 
members will remain confidential. 
 
What are the risks of this research? 
Some of the questions asked in this study might make you 
uncomfortable; however you are free not to answer any such 
questions if you do not wish to.  
 
What are the benefits of this research? 
This study might identify some of the challenges 
encountered by research investigators when seeking parental 
informed consent as well as gaps in the process. Findings 
will be used to develop a model that can address the 
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identified challenges and gaps. The findings will also 
contribute evidence that can be used to inform policy, 
develop research guidelines and standard operating 
procedures that may help to standardize the consenting 
process. 
What if I have questions? 
This research is being conducted by Mary Kasule at the 
Ministry of Health.  If you have any questions about the 
research study itself, please contact Mary Kasule, Ministry 
of Health, and P/Bag 0038 Gaborone. Tel: +267-363-2466. 
E-mail address: mkasule@gov.bw. Should you have any 
questions regarding this study and your rights as a 
participant or if you wish to report any problems you have 
experienced related to the study, please contact:   
Head of Department: Mr. P. Khulumani, Ministry of 
Health, Health Research Division, P/Bag 0038, Gaborone; 
Tel: 3632018; E-mail: pkhulumani@gov.bw 
 
 
 
 
Declaration by participant 
I have read or has been explained the information above, and 
I have had all my questions answered to my satisfaction. I 
voluntarily agree to participate in this focus group discussion 
Please indicate below whether you agree to participate in the 
focus group discussion 
___   I agree to be audio taped during my participation in 
this study. 
 Signature………………………………         
Date…………………… 
___   I do not agree to be audio taped during my 
participation in this study. 
 Signature………………………………..                   
Date 
Audio taping/Videotaping/Photographs/Digital 
Recordings 
This research study involves making audiotapes to allow 
data to come out in its detailed richness and allow research 
assistants to observe the participants and make notes. These 
tapes will be locked up in filling cupboards and only the 
research team will have access to the key. The tapes will be 
destroyed three years after close-out of the study. 
Please indicate below whether you agree to be audio taped. 
___   I agree to be audio taped during my participation in 
this study. 
 Signature………………………………         
Date…………………… 
___   I do not agree to be audio taped during my 
participation in this study. 
 Signature………………………………..                   
Date 
Declaration by researcher/research assistant 
I________________________   declare that: 
 I explained the information in this document to 
the participant. 
 I encouraged him/her to ask questions and took 
adequate time to answer them.  
 I am satisfied that he/she adequately understood 
all aspects of the proposed study 
Signature of researcher/research 
assistant__________________   
Date_________________________________ 
 
 
 
  
 
 
 
 
  
183 
 
APPENDIX 5: FOCUS GROUP TEAM CONFIDENTIALITY BINDING FORM 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
To ensure clear professional boundaries and protect the privacy of individuals participating in the focus groups, the focus 
group team agrees to the following: 
1. The information collected during the focus groups is strictly intended only for academic purposes. 
2. The focus group team agrees that it will not speculate about the identity of any particular focus group participant. 
3. Team members who observe a focus group will not record any personal identifying information in their notes or 
disclose any personal information in the debriefing sessions. 
4. Team members will maintain the confidentiality of each person and situation they may come in contact with. 
5. The facilitator (s) and note-taker(s) will obtain consent to the discussion and note taking from all focus group 
participants prior to the start of the discussion. 
 
_________________________________ 
Signature of Focus Group Team Member 
 
_________________________________ 
Date 
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APPENDIX 6: PARENTS/GUARDIAN CONSENT FORM 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric 
Patients 
 
What is this study about? 
This is a research project being conducted by Mary Kasule, for a Ph D study. I am inviting you to participate 
in this research project because your child is enrolled in a study that I have selected to use for my study. As a 
parent who agreed to enrol your child in a study about finding out more about the HIV disease treatment among 
children, you might be in a position to provide me with the information that I can use to answer some of my 
research questions. The purpose of this research project is to identify the challenges faced by parents/guardians 
who agree to have their children participate in studies that aim to find out about causes of HIV disease, and how 
it can be prevented and treated during the process of giving research investigators permission (informed 
consent) to enrol their children in the studies. It is hoped that the recommendations from this study will help in 
addressing these challenges therefore improve the informed consent process for child participation in HIV 
clinical trials. 
What will I be asked to do if I agree to participate? 
You will be asked to answer questions asked by a trained research assistant. The interviews will be conducted in 
a private room at one of the sites where HIV clinical trials involving children are conducted or any place that 
you find convenient. The interview should take less than an hour. The interviewer will be audio taping the 
session because we don‘t want to miss any of your important comments. The questions that you will answer will 
include questions on personal information, how the information about the study is given, your understanding of 
the information that you are given and how you decide to agree to enrol your child in the study. 
 
Would my participation in this study be kept confidential? 
We will do our best to keep your personal information confidential.  To help protect your confidentiality, all 
effort will be made to ensure that the tape recorders with the answers to your questions and any notes that will 
be made during the interview will kept in lockable filling cabinets which will remain locked at all times. The 
research investigator will be the only one with access to the key. Data that will be entered in the computer will 
be protected with a password only accessible to the research team. In case of any publications, or report about 
this research project, your identity will be protected to the maximum extent possible.   
 
What are the risks of this research? 
Some of the questions asked in this study might make you uncomfortable and you are free not to answer any 
such questions if you do not wish to.  
 
What are the benefits of this research? 
This study might identify the challenges encountered by parents/guardians when giving informed consent and 
the findings will be used to develop a model that can address the identified challenges. The findings will also 
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contribute evidence that can used to inform the authorities to set rules that may help to conduct the process of 
informed consent better. 
Do I have to be in this research and may I stop participating at any time?   
Your participation in this research is completely voluntary.  You may choose not to take part at all.  If you 
decide to participate in this research, you may stop participating at any time.  If you decide not to participate in 
this study or if you stop participating at any time, you will not be penalized and your child will continue to be 
treated for any illness each time you go to any health facility. 
What if I have questions? 
This research is being conducted by Mary Kasule at the Ministry of Health.  If you have any questions about the 
research study itself, please contact Mary Kasule, Ministry of Health, P/Bag 0038 Gaborone. Tel: +267-363-
2466. E-mail address: mkasule@gov.b. Should you have any questions regarding this study and your rights as a 
research participant or if you wish to report any problems you have experienced related to the study, please 
contact:   
Head of Department: 
Mr. P. Khulumani, Ministry of Health, Health Research Division, P/Bag 0038, Gaborone 
Tel: 3632018 
E-mail: pkhulumani@gov.bw 
Audio taping/Videotaping/Photographs/Digital Recordings 
This research project involves making audiotapes to allow data to come out in its detailed richness and allow 
research assistants to observe the participants and make notes. These tapes will be locked up in filling cupboards 
and only the research team will have access to the key. The tapes will be destroyed three years after close-out of 
the study. 
Please indicate below whether you agree to be audio taped. 
___   I agree to be audio taped during my participation in this study. 
 Signature………………………………         Date…………………… 
___   I do not agree to be audio taped during my participation in this study. 
 Signature………………………………..                   Date 
Declaration by researcher/research assistant 
 
I________________________   declare that: 
 I explained the information in this document to the participant. 
 I encouraged him/her to ask questions and took adequate time to answer them.  
 I am satisfied that he/she adequately understood all aspects of the proposed study 
 
Signature of researcher/research assistant__________________________ 
Date_________________________________ 
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APPENDIX 7: TETLA YA MOTSADI/MOTLHOKOMEDI WA NGWANA YA GO 
KA TSAYA KAROLO MO PUISANONG 
 
Setlhogo:  Tsela ya go tsaya tetla mo motsading go akaretsa bana mo ditshekatshekong tsa HIV 
 
Patlisiso e ke ka ga eng? 
Patlisiso e diriwa ke Mme Mary Kasule,  yo e 
leng moithuti. O kopiwa go tsaya karolo mo 
patlisisong e ka gore ngwana wag ago o tseneletse 
tshekatsheko e mmatlisisi a tlhopileng go e dirisa 
mo tshekatshekong ya gagwe. O le motsadi wa 
ngwana o ne wa dumela gore ngwana wa gago a 
tsenelele tshekatsheko e o go yone go sekasekiwang 
go itse dintlha tsa botlhokwa ka kalafi ya mogare 
wa HIV mo baneng. Mosekaseki o ne a lemoga fa o 
ka tswa o na le kitsiso e e ka mo thusang go ka 
araba dipotso dingwe tsa patlisiso ya gagwe. 
Maikaelelo a patlisiso e ke go leka go tlhaloganya 
ka dikgwetlho tse batsadi kgotsa batlhokomedi ba 
bana ba dumetseng gore bana ba bone ba tsenelele 
patliso ya go leka go itse ka mogare wa HIV ba 
lebaganeng le tsone. Mmatlisisi o leka go itse gore 
dikgwetho tse di ka emisiwa jang kgotsa di ka 
kganelwa jang fa motsadi/motlhokomedi a letlelela 
gore ngwana wa gagwe a tseye karolo mo 
ditshekatshekong tse. Re solofela fa dintlha tse 
mmatlisisi a tla di lemogang ka dikgwetlho di tla 
thusa basekaseki go tokafatsa tsela ya gore motsadi 
wa ngwana o ka fa tletla ya gore ngwana wa gagwe 
a tsenelele tshekatsheko e ya kalafi ya mogare wa 
HIV. 
Ke ya go kopiwa go dira eng fa nka dumela go 
tsaya karolo mo patlisisong e? 
O tla kopiwa go araba dipotso tse o tla di bodiwang 
ke mothusa mmatlisisi yo o rutetsweng tiro e. 
Potsoloso ya patlisiso e e tla tshwarelwa mo ntlong 
ee faphegeling, o tla bo o nale mmatlisisi fela. 
Dipotsolotso tse di tla tshwarelwa kwa lifelong le 
ngwana wa gago a tseneletseng ditshekatshekong 
teng kana ko wena o bonang go ka tshwanela kana 
fa go go siametseng teng. Potsolotso e e tla tsaya 
metsotso e sa feteng masome a marataro (oura). O 
tla botswa dipotsa ka botshelo jwa gago le ba 
lelwapa la gago, dipotso ka fa ba bongaka ba go 
fang  kitso ya tshekatsheko e ngwana wa gago a e 
tseneletseng, dipotso ka fa o tlhaloganyang kitso e 
o e filweng le ka fa o dumelanang le ba bongaka ka 
go letlelela gore ngwana wag ago go ka tsenelela 
tshekatsheko.  
A go tsenelela patlisiso e go tla nna sephiri sa me 
le mmatlisisi   
Re tla dira ka fa re kgonang ka teng gore kitso ka 
gago le botshelo jwa gago e itsiwe ke mmatlisisi 
fela. Sengwe le sengwe se re tla se dirang mo 
potsolosong ya patlisiso e se tla nna mo lifelong le 
le babalesegileng e bile le tla lotlelwa ka nako 
tsotlhe. Mmatlisisi ke ene fela a tla nna le selotlelo 
sa lefelo leo. Fa patlisiso e e ka tsengwa mo 
computareng go tla tsengwa dinomoro tsa sephiri 
go itsa o pe yo o senang tlela go ka bula mekwalo 
ya patlisiso e. Fa go ka dirigala gore patlisiso e e go 
ka kwalwa ka yo ne kgotsa go ka amoganwa kitso 
ka yone re tla netefatsa gore kitso epe ka ga wena 
ga e itsewe ke ope, le gore o mang go tla nna 
sephiri, e bile ga go kitla go itse ope gore o kile wa 
tsenelela patlisiso e.  
A go na le ditlamorago tsa go tsenelela patlisiso 
e?    
Dipotso dingwe tse o tla di botswang gongwe ga di 
na go go tsaya sentle mme o letlelesega gore o seka 
wa di araba fa o sa tseege sentle. 
Mosola wa patlisiso e ke eng? 
Patlisiso e e leka go tlhaloganya ka dikgwetlho tse 
batsadi kgotsa batlhokomedi ba bana ba dumetseng 
gore bana ba bone ba tsenelele ditshekatsheko. Re 
solofela fa dintlha tse mmatlisisi a tla di lemogang 
ka dikgwetlho di tla thusa basekaseki go tokafatsa 
tsela ya gore motsadi wa ngwana o ka fa tletla ya 
gore ngwana wa gagwe a tsenelele tshekatsheko e 
ya kalafi ya mogare wa HIV. 
A ke a patelesegang go tsenelela patlisiso e e bi le 
a ke kgona go emisa go tsaya karolo mo 
patlisisong e? Go tsaya karolo mo patlisong e ke 
boithaopo. O kgona go emisa go tsaya karolo o 
gololesegile. Fa o eletsa go tsaya karolo o ka dira 
jalo mme o letlelesega go emisa go tsaya karolo 
nako ngwe le ngwe. Fa o dumelane le go tsaya 
karolo mo patlisisong e, go o na go otlhaiwa e bile 
ngwana wag a go o tla tswelela ka go nna le seabe 
mo tshekatshekong ea a e tseneletseng.  
Fa ke na le dipotso?  
Patlisiso e key a ga mme Mary Kasule go tswa kwa 
lephatla la botsogo. Fa o na le dipotso  ka ga 
patlisiso e oka ikopanya le Mary Kasule, Lephatla 
la Botsogo, P/Bag 0038, Gaborone. Mogala  ke + 
267 363 2466. E-mail address: mkasule@gov.bw. 
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Fa o na le dipotso dingwe mabapi le patlisiso e 
kana mabapi le ditshwanelo tsa gago le go 
tseneleng patlisiso e ka na o batla go ikuela o na le 
di ngongorego mabapi le patlisiso e, o ka ikopanya 
le  
Mogolwane wa Lephatla la Botsogo 
Mr P. Khulumani, Lephatla la Botsogo, Lakalana la 
Dipatlasiso tas Botsogo, P/Bag 0038, Gaborone 
Mogala: 3632018 
E-mail: pkhulumani@gov.bw 
O kopiwa go supa fa o dumelana kgotsa o sa 
dumelane le go nna le seabe mo patlisisong ee. 
______ Ke a dumela go tsenelela patlisiso ee. 
 Saena fa/ Baa monwana fa 
…………………………….   Letsatsi  
…………………… 
_______Ga ke dumelane go tsenelela patlisiso ee. 
    Saena fa/ Baa monwana fa, fa o sa 
dumelane  …………………..  Letsatsi 
………………. 
Netefatso ya mmatlisisi/ kgotsa mothusa 
mmatlisisi 
Ke le ___________________________________ 
ke netefatsa gore: 
 Ke tlhaloseditse mongwe le mongwe yo o 
tsayang karolo mo patlisisong gore 
patlisiso e ke ya eng le gore ke eng ba 
kopiwa go tsaya karolo mo go yone. 
 Ke mo kgotlhaditse gore fa a na le dipotso 
a ka botsa e bile ke mo file sebaka ka 
araba dipotso.  
 Ke kgotsofalela gore o tlhalogantse 
sengwe le sengwe ka patlisiso e. 
Saena fa/ baa monwana (Mmatlisis/ mothusa 
mmatlisisi) 
……………………………………………. 
Letsatsi 
……………………………………………… 
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APPENDIX 8: PARENT SEMI-STRUCTURED INTERVIEW GUIDE (ENGLISH) 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric 
Patients 
Questionnaire #__ __ __ 
   Date: __ __/__ __/__ _ 
Thank you for agreeing to participate. Your participation in this study is voluntary and you have the liberty not 
to answer any of the questions. The information gathered will allow the authorities to improve the process of 
talking to parents of children enrolled in studies such as the one your child was in.  The information you give 
will remain confidential and will not in any way be used to identify you. 
Please remember that if you do not want to answer any specific questions, you are free to skip them. 
 
SECTION A: We would like to know about you, your child and your family        
 
1 Gender Male Female 
2 What is your age in years?   
3  Where do you live? 
 
Town/city Village Ward 
4 What is your highest level of 
education? 
Tertiary Senior 
school 
Junior 
school 
Primary 
School 
Non-
formal 
education 
None 
5 Do you know how to read and write Yes  No 
6 In which language can you read 
fluently and write well?  
English  Setswana Other (specify) 
7 Are you the mother (father, 
parents/guardians) of this child? 
Yes No 
8  How old is your child?   
9  If you are the guardian to this child, 
what is your relationship to this 
child?  
Grandmother Grandfather Auntie Uncle Other 
10  Has your child ever been in other 
research studies? 
Yes  No 
 
 
11 
How many research studies has your 
child been in? 
  
12 Have any of your other children been 
in any research studies? 
Yes  No 
13 How many times have you brought 
your child to see doctors in the last 
year?  
Very few 
times  
Few times  Many times Probe for 
frequency 
14  How many people live in your 
house?  
 
15 Who is the head of the house?   
16 What is your marital status? Co-
habiting 
Married Single Divorced Other  
17 Are you working?  
18 If you are working were do you 
work? 
 
19 What is the job of the child‘s father 
(mother)?  
 
20 The house where you live, is it 
for…? 
My Land Lord My Relative  My Employer  My Spouse 
21 What type of a house do you live in? High Cost Medium Cost Low cost SHAA House 
22 Does the house where you live have 
the following utilities? 
Electricity Running Water  Both (electricity and 
running water) 
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SECTION B: Tick the answer which is correct in your case 
1. Who talked to you before you agreed to have your child in the study?   
(i)    Doctor (ii) Nurse       (iii) Social worker     (iv) Friends (v) Other (specify) 
2. In which language were spoken to during the consenting process 
(i) Setswana (ii) English 
3. Were you asked to read and sign the consent form or someone read it to you? 
(i) I read and signed the consent form   (ii) the researcher/ nurse read it to me   
(iii) A family member read it to me   (iii) I read some sections and was helped to read 
others    
3. Do you remember how long the consent form in your study was? 
(i) Too long   (ii) Fairly long  (iii) long   (iv) short 
4. How much time after being told about the study did you take to agree to have your child in the study?  
(i) I agreed the same day      (ii) I agreed after a few days         (iii) I 
agreed after some weeks   .   
5. When you were discussing the study, did the nurse tell you about …? 
 
 QUESTION Yes No Don’t 
know 
1. Why your child needed to be in the study?     
2. Whether the medicines might have some bad effects on your child‘s health?    
3. How many times you and your child will be coming to the clinic during the 
study? 
   
4. How many times your child will receive the medicines?    
5. If there would be any payment you will receive for agreeing to have your 
child in the study?  
   
6. If you were free to stop your child any time from being in the study?    
7. How the doctors will decide which medicines to give your child?    
 
6. As you talked with the nurse about the study 
 QUESTION Yes  No Don’t 
know 
1. Did he/she speak in a language you understand?     
2. Did he/she explain clearly about the medicines your child would receive?    
3. Do you think all the information provided was important for you in deciding 
whether your child should join the study? 
   
4. Did he/she use any difficult medical terms you could not understand?    
5. Did he/she explain the difficult terms used?    
6. Did he/she provide you information about your child‘s disease?    
7. Did he/she test how well you had understood the information given?    
8. Were you given a chance to ask questions?    
9. Did you ask any questions?    
10. Were you satisfied with the information that was being provided?    
 
7. How important was it to you to get information about …? 
 QUESTION Very 
important 
Fairly 
important 
Not 
important 
at all 
1. Why your child needed to be in the study?     
2. Whether the medicines might have some bad effects on your child‘s 
health? 
   
4. How many times you and your child will be coming to the clinic 
during the study? 
   
5. How many times your child will receive the medicines?    
6. If there would be any payment you will receive for agreeing to have    
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your child in the study?  
7. If you were free to stop your child any time from being in the study?    
8. How the doctors will decide which medicines to give your child?    
 
8. How well informed do you think you are right now about …?  
 
  Very well 
informed 
Fairly well 
informed 
Not well 
informed 
1. Why your child needed to be in the study?     
2. Whether the medicines might have some bad effects on your 
child‘s health? 
   
3. How many times you and your child will be coming to the 
clinic during the study? 
   
4. How many times your child will receive the medicines?    
5. If there would be any payment you will receive for agreeing to 
have your child in the study?  
   
6. If you were free to stop your child any time from being in the 
study? 
   
7. How the doctors will decide which medicines to give your 
child? 
   
 
9. As you discussed the information about the study with the nurse, did you feel he/she was being…..? 
 
 QUESTION Yes  No Don’t 
know 
1. Honest     
2. Forcing you to agree    
3. Truthful     
4. Caring and sympathetic  to your feelings    
5. Knowledgeable about the study    
 
SECTION C: Please respond to each statement as best as you can by saying Yes, No, or don’t know for 
any of the studies your child joined 
 QUESTION Yes No Don’t 
know 
1. The main reason HIV research is done is to improve the treatment for future 
HIV patients 
   
2. The main reason for my child  joining the study is to receive  treatment    
3. The main reason for my child joining the study is to find out which medicine 
work best in order to help future children 
   
4. The main reason for my child joining the study is to find out which drugs are 
cheapest 
   
5. One of the major reasons for the study was to test the safety of a new HIV 
medicine. 
   
6. In this HIV study, each group of children received a different medicine.    
7. My child received the medicine which was being tried    
8. The doctors did not know the effect of the medicine used on my child    
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9. It is not clear whether the study will benefit my child    
10. There is no better way to treat my child‘s illness than using the medicines in 
the study. 
   
11. I was allowed to choose the medicines  my child received    
12. I knew how long my child‘s participation in the study was likely to last    
13. If I had not wanted my child to participate in the study, I could have refused.    
14. I could have had my child participate in the study without signing or putting a 
thumb on the consent form 
   
15. I could have withdrawn my child from the study at any time    
16. If I had withdrawn my child from the study he/she could still have been 
treated at the clinic? 
   
17. All the children in my child‘s study got the same medicines?    
18. Some children received medicines which were not  effective    
19. The study doctor decided which medicines each child would get based on 
chance 
   
20. The study doctor  decided which medicines each child would get based on 
what he/she thought was best for each child 
   
21. The study doctor  decided which treatment each child would get based on 
what each parent wanted 
   
22. I am free to take my child could drop out of the study any time.    
23. I was told how many times I would have to bring my child to the clinic after 
joining the study 
   
24. I was told the medicines my child was getting could have life-threatening 
side-effects 
   
25. I was told that other health workers or other people that are not directly 
involved in my care could look at my child‘s medical records 
   
26. I was told who will pay for my child‘s care if he/she was injured or became 
ill as a result of participating in this study. 
   
27. The consent form used in the study listed the names of people I should 
contact if I had any questions about my child‘s participation in the study. 
   
 
SECTION D: Please respond to each question as best as you can by choosing from the answers given. You 
can choose more than one answer. 
1. What was the most important reason for having child join the study?  
(i) To help future HIV-infected children   (ii) To have my child treated 
(iii) To receive the money being paid for participating    (iv) My child‘s illness 
 
2. If the study team was not going to give you P 30.00 each time you brought your child would you still have 
joined the study?(i)Yes     (ii) No      (iii) Don‘t know   
 
3. How much pressure, if any, did you feel from other people to join the study?      
(i) A lot of pressure.  (ii) A fair amount of pressure (iii) A little pressure (iv) No pressure at all   
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4. From the following list of people, please pick all the people from whom you felt any pressure to join the study                                                                                                                                                                                                     
 
 
 
 
 
 
 
5. How much pressure, if any, did you feel to join the study because your child is sick?     
(i) A lot of pressure (ii)  A fair amount of pressure  (iii) A little pressure  (iv)  No pressure   
  
6. Did you personally make the decision to have your child join the study? 
 (i)Yes     (ii) No 
   
7. Did any other person help you make the decision to have your child join the study? 
(i) Yes  (ii) No 
8. Who helped you decide to have your child join?  
 
(i)  The  doctors  (v) My family  
(ii)  The nurses (vi) Close friends  
(iii)  The health center staff (vii) Anyone else? Who was that person  
(iv)  My  spouse    
9. Could you have refused to have your child join the study if you had wanted to? 
 (i)Yes                         (ii) No        
10. Give reasons for your answer above? 
 
11. How easy would it have been for you to refuse to have your child join the study? 
(i) Very easy (ii) Fairly easy   (iii) Fairly difficult       (iv) Very difficult 
  
12. You agreed to join the study either by signing your name or by putting your thumbprint on a form. Which 
one of the following did you do?  
(i) Signed my name on a form   (ii) Put my thumbprint on a form     
13. Would you have preferred to join the study by telling the doctor, without having to sign your name (put your 
thumbprint) on the form?       (i) Yes    
 (ii) No  
      
Those are all of our questions—is there anything else you’d like to tell us? 
_____________________________________________________________________________ 
____________________________________________________________________________ 
_____________________________________________________________________________ 
 
Thank you very much for answering our questions!         End time: __ __:__ __ AM/PM 
(i) Doctor  (vi) Close friends  
(ii) Nurses   (vii) Anyone else? Who was that person?  
(iii) The health center     
(iv) My spouse      
(v) My Family       
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ANNEX 9: PARENT SEMI-STRUCTURED INTERVIEW GUIDE (SETSWANA) 
 
Setlhogo:  Tsela ya go tsaya tetla mo motsading go akaretsa bana mo ditshekatshekong tsa HIV 
                                                                                                             Nomoro patlisiso :____ 
             Letsatsi: __ __/__ __/__ _ 
                                        Nako ya go simolola: __ __:__ __ AM/PM 
 Ke lebogela go bo o dumetse go tsenelela puisano e. Go tsaya karolo ga gago ke boithaopo e bile o gololesegile go sa araba 
dipotso tse o sa batleng go di araba. Le fa go ntse jalo re solofela gore o tla tsaya karolo, ka kitso e re tlaa e bonang fa e ka re 
thusa go bona gore a go nale sengwe se se tlhokang go tokafadiwa.  Dikarabo tsotlhe di tla nna sephiri e bile ga gona yoo tla 
itseng gore ke tsa gago.  
Tsweetswee, gakologelwa gore o ka nkitsise fa go na le potso e o sa batleng go e araba re ka fetela kwa go e nngwe. O kgona 
go emisa go tsaya karolo nako nngwe le nngwe.  Fa o batla go emisa go tsaya karolo, ga gona go ama ngwana wag ago ka 
gope. O nkitsise fa o batla ke boelela potso nngwe kana o sa tlhaloganye potso nngwe.  
 
KAROLO YA NTLHA 
DINTLHA KA GA WENA 
Re batla go itse ka wena, ngwana wag ago le lelwapa la gago.                                                                                                   
1 Bong Rre Mme 
2 O wela fa dingwageng dife?  
3  O nna kae? Toropo Motse  
4 O ithutile/tsene sekolo go 
fitlhelela kae? 
Mmadikolo Sekolo se se 
golo (Senior) 
Sekolo se se 
golwane 
(Junior) 
Sekolo se 
se botlana 
Thuto ga 
e golelwe 
Ga ke a 
tsena 
sekolo 
5 A o itse go bala le go kwala? Ee Nnyaa 
6 O kgona go bala le go kwala puo 
efe sentle? 
Sekgoa Setswana E nngwe (Tlhalosa) 
7 A o mmaagwe, rragwe kgotsa 
motlhokomedi wa ngwana yo?  
Ee Nnyaa 
8  Ngwana wa gago o dingwaga di 
le kae? 
 
9  Fa o le motlhokomedi wa 
ngwana yo, le sikana jang? 
Nkuku Ntatemogolo Mmangwane 
Rakgadi 
Malome 
Rangwane 
Ba bangwe 
10 A ngwana wagago o kile a 
tsenelela dipatlisiso tse dingwe? 
Ee Nnyaa 
11 Di le kae?    Go feta Boraro 
12 A o na le bana bangwe ba ba 
kileng ba tsenelela dipatlisiso? 
Ee Nnyaa 
13 O tsisitse ngwana wa gago go 
bona ngaka ga kae ngwaga o o 
fitileng?  
gangwe gabedi Gararo Go feta botlhano 
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14  Go nna batho ba le kae mo 
ntlong ya gago? 
Babedi Bararo Bane Go feta Bone 
15 Tlhogo  ya lelwapa la gago ke 
mang? 
Nna Monna wa me Rre Mme Ba bangwe 
16 Seemo sagago sa lenyalo ke 
sefe? 
Ke nyetswe/nyetse Ga ke a 
nyalwa/nyala 
Ke kgaoganye le 
monna/mosadi 
Tse dingwe 
17 A o a bereka?  
18 Fa o bereka o bereka o le eng?  
19 rraagwe/mmaagwe ngwana wag 
ago o a bereka? 
 
20 Ntlo e le nnang mo go yone ke 
ya ga mang? 
Yame Mohirisi Losika Motho yo ke 
mmerekang 
Monna/Mosadi 
wa me 
21 Le nna mo ntlong e e ntseng 
jang? 
Ya madi a a kwa 
godimo 
Ya madi a a fa gare Ya madi a a fa 
gare 
Tse dingwe 
22 A le na le ditlamelo tse? Motlakase Metsi mo ntlong Motlakase le metsi 
 
KAROLO YA BOBEDI 
 
Re batla go itse gore go/gone go le botlhokwa go le kae mo go wena go itse dintlha dingwe tsa patlisiso pele o dumela go 
letlelela ngwana wa gago  go tsenelela patlisiso.  
1. O itsile jang ka tshekatsheko e pele o tsaya tshwetso ya go tsaya karolo? 
(i) Ngaka    (ii)    Mooki   (iii Mmaboipelego  (iv) Ditsala     (v) Seromamoa/TV   (vi) Pampiri tsa dikgang  (vii) Dipamprii 
tsa Ipapatso(viii) tse dingwe (Tlhaloso)  
2. O tlhaloseditswe ka tshekatsheko e go dirisiwa puo efe?  
3.  A o ipaletse pampiri ya go tsaya tetla kana o e baletswe ke mongwe? 
(i) ke badile ka ba ka baya monwana pampiri ya go tsaya tetla    1(ii) mmatlisisi o e mpaletse  2 (iii) Ke e baletswe ke 
mongwe wa lesika   3 (iii)      Ke badile bontlha bongwe  ke bo ke thusiwa ke ba bangwe  3 
 
4. O tsere nako e e kae o sena go bolelelwa ka tshekatsheko go tsaya tshwetso ya go tsaya karolo 
(i) ke tsere tshwetso lone letsatsi leo   (ii) Morago ga malatsinyana    (iii)  Morago ga dibeke   
 
5. Fa o ne o tlhalosetswa ka  tshekatsheko, a o ne o tlhaloseditswe tse di latelang? 
 
Potso Ee Nyaa Ke lebetse 
Maikaelelo a tshekatsheko e 1 2 98 
Ditlamorago  1 2 98 
Gore wena le ngwana wag ago le tshwanelwa ke go etela kokelwana ga kae? 1 2 98 
Gore ngwana wag ago o tlaa amogela molemo/diritibatsi ga kae? 1 2 98 
Gore a le tlaa fiwa phimolo dikeledi kana le duelelwa go tsaya karolo? 1 2 98 
Kgonagalo ya go emisa go tsaya karolo o gololesegile? 1 2 98 
Gore dingaka di tlaa tsaya tshwetso ya go fa ngwana wa gago 
molemo/diritibatsi ofe/dife? 
1 2 98 
                                                EE =1      NNYA =2       
6. Fa ngaka/mooki a go tlhalosetsa  ka tshekatsheko,  
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Potso Ee Nyaa Ke lebetse 
A o ne a bua ka teme e o e tlhaloganyang? 1 2 98 
A o go tlhaloseditse gore ngwana wa gago o tlaa fiwa melemo/diritibatsi efe/dife 
kana gore ngwana wag ago o tla dirwa eng? 
1 2 98 
A o go file dintlha tse dintsi thata? 1 2  
A o go file dintlha tse di lekaneng? 1 2  
A dintlha tsotlhe tse o di filweng di go thusitse go tsaya tshwetso ya go letelela 
ngwana wag ago go tsenelela tshekatsheko e? 
1 2 98 
A o dirisitse mafoko a a thata bongaka? 1 2 98 
A o ne a go tlhalosetsa mafoko a a thata? 1 2 98 
A o go boleletse dintlha ka bolwetsi jwa ngwana wagago? 1 2 98 
A o ne a rurifatsa gore o tlhalogantse go le kae ka dintlha tse a neng a di go 
bolelela 
1 2 98 
A o filwe tshono ya go botsa dipotso? 1 2 98 
A o ne wa botsa dipotso? 1 2 98 
 
7. Fa o tsaya tshwetso ya go tsenelela patlisiso, go ne go le botlhokwa go le kae mo go wena go tlhaloganya tse di 
latelang? Botlhokwa thata (1) , Botlhokwa  (2) , Botlhokwanyana (3)  Go ne go se botlhokwa(4) ? 
Potso     
Maikaelelo a tshekatsheko  1 2 3 4 
Ditlamorago 1 2 3 4 
Gore wena le ngwana wag ago le tshwanelwa ke go etela kokelwana ga kae? 1 2 3 4 
 Gore ngwana wag ago o tlaa amogela molemo/kalafi ga kae? 1 2 3 4 
Gore a le tlaa fiwa phimolo dikeledi kana le duelelwa go tsaya karolo? 1 2 3 4 
Kgonagalo ya go emisa go tsaya karolo o gololesegile? 1 2 3 4 
  Gore dingaka di tlaa tsaya tshwetso ya go fa ngwana wa gago kalafi efe? 1 2 3 4 
Botlhokwa thata (1) , Botlhokwa  (2) , Botlhokwanyana (3)  Go ne go se botlhokwa(4) ? 
 
8. O kare o itse go le kae ka tse di latelang? 
Ke itse thata(1) , ke itse mo go lekanetseng (2), Ke iste go le go nnye (3) Ga ke itse sepe(4)? 
Maikaelelo a tshekatsheko  1 2 3 4 
Ditlamorago 1 2 3 4 
Gore wena le ngwana wag ago le tshwanelwa ke go etela kokelwana ga kae? 1 2 3 4 
Gore dingaka di tlaa tsaya tshwetso ya go fa ngwana wa gago kalafi efe? 1 2 3 4 
Gore a le tlaa fiwa phimolo dikeledi kana le duelelwa go tsaya karolo? 1 2 3 4 
 Kgonagalo ya go emisa go tsaya karolo o gololesegile? 1 2 3 4 
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Kgonagalo ya gore wena kana ngaka a bo a sa iste gore ngwana o fiwa 
molemo/diritibatsi ofe/dife kana selekanyo  sele kae 
1 2 3 4 
Ke itse thata(1) , ke itse mo go lekanetseng (2), Ke itse go le go nnye (3) Ga ke itse sepe(4) 
 
9. Fa le bua ka tshekatsheko e le babatlisisi, a o ne wa iphetlhelela tse di latelang? 
A o ne a lebega a bua boammaaruri 1 2 98 
A o ne a dirisa puo e e patleletsang? 1 2 98 
A o ne a le boikanyego? 1 2 98 
A o ne a rekegela maikutlo a gago?  1 2 98 
A o ne a itse tiro ya gagwe? 1 2 98 
  
10.  A o kgotsofalela ka fa o tlhaloseditsweng tshekatsheko e ka teng? 
AROLO YA BORARO 
Re batla go itse gore o tlhalogantseng go le kae ka tshekatsheko e e o e tseneletseng? 
  Ee Nnyaa Ga ke itse 
1 Lebaka la konokono la go dira ditekelesto tsa  melemo ya mogare wa HIV go 
tokafatsa kalafi ya bana ba ba nang le mogare wa HIV  
1 2 3 
2 Ngwanake o tseneletse tshekatsheko e gore a bone kalafi 
 
1 2 3 
3 Ngwanake o tseneletse tshekatsheko e gore go bonwe gore melemo e e tlhwatlhwa 
tlase go gaisa ke efe? 
1 2 3 
4 Ngwanake o tseneletse tshekatsheko e gore e re mo isagong go bonwe gore melemo e 
e thusang bana Botoka ke efe? 
1 2 3 
5 Maikaelelo a matona a mmatlisisi ke go sekaseka pabalesego ya molemo o mosha wa 
HIV 
   
6 Mo tshekatshekong e e ngwanake a leng mo go yone, setlhopha sengwe le sengwe sa 
bana bat la se tla fiwa selekanyo se setona sa molemo go gaisa ditlhopha tse dingwe 
go fitlhela balwetsi ba babangwe ba simolola go nna le dikai tsa ditlamorago tse di 
diphatsa 
   
7 Melemo ya ga ngwanake e ne e le ya tekeletso fela    
8 Ditlamorago tsa molemo o dirisiwang mo go ngwanake ga di itsiwe.  1 2 3 
9 Ga go itlhalose gore a tshekatsheko e e tlaa solofela ngwanake molemo?  1 2 3 
10  Ga gona tsela e nngwe  e e botoka ya go fodisa bolwetsi jwa ga ngwanake ko ntle ga 
go dirisa melemo ya patlisiso e  
1 2 3 
11 Ke kgona go itlhophela gore ngwanake o tsaya molemo ofe 1 2 3 
12 Ke itse gore ngwanake o tla tsaka karolo mo patlisisong e go fitlhelela leng    
13 Fa ne ke sa batle ngwanake a tsenelela patlisiso e ke ka bo ke sa dumela gore a e 
tsenelele 
   
14 Ke ne ke ka nna ka dumela gore ngwanake a tsenelele patlisiso e ke sa baya monwana 
mo pampering ya teseletso go tsenelela patlisiso 
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15 Ke ne ke  itse gore ke kgona go gogela ngwanake morago gore a seka a tsaya karolo 
nako nngwe nngwe.  
1 2 3 
16 Ke ne ke itse gore fa ngwanake sa tlhole a tsaya karolo, o tlaa tswelela a bona kalafi 
ya bolwetsi jwa gagwe mo kokelong e.  
1 2 3 
17 Bana botlhe ba ba mo tshekatshekong e ba tlaa bona melemo 1 2 3 
18 Bana bangwe bane ba tshwaetswe  setlhopha se se fiwang molemo o o sa 
berekeng/fodiseng. 
1 2 3 
19 Bana botlhe mo tshekatshekong ba filwe molemo o o tshwanang.  1 2 3 
20  Ngaka ke ene a neng a tlhopha gore ngwana o tsaya molemo ofe. 1 2 3 
21 Ngaka ke a neng a tlhopha gore ngwana o tsaya molemo ofe a lebeletse gore ke eng se 
se siametseng ngwana 
1 2 3 
22 Ngaka ke ene a neng  tlhopha gore ngwana o tsaya molemo ofe a lebeletse gore 
batsadi ba batla eng 
1 2 3 
23 Ke ne ke letlelelwa go tswa mo tshekatshekong nako nngwe le nngwe 1 2 3 
24 Ke ne ke tshwanelwa ke go tsisa ngwana wag ago ko kokelong gantsi fa o sena go 
tsenelela tshekatsheko e? 
1 2 3 
25 Melemo o ngwanake a neng a tshwanetse go o fiwa o ne o na le o nale ditlamorago tse 
di tshosetsang matshelo 
1 2 3 
26  
Ke tla a atswiwa ka kalafi  ya ga ngwanake  fa a ka gobala e le ntateng ya go nna 
motsaya karolo mo patlisisisong e. 
   
27 Ke ne ke boletswe batho ba k eke ikopanyang le bone fa ken a le dipotso ka ga 
ngwanake e le mo tsaya karolo mo patlisisong e 
   
 
 
KAROLO YA BUNE : 
Re tlaa batla go itse gore go tsile jang gore o tseye tshwetso ya go tsaya karolo mo tshekatshekong e.  
1. Ke lebaka le fe le le dirileng gore o letelele ngwana wag ago go tsaya karolo mo patlisisong e. 
____________________________________________________________________________ 
2. Fa babatlisi ba ne bas a go fe P30.00 nako nngwe le nngwe fa o tla kokelong, a o ne o tlaa tsenelela tshekatsheko e fela? 
i) Ee  1 
ii) Nnyaa  2 
iii) GA KE ITSE 98 
iv)  
3. How A Oo neng o patleletswa ke bangwe go tsenelela patlisiso e (TLHOPHA E LE NNGWA) 
i) Ke patleleditswe thata          1 
ii) ke patleleditswe                           2 
iii) Ke patleleditswe go le go nnye          3 
iv) Ga ke a patleletswa gotlhelele                          4 
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4. Mo bathing ba ba latelang, ke mang yoo go patleleditseng go tsenlela tshekatsheko e 
 
5. O ne o ikutlwa o patlelesega go le kae go tsenelela patlsisiso e ka gore ngwana wag ago o a lwala? (TLHOPHA E LE 
NNGWE) 
i) Ke ne ke patlelesega thata  1 
ii) ke ne ke patlelesega                            2 
iii) Ke ne ke patlelesega go le go nnye            3 
iv) Ga ke a patlelesega gotlhelele              4 
6.A ke wena yoo tsereng tshwetso ya go letelela ngwana ya gago go tsenelela patlisiso e? 
i) Ee   1 
ii) Nnyaa                           2 
7. A go nale mongwe yoo go thusitseng go tsaya tshwetso ya go letelela ngwana wa gago go tsenelela patlisiso 
i) Ee               1 
ii) Nnyaa                          2   
8. Ke mang yoo go thusitseng go tsenya ngwana wa gago  mo tshekatshekong e? 
 
Ngaka 1  
Baoki 2  
Badiri ba kokelo 3  
Monna/Mosadi wa me 4  
Ba lelwapa 5  
Ditsala 6  
 Mongwe fela? Ke mang 
TLHALOSA GORE KA GO REN 
 
9.  A o ne o ka gana go letelela ngwana wag ago go tsenelela tshekatsheko e fa o ne o batla? 
i) Ee                                1 
ii) Nnyaa     2 
 
10. Fa mabaka a dikarabo tse di fa godimo 
 
____________________________________________________________________________ 
Ngaka 1 
Mooki 2 
Kokelo 3 
Monna/Mosadi wa me 4 
ba lelwapa   5 
Ditsala 5 
Mongwe o sele? Ke mang?  
Fa mabaka a gore ke eng ba ne ba go patleletsa…… 
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11. Go ne go ya go nna motlhofo go le kae mo wena go gana go tsenya ngwana wa gago mo tshekatshekong? 
 (TLHOPHA KARABO E LE NNGWE) 
Motlhofo thata     1 
Motlhofo                  2 
Go thata                   3 
Go thata thata     4 
12. O supile jang gore o dumela go tsenelela tshekatseko e? Ke sefe sat se di latelang se o se dirileng? (TLHOPHA 
KARABO E LE NNGWE) 
i) Ke kwadile leina la me mo fomomg   1 
ii) Ke beile monwana mo fomong                 2 
13. A o ne o ka batla go tsenelela patlisiso e ka go bolelela ngaka fela o sa kwale leina la gago kana o sa beye monwana mo 
fomong? 
i) Ee    1 
ii) Nnyaa     2 
14. Dipotso tsa rona di feletse - a go na le sengwe se o batlang go se re bolelela? 
_____________________________________________________________________________ 
Re lebogela thata go bo o arabile dipotso tsa rona                                     Nako ya go fetsa: __ __:__ __ AM/PM.  
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APPENDIX 10: PARENT INTERVIEW GUIDE 
 
Title: A Model for Obtaining Parental Informed Consent for HIV Clinical Trials Research with Pediatric Patients 
                                                                                                                                                      Questionnaire #:____ 
                Date: __ __/__ __/__ _ 
                                        Start time: __ __:__ __ AM/PM 
Thank you for agreeing to do this interview. Your participation in this study is voluntary and you have the liberty not to answer any 
of the questions; however I hope you will participate in this study, as the information gathered will allow me to find out if there is 
something during the process that requires adjustment and needs to be suggested to the authorities.  Also, if there is need for 
improvement in any of the steps. All of your responses will be confidential and will not in any way be used to identify you! 
Please remember that if you do not want to answer any specific questions, you can let me know and I will go on to the next 
question. You can stop the survey at any time. If you decide to stop, it will not affect your child‘s joining the study in any way. 
Also, please let me know if you would like me to repeat any questions or if you don‘t understand a question. 
You have just agreed to have your child join the study.  
SECTION A 
DEMOGRAPHIC DATA 
We’d like to know how about you, your child and your family                                                                                                     
1 Gender Male Female 
2 What is your age in years?   
3  Where do you live? Town/city Village Ward 
4a What is your highest level of education? Tertiary High 
school 
Junior 
school 
Primary Non-
formal 
education 
None 
4b Do you know how to read and write Yes  No 
4c In which language can you read fluent and 
write well?  
English  Setswana Other (specify) 
5 Are you the mother (father, 
parents/guardians) of this child? 
Yes No 
6  How old is your child?   
7  If you are the guardian to this child, what is 
your relationship to this child?  
Grandmother Grandfather Auntie Uncle Other 
8  Has your child ever been in other research 
studies? 
Yes  No 
8a How many research studies has your child 
ever been involved in? 
 
8b Have any of your other children been in any 
research studies? 
Yes  No 
9 How many times have you brought your 
child to see doctors in the last year?  
 
10  How many people live in your house?   
11 Who is the head of the house?   
12 What is your marital status? Married Single Divorced Other  
13 What type of job do you do?  
14 What is the job of the child‘s father 
(mother)?  
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15 Do you and your family own a house?  
16 The house where you live is it for your --? Land Lord My relative My employer My spouse 
17 What type of house do you live in? High cost Medium cost Low cost Other 
18 Does the house where you live have the 
following utilities? 
Electricity Running Water  Both electricity and 
running water 
 
 
SECTION B 
Information disclosure 
We would like to know how important it was to you to get information about certain topics when you were deciding whether 
to join the study. 
1. Who gave you information about this study before you made a decision to enroll your child?   
(i) O    Doctor    (ii) O    Nurse    (iii) O Social worker   (iv) O Friends      (v) O Other (specify) 
 
 
2. In which language were you spoken to during the consent process? 
 (i) Setswana      (ii) English       (iii) 
2a. Were you asked to read and sign the consent form or someone read it to you? 
(i) I read and signed the consent form      1(ii) the researcher read it to me    2 (iii) A family member read it to me   3 (iii)      I read 
some sections and was helped to read others    3 
3. How much time after were given to respond after being told about the study 
(i) Had to decide the same day   1 (ii) A few days 2   (iii) Weeks 3 (iv) Was told to take as much time as I wished.  4 
4. When you were discussing about the study, did the person who talked to you tell you about ……? 
 
 
 
1 The purpose of the study?  1 2 98 
2 The risks and side effects 1 2 98 
3 The number of clinic visits you and your child will have to make? 1 2 98 
4 The number of times your child will receive the treatment? 1 2 98 
5 Any compensation/payment you will receive for participation?  1 2 98 
6 The possibility of quitting the study freely? 1 2 98 
7 The way doctors will decide which treatment to give your child? 1 2 98 
 
YES =1      NO =2       
 
5. As you discussed about the study with doctor/nurse  
1 Did he/she communicate clearly in a language you could understand? 1 2 98 
2 Did he/she make the reasons why your child needed to join the study? 1 2 98 
3 Did he/she explain clearly the treatment your child would receive? 1 2 98 
4 Did he/she provide too much information? 1 2 98 
5 Did he/she provide too little information? 1 2 98 
6 Do you think all the information provided was important for you in deciding whether your child 
should join the study? 
1 2 98 
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7 Did he/she use too many difficult medical terms? 1 2 98 
8 Did he/she explain the difficult terms used? 1 2 98 
9 Did he/she provide you information about your child‘s disease? 1 2 98 
10 Did he/she test how well you had understood the information given? 1 2 98 
11 Were you given an opportunity to ask questions? 1 2 98 
12 Did you ask any questions? 1 2 98 
 
6. When you were deciding whether to join the study, how important was it to you to get information about [TOPIC]? Was it very 
important (1), moderately important (2), slightly important (3) or not important at all (4)? 
1 The purpose of the study? 1 2 3 4 
2 The risks and side effects? 1 2 3 4 
3 The number of clinic visits you and your child will have to make? 1 2 3 4 
4 The number of times your child will receive treatment? 1 2 3 4 
5 Any compensation you will receive? 1 2 3 4 
6 The possibility of quitting the study? 1 2 3 4 
7  The way doctors will decide which treatment to give your child? 1 2 3 4 
Very Important=1   moderately Important =2   slightly important =3   not at all important =4 
 
7. How well informed do you think you are right now about [TOPIC]? Would you say very well informed    (1) moderately 
informed (2), slightly informed (3) or not at all informed (4)? 
1 The purpose of the study? 1 2 3 4 
2 The risks and side effects? 1 2 3 4 
3 The number of clinic visits you and your child will have to make? 1 2 3 4 
4 The number of times your child will receive treatment? 1 2 3 4 
5 Any compensation you will receive? 1 2 3 4 
6 The possibility of quitting the study? 1 2 3 4 
7 The way doctors will decide which treatment to give your child? 1 2 3 4 
Very informed =1 moderately informed = 2    slightly informed = 3 Not at all informed =4 
 
8. As you discussed the information about the study with the research team member who was consenting, did you feel he/she was 
…..? 
 
 
1 Being sincere 1 2 98 
2 Using a dictatorial  or coercive language 1 2 98 
3 Transparent and honest 1 2 98 
4 Sensitive and sympathetic  to your feelings 1 2 98 
5 Competent  1 2 98 
 
9. Generally were you satisfied with the information that was provided? 
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SECTION B: We would like to know how well you have understood the information you have received about the study. 
Please tell us whether you agree, disagree or you are not sure about the statements the statements that will be read to you. 
Please respondent to each statement as best as you can by saying Yes, No or Don’t know 
No Statement Yes No Don’t know 
1 The main reason HIV clinical trials are done is to improve the treatment for future HIV 
patients 
1 2 3 
2 The primary reason for my child joining this study is to be involved in research. 1 2 3 
3 The primary reason for my child  joining this study is to receive  treatment 1 2 3 
4 The primary reason for my child joining this study is to find out which drugs are cheapest 1 2 3 
5 The primary reason for my child joining this study is to find out which drugs work best in 
order to help future children 
1 2 3 
6 One of researcher‘s major purposes is to compare the effects (good or bad) of two or more 
different ways of treating children with HIV in order to see which is better. 
1 2 3 
7 One of researcher‘s major purposes is to test the safety of a new HIV drug or treatment. 1 2 3 
8 One of researcher‘s major purposes is to find out the highest dose of a new drug that can 
be given without causing severe side effects. 
1 2 3 
9 In this HIV clinical trial, each group of children will receive a higher dose of treatment 
than the other groups until some patients start having serious side effects. 
1 2 3 
10 My child‘s treatment  is an investigational treatment 1 2 3 
11 The effect of the drug used in my child‘s study  is unknown 1 2 3 
12 It is not clear whether this study will benefit my child 1 2 3 
13 There is no better choice to treat my child‘s illness than using the treatment in this study. 1 2 3 
14 I can choose my child‘s treatment option 1 2 3 
15 I know how long my child will participation in the study is likely to last 1 2 3 
16 If I had not wanted my child to participate in this clinical trial, I could have refused for my 
child to do so. 
1 2 3 
17 I could have had my child participate in this clinical trial without signing or putting a 
thumb on the consent form 
1 2 3 
18 I can withdraw my child from the study at any time 1 2 3 
19 If I withdraw my child from the study he/she can still be treated at the clinic for his/her 
illness? 
1 2 3 
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20 All the children in my child‘s study will get treatment? 1 2 3 
21 Some children could be assigned to a group in which the drug given is not  active 1 2 3 
22 All the children in my child‘s study will get the same treatment? 1 2 3 
23 The study doctor  will decide which treatment each child gets based on chance, 1 2 3 
24 The study doctor  will decide which treatment each child gets based what he/she thinks is 
best for each child 
1 2 3 
25 The study doctor  will decide which treatment each child gets based what each parent 
wants 
1 2 3 
26 You are allowed to quit the study any time. 1 2 3 
27 Will you have to bring your child to the clinic many times after joining the study? 1 2 3 
28 The treatment my child is getting has got life-threatening side-effects 1 2 3 
29 The treatment my child is getting has got no side-effects 1 2 3 
30 The treatment my child is getting has got  moderate side-effects 1 2 3 
31 The treatment my child is getting has got severe side-effects 1 2 3 
32 Because my child is participating in this HIV clinical trial, it is possible that the study 
sponsor, other health workers or other people that are not directly involved in my care 
could review my child‘s medical records. 
1 2 3 
33 The consent form used in this HIV clinical trial describes who will pay for my child‘s 
treatment if he/she is injured or becomes ill as a result of participating in this study. 
1 2 3 
34 The consent form used in this HIV clinical trial lists the names of people I should contact 
if I have any questions or concerns about my child‘s clinical trial. 
1 2 3 
 
SECTION C: We’d like to know how you made the decision to join the study 
1. What is the most important reason you decided to have your child join this study? 
_____________________________________________________________________________ 
2. Were there any other reasons why you had your child join? 
i) Yes  (GO TO 3)    1 
ii) No                                                      2 
iii) DON‘T KNOW (GO TO 28)                          98 
3. What were some of those reasons? 
4. If the study team was not going to give you P 30.00 each time you brought your child would you still have joined the study? 
v) Yes    1 
vi) No    2 
vii) DON‘T KNOW  98 
5. How much pressure, if any, did you feel from other people to join the he study? Did you feel…? (CHOOSE ONE) 
v) A lot of pressure     1 
vi) A moderate amount of pressure    2 
 
 
 
 
  
205 
 
vii) A little pressure     3 
viii) Or no pressure at all?                            4 
 
6. From the following list of people, please pick all the people from whom you felt any pressure to join the study.  
1 Doctor 1 
2 Nurses  2 
3 The health center 3 
4 My spouse?  4 
5 My Family   5 
6 Close friends 5 
7 Anyone else? Who 
was that person? 
PLEASE 
 
8 Give reasons for your answer 
above………………………………
… 
 
7. How much pressure, if any, did you feel to join the study because your child is sick? Did you feel…? (CHOOSE ONE) 
v) A lot of pressure     1 
vi) A moderate amount of pressure    2 
vii) A little pressure     3 
viii) Or no pressure?                 4 
8. Did you personally make the decision to have your child join the study? 
iii) Yes     1 
iv) No  2 
9. Did any other person help you make the decision to have your child join the study? 
iii) Yes       1 
iv) No                                2   
10. Who helped you decide to have your child join?  
1 The  doctors  1  
2 The nurses 2  
3 The health center staff 3  
4 My  spouse 4  
5 My family  5  
6 Close friends 6  
7 Anyone else? Who was that person? 
8 PLEASE EXPLAIN WHY,  
 
11. Who made the decision to have your child join the study? Was it…. 
(CHOOSE ONE)     
1 The  doctors  1  
2 The nurses 2  
3 The health center staff 3  
4 My  spouse 4  
5 My family  5  
6 Close friends 6  
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7 Anyone else? Who was that person? 
8 PLEASE EXPLAIN WHY 
 
12. Could you have refused to have your child join the study if you had wanted to refuse? 
iii) Yes                              1 
iv) No       2 
13. Give reasons for your answer above? 
14. How easy would it have been for you to refuse to have your child join the study? 
Would you say…? (CHOOSE ONE) 
Very easy      1 
Moderately easy      2 
Moderately difficult      3 
Or very difficult?     4 
14. You agreed to join the study either by signing your name or by putting your thumbprint on a form. Which one of the following 
did you do? (CHOOSE ONE) 
iii) Signed my name on a form    1 
iv) Put my thumbprint on a form    2 
22. Would you have preferred to join the study by telling the doctor, without having to sign your name (put your thumbprint) on the 
form? 
iii) Yes       1 
iv) No       2 
Those are all of our questions—is there anything else you’d like to tell us? 
 
Thank you very much for answering our questions!         End time: __ __:__ __ AM/PM 
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APPENDIX 11:  BOTSWANA RESEARCH ETHICS COMMITTEE CLEARANCE 
LETTER 
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APPENDIX 12:  UNIVERSITY OF WESTERN CAPE RESEARCH ETHICS 
COMMITTEEN CLEARANCE LETTER 
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APPENDIX 13: TRANSCRIPTION OF FOCUS GROUP DISCUSSIONS  
 
1. TRANSCRIPT OF A FOCUS GROUP DISCUSSION HELD AT SITE A WITH THE TRIAL 
STAFF PARTICIPANTS  
 
Date 15 June, 2011 
Start Time 15.30hrs 
End Time 17.00hrs 
Number of participants 8 
Males 3 
Females 5 
Education Tertiary and post graduate levels in Nursing 
Mean age 35.5 
Discussion Language English 
Facilitators Dr. P. Ndebele 
 Mr. E. Kalengo 
 
 
F= Facilitator; P= Participant (NB: Participants codes not written for confidentiality purposes, therefore P was used 
to refer to all the participants). 
 
F: Are we done with the signing of the consent forms? 
Please sign the individual consent forms and the group 
consent form 
It‘s the requirement from the Botswana Ethics 
Committee and the University of Western Cape Ethics 
Committee. Confidentiality was assured as names will 
not appear in the write up. During the discussion we will 
be referring to you by the numbers provided namely; P1, 
P8, P5, P4, P9, P3, and P2 but these will not appear in 
the study report. 
 
F: Welcome to you all and we want to thank you for 
taking time off to participate in this discussion. We hope 
that through this research project you might benefit 
directly or some other people might benefit indirectly. I 
will start by saying that this is a discussion so you should 
feel free to chip in wherever you feel you want to come 
in with some contribution. Our role is to facilitate and we 
hope that we will respect each other‘s opinion. We would 
like to get some information on the kind of work you do 
as related to obtaining of IC. So we will go round and 
introduce ourselves. 
 
F: Just to follow up on those who said they are involved 
in recruiting can you explain more about the process. 
What exactly are you doing? On participants responds; I 
thought I heard you saying that you are involved in 
recruiting! 
 
F: Phone rings---------------Can you put your phones on 
silence! Laughter from the group! 
 
P: Most of the recruitment we do is from the clinics and 
the hospital so we work hand in hand with the hospital 
and the councillors in the community. So if they identify 
anyone meeting the criteria we ask them to refer them to 
us and when they come to our site we tell them about the 
study. If they are willing to participate then we talk to 
them in detail about the study. 
 
F: You want to add something? 
 
P: Yes, we meet with those who might be eligible for a 
particular study and talk to them about the study if they 
show interest we refer them to our site. 
 
F: I just want to find out how many of you have been 
involved in HIV Clinical trials? 
Silence in the room------------- 
 
P: One participant answered on behalf of the others. All 
of us currently we have two studies involving children. 
 
F: You are working with the parents and the children, 
what are the ages of the children you work with and 
working with the parents what do you think is the value 
of knowing about their culture within the country and the 
community? 
Silence…… 
 
P: What do you mean? When dealing with the client and 
the baby. I think it is very important because what they 
believe in or their cultural background would in a very 
big way influence the decision that they make. For 
example if you are asking an HIV positive mother not to 
breast feed but  to formula feed, you want to find out the 
challenges she will face at home and in the society. 
When you understand that then both of you are able to 
know how to work way around it unlike when you do not 
know. She will be breast feeding at home and formula 
feed when at the clinic. 
 
F: You saying the knowledge will assist the success of 
the study and also assist you as a researcher? 
 
P: Yes it assists the participants to make an informed 
decision. 
 
P: The parents feel involved and accommodated. 
 
P: It helps to understand how many people have an 
influence on the decision the parent makes, you might be 
talking directly to the baby‘s mother but her decision 
might be influenced by the grandmother. It helps the 
retention of participants and helps the participant to give 
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information to other people that are involved in the care 
of the child. 
 
F: Any other comments? Looking at the parents you deal 
with what is the level of education of these parents in 
general? 
 
P:  Junior secondary most of them 
 
F: Do you think there is any reason for this level of 
education? 
 
P: This is likely to happen in a rural setting because of 
the location being in a rural area. Most people that are 
highly educated are working in the city. 
 
P: Most of the parents here stay at home they are not 
working, and this is the group that is most sexually 
active. 
 
F: The studies that you are participating in what Phase 
are they? Expressions of surprise from the participants. 
Uh!! Surprised Phase?  
 
F: Yah! Phase! Phase I, II, III or IV? 
Silence…………… 
 
P: Most of them are phase III. 
 
F: Has any of you participated in a Phase I study? The 
audience is quiet and facial expression shows they are 
not sure of the Phases. 
 
F: Looking at how risky the studies are, how would you 
classify the studies you are working on in terms of risk? 
 
F: Is it minimal risk or high risk it is your own opinion? 
 
P: Both studies I am working on are of minimal risk 
because we are using drugs which are already there we 
know the side effects, other countries have been using 
them. But the vaccine drugs are being given to HIV 
positive children!!! 
 
F: So you say there is minimal risk because these 
products are being used elsewhere? Because you know 
about these products that is how you classify the 
categories. 
 
F: Asks another participant, do you have a different 
opinion? 
 
F: How do you look at these studies in terms of risk? Do 
you think that they are risky or minimal risk? 
 
P: Minimal risk 
 
P: I do not think am very clear with the question!  
 
F: If we were to ask you to bring your child into these 
studies would you be ok with it? 
 
P: I do not have a problem because I know all about the 
drugs that are being used, they have been proven safe. 
 
P: I see you laugh and I would like you to explain as to 
what you mean because when you say, these are 
interventional studies, the interventions are they of any 
risk, so far we have talked about drugs but there are other 
interventions like blood draws, we do understand the 
risks that come with blood collections. We look at the 
number of times blood will be collected, the sensitivity 
around collecting blood from pediatric patients. The 
other risk is the one associated with HIV because those 
who see the parents coming to the site will say Oh! So 
she is in this study it means she is HIV positive or her 
child is HIV positive. All these are some of the risks. 
 
F: So having heard this description from her you still 
classify the studies as minimal risk? I am asking your 
colleague. 
Laughter from the group!!!.... 
 
P: Adamant...  I am still saying that! Laughing……… 
 
F: Any other contribution on this one? What is our 
understanding of informed consent? Silence!!!! until the 
facilitar says ‗I will start off with you since you are 
sitting close to me! Laughter from the group… 
 
P: Unfortunately this is the wrong person sitting next to 
you!!  Laughter again from the group! I am hardly new 
here not even a month! But anyway from the professional 
point of view to me an informed consent means you do 
understand every process every intervention, every 
information that you are supposed to be given, you have 
to understand and you have it in the tip of your mind. So 
you can make a decision whether to get into it or to get 
out. 
 
F: So you are emphasizing on total understanding of 
everything related to that study.  
P: Yes and you may be a source of information for other 
clients. 
 
P: I would say it a process by which you are to know the 
objectives, the risks and benefits, of entering a study. 
 
F: Do you want to add something? 
 
P: Added that the client must be told of the choices 
available. 
 
P: Adds…..the emphasis of saying that signing an 
informed consent does not mean you cannot change your 
mind. That‘s why each time they come for a study visit I 
ask them are you still interested in being in the study? Do 
you still remember why you in the study just to make 
sure that they did not bind themselves, they are still 
volunteers. Even when they come back and change their 
mind we counsel them and refer as appropriate  
 
F: Now thinking about your own experience in dealing 
with these clients what do you think is their 
understanding of the informed consent process?  
Emphasizes, their own understanding? 
 
P: For me I would say their understanding is related to 
their understanding of research because in my personal 
view I believe there is still limited understanding of the 
difference. There is a thin line between the care they get 
from the public facilities and the care they can get here 
such that on referral one can ‗I am coming from the clinic 
because I was told to come‟ We ask them do you 
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understand why you are here and they respond to say „No 
I have just come‟. Until you get them to understand that 
this a research institution not like the other clinics where 
you just come in to get the baby checked. 
 
F: Ok from what you are saying when they come from 
the clinic to the research site they think they are coming 
for routine care. So you have to first make them 
understand that this is a different situation. From your 
experiences do you think you are succeeding in doing 
that? 
 
P: Informed consent is a process which you have to 
explain again and again to find out whether they 
understood. I think we have got to that level but we 
continue reminding them as it is a process. 
 
F: On average for most of the parents referred how long 
does it usually take to agree to enrol in the study? First 
day they come? 
 
P: Most of them do agree on first contact may be because 
of they have already heard about the study  in the village 
, from health care workers, so by the time they come they 
already have some idea of what is going to happen. 
Although a few need a longer time to go home and think 
about but most of them will be ok. 
 
P: Most of the times those who ask for more time it is 
not that they did not understand , they have to go back 
and consult somebody or to think  more what you have 
just said to them. We have other clients who have 
participated in other studies who come as self-referrals 
because they see our posters some even call to request to 
come and know more about the study. 
 
P: Some just drop in and say I was in a study which 
ended and now I am pregnant is there any other study I 
can enrol in? 
 
F: Why do you think they come as self-referral?  
 
P: Why they want to come? Loud laughter!! ‗We do the 
best‘ laughter from the group. 
 
P.  If the previous relationship was beneficial   to the 
child I think that‘s why they come. 
 
F: Is it because some of the services are not available at 
the clinics or the hospital? 
 
P: Services like tests take longer like 3 months compared 
to two weeks at the research site. Also the congestion at 
the public clinics. 
 
F: So parents are attracted by the benefits like the special 
treatment they get. Facilitator notices a participant who 
has been very quiet and probes them to say something. 
‗Let‘s hear your views‘ 
 
P: I do agree but may be one comment. When these 
clients come, we do not only focus on the study, we use a 
holistic approach, if they have other illnesses we attend 
to them. 
 
F; Yes! 
 
P: Yes I was going to say, in one or two encounters in 
my experiences ‗clients never say ‗NO‘ on your face or 
say I will think about it, they just never come back to 
you. When you follow up then they either say ‗I don‘t 
think I am interested or my parents said no‘. The can‗t 
say no face to face. 
 
F: Why do you think this is the case? 
 
P:  I knew this will come!! Loud laughter from the whole 
group! I don‘t know but from a professional point of 
view it is difficult for a patient to say no to a health 
worker, somebody they believe is always giving them the 
health care. 
 
F: Do you think it is something cultural? 
 
Everybody nodes!! A participant  goes on to say that 
there might be  some other cultural issues like some 
people say ‗my parents said my child should not 
participate‘ So the decision is being made by someone 
else. 
 
F: Yes! 
 
P: According to Batswana culture you do not make a sole 
decision you have to consult people back home so that is 
why they can‘t say no on your face. 
 
F: You have your research site offering high care quality 
and offer everything special. Do you think the decision 
they make is voluntary or because of the benefits they 
receive? 
 
P: Usually we do encourage them to make voluntary 
decisions even though there are some benefits they can 
get in the study. 
 
F: What you mean is that you emphasize that they have 
to make their voluntary decision? But what do you think 
is the effect of these offers on the side which are better 
than what the public facilities offer? 
 
P: To guard against undue influence we have an 
assessment of understanding conducted by an 
independent person before the final signing. If the person 
does not get half of them correct we go back and talk 
about the study until we get satisfactory answers. 
 
F: In your assessment, have you ever told a client that 
you do not understand we can‘t enrol you into the study? 
 
P: We re-assess, we give them the form to take home and 
ask them to ask another person to read for them. Usually 
we test the understanding again. If this fails we can bring 
in a witness to listen to what we are saying. If the witness 
understands what we are saying and the patient wants to 
enrol in the study the witness will sign and the patient 
also signs. 
 
F: What if the witness says they understand but still you 
assess the potential participant and they still fail. 
 
P: The group laughs and many say they have not 
experienced such a situation. Sometimes patients do not 
understand because of the anxiety of being in a health 
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care set up. So they may need to talk to someone they are 
more comfortable with. 
 
P: We all play a role in the documentation of the 
informed consent form.  
 
F: For you what role are you playing? 
 
F: Do prepare the form or it is prepared by the 
sponsor/Principal Investigator?  
 
P: The form is brought to us prepared and we are asked 
to make comments. 
 
F: How long are the consent forms? 
 
P: Between 13-14 pages 
 
F: What do you think about that length? 
 
P: Yah!  It‘s long. That‘s the problem  
 
F: Do you think a huge chunk can be chopped out of it? 
 
P: It‘s lengthy but it is worth it! 
 
P: We are not saying we are happy but what we are 
saying if there could be model that ensures that all the 
information is included but not that lengthy! 
 
P: In my opinion I think the pages are Ok although the 
package looks bulky but if someone is at home with all 
the time to read they can understand. The form is well 
detailed unlike when you summarize, the person 
conducting the consent process would understand but the 
one helping the patient to read at home might not 
understand. So may be encouraging the participants to 
read a few pages at a go until they understand. I think it 
is important that they get all the information. 
 
P: When designing a consent form you need to think of a 
broader picture as to who is going to read the consent 
form different readers require different information, 
researcher, participant, spouse, public etc. So if all the 
information is available in the 14 pages. I have attended a 
workshop which you conducted and you asked that same 
question ‗How long should a consent form be?‘ and we 
never reached an agreement up to today. Take into 
consideration all the reader‘s needs.  
 
F: So what is your comment now?  
 
P: I am still saying we need to summarize! 
 
F: Let‘s continue. 
 
P: I hope we can find the best way and I am hoping the 
student will come back and tell us the best way!! Because 
even if it is long it is how you administer it that matters!! 
Establish what the patient wants to know and start with 
that! Take your time 
F: Regarding the documentation of the consent from are 
there specific challenges that you have encountered? 
 
P: Use of language, we do appreciate that Setswana has 
the written and spoken part, but now you come to say 
some English words in the Setswana way  translation. 
  
F: What are the participants saying about the ICF? (No 
answer to this one). 
 
F: Are there any recommendations? 
 
P: Put it in the day-to-day language. Although I do not 
know how it will be considered by HRDC whether they 
will think it is ethical. 
 
P: But Setswana has different dialects, from different 
ethnic groups. Some English words do not exist in 
Setswana. My recommendation is that; bring all the 
Setswana language specialist and people of different 
ethnic groups to contribute to the translation. 
 
F: Who is the first contact person the parents talk to? 
 
P: The receptionists refer them to the research nurses. 
 
F: To what extent are the doctors involved in the 
informed consent process? Quiet? F: asks again what is 
the role of the doctors? 
 
P: The administration of the consent form is mainly the 
role of the nurses; the doctors only try to check levels of 
understanding. 
 
P. When the patient goes to the doctor they will just ask 
whether the patient understood what they were told by 
the nurse. 
 
P: The doctors are not much involved in the IC 
administration but before the patient is enrolled they ask 
them some questions to check understanding. 
 
F: We touched on full disclosure earlier on. What is your 
comment of full disclosure? Do you think that it is 
feasible? Silence! The facilitator asks again ‗Do you 
think it is? 
 
P: At a go it is not possible! 
 
F: So what are you saying? 
 
P: What I think is to emphasize that it is a process, you 
keep revisiting, providing more information and 
encourage asking questions and over time they get to 
know more. 
 
P: I can start by giving all the necessary information but 
do not ask me which information is necessary ‗Loud 
laughter!!!‘ I wish there was a word I can use. 
 
P: I think there is core- information to be given first 
because a client cannot remember everything. 
 
F: When should the participant have full disclosure, is it 
at the administration of first dose or before? 
 
P: We must realize that informed consent process is an 
on-going process so that even when we assess we just 
want to see a comfortable level of understanding because 
a client cannot take in all the information first time? That 
is when in assessment we do not go into too much 
details. 
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F: We need a comfortable level of understanding then 
ask questions later?  
 
P: How long will the study take, benefits, risks? 
 
F: Do you think the parents understand the difference 
between routine care and research? 
 
P: It differs by parent. Like one parent asked that ‗When 
you say you can„t help me with my other problems and 
you are referring me to the local clinic is it fair? I do not 
want to go here and there. 
 
F: You have already said that you are assessing 
understanding. How do you assess this? 
 
P. We use questionnaires mainly after the first contact. 
Then you can randomize certain questions at each 
following visit. 
 
F: Positive! 
  
P: Yesterday I had a client told me that ‗I wish 2001 
when I had my child this study was there; I do not think I 
could have lost my child‟.  
 
F: Any other negative comments? 
 
F: In summary can you recommend on how the process 
can be improved? Now you are only thinking only about 
going home!!.... 
P. Although the form looks bulky but it is worth it 
because everything is inclusive‘. I am happy but if we are 
going to conduct a study in the community let‘s call the 
community members to help us translate the ICF as per 
their community. 
 
P: But then the community has people from different 
places laughter from the group!! So the issue of language 
remains an unresolved issue but we have to find a 
meeting point‘ 
 
P: Lack of communication due to the shortfall of some 
Setswana words that do not exist in English or vice-
versa. 
 
F: Do you have any other comments or questions? 
 
P: How can we cater for the challenged parents, like 
those that are deaf, blind, mentally sick or retarded? 
 
F: But so far you haven‘t had such? 
 
Group answers ‗No‘. 
 
F: I think that is a very important point you are raising. 
Thank you very much. 
 
F: Thank you for participating in this study. 
 
Time: 17.00hrs
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APPENDIX 14: TRANSCRIPTION OF FOCUS GROUP DISCUSSIONS  
 
TRANSCRIPTION OF A FOCUS GROUP DISCUSSION WITH TRIAL STAFF 
PARTICIPANTS AT SITE B 
 
 
SUMMARY OF PARTICIPANTS 
 
 
Date 16 June, 2011 
Start Time 17.30hrs 
End Time 18.00hrs 
Number of participants 10 
Males 3 
Females 7 
Education: Tertiary and post graduate levels in Nursing 
Mean age 35.5 
Discussion Language English 
Facilitators Dr. P. Ndebele 
 Mr. E. Kalengo 
 
F= Facilitator; P= Participant (NB: Participants codes not written for confidentiality purposes, therefore P was used to refer 
to all the participants). 
 
Time End: 17.00hrs 
 
The discussion started off by the facilitors and participants introducing themselves. 
 
F:   Thank you very much for coming to participate in 
this discussion. It is after work and all of you look tired 
but bear with us, we     deeply appreciate your presence. l 
will be facilitating this discussion and my two colleagues 
will also be assisting with making notes and 
observations. So ladies and gentleman, we want to thank 
you very much for agreeing to participate in this 
discussion. I am hoping that it is going to be a short 
discussion and let me emphasise from the beginning that 
feel free in this discussion. It‘s not about... ….the right 
answers but about our own opinions as individuals. 
 
We are going to be using tags labelled P1-P10, due to 
confidentiality we are not going to refer to you by your 
names during the     and write up. So l would encourage 
you to put the tags where l can see them clearly so that 
when we are transcribing it is easy to know who said 
what! During the discussion we will be referring to you 
by the numbers provided namely but these will not 
appear in the study report. 
 
F:   I will give you a few minutes to read through the 
personal informed consent and the group informed 
consent. The idea of having the personal informed 
consent is to indicate that you have been provided with 
information about the study and have understood that 
information and you voluntarily agree to participate in 
the study. The group informed consent is for each 
participant to assure us that what has been discussed in 
this room will remain in this room and will not be 
discussed anywhere outside the group either among 
yourselves or with anyone else. 
 
F: We are interested in research involving children. Can 
you confirm whether all of you have been involved in 
research involving children? 
 
P: All participants confirmed by saying yes or nodding. 
 
F: What is the general education of the parents who bring 
their children to the research sites where you work? 
 
P: Majority of the parents do not have that much of the 
literacy may be dependent on age, majority could have 
primary level. 
F: Do you think there is a reason for this? 
 
P: These are the people interested/keen in participating in 
studies. Those with high education are giving excuses 
like; „they are busy at work or will get back to you‟ 
 
P: Economic status also plays a very important role and 
we recruit from facilities where people from the 
lower economic strata access health services, so we 
do not see people from the high social economic 
status that much. 
 
P: The other important factor is that we recruit from 
public facilities and we are guided by statistics. We 
go to places where there is high burden of disease 
where recruitment will be quicker. 
 
P: It is very interesting when you talk about levels of 
education; you find that majority of these people 
from the low social economic strata are submissive to 
health personnel. The other reason might be that they 
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do not understand policies, their rights etc. So they 
believe that as patient you have to „listen‟ and that‘s 
why they can be exploited and cannot say ‗No‘ to 
enrolment of their children. They believe in the 
learned and can be influenced easily. 
 
F: How do you go about reaching your sample size? 
 Can you explain more about the recruitment 
strategy? 
 
P: Laughs!! The whole process? Pause……………….  
 
F: Yes! The whole process!  
 
F: We are so much interested in research that involves 
children. So I just want to have some confirmation of 
how many of us have been involved in pediatric 
research. I guess it is all of us? 
 
P: Everybody nods in agreement and some whispered in 
agreement. 
 
F: Thank you very much for conforming that! Now we 
are basically looking at the parents of guardians that 
we deal with. Let‘s just look at their levels of 
education. What is the general level of education of 
the parents and guardians that you dealing with in 
research involving the little ones? Yes! 
 
P: Hum……….-Yah no! Majority of our parents do not 
have that much literacy so they are probably I would 
say, depending on age some have average education 
but majority of primary caregivers are relatives, 
grandparents, aunties an you find that may be a child 
is being taken care of by the relatives since some are 
orphans. So these are the people who normally face 
challenges of signing for consent for the pediatric 
population.  
 
F:  You mentioned the issue of the low literacy. At what 
level would you place them? Primary, junior 
secondary, secondary or     college level? 
 
P: Majority on average they have primary level. 
 
F: And do you think that there is any reason for this? I 
am trying to look at the situation that you are looking 
at; do you think that there might be any reason why 
you end up having those parents/ guardians with low 
levels of education? 
 
P: You mean......which /the reasons that can affect the 
trial? 
 
F: No the reason why you have the majority of those 
parents and guardians having low levels of education 
is that these are the ones you see at your site? 
 
F: Hum ….the question is, for example do you get some 
university graduates? 
P: Well…………….  
 
P: I think that these are the people whom you approach; 
they are the only people interested in listening. You 
find that those people of higher education, they will 
tell you that they are in a hurry going to work or l 
welcome back to you. They are always giving 
excuses those people with higher education 
(expressed with anger and frustration) but the ones 
with middle and lower education, they are always 
keen to learn and participate in studies. Probably that 
is why we have the majority of them. 
F: Thank you very much! 
 
P: Yes…….I believe that economics plays a very 
important role because we don‘t recruit from private 
facilities we recruit mainly from public facilities and 
therefore people who are from the lower strata of the 
economy will be the ones that access and make use 
of the public facilities and therefore are easily 
accessible to us we do not see people of higher 
education status therefore possibly higher strata 
income. 
 
F: Oh yes, anyone wants to add something? 
 
Interruption by another participant! 
 
P: I think that these are people …… interruption by 
another participant. 
 
P: I think the other thing is that like we are using the 
public facilities and usually when we are choosing 
the sites we are guided by statistics of the burden of 
disease because of the timelines of the trials. We 
want to go to the areas where you know that there 
will be high chances that you will get the participants  
and get the numbers quicker, so you find these areas 
are usually where people in low income/strata and 
hence they have statistics of diseases like TB. But if 
you go to high income status areas you hardly get 
any patients. 
 
P:  It is very interesting when you talk about levels of 
education, concerning clinical trials like we said 
when we are looking at the economic bracket like my 
colleague has just said majority of those people are 
the ones that will access to health facilities. So 
majority of them it is a fact are of the lowest 
economic bracket and those are the people who can 
be submissive like to the instructions of the health 
workers and even when introducing a study it is 
easier to be successful if you are targeting those 
groups because they do not understand the policies 
and probably they do not understand their rights 
because of the level of education to an extent that 
they cannot say ―NO‖ (said with emphasis and 
louder!). They believe that as a health professional if 
you are from the community or is it culture or how 
they grew up? You have to know that you must listen 
to instructions. Sometimes you do not have to 
question. So that is why sometimes they can be 
exploited easily by the learned just because they do 
not understand their rights that much, they have 
rights but they don‘t know that much, so they cannot 
say ―NO‖. So they believe in the learned because 
they know that whatever they say is what is good for 
them. 
 
F: Interrupts, Thanks very much! 
 
P: (continues and agitated)....That‘s why they can be 
influenced easily!  
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F: I think already so many issues have come out and 
from our colleague here, there was the issue of 
sampling strategy. As you think about reaching your 
target. How do you go about it as a researcher or a 
research team? Then there are issues about the low 
levels of education and low social economic status 
which also comes into play. I think we will discuss 
more of this as we proceed with our discussion. But 
you touched on the issue of recruiting from public 
facilities. Can you explain more about the 
recruitment strategy? How do you recruit? 
 
P: Um.... there are quite a number of strategies but the 
one we commonly use is referral. We go and talk to 
the health care workers at the facilities and tell them 
what we are doing and the kind of people we are 
looking for so that if they come across the criteria of 
people they let us know. 
 
F: I am also relating to what you are saying that referral 
can come from someone that they trust and look up 
to. Let me look at the phases of the clinical trials that 
you have been involved in.  Has anyone participated 
in a: PHASE I _ (Some whispers from group) No? F 
continues…..PHASE II, Phase III -    (A few ‗Yes‘) 
Phase III- (Again a few ‗Yes‘) The facial expression 
from most group members was that they are not very 
clear of what these phases were!                
P: Requests an explanation of the phases from the 
facilitator! How do you categorise your phases? 
  
F: Gives a brief explanation of the Phases. Another 
participant joins in the explanations and seemed sure 
of the phases. 
Briefly I can say, Phase I is first in human where you 
have the intervention tested on a few health subjects 
say up to 20……  
Another participant joins in to explain and seemed very 
confident of the phases. 
 
F: continues, Phase two is dose finding. Another 
participant comes in to follow up on the explanation: 
This mainly continues to tests for safety and efficacy 
.Silence in the room! 
 
F: Phase III tests for efficacy and safety with larger 
groups of volunteers. How effective the drug will be. 
Phase IV post approval mainly checking for side 
effects. Right! We have all agreed that we have been 
involved in clinical trials. 
 
F: We are always talking about informed consent what 
does it mean to you? 
Silence in the room! 
 
P: Uh…what does it mean to us? Laughter!! Ok it means 
to me as a research nurse as someone that conducts 
the informed consent process, it means that the 
person that I will be obtaining consent from should 
be informed, they should be knowing about the 
study, they should be knowing the benefits, risks, the 
number of participants, just a lot about the study so 
that when they decide to take part in the study, they 
really know what we are talking about. It is not just 
to make someone sign but to make sure that that 
person has understood and after reading the informed 
consent form to the potential participant or after they 
have read it , you have to ascertain that indeed they 
have understood so that is the most important thing. 
 
F: How do you ascertain that they have understood? 
 
P: We usually have an assessment of understanding after 
discussing the informed consent form. You have a 
tool to assess if the person has understood and tool, if 
they are not able to answer your questions, there is 
still nothing wrong with going back and discussing 
the informed consent form to giving it to them so that 
they can go home and digest it and come back the 
next day and when you think they have understood 
that s when they can sign. 
 
F: Have you had any cases where you give this form , 
you spend so much time with them but still you 
assess and realize that  you are not happy with their 
level of understanding? Have had any such cases?  
 
P: Personally I have never had such a case because our 
informed consent forms are ‗very easy‟ to 
understand, they are put in a language that is 
simplified. I think someone who would not 
understand after going over and over would be 
someone may be with another problem…Everyone 
bursts into laughter!!!!.  Someone from the audience 
comments, ‗learning disability‟ laughter continues. 
 
P: It is possible!  We have come across a certain client 
whereby we have even had to refer her to come with 
a guardian so the guardian can be able to understand 
and explain to the potential participant. 
 
F: How old was that client? 
 
P: I am sure was above 18 or 20 can‘t remember very 
well! We suspected that probably like we have been 
discussing or she was saying because of low literacy 
levels. That‘s why most of the clients do not 
understand but they are willing to participate. In such 
cases we ask them to come with a guardian. 
 
F: Looking back at that one, was the client signing 
because they had understood or because there was a 
guardian? 
 
P: Ok, it came out later to be known that the client did 
not know how to read or write but had not disclosed 
this to us. So the guardian had to intervene. 
 
P: Raises a hand to contribute. I was once involved in 
two clinical trials in an assessment of understanding 
or comprehension and in those we had a set of 
questions that a client had to get correct. If a 
participant got any of those questions wrong, it 
would be clear to us that they had not understood. 
But there was no harm in asking them to come back 
and we gave the informed consent form to take 
home. If they came again and got the question right 
then they could enrol their children. It was stipulated 
in the protocol that should a potential participant get 
any of those particular questions wrong, they should 
not be enrolled in the study and this was explained to 
the potential participant at the start. 
 
 
 
 
 
  
217 
 
F: And were there some that you sent home to say we are 
done with you? Laughter from the group!!! What 
kind of questions were in that comprehension test? 
 
P: Ah! They were purely questions to answer the study 
objectives. If we asked a question like; will this 
medicine prevent your child from getting HIV and 
the client says ‗Yes‘ we would know they did not 
understand the study.  
 
P: Interruption! May be just to add on to that, if someone 
was given a second chance you could use another 
method of explaining to them about the study. For 
example in one study potential participants listened 
to an audio taped consent form so that even if 
someone was illiterate  they would have a chance to 
listen to the information over and over , then come 
and re-test. However after a certain number of times 
of failing, the client would not be allowed to retest 
because it shows lack of understanding. 
 
F: Thank you very much! So those are the high standards 
of clinical trials! As we are looking at the issue of 
informed consent, there is also this thing about the 
designing of the informant consent form! Ah! One of 
you said that you play a role in the documentation… 
Silence in the room…. Right, I thought you said so? 
 
P: No not to design but in validating the translation.  
F: Ah! Ok. Has anyone played a role in the designing of 
the consent form? Yes please go ahead! 
 
P: Yes 
 
F: What was your role? 
 
P: Laughs!! Uh! Designing a consent form? (Laughs like 
is doubtful whether consenters are involved!) 
 
F: Yes what was your contribution? 
 
P:Ok, first there will be a protocol, then you come up 
with the informed consent form  which involves the 
potential participants, then it has to have a couple of 
components that the patient needs to know and 
endorse with his/her signature. 
 
P: The other thing is that you will also know that there 
will be a screening part form the protocol and the real 
participation. The potential participant has to agree to 
the screening to make sure that the potential 
participant is interested and it is not automatic that 
they will participate. It is only when they meet the 
eligibility criteria, then they can go through the 
consenting process (it was not clear whether a 
separate consent form for screening is prepared and 
approved by the ethics committee).When preparing a 
consent form you highlight the key elements that you 
want the potential participant to understand, like 
rights, voluntariness. 
 
P: I think one other thing is that the form needs to be 
simple, translated and back translated, avoid use of 
jargon as much as possible. 
 
P: Interruption! And you are also supposed to have a 
‗lexicon‘ that standardizes the language so that if you 
have two research nurses one sort of like a dichotomy 
all the nurses use the same language. 
 
F: Is this available at all the other institutions or you are 
going to cook one? Loud laughter from the audience, 
when another participant says „Yes‘. 
 
F: We have already highlighted some of the challenges in 
coming up with the forms but we also want to get 
some of the practical experiences in terms of some of 
the challenges that colleagues  have met be it in 
terms of designing or using the forms. 
 
P: One of the major challenges is the ‗trust‘ parents have 
in the health workers. Some research investigators 
when they are consenting they might just summarize 
the contents without stressing certain details but the 
parent will be ‗rushing‘ to append their signatures! 
Loud laughter from the group… Participant 
continues, the level of education, it is a serious 
problem. The children are very submissive to the 
parents. When it comes to assent majority of them do 
not know what they are being enrolled into, do not 
know the risks because of lack of competence due to 
age. The [children] should know that there are no 
monetary benefits. Majority of them get transport 
money but they have to know that this is not 
payment! (Explained with a lot of emphasis). 
 
F: Do you make it clear what the money (P30.00) is for? 
 
P: It is clearly stated in the consent form! 
 
F: Insists on the question! I am asking is it clear to them? 
 
P: It is clear that this is money is for transport. Every 
clinical trial consent form has a statement to say that 
you will not be paid for participating for participating 
in the study and then there is a clause about payment 
for participation! We emphasize that this money is 
for inconvenience caused, travel fair to your home!! 
[The researcher assumes that parents understand all 
the content of the consent form! This does not seem 
sensitive to parent needs]. 
 
P: Another participant comes in again and looking like 
there is pertinent issue to clarify!! And another thing 
concerning transport money, I still feel that it has to 
be reviewed by the ethics committee because 
transport charges are continuously going up! But I do 
not know when it comes to research they forget about 
this part! Loud laughter from the group!!!....Like in 
South Africa, our neighbours their standard is around 
R200.00. Compared to P30.00! You can see that 
Botswana reviews research policies but does not look 
at things like transport costs (Expressed with 
disappointment). Those with louder voices should 
make noise! They should not only be interested in 
their own academic benefits!!  
 
F: Thank you very much for highlighting that one! It can 
be one of the study recommendations! 
 
P: Ah!... I am still interested in that one! Sometimes we 
have very sick patients who need to hire a special tax 
to get to the research center and the P30.00 is just 
enough for a single a single trip and the tax will not 
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wait .Everybody in the group all nodded in 
agreement to the problem!! 
 
F: Somebody mentioned that if the nurse has dealt with 
client for a long time, the client is not even interested 
in knowing the details of consenting process. The 
parent just signs the consent form. How many of you 
share the same view that being familiar with the 
parent they just want to participate? 
 
P: As a client whether you explain to me in all possible 
ways that this is not a clinical care but is research, if I 
have a child who is very sick, I really want the child 
to be helped and I would have tried everywhere else. 
If someone comes to me and says that it is possible 
for me, at the back of my mind it‘s like my child is 
getting care and appropriate help. 
 
P: Some clients come and tell you that ‗I have been 
involved in another study, so just let me sign. I know 
everything‘ .They think all the study processes are 
the same. 
 
F: Why do you think someone would adopt such an 
attitude? One issue coming up is that of trust. The 
fact that I know you and you have done nice things 
for me before in the previous study…. Laughter from 
the group….you can‘t harm my child in this one. Are 
there any other reasons why someone would adopt 
such an attitude? 
 
P: It‘s often like that! If you have previously interacted 
with your clients and you get to know them very 
well. Whether you try to do things professionally you 
already see that they have already made a tick 
psychologically have the ‗halo effect‘ you know your 
master is right and you trust! 
 
P: The care that they receive from the research centers. 
You find that we are more patient with our clients in 
the sense that  when they have a problem we sit down 
with them , talk to them and we give a lot of time and 
we also attend to their other clinical problems. ―We 
take so much care of them‖. When you tell them that 
their study is ending… ‗laughs‟…and you are taking 
them off the study they get really sad and will tell 
you that ‗if there is another study that I can enrol 
into please let me know ‗ Sometimes  they even come 
to inquire if there is on-going study they can join 
because they believe so much in the care given. They 
tend to forget about the research aspect.  
F: Do you think that voluntariness still exists despite 
what you have just said? 
P: Yes, it is still there, because even if they come for 
another study we go through the consent form 
information like from A-Z. I keep probing and keep 
them attentive. I tell them am going to test you at the 
end and if you do not get the answers correct you will 
not enrol your child in the study. 
 
F: I see you carrying a carrot on one side and a stick on 
the other side and you are saying before you sign you 
cannot enjoy all these benefits!!! Loud laughter from 
the group!!... 
 
F: Yes, the one with the hand up.  
 
P: I wanted to just clear a bit of confusion into the whole 
thing of participants trusting and … you know there 
is another element to it. An element of, ‗I come here 
there are not so many people although it‘s far from 
where I live, I will come here because people who 
know me they will not see me, so they avoid stigma. 
I think there still that element! 
 
P: But again when you talk about stigma amongst our 
clients, you find that those still having the idea of 
stigma they are still shy to come and participate in 
research, they want to go to public facilities.  
 
F: This a general question! Would you consider the care 
at the research center as coercion or undue influence? 
 
P: I can really say once somebody has participated in a 
study, even when a friend comes to them and says 
‗some people approached me and they want me to 
enrol my child in a study‘….and is not sure whether 
he/she will be making a good decision to participate.  
Usually after getting advice from the friend, they come 
back the next day excited  to say ‗I have made up my 
mind‟ my friend has also told that she was in this 
study and it is very, very, good‘. I know her child was 
very, very, ill and now the child is fine‘. This I can 
really say is one thing that attracts people to studies 
or research.  
 
P: Just to add on to that, I know my institution provides 
the best care and our clients are very happy and are 
resistant to go to public facilities after the study ends. 
May be it might be influencing the consenting in a 
certain way!! 
 
P: Interrupts! What we can say for sure is that we are 
doing research and are not interested in just 
recruiting and we are going to do everything possible 
to continue being attractive, whether this is ethical or 
unethical is another thing! Everybody bursts into 
laughter!!... 
 
P: I would say what we are giving is standard care but we 
are able to do it because we do not have as much 
burden like lots of patients, or long queues. I am sure 
the doctors and nurses in the public facilities did not 
have a lot of work they would probably also does the 
same thing! 
 
F: Oh you are smiling all the time!!... Laughter! …. 
 
P: I think maybe they just said all I wanted to say, but I 
think as a researcher you have to go through 
intensive training especially human protection or 
human rights Also since we know this is voluntary 
we try as much as possible to be nice so nice to our 
clients and I think it something that attracts them 
also. And like P5 said, one argument could be that 
the work load in research is not as much as in the 
public facilities. 
 
P: Just another thing, research programs have time 
frames e.g. three years. Joke: I want at the end of that 
time to have my job done and have my contract 
renewed so, am going to do what is expected of me. 
Laughter! Unlike in the public facilities where 
employment is permanent and pensionable. In my 
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setting if a patient takes a complaint to the PI or the 
ethics committee it tarnishes the name of the 
institution and I do not have my contract renewed!! 
Loud laughter from the group!!... 
 
P:Like myself I worked for an organization for 3 years 
then went back to public service , but I  could see that  
am a different person than before I passed through 
research. The way the informed consent is conducted 
for treatment is like a forceful signing. 
Sometimes clients are left until they get to  point when 
they cannot say ‗NO‘ and the health personnel do not 
have that much time to sit with a patient and explain. 
For example a health worker might just come to the 
ward and say „Mum, am taking to theatre to extract 
this baby so that you do not have complications, do 
you understand‟ Answer: ‗Yes‘. Health worker: ‗Sign 
here‟ loud laughter from the group!!... In a study I sit 
with a client and explain and ask questions, I don‘t 
just say…‘you give the baby teaspoon every day at 
8.00 am and 8.00pm! So [mma] give this medicine, if 
you do not your child will get infected‘. I think they 
[health workers] need to be taught. Again us we are 
just doing the research we are not going to be 
involved in the treatment like the roll out of HAART. 
I am afraid that we are giving the responsibility to 
people who have not been in a research environment 
and they do not know the [instructions]! Surprise!! 
 
P: Cracks a joke! The recommendation should go to the 
permanent Secretary! Group laughs and gives 
applause!!! 
 
F: Let‘s look at these parents and guardians who are 
coming to your research sites. Who is the first 
contact to talk to them about the study even those 
referred from the clinics? 
 
P: You know at our institution wherever there is a 
research we have to first teach everyone, all 
employees at the study site even the cleaners, 
receptionists and security guards! So they know 
how/where to direct the clients. Participants should 
only not be known by   certain group of people! After 
the receptionist has given them a ‗warm welcome‘ 
laughter! Then clients are directed to the study 
coordinators who explain everything. Then they are 
taken to the PI and the investigator [consenter] will 
be there. Somebody whispers from the audience 
‗Gives them a cup of tea‟ laughter! 
 
P: I do not think tea is ethically allowed! It might be seen 
as a bribe! Group continues laughing! 
 
F: So what roles to the clinicians/doctors play in 
consenting? 
 
P: Hum… Not much! Whispers from the group ‗No‘ 
 
P: Depending on the complexity of the study, sometimes 
the consent is conducted by the doctors especially 
some studies that are very clinical. But on the whole 
doctors are not that much involved. More whispers 
from the group saying ‗No‘. 
 
F: But what would you like to see? What kind of 
involvement from the doctors, to what extent should 
they be involved? 
 
P: The problem with our doctors is that majority are not 
Batswana, and we administer the consent primarily in 
Setswana. So this is a challenge. 
 
P: At my site the doctor conducts informed consent 
sessions, collects specimens etc so it depends on the 
studies and sites! 
 
F: When you are looking at the informed consent 
process, do you think full understanding is feasible? 
Do you think you are achieving that with the parents 
that you are dealing with?  
 
P: Majority of people do not understand despite the care 
given. It depends on the study. Some studies are very 
complex. 
 
F: Thank you so much for your participation the student 
will make sure to give you a report of the findings 
and recommendations. 
 
End of interview 18.00 hrs 
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APPENDIX 15: TRANSCRIPTION OF THE INDEPTH INTERVIEWS 
 
IN-DEPTH INTERVIEW: 1 
Date 09.05.2011 
Interview No 0001 
Stat time 14.55hrs 
Gender Male 
Age 30-40 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
Education Diploma in nursing science 
  
The research assistant began the interview by introducing themselves and going through the consent 
form and have it signed by the respondent. 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? 
R: Participant: We have done Good Clinical Practice. We do 
it continuously. We do it annually, like mine expires end of 
October, 2011. 
Q: Do you have any specializations in pediatrics? 
R: I have some experience for working in the pediatric ward 
for about 2 years. 
Q: Which Phase of clinical trial have you been involved in? 
R: Two clinical trials 
Q: What was the risk category of the clinical trial you 
recently conducted?  
R: There is no risk or less than minimal because the other 
one was just a psycho-social study. 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
R: Most of them are primary. 
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
R: Mid 50s, mainly mothers and grandmothers. Most of 
them are grandmothers. 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
R: Most of them because they were previously involved in a 
clinical trial before. 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
R: Mainly low income strata 
Q: How do you rate the importance of prior of knowledge of 
a research investigator about Botswana culture, values and 
beliefs before the start of the study?  
Q: Do you think this knowledge plays any role in the 
success or failure of a consenting process? (Please explain) 
R: Maybe when it comes to language, for example when 
you go to Bokalaka (Northern Botswana) you have to be 
knowing the language, you might experience language 
barriers that you have to be prepared for. Yes, it can affect 
the success of the study because maybe every time you go, 
you will meet those who don‘t speak Setswana. 
Q: Who prepares the consent form that you use in the 
clinical trial? 
R: Most of them the PI (Principal Investigator) then most of 
us do the translation. Maybe...I don‘t know. 
Q: On average how many pages is your consent document? 
R: Most of them are 1 page. Most of them are compressed 
into 1 page or 1 page and a half. You don‘t have to be long 
because they have to read.  
Q: Which research guidelines are you familiar with 
regarding the protection of research participants and how 
helpful they are to the consenting process?  
R:  We are using Botswana Guidelines and Good Clinical 
Practice. The Botswana Guidelines from the ministry of 
Health and Botswana laws. 
Q: GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms include 
all these elements and are you able to go through all these 
during your sessions?  
R: No, there are no gaps.  We follow those rules. Yes, you 
have to stick to all the guidelines. 
Q: What challenges do you encounter from the sponsors 
regarding the requirements for preparation of the informed 
consent document for the clinical trial if applicable? 
R: Um....I don‘t know because the study coordinator handles 
most of those so it‘s a smooth process. We just translate. 
Maybe if it was in English we translate to Setswana, and 
then we take them to the ministry, I don‘t know what they 
are doing there.  
Q: What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
 
R: Not answered 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
PR Mostly clinic contact, especially from the clinics or some 
referrals. We also use the system from the other studies, so 
we can just call. If there are no contacts and you can‘t follow 
you just go to the next patient. 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: Research nurses. 
Q: In what language are the discussions of the information 
about the study held? 
R: Primarily Setswana, if they prefer English, it‘s available. 
Q: In what language are the discussions of the information 
about the study held? 
R: Verbally in Setswana but a patient might prefer English.  
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Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: Hey, I don‘t think there is any problem with explaining 
the consent. The only problems comes with asking 
questions, some of the questions we are asking are culturally 
sensitive, they were not polite. Like in one study there were 
some questions where you had to ask about sex and they are 
culturally inappropriate. Yes, it‘s difficult to present that 
question. The other study we were doing, they didn‘t like to 
interrupt the treatment, at first they didn‘t like but after some 
time they liked it. 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
R: Too much! 
Q: Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria do you 
use? 
R: You have to state everything because this is voluntary.  
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language? 
R: Sometimes there is too much technical language, so you 
have to go in and try to explain more. Yes, it‘s necessary 
especially when you are dealing with drugs. Yah, you have 
to break it down or ask in a polite way. 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? 
PR They don‘t like it before you can even introduce the 
research. They say their children are being used too many 
times. They are not interested.b. Do the parents understand 
the difference between research and treatment? They know! 
If you come down and explain then they will listen. 
Q: Do the parents/guardians ask any questions? If yes what 
are usually their main concerns? 
PR Yes, about the outcome of the studies, what are we 
supposed to do? Are there any risks to my child? What about 
the safety of the child, duration of study, the number of 
visits but we reimburse for transport as they come.  
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R: We ask again do you understand, and if they say yes, we 
assume they are ok. You have to ask if they really 
understand. I think most of them here, they trust the research 
team. But some of them it‘s because they will be given 
money for transport.  
Q: According to your observation, what is usually the 
general emotional state of the parents/guardians during the 
consenting process? 
R: Um....I think most of them are stressed they don‘t want to 
be seen doing many things here; they just want to be seen 
once and be done. There is stigma associated with the clinic 
because now the child will be seen coming to the clinic. 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: We just have to ask them do they know what you are 
talking about. It‘s verbal. For some they could read but they 
are just lazy, they are lazy to read then when you ask them 
they say they are fine. 
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: Most of them they are bored, attentiveness is a bit low.  
There would usually be about 60 patients at the clinic so by 
the time we talk to the patients they are tired of waiting. We 
take patients by referral and self-referral. 
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: To understand……? About 10 minutes because they 
don‘t want to be here longer. I have to read in Setswana then 
explain to them so about 10 to 20 minutes. 
Decision Making 
Q: Approximately how much time do you think should be 
given to the parents/guardians to make a decision? 
R: (Laughs)...um but if it‘s a psycho-social survey they can 
make the decision then but if it‘s a clinical study then they 
have to go back home  then they come again next time, so if 
you have the questionnaires they can make the decision right 
away in 30 minutes. They can consult the husband, let‘s say 
we are here for 3 weeks; we give them a time, like if we are 
finishing before end of April we tell them to come before 
end of April. 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants even if the person who has 
brought the child to the clinic agrees to participate? 
R: Most of the time it‘s the husband but sometimes the child 
is accompanied by an aunty so they have to consult the 
mother. Or for some of them the mother is dead so we see 
the grandmother. 
Q: Do all the parents insist on consulting with the spouse or 
family before making a decision? 
R: Yes, it‘s very important. There are research nurses or 
teams. 
Q: Who do you mainly consult before enrolment of the child 
into the study? 
P: Mostly the husbands. 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain informed 
consent? 
R: Yes, in some of the systems. But we understand they 
have to take time.  
Q: How do they indicate their agreement to the children‘s 
participation in clinical research? 
R:  By signing on the consent form. 
Q: How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: It depends; I think 5 percent of them would just sign the 
form and move on. Most of them are just ok; they know 
what they are doing.  
Q: How do you facilitate the decision-making process? 
R: One thing is, I have to show the parents the benefits of 
research.  
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think might 
influence the parents/guardians to agree to enrol their 
children in the study? 
P: Um....I don‘t know, I don‘t think I know one because 
normally we check everything unless it‘s there culture and 
they don‘t want to be involved in the study. 
Q: Describe any measures you put in place to ensure that 
participants and the consenting parents/guardians do not feel 
coerced or pressured to join the study as well as continued 
consent during the study. 
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R: I think most of the time it‘s included in the consent that 
this voluntary and at any point you can take your child out of 
the study. 
Q: Describe any general challenges you encounter in 
seeking informed consent from parents/guardians/child? 
R: Translation, some of the words in English it‘s hard to 
translate into Setswana then you lose the meaning and the 
Setswana one seems to be longer and patients get tired.  
Q: Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
R: Um.....I think the only thing is to make sure the consent is 
straight to the point as possible so you don‘t take a lot of 
time reading.  
Q: Do you involve competent children in the consent 
process? 
R:  You say children? Yes, we can go to children who are 18 
and the mother is the one who gives the consent. If the 
mother is under 21 then the caregiver gives the consent.  
Q: Children of what age do you engage in the consent 
process? 
R: Not answer given. 
End: 15.25hrs 
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IN-DEPTH INTERVIEW: 2 
Date 11.05.2011 
Interview No 0002 
Stat time 15.04 hrs 
Gender Female 
Age 30-40 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
Education Diploma in nursing science 
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? 
R: Human subjects protection, GCP 
Q: Do you have any specializations in pediatrics? 
Participant: Over 10 years of work experience in pediatric 
environment and 1 year of pediatrics research 
Q: Which Phase of clinical trial have you been involved in? 
R: No answer 
Q. What was the risk category of the clinical trial you 
recently conducted?  
R: You mean the pediatrics study? Minimal risk and 
benefit? Vaccine has minimal risk with HIV positive 
children, Could be risky because of the vulnerability of the 
children 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in 
clinical trials? 
R: On average around junior school, we have some who 
have gone up to tertiary. Very few have no education at all 
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from 
for their children‘s   participation in clinical research? 
R: On average from 26-30, 31-35 fewer as we go up, 
grandparents 
Q14.On average how many of your participants have 
previous experience with research on HIV disease? 
R: No answer 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies?  
R: Very low, Waho!! Majority medium. We find some 
above average but very few, university but also not 
extremely high 
Q: How do you rate the importance of prior of knowledge of 
a research investigator about Botswana culture, values and 
beliefs before the start of the study?  
R: A few who use traditional medication but do not want to 
stop .It is a common practice but very few admit using it. 
Q: Do you think this knowledge plays any role in the 
success or failure of a consenting process. (Pease explain) 
R: The belief might affect someone do decline 
Q: Who prepares the consent form that you use in the 
clinical trial? 
R: Only involved in translations otherwise it‘s pre-prepared. 
At times if we were consulted we could change some 
things. 
Q: On average how many pages is your consent document? 
R: The least 5 pages most bulky 19 pages 
Q20.Which research guidelines are you familiar with 
regarding the protection of research participants and how 
helpful they are to the consenting process? GCP guidelines 
recommend that both the informed consent discussion and 
the informed consent form should include the twenty 
elements. Do your consent forms include all these 
elements and are you able to go through all these during 
your sessions?  
R: Belmont report, Nuremberg Code but in practice we do 
not normally apply them Laughter!!I never go back. 
Botswana Laws are a barrier because in our community 
there lots of young mothers 18 and able to understand with 
no other relative that consent for them but would benefit 
from the study. Some get very emotional and upset if they 
are declined.  
Q21. GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms 
include all these elements and are you able to go through 
all these during your sessions?  
R: No answer 
Q: What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
R: I do not have much information coordinators are 
responsible.  
R: Challenges: Translation Uh! Ya!... English words which 
do not exist in Setswana but we find a way. But sometimes 
lose meaning. I read, encourage questions stop along the 
way, give a copy to take home and come back with 
questions. But reading in Setswana is very difficult but 
with experience am getting used. With the Setswana 
consent form familiarize so it is a conversation. 
Participants often get impatient when it is too long lose 
concentration. Recommend a shorter version some things 
are made to long or too detailed for the patient. Legally 
you are expected to give all the information 
Q: What challenges do you encounter from the sponsors 
regarding the requirements for preparation of the informed 
consent document for the clinical trial if applicable? 
R: No answer 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R: Put flyers at the clinics, use recruiters give a brief 
overview and we discourage them to be coercive. We 
explain details when the patients come to the clinic 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: Usually the study nurses. 
Q: In what language are the discussions of the information 
about the study held? 
R: Setswana but some prefer English. Laughter!! Most 
educated Batswana prefer to use English. 
Q: How is the information about Clinical trials 
communicated to participants?  
R: Communicate verbally and give them to read at home 
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: I do not find any section difficult because I lay the points 
as they are may be studies that are too scientific 
Pharmacokinetics, pharmacodynamics. Scientific terms in 
a consent form brief somebody in the simple way, 
Gastroenteritis =say diarrhoea 
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Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have 
conducted? 
R: Some have too much information others average.  
Q: Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria do 
you use? 
R: Explain, read, and give the form to take home, ask 
questions.   
Q. How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language? 
R: Quality scientific studies are a challenge some studies can 
be too complex 
Q: Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria do 
you use?  
R: Give all the information 
 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? 
R: Majority are Ok (laughter!!!) meaning happy to be 
participating others are anxious 
Q. Do the parents understand the difference between 
research and treatment? 
R: Initially not but as they are explained they understand 
Q: Do the parents/guardians ask any questions? 
R: Yes the literate ones usually do but the less educated do 
not 
Q: If yes what are usually their main concerns? 
R: Safety of the child, benefits 
Q: If no questions are asked do you find out why? 
R: They say they have understood everything. A few say 
(laughter!!!) they did not understand. Those that ask 
questions it is out of understanding. 
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R: When they hear about procedures their children will go 
through, they go into a bit of panic and even pay more 
attention. 
Q: According to your observation, what is usually the 
general emotional state of the parents/guardians during the 
consenting process? 
R: Usually not emotionally stable, worried about baby or 
naturally am not clever but ask you to go over again 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: We have an assessment tool after discussion we test and 
if not getting the right answers we go back. Ask why they 
can‘t grasp, lack of concentration etc  
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: Beginning they concentrate. Along the way ask or talk 
about the baby to distract, play with the baby, 
concentration will pick. 
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: At least 45min I would recommend that those who 
prepare the consent forms should aim at something not 
more than 45 min long. 
 
Decision Making 
Q: Approximately how much time do you think should be 
given to the parents/guardians to make a decision? 
R: Usually I give an appointment for potential participant to 
come back. Depending on the potential participant, some 
say straight away Iam ―Sure I want to join‖ They do not 
think of the payment because the money paid is too little 
to coerce them (P30.00).if hesitant, I let them go home and 
return. 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants‘ even if the person who 
has brought the child to the clinic agrees to participate? 
R:  No answer 
Q: Do all the parents insist on consulting with the spouse or 
family before making a decision? 
R: I only involve them when there is a problem. Those who 
wish to consult husbands are usually the young mothers. 
Q: Who do you mainly consult before enrolment of the child 
into the study? 
R: Grandparents and friends at times 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain 
informed consent? 
R: Yes it does and is necessary 
Q: How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: If they have made a decision they have no problem with 
signing 
Q: How do you facilitate the decision-making process? 
R: Explain what the study is about Emphasize freedom to 
make a decision. Allow as much time as required. Explain 
asked question to participant satisfaction. Allow and 
encourage them to consult 
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think 
might influence the parents/guardians to agree to enrol 
their children in the study? 
R: Oh! Those who do not believe in western medicine do 
not, even come to the clinic because their beliefs do not 
allow 
Q: Describe any measures you put in place to ensure that 
participants and the consenting parents/guardians do not 
feel coerced or pressured to join the study as well as 
continued consent during the study. 
R: We assure them that its voluntary and you can withdraw 
any time .There is a possibility of some things to coerce 
like care being better than public facilities hem but not 
obvious thing  
Q: Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
R: Reduce time spent at the clinic. Educate communities on 
importance of C/T (new knowledge, medicines to save 
lives). Put in an education component especially on 
benefits. Encouraging mothers to recruit, we do not do it 
but their friends tell them about the study and they come. 
 
Thank you for participating in this study. End time: 15.30
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IN-DEPTH INTERVIEW: 3 
Date 18.05.2011 
Interview No 0003 
Start time 14.35 
Gender Male 
Age 30-40 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
Education Diploma  
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? 
R: GCP, Bioethics, Ethics seminars and workshops, 
Q: Do you have any specializations in pediatrics? 
R: I worked in the pediatric environment for many years 
before joining research 
Q10. Which Phase of clinical trial have you been involved 
in? 
R: Phase II & III (Drug intervention). Respondent is not 
confident about the answers. 
Q: What was the risk category of the clinical trial you 
recently conducted?  
R: Less than minimal risk 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
R: Primary and secondary 
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
R: 26 years and above but those over  45 would not be the 
biological parents majority grandparents/caregivers 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
R: did not answer the question 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
Generally low 
R: Low income majority 
Q: How do you rate the importance of prior of knowledge of 
a research investigator about Botswana culture, values and 
beliefs before the start of the study?  
R: Very important (Very passionate about this point).To get 
basic information about a patient; get all the details to 
understand the client. Consider the rights and welfare 
Q: Do you think this knowledge plays any role in the 
success or failure of a consenting process? 
(Please explain) 
R: Can affect the success of the process 
Q: Who prepares the consent form that you use in the 
clinical trial? 
R: Study coordinator and doctors who is involved in the 
study 
Q: On average how many pages is your consent document? 
R: Depends on the study because all details must be 
included incorporate all information necessary for 
understanding, not coercive example collection of blood, 
what they will experience expected discomfort 
Q: Which research guidelines are you familiar with 
regarding the protection of research participants and how 
helpful they are to the consenting process? GCP guidelines 
recommend that both the informed consent discussion and 
the informed consent form should include the twenty 
elements. Do your consent forms include all these elements 
and are you able to go through all these during your 
sessions?  
R: Declaration of Helsinki, ICH-GCP, Botswana Clinical 
Trials Guidelines -Ministry of Health 
Q: GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms include 
all these elements and are you able to go through all these 
during your sessions?  
What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
R: Delays especially national ethics committee. 
Q: What challenges do you encounter from the sponsors 
regarding the requirements for preparation of the informed 
consent document for the clinical trial if applicable? 
Not answered 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R: Establish inclusion criteria and phone patients who are 
eligible .No advertisements at the clinics, do not get 
referrals, national program 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: Study coordinator, PI and doctors-research team 
Q: In what language are the discussions of the information 
about the study held? 
R: Mainly Setswana but can be done in English as well 
Q: How is the information about Clinical trials 
communicated to participants (language?) 
R: Must be communicated in a language that is appropriate 
but both verbal English and Setswana choices are made 
available. 
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: Technical terms 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
R: Too much but it is necessary and part of the ethical 
principles 
Q: Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria do you 
use? 
R: Disclose all the information as an ethics principle 
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language? 
R: Too complex 
Q: Considering the risks involved in clinical trials, when 
disclosing information to participants, which criteria do you 
use?  
R: Disclose all the information as an ethics principle 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? 
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R: More anxious than when they come in some seem 
satisfied. 
Q: Do the parents understand the difference between 
research and treatment? 
R: Participant: Yes parents understand the difference 
between research and treatment 
Q: Do the parents/guardians ask any questions? 
R: Yes 
Q. If yes what are usually their main concerns? 
R: Safety of child, 
Q: If no questions are asked do you find out why? 
R: Not answered 
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R:  Fear to be involved in research, lack of understanding 
concern about future risks 
Q: According to your observation, what is usually the 
general emotional state of the parents/guardians during the 
consenting process? 
R: Excitement but this should not be taken for granted. 
Some parents are calm because they are familiar with 
research 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: verbally but there is no written test to assess 
understanding 
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: High 
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: Give as much time as they client needs, do not push 
them! 
Decision Making 
Q: Approximately how much time do you think should be 
given to the parents/guardians to make a decision? 
R: Main concern should be protection of participants so give 
them time to think about your request and to consult 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants even if the person who has 
brought the child to the clinic agrees to participate? 
R: Very important because it can help to retain them on the 
study 
Q: Do all the parents insist on consulting with the spouse or 
family before making a decision? 
R: Yes  
Q: Who do you mainly consult before enrolment of the child 
into the study? 
R: Spouse, grandmother, grandfather, uncles, auntie or 
whoever relative is relevant 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain informed 
consent? 
R: Yes 
Q: How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: By putting a signature on the consent form 
Q: How do you facilitate the decision-making process? 
R: Guide them through the information given and give the 
consent form to carry home and read or be read to 
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think might 
influence the parents/guardians to agree to enrol their 
children in the study? 
R: Economic -some cannot afford transport to get to the 
clinic so they are attracted by the re-imbursement given. 
That‘s the end of the interview. Thank you so much for your 
time. 
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IN-DEPTH INTERVIEW: 4 
 
Date 24.05.2011 
Interview No 0004 
Start time 15.18 hrs 
Gender Female 
Age 30-40 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? 
R: Yes, although it was not a specialization. 
Q: Do you have any specializations in pediatrics? 
R: Yes I did pediatric courses at school. I also have   4 years 
of experience in conducting studies involving parents and 
children 
Q. Which Phase of clinical trial have you been involved in? 
R: Mostly Phase III and IV 
Q: What was the risk category of the clinical trial you 
recently conducted?  
Participant: Mostly minimal but one study that involved 
drug intervention was greater than minimal risk. 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
R: Mostly Primary and Junior school we have a few tertiary 
or those who dropped out of school early. I prefer those 
without too much education because they will follow what 
they are told  
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
R: Most parents are 21 years and above because of the age 
of consent but there are also a lot of grandparents to consent 
for minors 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
Generally low 
R: Very few especially those who have been in studies as 
pregnant women and they enrol their children in studies. 
Q: How do you rate the importance of prior of knowledge of 
a research investigator about Botswana culture, values and 
beliefs before the start of the study?  
R: Promotes  understanding  ways of respecting  participants 
for example,  those who say must go back and consult-it is 
usually an indirect  way of refusal  but some come with  
their minds made up. Knowledge of the local language is 
also important for understanding. 
Q: Do you think this knowledge plays any role in the 
success or failure of a consenting process? 
R: I think you cannot take out the culture; we go through the 
Kgotla before. On one study I was asked whether I have 
talked to the Kgosi before. I have had an experience where 
they admit that they have taken traditional medicines. 
Inhalations but we respect their culture we can stop them. It 
is a problem to ask the mother and father to join because a 
lot of women are single mothers even those who have are 
not so much involve come to drop them. Once they say they 
want to consult it is an indirect way of refusing although a 
few agree need for education to involve partners. 
R: The forms are prepared by the research team, use the 
format from the sponsor but contextualize to the culture of 
Botswana setting especially for Multi-center studies. The 
Principal Investigators consult with the research team and 
study coordinators and senior nurses help. 
Q: On average how many pages is your consent document? 
R: Usually long but nurses are able to summarize the 
information from lengthy forms to about six pages, a page 
sometimes. Although the forms are long nurses with 
experience know how to pick important issues 
Q: Which research guidelines are you familiar with 
regarding the protection of research participants and how 
helpful they are to the consenting process? GCP guidelines 
recommend that both the informed consent discussion and 
the informed consent form should include the twenty 
elements. Do your consent forms include all these elements 
and are you able to go through all these during your 
sessions?  
R: We all do Good Clinical Trial Practice training so am 
familiar with GCP guidelines and refer to these documents. 
All of us are trained in GCP because it is a requirement by 
the institution that everyone is trained 
Q: GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms include 
all these elements and are you able to go through all these 
during your sessions?  
What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
 
R: Uh! I would not say I have encountered much problems. 
At the Ethics committee I prefer submitting my application 
to a particular person other than the registry to avoid losses. 
There are also delays, we asked to do lots of corrections not 
to pay the participants much but only for compensating 
transport which is not much compared to what participants 
in other countries pay. 
Q: What challenges do you encounter from the sponsors 
regarding the requirements for preparation of the informed 
consent document for the clinical trial if applicable? 
R: We are not involved with sponsors 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R:  We hardly use the radio, but we use mainly posters put at 
the clinics. We also use the patient meetings, wards antenatal 
clinics in the rural areas. A few patients come from private 
clinics 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: Recruiters and nurses. The recruiters go with the nurses 
for better interaction. We also get self-referrals who have 
heard about the study from the community. Some parents 
call to inquire about the study after they have heard about 
the benefits. 
Q: In what language are the discussions of the information 
about the study held? 
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R: Mainly the local official language Setswana, but a few 
prefer English. 
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: The procedures and risks can be a challenge to explain 
because of the scientific terms. Also concepts like 
randomization. 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
R: The information is usually a lot because of the length of 
the consent forms and the short time one to go through the 
form. 
Q: Do you consider all the information relevant for the 
participant to make an autonomous decision? 
R: Yes but for the level of the participant some of the 
information might not be relevant especially the medical 
explanations and details of treatment and laboratory tests. 
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language? 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? 
R: You find that initially some are very anxious because of 
the nature of illness of their children but as we explain some 
of the things they become calm and with time some even 
become happy and do not look as hopeless as the time they 
came. 
Q: Do the parents understand the difference between 
research and treatment? 
R: Sh! .. we try to explain but it is difficult to tell for many 
of them. To me it seems like they think they have come for 
their child‘s treatment. But we emphasize this a lot during 
the consenting process.  
Q: Do the parents/guardians ask any questions? 
R: Not that much especially those with low education. I feel 
they still have that mentality that the health professional is 
always right. But some do especially about the safety of 
their child. 
Q: If yes what are usually their main concerns? 
R: They mainly want to know how experimenting on the 
child might affect the child physically, whether the child will 
get better, mainly child safety issues. 
Q: If no questions are asked do you find out why? 
R: Really I have never found out why, but I think it might be 
a cultural thing where they do not want to look like they are 
questioning. I t might also be fear of the unknown. Like they 
would rather not know what lies ahead. 
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R: I think it is the culture. The power issue!... considering 
that the doctor or nurse is a respected member of the 
community and the assumption that they know what is best 
for the child. 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: Verbally by using a test of understanding quiz. 
Sometimes even asking just general questions not really 
related to the study just to change the topic a little during the 
consenting process. 
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: Ah! It‘s is difficult to judge because some just stare at 
you as you talk or read to them which might look like they 
are paying attention. Some would be very tired after a long 
day you can really see they are more worried about how they 
will get home 
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: It depends on how understanding is being judged. If the 
parent does not seem to understand we can even ask them to 
come another time after having someone read and explain to 
them. 
Decision Making 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants even if the person who has 
brought the child to the clinic agrees to participate? 
R: It would be good for the two parents to be consulted but 
we meet a lot of young single mothers whose spouses are 
not so much involved in the care of the child. It is always 
good to get the blessing and to have the support of the 
relatives because they all take care of the child and they 
show concern. Even the culture encourages this. Also in case 
anything goes wrong, the blame is not only shifted to the 
institution. 
Q: Do all the parents insist on consulting with the spouse or 
family before making a decision? 
R: Yes a lot of them do even after they have agreed at the 
clinic they will go back and talk   to their families. 
Sometimes you find that they will not come for the next 
appointment and when you phone them they say the 
relatives did not approve. However those whose spouses are 
not aware of the status of the parent and child are hesitant to 
consult the spouse. 
Q: Who do you mainly consult before enrolment of the child 
into the study? 
R: Mostly the grandmothers to the child or anyone the 
parent can suggest. 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain informed 
consent? 
R: Ya!.. it really makes a difference because it is like a 
secret that is coming out and the parent is relieved that 
someone knows about the situation and will give support. It 
also improves the level of involvement in the research and 
adherence to the instructions. 
Q. How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: Again as I said, they do not seem to mind especially 
before they get a good understanding of the difference 
between research and treatment. Signing means they will get 
help. Another thing is the culture of not questioning.  
Q:  How do you facilitate the decision-making process? 
R: Emphasizing that the participation is voluntary and 
telling the truth about the uncertainties of the study so the 
parent understands the benefits and risks. Allowing as much 
time as required for someone to decide not to rush them. 
Q: Describe any measures you put in place to ensure that 
participant and the consenting parents/guardians do not feel 
coerced or pressured to join the study as well as continued 
consent during the study. 
R: I assure the parents from the beginning that enrolling the 
child is voluntary. I also do not mention that there will be a 
compensation for travel at the beginning. 
Q: Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
R: There is need to shorten the forms and simplify them. 
More education to the public about the importance of 
research and clear some of the misconceptions. 
 
Thank you that is the end of our interview. End time: 15.54 
hrs
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IN-DEPTH INTERVIEW: 5 
Date 22.03.2011 
Interview No 0005 
Start time 15.08 hrs 
Gender Female 
Age 20-30 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
Education  
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
 
Q. Have you had any specialized training in ethics of 
conducting clinical trials research?  
R: I did the GCP, Good clinical practice... and....um I 
haven‘t done any communication skills but ………………. 
Q: What on-going training on protection of human subjects 
are you receiving? 
Participant:  We do renew every time, it takes a year then we 
renew. 
Q: Tell me about purpose of the clinical trial you are 
involved in. 
R: the studies that we are doing according to my 
understanding...um...there is this other one, we are dealing 
with pregnant women and we want to see whether, how 
many times or how much of the drug can prevent or reduce 
the virus from the mother to the baby. Its drug intervention. 
The other one is dealing with babies. That one we are 
dealing with drugs and we want to see how they help the 
positive babies, we want babies who are less than 3 months. 
 
Q: Explain your role in clinical trial have you been involved 
in? 
R: um...my role is to go out to clinics and identify people 
who are eligible for studies then I recruit them to the study. I 
just tell them everything about the study, if they agree that‘s 
when they will come to the site, if they don‘t agree then 
that‘s fine, they don‘t participate. 
 
Q: Briefly carry me through the consenting process. 
R: ....um....I think for people who are consenting for our 
studies, for us I tell them about the study, I tell them the 
negative or disadvantages and the advantages. From there, 
that‘s when we sign. The consenting and signing is done 
here, so the agreeing and explaining is done here in our 
facilities. For them to come here we say everything and 
show them everything about our study then they agree to 
join the study, that‘s when they come. If the don‘t agree, 
they don‘t come here. We don‘t do any paper work at the 
clinic; we just explain the whole process of the study and tell 
them everything about the study and when they come here, 
that is when they do the writing. 
 
Q: Which phase of clinical trial have you been involved in? 
R: drug related studies 
 
Q: What was the risk category of the clinical trial you 
recently conducted?  
R: Low, maybe let me say about the babies. We are doing 
the same thing they do at the government. They come here 
and we start with doing the PCR, and do HIV test. With 
pregnant women, I don‘t think there is a little risk because 
we draw blood so we prick them and we do many tests but I 
haven‘t seen any other danger. 
Q: Are clinicians involved in the consenting process? 
R: Yah, the nurses...here, the nurses are the ones who are 
involved. Normally, as far as I know, for the patients she 
meets the nurses do most of the consent and tells her what, 
then the doctor only comes to consult. 
Yah, since I came here 3 years ago, it seems like its working 
well because with the consenting part, they are repeating 
what we told the patient at the clinic so it‘s easy to 
understand. 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
Participant: ...um.... junior secondary. 
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
Participant:  around 30, let‘s say 30 to 35. 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
R: (sighs) not a lot. Not a lot. 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
R:  (Laughs)...one thing that I have noticed is that most of 
these patients are of low to medium. High or whatever, it‘s 
so rare to find them because they are able to go to a private 
doctor. 
Q: Who prepares the consent form that you use in the 
clinical trial? 
R:...um.. consent document.....the last time I heard about 
consent some of the coordinators...um, they were translating. 
To tell the truth they are the ones who prepare the consent. 
Then we have the site or they call the head nurse who is the 
overseer of everything at the site. They also have the input. 
Also the doctors, they have input. 
Q:GCP requires that consent form be in a language the 
participant best understands. Does translating only into 
Setswana have an impact on understanding the study? 
R: The consent is in English then we translate. To me, this is 
not a problem. Some time ago, many people even those who 
can‘t read, they felt like Setswana somehow it‘s difficult. 
There are some other words that a difficult to understand. So 
to me, it important to master even for some who feel they 
understand English better.  
When recruiting, I use Setswana. 
You mean in Botswana? Yes....what language, what do you 
mean by language? Yah, that other side of Botswana I think 
it will be a problem. 
Q:. On average how many pages is your consent document? 
Participant: (sighs)........um....Sometimes they can take at 
least 30 pages. You mean the consent. It‘s like a book, so 
they have to read everywhere so that the participant can 
understand, so they can be able to make that decision, so 
they read everywhere. So sometimes it‘s long. Sometimes it 
can take 30 minutes. They also ask questions. 
Q: Which methods have you tried for the consenting 
process? 
Participant: Us, we use just use flyers. This is what we have 
(shows a poster on the wall). Also patient contact 
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Q: Which guidelines do you use to guide the consenting 
process? 
R:. I go to these places because we look for these pregnant 
women. We, I have identified the days when the doctor 
comes to give ARVs, so I target those days. 
Q: GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms include 
all these elements and are you able to go through all these 
during your sessions?  
R: Yes, we follow them 
Q. What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R: Us, we use just use flyers or this is what we have (shows 
a poster on the wall). Also patient contact 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: At the clinic, it‘s the recruiter. 
Q: In what language are the discussions of the information 
about the study held? 
R: Setswana 
Q: How is the information about the clinical trial 
communicated? 
R: By talking to the patient.  
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: Um....for now I haven‘t found any difficult part because 
normally, for those living with HIV, the babies who are born 
by HIV mothers according to the Ministry of Health and 
Government of Botswana, all babies are going to be tested 
whether HIV positive or not......so we test babies, after 
knowing those results, we take it from there because we are 
more focused on positive babies. 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
R: um.....to me, sometimes it feels like it‘s too much and 
sometimes I feel like we are just confusing her. We are 
telling the mother, that time when you came for registration, 
the baby is going to be tested.....then we start telling them, 
we are from Harvard, this and that.....  We are the ones who 
weigh them because there is so much shortage at the clinics, 
we are the ones who do bloods because there is so much 
shortage and so many things. We do everything, wherever, 
we help pull out the files in order to identify them. We help 
the doctors......by helping the doctor we can identify the 
patients. You do everything that is going to get the patients, 
sitting is not going to help.  
Q: Concerning risks when disclosing to participants, would 
you prefer to..... 
R: Um...we have forms. Normally if someone has waited for 
a long time, I just make an appointment then we meet 
another time. So we have booking forms. Each one of us has 
these forms 
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language?  
Participant: No, I think most of the time its fine. 
 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? Do the parents 
understand the difference between research and treatment? 
R: Um...one thing that I have noticed, there was so much 
shortage so sometimes if I come and say there is this study, 
babies being tested what, what, what, to them it‘s always 
like when should I come, it‘s not a struggle because they 
also believe babies have  to be tested. There are so many 
people, somehow the main focus is to attend to all of those 
especially with ARVs because it‘s like ARVs is the main 
focus. 
Q: Do the parents/guardians ask any questions? 
R: They, for now I haven‘t had any questions because to 
them we are going to help them by testing the babies and 
after the results that‘s when we will talk about the study.  
Q: If yes what are usually their main concerns? 
Participant:  None 
Q: If no questions are asked do you find out why? 
R For now, they just want to test their babies. So we don‘t 
force them. 
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R: Or for some after we test the baby we explain everything 
about the study, then they say no, we don‘t want to 
participate in the study, they just wanted the baby to be 
tested. We don‘t push them.   It‘s not like they don‘t 
understand.  
Q: According to your observation, what is usually the 
general emotional state of the parents/guardians during the 
consenting process? 
R: Not answered 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: Because, normally it‘s not us who do the administration 
of the consent, we do it but that one, we normally push it to 
the midwife or nurse. We don‘t want to make it like we 
coerce or bribe them to participate. So normally we just ask 
them....  
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: um......the illiterate ones look bored so we keep on asking 
them do you understand or do you understand when you 
were told about PMTCT, do you understand why you were 
given those medications, so we can check if they understand.  
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: Most of the time because people don‘t understand, they 
have to come again. Then we have to keep asking why were 
you given those drugs, when is the baby due, and what did 
they say about the baby. Those are the questions we ask 
them. 
Decision Making 
Q: Approximately how much time do you think should be 
given to the parents/guardians to make a decision? 
R:  For me, for me....I think 2 days to a week looking at 
some of them who have HIV positive babies for them to 
calm down for a while, for them to go for counselling to 
offer them that because for some of them we do offer that. 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants even if the person who has 
brought the child to the clinic agrees to participate? 
R: the partners, their mothers because some will say, I have 
to go talk to my mother then I‘ll come back. Then I‘ll call 
them mid-week to check them.  
Q: Who do you mainly consult before enrolment of the child 
into the study? 
R: The mother. 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain informed 
consent? 
R: It delays the consent process but there‘s nothing you can 
do because for me, if someone says I have to consult that 
one I don‘t doubt it, I just let them. Another one, she said 
she had to talk to her mother and father because it was a step 
child but I had to push her a bit because of the time she was 
to take the medication so she could take the medications on 
time. We did the bloods, everything, even when they don‘t 
quality for our study. 
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Q: How do the parents/guardians indicate their agreement 
for their child to participate? 
R: They sign the consent form. 
Q: How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: They are happy because most of the time parents want 
good health for my child, to them we can help them so even 
if the child is in the study its fine. 
Q: How do you facilitate the decision-making process? 
R: um...it‘s mainly the study nurse. For us, what I can say 
about recruitment is yes, I feel the way I understand the 
work, for people to come here it‘s because of us. As I said, I 
did counselling and stuff, even in social work, sort of 
counselling and communication, most of us we did 
counselling courses I feel  we are the root of everything 
because we recruit and sometimes after some time they 
disappear then we wander what happened. So in research 
recruitment has the big part. 
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think might 
influence the parents/guardians to agree to enrol their 
children in the study? 
R: To me, I feel like with working in the with clinic people 
who are I don‘t know who are always critical and to them 
when they see people who are doing research, they see 
people who are not interested in health but are interested in 
making money out of them. I think it‘s going down, because 
when we go to the clinic today they can start calling me, so 
that can help. And then the other thing, most of our patients, 
I don‘t know if they are poor or what because telling a 
patient you have to come to the clinic for this and that, you 
have to call a driver to go collect that person and bring the 
person to the clinic, it‘s difficult. Like in Gaborone, most of 
the people are renting, so we get their contacts then they 
change and they lose their cell phones and that is a 
challenge. Or you try to call the partner and the phone is off.  
Q: Describe any measures you put in place to ensure that 
participants and the consenting parents/guardians do not feel 
coerced or pressured to join the study as well as continued 
consent during the study. 
R:  To tell the truth, I know that as recruiters we are the first 
people to meet so our aim is to protect the people. Our aim is 
if a participant is coming and they have social problems we 
get professional counselling for them and take them to 
professional counselling. Not only that, when they come we 
give them counselling even after they decide they are not 
participating to help them. Even in our diaries, you will see a 
name of somebody who needs to go for counselling. 
Q: How do you ensure continued consent during the study? 
R: When they come for appointments, we keep asking them 
about the study. 
Q: Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
R: Yah...I have to say, I don‘t remember anything or adding 
anything on what is done in the process. 
I know that for us, sometimes there will be like some 
decisions have been made about participants and you get to 
hear. So I am like it‘s us who get these patients why can‘t 
we be involved in decision making or consulted for 
guidance. But sometimes, we are the ones who call people, 
so when we see them suffering, it will hit back on us.  
Q: How do you involve members of the community to 
recruit participants? 
R: One thing that I feel like we, I feel like many people do 
not understand what we do when the child comes. Nurses or 
doctors, I feel like especially like this other time when I was 
asking one of the doctors, I was asking do you think it‘s 
important for people to know because when you go to the 
communities, they don‘t know anything about research. 
Even, with people we make sure that they understand what 
we do. 
 
That‘s the end of the interview. Thank you so much for 
participating in this study. 
 
End time: 16.09 hrs 
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IN-DEPTH INTERVIEW: 6 
Date 18.03.2011 
Interview No 0006 
Start time 15.00hrs 
Gender Female 
Age 40-50 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
Education  
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? What on-going training 
on protection of human subjects are you receiving? 
R: We do our GCP then do what do they call it.......clinical 
ethics I think......but its online, most of the time when you 
start with Harvard you have to undergo that training before 
you can even start handling the patients every 2 years. We 
also have to do the training. You have to renew every 2 
years and if you don‘t renew it usually goes with your 
contract. Sometimes they cannot renew the training then 
even your contract may not be renewed. 
Q: Tell me about purpose of the clinical trial you are 
involved in. 
R: Most of them that I am involved now in are drug 
interventions. 
Q: Explain your role in clinical trial have you been involved 
in? 
R: No, not necessarily an administrator. I do administration 
especially concerning the study related things. Maybe 
dealing with IRBs, making submissions to the IRBs but I do 
help the nurses in recruitment. Usually there are recruitment 
officers who go to sites and bring in the patient. But you find 
when the patient comes here, they come not everything was 
explained. They are just told, ―there is a study at Harvard. It 
looks like you can qualify for that study, are you interested 
to join in?‖ So sometimes when they have a lot of patients I 
help with that because I am interested in working with 
patients. 
Q: , Briefly carry me through the consenting process. 
R:  Ok usually what happens; these patients will be recruited 
and when they come, they will be divided according to 
where they go because we have different studies at Harvard 
so it depends whether the patient was recruited for a clinical 
or non-clinical trial. So you find when the patient comes we 
take them to the waiting room...........and serve them on first 
come first serve basis. Then you will bring the patient here 
and the first thing when they come is to introduce yourself to 
her, then from there you have to make her know where she 
is. Because people will just be saying, I‘m going to the 
hospital or clinic; she doesn‘t even know what we do. So 
you have to explain that you have come to this clinic to enrol 
your child in a research study for HIV. So after that, is when 
you ask the patient is she interested to hear more about the  
study. 
Q: What was the risk category of the clinical trial you 
recently conducted?  
R: For the patient or for us?...... Oh for the patient!......No I 
wouldn‘t say they are at risk because, for the studies I have 
worked with, they have helped a lot of patients because you 
will find you are dealing with HIV positive patients and with 
all those interventions that the studies are doing, at the end 
of the day, they go back to negative....... Because if I look at 
the studies I have worked on,  at the end of the day, you will 
find that out of 100 kids that were born to HIV positive 
mothers only 15 were HIV positive and the rest were HIV 
negative, and even the patients are very happy about this.  
Regarding risk, I would say the studies had very minimal, 
yes very minimal risk! Mostly, you may find that out of 100 
patients we see, you can only have 2 patients who reacted to 
the study. Most of them are doing very well. 
Q: Are clinicians involved in the consenting process? 
R: Nurses, mostly you may find that for doctors, most of 
them are not Batswana. Most of the doctors are foreigners 
so; most of the consent process is done by nurses. 
Q: Do you think this is a problem? 
R: I don‘t think that is a problem.  No, I think its fine 
because, during the consultation even those doctors who are 
foreigners, most of them have learnt Setswana and they are 
able to greet the patients even to ask the patient, do you 
understand what you are going to do, do you know the study 
that you are involved in.......in the consultation, the nurse is 
always there to help. 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
R: I think it depends where you are working. The education 
level of the patients varies in the rural areas but when you 
come into Gaborone, Gaborone is a city, most of the patients 
they have their university degree, and they have a diploma. 
Most of them have gone up to form 5 but when you get to 
rural areas, you find that most patients are form 3 or 
standard 7. So it depends on site location. 
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
R: Yes, I think there is every age because I think with our 
studies; we start from 18 years and above but you mostly 
find people in their 30s. 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
R: Mmmm... Not a lot of them, but I realise that some  
patients already knew about research from previous studies 
It‘s like they had the decision of having another child 
because they knew the research centre was going to help 
them. Laughter!!!! 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
R: Participant: I think most of them they are lower and 
middle status. I have realised that most of them with high 
income don‘t come to the clinic; a lot of them prefer to go to 
the private doctors.  
Q: Who prepares the consent form that you use in the 
clinical trial? 
R: What happens usually with our studies when the sponsor, 
it‘s like its prepared by the sponsor, so when it comes, as 
study coordinators we have to customise it to our standards, 
to Botswana standards, so we have our standard of 
care....culturally.  Then from there, they come in English, so 
they are supposed to be translated into Setswana. I translate 
from Setswana to English then back to Setswana... back 
translation so I am one of the people who have been highly 
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involved with the translation even for other studies not 
necessarily for our studies.  
Q: GCP requires that consent form be in a language the 
participant best understands. Does translating only into 
Setswana have an impact on understanding the study? 
R: I think it would only be a problem if the studies were 
being conducted in those areas but those people with 
different languages like Kalanga, Sesame...when they are in 
Gaborone most of the time they come to work so they don‘t 
have a problem with it, Setswana some they even prefer 
English consent. It‘s up to the choice of the patient what 
language to use because usually we have both consents. If 
she wants to use Setswana its Setswana, if she wants English 
it‘s not a problem but majority would love to use Setswana 
because it‘s easier when you are talking to them because out 
of 100 only 1 patient will use the English consent. 
Q: On average how many pages is your consent document? 
R: On average 20 pages, I know the biggest one was about 
22 pages but you will find that sometimes it‘s up to 22 pages 
because it involves pages of the intervention which at the 
end of the day you can take and extract from that and put it 
aside and wait for the patient to consent and after they have 
consented that you can tell them about it. They can be short 
but when you translate to Setswana they will go up to 25 
pages. 
Q: Which methods have you tried for the consenting 
process? 
R: Most of the intervention studies that we have done before 
we used to have pictures whereby the mother can see which 
drug they will be giving the baby. I think they are very good, 
it made the patient to understand better than when you just 
explain to them. Those pictures were even in colour form. 
Mostly, I prefer to use the short forms to describe the long 
terms used for drugs to make it easier for them to 
understand. 
Q: Which guidelines do you use to guide the consenting 
process? 
R: Yah, usually we use the Botswana Drug Guide, the ARV 
guidelines for Botswana, we also use them to refer for and to 
make comparisons because we have to at the same time keep 
to the standard of Botswana guidelines. We use the same 
Botswana Guidelines because we are not supposed to give 
the patient something that when she leaves she is not able to 
get from the Government. Usually, we make sure that our 
standard of care goes in line with the standard of care they 
can get anywhere in Botswana. 
Q: Good Clinical Practice (GCP) guidelines recommend that 
both the informed consent discussion and the informed 
consent form should include the twenty elements. Do your 
consent forms include all these elements and are you able to 
go through all these during your sessions?  
 
R: Yes, we follow them. 
 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R: Usually we have posters, we have flyers. Our recruiters 
they go to the public clinics every morning and they talk to 
the eligible patients. Sometimes we even go to areas outside 
of Gaborone 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: During recruitment, they are being recruited by our 
recruitment officers from the clinics, then they come to our 
study clinic then that‘s when they meet the nurse. 
Q: In what language are the discussions of the information 
about the study held? 
R:  mainly Setswana 
Q: How is the information about the clinical trial 
communicated? 
R: By talking to the patient.  
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: Ah I think.....Mostly, the consent form is something that 
is very straightforward. The other thing is it depends, you 
will find with me, I have an experience, I have worked with 
research for quite some time, so I‘m able to address different 
patients and  I think the best thing is to find out how much 
your patient can understand so you can use it to talk to her. 
It‘s like you break it down into a simple language. There are 
some patients who are slow learners, you have to observe 
that, there are some patients who are very shy even to ask 
you questions, when they don‘t even understand. So, most 
the time, when I do it, usually I assess my patient about 
understanding to understand what kind of patient. Usually I 
make sure I recap. I read a paragraph then I recap with her 
then give her time to ask questions. 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
Participant: Yah, you can say they have too much 
information. When you think someone is here and you are 
reading a 20 page document, you can‘t really expect her to 
understand all that depending on the patient, it‘s too much 
information. Usually our exercise is that usually after the 
patient has consented you are supposed to give them a copy. 
I always encourage them to go and read at home, at least 
page to page, so at least when she continues to come for her 
visits, she will have some questions that she would like to 
ask. And every time you want to be sure that the patient has 
understood the consent process. So every time the patient 
comes for every visit, you talk to her, remind her about our 
study, find out if she still remembers the drugs that are going 
to be used, it‘s very important. 
Q: Concerning risks when disclosing to participants, would 
you prefer to..... 
R: Mostly, I will give the patients all the information but at 
the end of the day having the experience of having worked 
with patients, you always tell them the truth because 
sometimes you may not experience the side effects but I 
have to tell you this so you know, because it doesn‘t mean 
that everything I have told is going to happen to you. Also 
you have to tell the patient......some they may have a 
headache some have never experienced a headache. Some 
may have dreams which they do not normally have but you 
have to tell the patient exactly everything so that the patient 
makes an informed decision, she understands the risks she is 
going through when she takes part in the study. 
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language?  
R: I wouldn‘t say that because when you come to drugs, 
how you can break it down for the patient to understand. 
Yah, you have to try to speak the language that the patient 
will understand....you have to really try to make sure the 
patient understands 
. 
Understanding 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: Usually with our studies we have a document called level 
of understanding. It‘s just a paper I think it has about 10 to 
15 questions. Those questions are like a summary to the 
whole consent form. So at the end of the day, you talk to 
those patients if she doesn‘t understand sometimes we 
postpone the process or the patient might say we give her the 
consent and she goes and reads it again at home and 
tomorrow we make an appointment and she comes again 
then we test, we ask her all those questions again so you can 
assess the level of how she has understood the whole 
process.  Then usually we make a score. If somebody has 
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scores 10 out of 15 we feel that she has understood then we 
can make a recap on those that she was not clear on. Usually 
the patient.......it depends on the study, if she gets 7 then 
maybe you have to go over the process again. 
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: When you deal with pregnant mothers, sometimes it‘s a 
bit difficult because you find that this patient was in the 
clinic the whole morning, then our recruiter maybe finds her 
around 11 then she comes here to the site, so most of the 
time when it‘s like that, we book them for the other day and 
usually we do ask. We are having a consent form which is 
about 20 pages and we are going to be reading, explaining 
and asking questions, so do you think you make it because 
sometimes it take an hour so we make our patient understand 
that. I have found that dealing with pregnant mothers it‘s a 
bit sensitive unlike dealing with patients who are just. 
 
Decision Making 
Q: Approximately how much time do you think should be 
given to the parents/guardians to make a decision? 
R: Sometimes I think it depends on the patient, some 
patients will say, ok, I have understood that, but since I‘m 
supposed to consult my husband, let me go talk to him. But 
usually we encourage them to bring those partners so we can 
do explanation to both of them. You will find if you bring 
them as partners, she knows the other partner, I mean they 
have been partners for some time so he knows the level of 
understanding of that wife of hers. So you find that when the 
other partner is there, when she doesn‘t get it, then it‘s 
better. So usually we encourage them to bring partners.   
Q: How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: Most of the time you will find they are comfortable with 
signing the consent document because most of the time if we 
are suspicious, sometimes we even involve a different 
counsellor. You might try to talk to that patient, and it‘s like 
the patient is not comfortable with you and the patient 
doesn‘t really, her level of understanding is low so 
sometimes you may find that another trial staff can do a 
better job then you refer the parent too that person. Young 
people would prefer somebody younger. I think it depends.... 
Q: How do you facilitate the decision-making process? 
R: I think once the patient has understood whatever you 
have explained; it should be out of interest. Even the patient, 
she also has to if she thinks it will benefit her, I think it‘s out 
of benefit because once you have explained everything to 
her she has to understand if it will benefit her of what. If she 
knows that it‘s going to benefit her, it makes it easier to 
make the decision. 
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think might 
influence the parents/guardians to agree to enrol their 
children in the study? 
R: I think a lot of them. Sometimes you find that the patient 
stays in town and she is very interested in participating in 
the study but when she thinks she will be coming from far, 
jumping on the combi to the station then from the station to 
the clinic they may feel that it will be too far and she will not 
be having money for transport. So most of the time she will 
prefer not to be in the study because she can access help 
from nearby centers. Maybe then for us, usually we do some 
compensation for transport money to help them. 
Q: Describe any measures you put in place to ensure that 
participants and the consenting parents/guardians do not feel 
coerced or pressured to join the study as well as continued 
consent during the study. 
R  Exactly, because sometimes....I mean with HIV/AIDS, 
it‘s like a lot of people they know that if somebody is health 
worker and comes to you and says this can you help, a lot of 
them develop trust. The doctor cannot say this if this can‘t 
help me. Most of the time we don‘t want to talk about the 
compensation, it usually comes at last and we even come to 
a point whereby you ask a patient, do you think you will 
manage to come to the clinic with all the visits because it‘s 
like you are going to have 15 visits in this study then she 
says yes I think I can manage because I will get the money 
from somewhere because I need these visits. I will see what 
to do. Usually that‘s what they do then you can see that she 
knows that this can help her, how she‘s going to get to the 
place, it doesn‘t matter. So the compensation usually it 
comes at last because we don‘t want to use it as coercion. 
We don‘t want to tell them you will get P30 in the consent 
process because sometimes you may find that the patient just 
consents because she needs to be helped but she has not 
understood the consent.  
Q: How do you ensure continued consent during the study? 
R: So every time she comes, we have to make a recap and 
ask her do you still understand why you are in this study, do 
you remember the drugs that are going to be used, do you 
remember the side effects of the drugs. It has to be an 
ongoing process throughout the study 
Q: Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
R: The other thing maybe what we can do is the consent 
shouldn‘t be too long maybe because if it‘s too long it makes 
the patient to be here for too long, I think that is the thing we 
need to do. I think it needs to be a bit short and it becomes 
brief and to the point, it‘s like at the end of the day, the 
patient doesn‘t get all because it‘s a summary but don‘t 
worry that‘s it‘s a summary, we elaborate everything. 
 
This is the end of our interview. Thank you for participating 
in this study.   
 
End time: 15.35hrs 
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IN-DEPTH INTERVIEW: 7 
Date 04.04.2011 
Interview No 0007 
Start time 15.25hrs 
Gender Female 
Age 30-40 
Discussion Language English 
Research Assistant Ms. Faith Mompati-Ketshogile 
 
The research assistant began the interview by making introductions and going through the consent form and have it signed by the 
respondent. Respondent characteristics were not included in the write up for anonymity and confidentiality purposes. 
 
Q: Have you had any specialized training in ethics of 
conducting clinical trials research? 
R: Yes, although it was not a specialization. 
Q: Do you have any specializations in pediatrics? 
R: Yes I did pediatric courses at school. I also have   4 years 
of experience in conducting studies involving parents and 
children 
Q. Which Phase of clinical trial have you been involved in? 
R: Mostly Phase III and IV 
Q: What was the risk category of the clinical trial you 
recently conducted?  
Participant: Mostly minimal but one study that involved 
drug intervention was greater than minimal risk. 
Q: On average, what generally is the highest level of 
education attained by the majority of the parents/guardian 
who give consent for their children‘s participation in clinical 
trials? 
R: Mostly Primary and Junior school we have a few tertiary 
or those who dropped out of school early. I prefer those 
without too much education because they will follow what 
they are told  
Q: On average, what is the average age of the 
parents/guardians whom you have obtained consent from for 
their children‘s   participation in clinical research? 
R: Most parents are 21 years and above because of the age 
of consent but there are also a lot of grandparents to consent 
for minors 
Q: On average how many of your participants have previous 
experience with research on HIV disease? 
Q: What generally is social economic status of the majority 
of the parents/guardians who participate in your studies? 
Generally low 
R: Very few especially those who have been in studies as 
pregnant women and they enrol their children in studies. 
Q: How do you rate the importance of prior of knowledge of 
a research investigator about Botswana culture, values and 
beliefs before the start of the study?  
R: Promotes  understanding  ways of respecting  participants 
for example,  those who say must go back and consult-it is 
usually an indirect  way of refusal  but some come with  
their minds made up. Knowledge of the local language is 
also important for understanding. 
Q: Do you think this knowledge plays any role in the 
success or failure of a consenting process? 
 
 
 
 
 
 
 
 
R: I think you cannot take out the culture; we go through the 
Kgotla before. On one study I was asked whether I have 
talked to the Kgosi before. I have had an experience where 
they admit that they have taken traditional medicines. 
Inhalations but we respect their culture we can stop them. It 
is a problem to ask the mother and father to join because a 
lot of women are single mothers even those who have are 
not so much involve come to drop them. Once they say they 
want to consult it is an indirect way of refusing although a 
few agree need for education to involve partners. 
R: The forms are prepared by the research team, use the 
format from the sponsor but contextualize to the culture of 
Botswana setting especially for Multi-center studies. The 
Principal Investigators consult with the research team and 
study coordinators and senior nurses help. 
Q: On average how many pages is your consent document? 
R: Usually long but nurses are able to summarize the 
information from lengthy forms to about six pages, a page 
sometimes. Although the forms are long nurses with 
experience know how to pick important issues 
Q: Which research guidelines are you familiar with 
regarding the protection of research participants and how 
helpful they are to the consenting process? GCP guidelines 
recommend that both the informed consent discussion and 
the informed consent form should include the twenty 
elements. Do your consent forms include all these elements 
and are you able to go through all these during your 
sessions?  
R: We all do Good Clinical Trial Practice training so am 
familiar with GCP guidelines and refer to these documents. 
All of us are trained in GCP because it is a requirement by 
the institution that everyone is trained 
Q: GCP guidelines recommend that both the informed 
consent discussion and the informed consent form should 
include the twenty elements. Do your consent forms include 
all these elements and are you able to go through all these 
during your sessions?  
What challenges do you encounter from the ethics 
committees that review your consent form if applicable? 
 
R: Uh! I would not say I have encountered many problems. 
At the Ethics committee I prefer submitting my application 
to a particular person other than the registry to avoid losses. 
There are also delays, we asked to do lots of corrections not 
to pay the participants much but only for compensating 
transport which is not much compared to what participants 
in other countries pay. 
Q: What challenges do you encounter from the sponsors 
regarding the requirements for preparation of the informed 
consent document for the clinical trial if applicable? 
R: We are not involved with sponsors 
Information disclosure 
Q: What recruitment methods do you use to let 
parents/guardians know about this study?  
R:  We hardly use the radio, but we use mainly posters put at 
the clinics. We also use the patient meetings, wards antenatal 
clinics in the rural areas. A few patients come from private 
clinics 
Q: Who talks to the parents/guardians/children about the 
clinical trial when they came to the hospital/clinic? 
R: Recruiters and nurses. The recruiters go with the nurses 
for better interaction. We also get self-referrals who have 
heard about the study from the community. Some parents  
call to inquire about the study after they have heard about 
the benefits. 
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Q: In what language are the discussions of the information 
about the study held? 
R: Mainly the local official language Setswana, but a few 
prefer English. 
Q: From your experience, which of the following elements 
of the consent form do find difficult to communicate to 
participants and why? 
R: The procedures and risks can be a challenge to explain 
because of the scientific terms. Also concepts like 
randomization. 
Q: How would you rate the amount of information provided 
to the parents/guardians in the studies you have conducted? 
R: The information is usually a lot because of the length of 
the consent forms and the short time one to go through the 
form. 
Q: Do you consider all the information relevant for the 
participant to make an autonomous decision? 
R: Yes but for the level of the participant some of the 
information might not be relevant especially the medical 
explanations and details of treatment and laboratory tests. 
Q: How would rate the complexity of the technical language 
used in the consent document and how do enhance 
understanding of such language? 
Understanding 
Q: How do majority of participants initially react to 
experimentation on their children? 
R: You find that initially some are very anxious because of 
the nature of illness of their children but as we explain some 
of the things they become calm and with time some even 
become happy and do not look as hopeless as the time they 
came. 
Q: Do the parents understand the difference between 
research and treatment? 
R: Sh! .. we try to explain but it is difficult to tell for many 
of them. To me it seems like they think they have come for 
their child‘s treatment. But we emphasize this a lot during 
the consenting process.  
Q: Do the parents/guardians ask any questions? 
R: Not that much especially those with low education. I feel 
they still have that mentality that the health professional is 
always right. But some do especially about the safety of 
their child. 
Q: If yes what are usually their main concerns? 
R: They mainly want to know how experimenting on the 
child might affect the child physically, whether the child will 
get better, mainly child safety issues. 
Q: If no questions are asked do you find out why? 
R: Really I have never found out why, but I think it might be 
a cultural thing where they do not want to look like they are 
questioning. I t might also be fear of the unknown. Like they 
would rather not know what lies ahead. 
Q: What do you think is the most common reason for the 
parents/guardians not asking questions? 
R: I think it is the culture. The power issue!... considering 
that the doctor or nurse is a respected member of the 
community and the assumption that they know what is best 
for the child. 
Q: How do you test the level of understanding of the 
information provided about the trial? 
R: Verbally by using a test of understanding quiz. 
Sometimes even asking just general questions not really 
related to the study just to change the topic a little during the 
consenting process. 
Q: How would you rate the level of attentiveness of the 
parent/guardian during the consent process? 
R: Ah! It‘s is difficult to judge because some just stare at 
you as you talk or read to them which might look like they 
are paying attention. Some would be very tired after a long 
day you can really see they are more worried about how they 
will get home 
Q: How much time do you think is appropriate for the 
informed consent process to enable understanding? 
R: It depends on how understanding is being judged. If the 
parent does not seem to understand we can even ask them to 
come another time after having someone read and explain to 
them. 
Decision Making 
Q: Is it important to you to always consult the two parents or 
the relative(s) of the participants even if the person who has 
brought the child to the clinic agrees to participate? 
R: It would be good for the two parents to be consulted but 
we meet a lot of young single mothers whose spouses are 
not so much involved in the care of the child. It is always 
good to get the blessing and to have the support of the 
relatives because they all take care of the child and they 
show concern. Even the culture encourages this. Also in case 
anything goes wrong, the blame is not only shifted to the 
institution. 
Q: Do all the parents insist on consulting with the spouse or 
family before making a decision? 
R: Yes a lot of them do even after they have agreed at the 
clinic they will go back and talk   to their families. 
Sometimes you find that they will not come for the next 
appointment and when you phone them they say the 
relatives did not approve. However those whose spouses are 
not aware of the status of the parent and child are hesitant to 
consult the spouse. 
Q: Who do you mainly consult before enrolment of the child 
into the study? 
R: Mostly the grandmothers to the child or anyone the 
parent can suggest. 
Q: Does the involvement of a participant's spouse or 
relative(s) influence the time necessary to obtain informed 
consent? 
R: Ya!.. it really makes a difference because it is like a 
secret that is coming out and the parent is relieved that 
someone knows about the situation and will give support. It 
also improves the level of involvement in the research and 
adherence to the instructions. 
Q. How do the parent(s)/guardian(s) react to being asked to 
sign a consent form? 
R: Again as I said, they do not seem to mind especially 
before they get a good understanding of the difference 
between research and treatment. Signing means they will get 
help. Another thing is the culture of not questioning.  
Q:  How do you facilitate the decision-making process? 
R: Emphasizing that the participation is voluntary and 
telling the truth about the uncertainties of the study so the 
parent understands the benefits and risks. Allowing as much 
time as required for someone to decide not to rush them. 
Q: From your interaction can you identify any social, 
cultural, economic or any other factors that you think might 
influence the parents/guardians to agree to enrol their 
children in the study? 
R: The most important influence is the culture and mentality 
of trust about health workers that they are always right. 
Poverty might also play a part for some parents knowing that 
they can only get help from research. Also the good care and 
compassion shown to the parents.  
Q: Describe any measures you put in place to ensure that 
participant and the consenting parents/guardians do not feel 
coerced or pressured to join the study as well as continued 
consent during the study. 
R: I assure the parents from the beginning that enrolling the 
child is voluntary. I also do not mention that there will be a 
compensation for travel at the beginning. 
Q:Please give any recommendations that would help in 
enhancing the informed consent process for child 
participation in clinical Trials. 
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R: There is need to shorten the forms and simplify them. 
More education to the public about the importance of 
research and clear some of the misconceptions. 
 Thank you that is the end of our interview. 
 
That is the end of our interview. Thank you for participating 
in this study. 
 
End time: 17.11hrs 
 
 
 
 
 
